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General introduction
1Congenital heart defects are the most common of all birth defects, occurring in approxi-mately 1 in every 100 live births.1-3 One of the major forms of congenital heart disease 
is left ventricular outfl ow tract disease, accounting for approximately 5-10% of cases.1,3,4 
Especially in adults, diseases of the left ventricular outfl ow tract and proximal aorta are 
becoming increasingly clinically important.
The left ventricular outfl ow tract connects the left ventricle to the aorta. The left 
ventricular outfl ow tract contains the aortic valve, which opens during ventricular con-
traction and closes during ventricular relaxation to ensure that blood only fl ows in the 
correct direction to the systemic circulation. Congenital defects of the left ventricular 
outfl ow tract usually concern obstructions (aortic stenosis), most frequently at the level 
of the aortic valve (aortic valve stenosis, 75% of cases) or below the level of the aortic 
valve (subvalvular aortic stenosis, 20%) and rarely above the level of the aortic valve 
(supravalvular aortic stenosis, 5%).4,5 Defects of the left ventricular outfl ow tract may 
also concern leaking of the aortic valve (aortic regurgitation), although this is rarely the 
primary dysfunction of the aortic valve. Aortic regurgitation is most often secondary to 
other cardiac disease, concomitant to aortic stenosis or iatrogenic.6 The functioning of 
a healthy aortic valve, aortic valve stenosis and aortic valve regurgitation are depicted 
in Figure 1.
figure 1.
The clinical presentation of aortic stenosis varies largely depending on the severity of 
stenosis, ranging from severe critical aortic stenosis presenting in the fi rst year of life and 
requiring urgent intervention to a milder disease course only becoming apparent and/
or clinically relevant in adolescence or adulthood. Aortic stenosis is usually progressive 
in nature and most patients diagnosed with aortic stenosis at a pediatric or young adult 
age will require one or multiple (surgical) interventions during the course of their lives.7,8
14
treatMent oPtions
subvalvular aortic stenosis
Subvalvular aortic stenosis is usually treated by surgical enucleation or excision of the 
subvalvular obstruction, the extent of which may vary from a minor fibrous ridge (dis-
crete subvalvular aortic stenosis) to a narrow fibromuscular tunnel. Although surgery 
in this regard can often be achieved with low mortality and satisfactory hemodynamic 
result, there is a substantial risk of recurrence and subsequent reintervention and it 
remains difficult to predict which patients are more prone to recurrence.9
aortic valve disease
In the case of aortic valve stenosis in neonates, infants and children, the initial treat-
ment is usually percutaneous balloon aortic valvuloplasty. However, there is a high risk 
of residual or recurrent valve stenosis and/or the development of valve regurgitation. 
Therefore, most patients will require reintervention after initial balloon valvuloplasty in 
the form of redo percutaneous balloon valvuloplasty, surgical valvuloplasty/aortic valve 
repair, or aortic valve replacement.10-12
In the case of substantial aortic valve regurgitation (either at initial presentation or as a 
result of prior percutaneous or surgical valvuloplasty) or if there is substantial residual 
or recurrent aortic valve stenosis after prior valvuloplasty, surgical intervention is often 
indicated. Surgical intervention is also usually employed as the initial intervention in 
adults due to poor results and limited benefit of percutaneous balloon valvuloplasty in 
adults.13 If stenosis is not isolated to the valvular level, but is rather a multilevel stenosis 
that also includes subvalvular and/or supravalvular obstruction, surgery is also most 
often the treatment of choice.9
In aortic valve surgery, it is preferred to repair the valve whenever possible, because 
all currently available valve substitutes for valve replacement have drawbacks when 
compared to an adequately functioning native aortic valve. However, depending on the 
anatomy and mechanism of dysfunction, a hemodynamically satisfactory and durable 
result can only be achieved with valve repair in a limited proportion of cases.14 Therefore, 
most patients will require replacement of the aortic valve, either if the valve is found 
not to be amenable to repair at initial surgery or as a reoperation after primary valve 
repair if there is residual or recurrent valve dysfunction.14-16 Various valve substitutes 
are currently available for aortic valve replacement, each with their own benefits and 
drawbacks.17-20
15
General introduction
1Mechanical prosthesesThe primary advantage of mechanical prostheses (Figure 2) is their long-term durability. 
They are also easily implanted and readily available. However, they require lifelong anti-
coagulation due to their increased thrombogenicity, which gives rise to a substantial risk 
of thromboembolic and bleeding complications. Furthermore, the anticoagulation re-
quired for mechanical prostheses (vitamin K antagonists) does not provide a stable level 
of anticoagulation with a fixed daily dose due to specific pharmacological properties. 
This therefore requires frequent blood testing of the anticoagulation level (international 
normalized ratio, INR) with subsequent changes in the daily dose of anticoagulation to 
be made. In addition to these requirements of INR regulation, patients are faced with the 
ticking sound that the valve makes with every heartbeat, restrictions on participation in 
certain types of athletic activity, and female patients with mechanical heart valves face a 
substantial risk of serious anticoagulation-related complications during future pregnan-
cies. Consequently, mechanical valve prostheses have been found to be associated with 
substantial impairments in quality of life in non-elderly adult patients when compared 
to alternatives.18,19 Moreover, in growing children, mechanical prostheses do not grow 
along with the growing child, with the consequent potential for the development of 
patient-prosthesis mismatch over time.17
figure 2. Mechanical prosthesis (St. Jude Medical valve, Abbott Laboratories, Chicago, Illinois, USA)
Bioprostheses
The main advantage of commercially available bioprostheses (xenografts, made from 
bovine or porcine tissue, see Figure 3) is that they have a lower thrombogenicity than 
mechanical prostheses and, therefore, do not require lifelong anticoagulation. Conse-
quently, they are associated with lower risks of thromboembolic and bleeding complica-
tions than mechanical prostheses. They also do not carry the anticoagulation-related 
risks of mechanical prostheses during pregnancy and do not make any sound in normal 
functioning. Similar to mechanical prostheses, they are also easily implanted and readily 
available. However, they have a limited durability and are subject to valve deterioration 
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over time, particularly in younger patients. Consequently, patients with bioprostheses 
face a higher risk of reintervention over time than patients with mechanical prostheses. 
Additionally, as with mechanical prostheses, in growing children there is potential for 
the development of prosthesis-patient mismatch over time.17,18
figure 3. Bioprosthesis (INSPIRIS RESILIA valve, Edwards Lifesciences, Irvine, California, USA)
Pulmonary autografts
Aortic valve replacement with a pulmonary autograft, also known as the Ross procedure, 
involves transplantation of the patient’s own pulmonary valve (pulmonary autograft) 
to the aortic valve position and implantation of another valve substitute, such as an 
allograft or bioprosthesis, in the pulmonary position. It provides an autologous, living 
aortic valve substitute which has been shown to provide hemodynamically superior re-
sults to mechanical prostheses and bioprostheses, diameter increase along with somatic 
growth in children contrary to mechanical prostheses and bioprostheses, and greater 
durability than bioprostheses in non-elderly patients when performed in centers of 
expertise. In addition, similar to a bioprosthesis, it provides low thrombogenicity, avoid-
ance of lifelong anticoagulation, safety during pregnancy and absence of valve sound. 
However, the Ross procedure is far more complex and technically demanding than the 
implantation of a mechanical prosthesis or bioprosthesis. Moreover, the autograft is 
subject to structural deterioration and subsequent requirement for reintervention over 
time, despite numerous techniques having been developed to reinforce the autograft 
at implantation. Also, the valve substitute in the right ventricular outflow tract (RVOT) 
imparts an additional risk of reintervention.17,18,20 Consequently, although the Ross 
procedure is frequently performed in growing children due to its specific benefits in this 
patient population, its application in adults is far more limited.21,22
17
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1AllograftsThe aortic valve may also be replaced by an allograft (human cadaveric donor valve). 
However, in current practice allografts have been largely abandoned as an aortic valve 
substitute due to high rates of structural deterioration and (complex) reintervention 
along with their limited availability dependent on donor supply.23,24 Their current role in 
aortic valve replacement is mostly limited to rare cases of complex endocarditis. Beyond 
the setting of aortic valve replacement, they are widely used for right ventricular outflow 
tract reconstruction in both children and adults.
Tissue engineered valves and TAVI
Tissue engineered heart valves are currently under development and aim to provide a 
living autologous heart valve substitute without the limitations of currently available 
valve substitutes. Additionally, there is growing interest in transcatheter aortic valve 
implantation (TAVI) as a primary intervention in increasingly younger and lower risk 
patients. However, tissue engineered heart valves are still experimental and have not yet 
reached clinical practice and transcatheter aortic valve implantation is currently limited 
to elderly patients. These ongoing developments are therefore beyond the scope of this 
thesis.
outcoMe after surgery anD Decision-Making
Considering the above, clinicians and (parents of ) patients often face many difficult 
decisions during the course of these patients’ lives. Congenital left ventricular outflow 
tract disease usually allows for an active life well into adulthood, but often with impor-
tant consequences for lifestyle and life planning and requiring multiple crucial treat-
ment decisions to be made along the way.13,19,25 These decisions often have important 
implications for the patient’s further life with regard to longevity, pregnancy, career 
planning, athletic endeavors and daily life, particularly in young patients with dynamic 
lifestyles.13,26 Consequently, such decisions are highly value-sensitive and often difficult. 
For instance, in the selection of a valve substitute for aortic valve replacement, it has 
been demonstrated that there is an exceedingly wide variation in preferences between 
individual physicians: for a given patient with a specific patient profile some physicians 
would always choose a mechanical prosthesis while other physicians would always 
choose a bioprosthesis for the very same patient.27 This large individual variability in pref-
erences has also been demonstrated among patients undergoing aortic valve surgery 
in trade-offs between quality of life and quantity of life.28,29 Considering the complexity 
and value-sensitivity of such decisions and their consequences for the patients’ further 
lives, it is of crucial importance to involve patients in decision-making. Therefore, recent 
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international clinical practice guidelines recommend a shared decision-making process 
in prosthetic heart valve selection that accounts for the informed patient’s values and 
preferences.30,31
However, adequately informed physicians and (parents of ) patients are an essential 
requirement for effective decision-making. Although there have been decades of 
experience worldwide with the aforementioned treatment modalities and a wealth of 
follow-up has been obtained, there remains substantial uncertainty about outcome af-
ter surgery. Evidence on outcome after surgery is scattered across an exceedingly large 
number of publications and reported outcome varies strongly among publications.20,32 
Moreover, outcomes are often reported in formats that are not meaningful for incorpo-
ration in daily practice and may not be readily interpretable by physicians and (parents 
of ) patients alike. This makes it difficult for physicians and (parents of ) patients to draw 
inferences on what patients can be expected to face after surgery, which complicates 
decision-making. As a further consequence, as demonstrated in middle-aged and el-
derly patients undergoing aortic valve replacement, limited disease-related knowledge 
among patients also makes it difficult for patients to be as involved in decision-making 
as patients and physicians would prefer, despite broad support for shared decision-
making among physicians and patients alike.27,33
There is increasing international evidence that (parents of ) patients may not always be 
sufficiently informed and involved, which has been previously shown to lead to substan-
tial impairments in quality of life, anxiety, depression, poor treatment adherence, poor 
health behaviour, suboptimal treatment decisions and poorer clinical outcome, and also 
to poorer healthcare utilization and higher healthcare costs.34-48
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In response to the above, this thesis aims to make sense of outcome after congenital left 
ventricular outflow tract surgery and improve evidence-based decision-making, patient 
information and patient involvement by investigating the following research questions:
what is long-term outcome after congenital left ventricular outflow tract surgery?
This research question will be investigated by:
•	 Obtaining	robust	estimates	of	long-term	outcome	after	left	ventricular	outflow	tract	
surgery in children and young adults (Chapters 2-7)
•	 Exploring	possibilities	for	patient-tailored	outcome	modeling	and	decision-making	
by developing methodology for tailoring outcome models to patient- and procedure-
related factors (microsimulation, Chapters 4-6) and investigating factors associated 
with outcome (Chapter 2)
•	 Investigating	methodology	for	evaluating	developments	in	the	treatment	of	these	
patients aimed at improving outcome (Chapter 8)
How can evidence on outcome be effectively conveyed to physicians and patients 
for implementation of informed shared decision-making in practice?
This research question will be investigated by:
•	 Exploring	 methodology	 for	 translating	 evidence	 on	 outcome	 to	 a	 format	 that	 is	
meaningful to physicians and (parents of ) patients alike and can be readily imple-
mented in clinical practice (microsimulation, Chapters 4-6)
•	 Investigating	patient/parent	disease-related	knowledge,	 the	availability	of	patient	
information and patient/parent comprehension of the available information (Chap-
ter 9)
•	 Developing	and	testing	interventions	for	improving	patient	information	and	(shared)	
decision-making (Chapters 10-12)
20
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aBstract
Background
Sub-valvular aortic stenosis (SAS) is a common form of left ventricular outflow tract 
(LVOT) obstruction, which can lead to aortic valve damage. Although surgery for SAS is 
an accepted treatment, the timing of surgical intervention of SAS remains controversial. 
This review aims to establish an overview of the natural history and outcome after sur-
gery and factors associated with prognosis in paediatric SAS patients. 
Methods
We searched PubMed and EMBASE for studies that reported factors that negatively af-
fected the prognosis of patients with SAS. Studies were included if they were written in 
English, published between 1 January 1997 and 31 December 2012 and the mean pa-
tient age was <18 years at the time of study entry. Studies were excluded if the study size 
was <20 patients. A distinction was made between natural history and surgical cohorts. 
results
Twenty-four studies were included in this review, encompassing a total of 809 natural 
history and 1476 surgical patients. Fifty-one percent of natural history patients required 
surgery. After surgery, there was a substantial reoperation rate. Higher LVOT gradient 
and the presence of aortic regurgitation (AR) were identified as the foremost indepen-
dent predictors of a worse outcome. Valve-to-membrane distance was also found to be 
associated with prognosis, although the results were contradictory. 
conclusions
This systematic review underlines the importance of LVOT gradient, aortic valve-to-
membrane distance and AR in surgical decision-making in paediatric SAS patients. There 
is need for collaborative effort to further study the optimal timing of surgery based on 
LVOT gradient, valve-to-membrane distance and the presence of AR.
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introDuction
Sub-valvular aortic stenosis (SAS) is an important type of left ventricular outflow tract 
(LVOT) obstruction, which is usually progressive 1 and accounts for 8-20% of all forms of 
LVOT obstruction.2 The extent of the malformation varies from a minor fibrous ridge on 
the sub-valvular ventricular septum (discrete SAS, DSAS; 70-80% of cases) to a narrow 
fibromuscular tunnel.2 SAS can exist as an isolated disease, but is in 50-60% of the cases 
associated with other congenital cardiac anomalies.3, 4 The most important and well-
known late complication of SAS is aortic regurgitation (AR), which occurs in >70% of 
discrete SAS patients 5 and is usually progressive. A certain incidence of postoperative 
recurrence of obstruction is also reported in patients with SAS.6 In exceptional cases, 
SAS was suggested to be related to sudden death.7
Patients with a stable peak LVOT gradient of 30 mmHg or less are usually treated 
medically. Similarly to aortic stenosis, an intervention is indicated in patients with a peak 
LVOT gradient of >50 mmHg. In patients with a peak LVOT gradient between 30 and 50, 
surgery is considered based on symptoms, age and rate of disease progression.8
In this setting, timing of surgery remains an issue of dispute. There may be practice varia-
tion, fitting with a lack of treatment guidelines for SAS.9 To prevent progressive valvular 
damage and ventricular hypertrophy, early surgery is proposed by some groups, claim-
ing that younger patients and patients with low LVOT gradients have the best surgical 
outcomes.4, 10 However, other investigators believe that prophylactic intervention has no 
benefits and is therefore not necessary.11
We carried out a systematic review to establish an overview of the natural history and 
outcome after surgery in paediatric SAS patients, and identify factors associated with 
prognosis.
28
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search strategy and selection of studies
To identify prognostic markers in paediatric SAS, we conducted a systematic review ac-
cording to the PRISMA guidelines.12 We carried out a PubMed and EMBASE search with 
the following query: aortic stenosis[MeSH] AND (subaortic[All fields] OR subvalvular[All 
fields] OR subvalvar[All fields]). We limited our search to studies that were conducted in 
humans, published in the last 15 years (1 January 1997-31 December 2012) and written 
in English. We also applied a limit on the mean age of the patients at diagnosis (<18 
years old). If the age at diagnosis was not reported, mean age at surgery <18 years was 
used.
The resulting papers were then screened manually on relevance by two independent 
investigators (Jonathan R.G. Etnel and Laura G. Spaans). Studies were included if they 
reported clinical outcome in patients with SAS. Studies were excluded if the study size 
was <20 patients or if the full text was not available. If there was an overlap in study 
populations, only the most recent or most complete study was included. In case of 
disagreement on including a paper, an agreement was negotiated.
The following baseline variables were recorded: mean age at diagnosis, mean age at 
surgery and last follow-up, gender, SAS-type (discrete or tunnel-type) and the presence 
of concomitant cardiac lesions such as bicuspid aortic valve (AV), ventricular septal 
defect (VSD), atrial septal defect and coarctation of the aorta.
Adverse outcome was defined as overall mortality for the natural history cohort stud-
ies, early (<30 days after surgery) and late mortality for the surgical cohort studies, the 
development and/or presence of AR, AR progression, mitral regurgitation (MR), LVOT 
obstruction progression, surgical intervention, postoperative residual LVOT gradient, 
postoperative arrhythmia, recurrence and reoperation. All reported pressure gradients 
were measured by echocardiography.
Upon inclusion, studies were grouped as follows: (i) studies that reported the natural 
history of SAS and (ii) those that reported the outcomes in surgical patients, the core 
distinction between the two groups being that the natural history studies included 
both surgical and non-surgical patients and the surgical studies included only surgical 
patients. If a natural history study reported the outcomes of their surgical sub-cohort 
separately, the respective sub-cohort was assigned to the surgical study group for data 
pooling.
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statistics
Inverse variance weighted pooling was performed on all patient characteristics and 
outcomes using Microsoft Office Excel 2011 (Microsoft Corp., Redmond, WA, USA). Early 
mortality and postoperative arrhythmia risk and linearized event occurrence rates, ex-
pressed as a percentage per year, were pooled on a logarithmic scale. In case a particular 
event was reported not to occur in an individual study, then for the analyses it was as-
subvalvular[All fields] OR subvalvar[All fields]). We limited our
search to studies that were conducted in humans, published in the
last 15 years (1 January 1997–31 December 2012) and written in
English. We also applied a limit on the mean age of the patients at
diagnosis (<18 years old). If the age at diagnosis was not reported,
mean age at surgery <18 years was used.
The resulting papers were then scre ned manually on relevance
by two independent investigators (Jonathan R.G. Etnel and Laura
G. Spaans). Studies were included if they reported clinical outcome
in patients with SAS. Studies were excluded if the study size was <20
patients or if the full text was not available. If there was an overlap in
study populations, only the most recent or most complete study
was included. In case of disagreement on including a paper, an
agreement was negotiated.
The following baseline variables were recorded: mean age at
diagnosis, mean age at surgery and last follow-up, gender, SAS-type
(discrete or tunnel-type) and the presence of concomitant cardiac
lesions such as bicuspid aortic valve (AV), ventricular septal defect
(VSD), atrial septal defect and coarctation of the aorta.
Adverse outcome was defined as overall mortality for the natural
history cohort studies, early (<30 days after surgery) and late mortal-
ity for the surgical cohort studies, the development and/or presence
of AR, AR progression, mitral regurgitation (MR), LVOT obstruction
progression, surgical intervention, postoper tive r sidual LVOT gra-
dient, postoperative arrhythmia, recurrence and reoperation. All
reported pressure gradients were measured by echocardiography.
Upon inclusion, studies were grouped as follows: (i) studies that
reported the natural history of SAS and (ii) those that reported the
Figure 1: Flowchart of study selection.
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figure 1. Flowchart of study selection.
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sumed that 0.5 patient experienced the event. If means were not reported, medians 
were used as a substitute. When only the range or interquartile range was provided as 
opposed to the standard deviation (SD), the range was divided by 4 and the interquartile 
range was divided by 1.35 as an approximation of the SD. Funnel plots were used to 
investigate publication bias. Heterogeneity among the included studies was analysed 
with both the Cochran Q statistic and the I2 index. Statistical significance was inferred 
at a P < 0.05.
To compare annual mortality rates of the pooled natural history studies with the gen-
eral population, Dutch population death rates for gender-matched 6-year olds were 
obtained from the Central Bureau of Statistics.
results
literature search
Figure 1 illustrates the literature search process. A total of 24 studies, 7 natural history 
and 17 surgical studies, were included in the systematic review. These were all retrospec-
tive cohort studies. Summaries of the characteristics of all included studies are illustrated 
in Table 1. Two of the included natural history studies 13, 14 also reported the outcomes 
of their surgical sub-cohort separately. These results were included in the pooling and 
analysis of the outcomes of the surgical studies. The funnel plots showed evidence of 
possible publication bias with regard to early mortality.
natural history
A total of seven natural history studies met the inclusion criteria.8, 13-18 Table 2 shows the 
pooled patient characteristics of the subjects included in the natural history studies. 
Table 3 shows the pooled outcome measures of the natural history studies. Figure 2 rep-
resents the cumulative incidence of mortality based on the pooled linearized mortality 
rate of the natural history studies compared with the general age- and gender-matched 
population. Table 4 shows an overview of all the reported statistically significant 
independent predictors of surgery, LVOT obstruction progression and AR found by 
multivariable analysis in the included natural history studies. Additionally, McMahon et 
al. 8 identified thin AV leaflets and associated VSD as independent predictors of being a 
low-risk patient (no DSAS surgery, no AR, peak LVOT gradient ≤30 mmHg).
surgical outcome
A total of 17 surgical studies 1, 9, 19-33 were included in this review, and 2 of the included 
natural history studies 13, 14 also reported the outcomes of their surgical sub-cohort 
separately, for a combined total of 19 surgical cohorts. Table 2 shows the patient char-
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acteristics of the subjects included in the surgical studies. Table 5 shows the pooled 
outcome measures of the surgical studies. Figure 2 represents the cumulative incidence 
of mortality and reoperation based on the pooled linearized mortality and reoperation 
rates of the surgical studies. Table 6 shows an overview of all the reported statistically 
significant independent predictors of AV dysfunction, mitral valve (MV) dysfunction, 
table 1. Characteristics of included studies
first author year of 
publication
inclusion 
period
no. of 
patients
age at 
diagnosis 
(years)
Mean follow-
up (years)
natural history
Drolet 2011 1985-1998 74 5.2 ± 0.4 10.4
Lopes 2011 1982-2009 51 15.0 ± 14.0 17.7
Karamlou 2007 1975-1998 313 0.6 ± 4.25 9.1
Babaoglu 2006 1990-2004 78 4.3 ± 4.5 4.8
McMahon 2004 - 220 3.9 ± 12.6 7.2a
Tutar 2000 1993-1998 21 <18 2.1
Bezold 1998 1988-1993 52 - -
total 809
surgical
Van der Linde 2012 1980-2011 313 17.1 ± 14.9b 12.9a
Drolet 2011 1985-1998 49 7.8 ± 0.6b 10.4
Lopes 2011 1982-2009 34 - 17.7
Valeske 2011 1994-2009 81 4.8 ± 4.1 7.5
Booth 2010 1995-2006 48 7.2 ± 6.0b 3.4
Hirata 2009 1990-2007 106 7.2 ± 4.9b 6.9
Dodge-Khatami 2008 1994-2006 58 4.3 ± 3.4b 2.7a
Geva 2007 1984-2001 111 5.4 ± 8.7b 8.2a
Darcin 2006 1995-2001 21 12.6 ± 16.2 3.3
Ruzmetov 2006 1960-2005 140 9.4 ± 4.7b 9.8
Marasini 2003 1994-2000 45 <18 2.0
Cohen 2002 1994-2000 73 9.5 ± 15.3 3.3
Paul 2002 1994-2001 21 - -
Talwar 2001 1990-1998 45 - 5.6
Parry 1999 1992-1996 37 7.5 ± 8.6b 2.3
Serraf 1999 1980-1997 160 10.0 ± 7.5b 13.3a
Lampros 1998 1982-1996 36 7.1 ± 11.6 7.4
Brauner 1997 1982-1995 75 6.0 ± 11.0b 6.7
Rayburn 1997 1980-1994 23 13.3 ± 2.5 3.3
total 1476
‘-’: variable not reported. aMedian follow-up. bAge at surgery.
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table 2. Patient characteristics
study age at
diagnosisa
age at
surgerya
Male
(%)
tunnel-type
(%)
Bicuspid
av (%)
vsD
(%)
asD
(%)
coa
(%)
natural history
Drolet (2011) 5.2 ± 0.4 7.8 ± 0.5 64.9 0.7 13.5 - - -
Lopes (2011) 15.0 ± 14.0 14.0 ± 2.9 54.9 9.8 2.0 9.8 5.9 5.9
Karamlou (2007) 0.6 ± 4.25 3.8 ± 4.7 61.0 0.1 10.9 - - -
Babaoglu (2006) 4.3 ± 4.5 - - - - - - -
McMahon (2004) 3.9 ± 12.6 - 59.1 0.2 25.5 31.8 - 19.5
Tutar (2000) 6.7 ± 3.3 - 66.7 - - 47.6 - -
Bezold (1998) - - - 1.0 23.1 11.5 - 13.5
Pooled total 5.03 (4.95-5.13) 7.72 (7.59-7.85) 60.59 (56.92-64.26) 0.23 (0.00-0.58) 10.68 (8.49-12.88) 21.89 (17.69-26.08) 5.88 (0.00-12.34) 14.01 (10.29-17.74)
I2 99% 100% 0% 32% 92% 90% - 81%
χ2 P-value <0.0001 <0.0001 0.77 0.32 <0.0001 <0.0001 - 0.02
surgical
Van der Linde (2012) 8.0 ± 8.1 17.1 ± 14.9 52.1 - - 23.0 5.8 15.3
Drolet (2011) 4.5 ± 0.4 7.8 ± 0.6 - 1.0 - - - -
Lopes (2011) - - - - - - - -
Valeske (2011) - 4.8 ± 4.1 65.4 - - - - 34.6
Booth (2010) - 7.2 ± 6.0 60.4 - 20.8 - - -
Hirata (2009) - 7.2 ± 4.9 57.5 - - - - -
Dodge-Khatami (2008) - 4.3 ± 3.4 - 3.4 - 29.3 20.7 5.2
Geva (2007) 3.7 ± 8.7 5.4 ± 8.7 61.3 0.5 32.4 23.4 - 13.5
Ruzmetov (2005) - 9.4 ± 4.7 56.4 0.4 - 17.1 6.4 16.4
Darcin (2003) - 12.6 ± 16.2 57.1 - - 28.6 4.8 2.4
Marasini (2003) - 7.3 ± 4.1 57.8 - 20.0 11.1 8.9 15.6
Cohen (2002) - 9.5 ± 15.2 - - - - - -
Paul (2002) - - - - - - - -
Talwar (2001) 8.0 ± 5.3 - 64.4 - - - - -
Parry (1999) - 7.5 ± 8.6 - 1.4 - - - -
Serraf (1999) - 10 ± 7.5 66.9 21.3 - - - -
Lampros (1998) - 7.1 ± 11.6 69.4 - - - - -
Brauner (1997) - 6.0 ± 11.0 58.7 9.3 22.7 - - -
Rayburn (1997) - 13.3 ± 4.5 - - - 13.0 - 8.7
Pooled total 4.56 (4.46-4.68) 7.95 (7.79-8.10) 59.18 (56.40-61.97) 0.90 (0.20-1.62) 25.10 (20.05-30.15) 20.60 (17.65-23.55) 6.61 (4.60-8.62) 12.75 (10.48-15.02)
I2 96% 96% 28% 88% 29% 44% 49% 81%
χ2 P-value <0.0001 <0.0001 0.23 <0.0001 0.37 0.15 0.16 <0.0001
Expressed as: ‘mean ± SD’ and ‘percentage (95% CI)’.
In case a characteristic was reported not to occur, for pooling purposes, it was assumed that the character-
istic was present in 0.5 patient.
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table 2. Patient characteristics
study age at
diagnosisa
age at
surgerya
Male
(%)
tunnel-type
(%)
Bicuspid
av (%)
vsD
(%)
asD
(%)
coa
(%)
natural history
Drolet (2011) 5.2 ± 0.4 7.8 ± 0.5 64.9 0.7 13.5 - - -
Lopes (2011) 15.0 ± 14.0 14.0 ± 2.9 54.9 9.8 2.0 9.8 5.9 5.9
Karamlou (2007) 0.6 ± 4.25 3.8 ± 4.7 61.0 0.1 10.9 - - -
Babaoglu (2006) 4.3 ± 4.5 - - - - - - -
McMahon (2004) 3.9 ± 12.6 - 59.1 0.2 25.5 31.8 - 19.5
Tutar (2000) 6.7 ± 3.3 - 66.7 - - 47.6 - -
Bezold (1998) - - - 1.0 23.1 11.5 - 13.5
Pooled total 5.03 (4.95-5.13) 7.72 (7.59-7.85) 60.59 (56.92-64.26) 0.23 (0.00-0.58) 10.68 (8.49-12.88) 21.89 (17.69-26.08) 5.88 (0.00-12.34) 14.01 (10.29-17.74)
I2 99% 100% 0% 32% 92% 90% - 81%
χ2 P-value <0.0001 <0.0001 0.77 0.32 <0.0001 <0.0001 - 0.02
surgical
Van der Linde (2012) 8.0 ± 8.1 17.1 ± 14.9 52.1 - - 23.0 5.8 15.3
Drolet (2011) 4.5 ± 0.4 7.8 ± 0.6 - 1.0 - - - -
Lopes (2011) - - - - - - - -
Valeske (2011) - 4.8 ± 4.1 65.4 - - - - 34.6
Booth (2010) - 7.2 ± 6.0 60.4 - 20.8 - - -
Hirata (2009) - 7.2 ± 4.9 57.5 - - - - -
Dodge-Khatami (2008) - 4.3 ± 3.4 - 3.4 - 29.3 20.7 5.2
Geva (2007) 3.7 ± 8.7 5.4 ± 8.7 61.3 0.5 32.4 23.4 - 13.5
Ruzmetov (2005) - 9.4 ± 4.7 56.4 0.4 - 17.1 6.4 16.4
Darcin (2003) - 12.6 ± 16.2 57.1 - - 28.6 4.8 2.4
Marasini (2003) - 7.3 ± 4.1 57.8 - 20.0 11.1 8.9 15.6
Cohen (2002) - 9.5 ± 15.2 - - - - - -
Paul (2002) - - - - - - - -
Talwar (2001) 8.0 ± 5.3 - 64.4 - - - - -
Parry (1999) - 7.5 ± 8.6 - 1.4 - - - -
Serraf (1999) - 10 ± 7.5 66.9 21.3 - - - -
Lampros (1998) - 7.1 ± 11.6 69.4 - - - - -
Brauner (1997) - 6.0 ± 11.0 58.7 9.3 22.7 - - -
Rayburn (1997) - 13.3 ± 4.5 - - - 13.0 - 8.7
Pooled total 4.56 (4.46-4.68) 7.95 (7.79-8.10) 59.18 (56.40-61.97) 0.90 (0.20-1.62) 25.10 (20.05-30.15) 20.60 (17.65-23.55) 6.61 (4.60-8.62) 12.75 (10.48-15.02)
I2 96% 96% 28% 88% 29% 44% 49% 81%
χ2 P-value <0.0001 <0.0001 0.23 <0.0001 0.37 0.15 0.16 <0.0001
Expressed as: ‘mean ± SD’ and ‘percentage (95% CI)’.
In case a characteristic was reported not to occur, for pooling purposes, it was assumed that the character-
istic was present in 0.5 patient.
‘-’: variable not reported; AV: aortic valve; ASD: atrial septal defect; CoA: coarctation of the aorta; FUP: fol-
low-up; VSD: ventricular septal defect.
aAge in years.
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recurrence and reoperation found by multivariable analysis in the included surgical 
studies. Additionally, Serraf et al. 9 found preoperative NYHA functional class to be an 
independent predictor of early mortality. When viewing overall mortality rate, hypoplas-
tic aortic annulus and mitral stenosis were both identified as independent risk factors. 
Also, Parry et al. 20 identified higher preoperative peak LVOT gradient as an independent 
predictor of higher residual early postoperative peak LVOT gradient.
table 3. Outcome measures of natural history studies
study surgery (%) Mortality (%/year)
Drolet (2011) 66.2 (55.4-77.0) 0.06 (0.00-0.63)
Lopes (2011) 66.7 (53.7-79.6) -
Karamlou (2007) 50.8 (45.3-56.3) 0.14 (0.12-0.36)
Babaoglu (2006) 30.8 (20.5-41.0) -
McMahon (2004) 49.5 (42.9-56.2) 0.06 (0.03-0.36)
Tutar (2000) 47.6 (26.3-69.0) 1.13 (0.02-11.02)
Bezold (1998) - -
Pooled total 50.81 (47.31-54.31) 0.12 (0.02-0.78)
I2 87% 0%
χ2 P-value 0.0002 1.00
Expressed as percentage (95% CI).
In case an event was reported not to occur, for pooling purposes it was assumed that 0.5 patient experi-
enced the event.
‘-’: variable not reported.
represents the cumulative incidence of mortality based on the
pooled linearized mortality rate of the natural history studies com-
pared with the general age- and gender-matched population.
Table 4 shows an overview of all the reported statistically signifi-
cant independent predictors of surgery, LVOT obstruction pro-
gression and AR found by multivariable analysis in the included
natural history studies. Additionally, McMahon et al. [8] identified
thin AV leaflets and associated VSD as independent predictors of
being a low-risk patient (no DSAS surgery, no AR, peak LVOT gra-
dient ≤30 mmHg).
Surgical outcome
A total of 17 surgical studies [1, 9, 19–33] were included in this
review, and 2 of the included natural history studies [13, 14] also
reported the outcomes of their surgical sub-cohort separately, for
a combined total of 19 surgical cohorts. Table 2 shows the patient
characteristics of the subjects included in the surgical studies.
Table 5 shows the pooled outcome measures of the surgical studies.
Figure 2 represents the cumulative incidence of mortality and reo-
peration based on the pooled linearized mortality and reoperation
rates of the surgical studies. Table 6 shows an overview of all the
reported statistically significant independent predictors of AV dys-
function, mitral valve (MV) dysfunction, recurrence and reoperation
found by multivariable analysis in the included surgical studies.
Additionally, Serraf et al. [9] found preoperative NYHA functional
class to be an independent predictor of early mortality. When
viewing overall mortality rate, hypoplastic aortic annulus and mitral
stenosis were both identified as independent risk factors. Also, Parry
et al. [20] identified higher preoperative peak LVOT gradient as an
independent predictor of higher residual early postoperative peak
LVOT gradient.
DISCUSSION
This systematic review provides an overview of published data on
the natural history of paediatric SAS and outcome after surgery,
and identifies several determinants of prognosis in paediatric
cases of SAS, including factors that are helpful in establishing surgi-
cal indications in these patients.
Natural history
This systematic review shows that SAS usually presents before the
age of 10 years and 60% concerns males. Associated cardiac
anomalies appear to be less common than previously reported
[3, 4]. The progressive nature of the disease is underlined by the
common need for surgery in half of the included patients. Mortality
rates are slightly higher than in the age- and gender-matched
general population.
Left ventricular outflow tract gradient. Five of the seven
included natural history studies [8, 13–15, 17] confirm that a higher
LVOT gradient at diagnosis is an independent predictor of various
adverse outcomes such as AR, faster AR progression, faster
progression of LVOT obstruction and surgical intervention. One of
the other studies [16] found that the peak LVOT gradient was
significantly higher in patients with progressive AR than in those
whose AR showed no signs of progression, but did not perform
multivariable analyses on their data. The observation that LVOT
outflow tract obstruction severity is correlated with AR progression
provides important information for prognostication and clinical
decision-making.
Table 3: Outcome measures of natural history studies
Study Surgery (%) Mortality (%/year)
Drolet (2011) 66.2 (55.4–77.0) 0.06 (0. 0–0.63)
Lopes (2011) 66.7 (53.7–79.6) –
Karamlou (2007) 50.8 (45.3–56.3) 0.14 (0.12–0.36)
Babaoglu (2006) 30.8 (20.5–41.0) –
McMahon (2004) 49.5 (42.9–56.2) 0.06 (0.03–0.36)
Tutar (2000) 47.6 (26.3–69.0) 1.13 (0.02–11.02)
Bezold (1998) – –
Pooled total 50.81 (47.31–54.31) 0.12 (0.02–0.78)
I2 87% 0%
χ2 P-value 0.0002 1.00
Expressed as percentage (95% CI).
In case an event was reported not to occur, for pooling purposes it was
assumed that 0.5 patient experienced the event.
‘–’: variable not reported.
Figure 2: Cumulative incidence of death and reoperation extrapolated from meta-analysis.
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figure 2. Cumulative incidence of death and reoperation extrapolated from meta-analysis.
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table 4. Significant independent predictors found by multivariable analysis in the natural history studies
author/year 
of publication
Predictors of 
surgery
Predictors of lvoto 
progression
Predictors of ar lvot gradient cut-
off values
Drolet (2011) ↑ preoperative 
peak LVOT gradient, 
presence of 
preoperative AR
- - -
Lopes (2011) - - Peak LVOT 
gradient >50 
mmHg at 
diagnosis, ↑ left 
ventricular mass
50 mmHg peak
Karamlou 
(2007)
↑ mean LVOT gradient 
at diagnosis, ↑ “ mean 
LVOT gradient at 
diagnosis, “
Mean LVOT gradient >30 
mmHg at diagnosis, initial 
aortic valve thickening, 
attachment of SAS to the 
mitral valve
↑ AR progression: 
Mean LVOT 
gradient >30 
mmHg, ↑ time 
from diagnosis
30 mmHg mean
McMahon 
(2004)
- - ≥Moderate 
AR: peak LVOT 
gradient ≥50 
mmHg at 
diagnosis, age ≥17 
years at diagnosis
50 mmHg peak
Bezold (1998) - ↑ initial peak LVOT 
gradient (mmHg), anterior 
MV leaflet involvement, ↓ 
end-diastolic indexed
AV-to-membrane distance
- (non-progressive) 
<20 mmHg 
<(intermediate) 
<40 mmHg 
<(progressive) peak
AV: aortic valve; AR: aortic regurgitation; LVOT(O): left ventricle outflow tract (obstruction); MV: mitral valve.
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table 5. Outcome measures of surgical studies
study early mortality (%) late mortality (%/
year)
reoperation (%/
year)
Postoperative 
arrhythmia (%)
Van der Linde (2012) 0.3 (0.2-1.8) 0.2 (0.2-0.3) 1.4 (1.4-1.8) 5.4 (5.3-8.7)
Drolet (2011) 1.0 (0.0-9.9) 0.2 (0.0-1.6) 3.3 (3.1-6.1) 6.1 (5.1-18.1)
Lopes (2011) - - 1.3 (1.2-2.6) 23.5 (22.1-46.6)
Valeske (2011) 1.2 (0.6-7.1) 0.1 (0.0-0.8) 4.1 (4.0-6.1) 11.1 (10.5-21.2)
Booth (2010) 1.0 (0.0-10.1) 0.3 (0.0-3.0) 4.3 (4.0-8.9) -
Hirata (2009) 0.9 (0.5-5.4) 0.1 (0.1-0.8) 1.1 (1.0-2.2) -
Dodge-Khatami (2008) 0.9 (0.0-8.4) 0.6 (0.3-3.6) 7.0 (6.7-12.6) 1.7 (0.9-9.9)
Geva (2007) - - 1.8 (1.7-2.9) -
Ruzmetov (2005) 2.9 (2.5-7.4) 0.3 (0.3-0.9) 1.1 (1.1-1.8) -
Darcin (2003) 2.4 (0.0-23.1) 0.7 (0.0-7.0) 2.9 (2.2-10.6) 9.5 (7.2-35.0)
Marasini (2003) 1.1 (0.0-10.8) 0.6 (0.0-5.4) 1.1 (0.6-6.4) -
Cohen (2002) 0.6 (0.0-6.7) 0.2 (0.0-2.0) 3.3 (3.1-6.6) -
Paul (2002) - - - -
Talwar (2001) 1.1 (0.0-10.8) 0.2 (0.0-1.9) - -
Parry (1999) 1.4 (0.0-13.1) 0.6 (0.0-5.8) 0.6 (0.0-2.3) -
Serraf (1999) 3.1 (2.8-7.4) 0.2 (0.2-0.5) - -
Lampros (1998) 1.4 (0.0-13.5) 0.2 (0.0-1.8) 3.8 (3.6-6.9) -
Brauner (1997) 0.7 (0.0-6.5) 0.1 (0.0-1.0) 2.6 (2.5-4.4) 1.3 (0.7-7.6)
Rayburn (1997) 2.2 (0.0-21.1) 1.3 (0.7-7.5) 2.6 (2.0-9.6) 13.0 (10.9-38.6)
Pooled total 2.05 (0.61-6.41) 0.22 (0.09-0.55) 2.04 (1.52-2.62) 7.66 (3.60-13.57)
I2 0% 0% 61% 67%
χ2 P-value 0.95 1.00 0.001 0.007
Expressed as percentage (95% CI).
In case an event was reported not to occur, for pooling purposes it was assumed that 0.5 patient experi-
enced the event.
‘-’: variable not reported.
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table 6. Significant independent predictors found by multivariable analysis in the surgical studies
author/year 
of publication
Predictors of av/Mv dysfunction Predictors of recurrence/
reoperation
lvot gradient 
cut-off values
Van der Linde 
(2012)
≥Moderate postoperative AR: 
preoperative peak LVOT gradient 
≥80 mmHg
Reoperation: Female gender, ↑ 
LVOTO progression, preoperative 
peak LVOT gradient ≥80 mmHg, ↑ 
difference between preoperative and 
postoperative gradients
80 mmHg peak
Drolet (2011) - - -
Lopes (2011) Recurrence: Peak LVOT gradient >50 
mmHg at diagnosis, ↓ time from 
diagnosis to surgery
50 mmHg peak
Booth (2010) - Recurrence: ↓ Age at surgery
Hirata (2009) - Recurrence: ↓ Age at surgery, ↑ 
preoperative peak LVOT gradient, 
resection without myectomya
Reoperation: Associated CoA, 
resection without myectomya
Dodge-
Khatami (2006)
- No independent predictors identified -
Geva (2007) - Recurrence: Diastolic AV-to-
membrane distance <5 mm and 
associated Shone’s syndrome.
Reoperation: Systolic AV-to-
membrane distance <6 mm and peak 
LVOT gradient ≥60 mmHg
60 mmHg peak
Ruzmetov 
(2005)
- No independent predictors identified -
Paul (2002) MR: Diastolic indexed AV-to-
membrane distance ≥8 mm/m
- -
Talwar (2001) - - -
Parry (1999) ≥Mild early postoperative AR: ↑ 
preoperative peak LVOT gradient, 
mild/moderate preoperative AR
≥Mild late postoperative AR: ≥mild early 
postoperative AR, ↑ early postoperative 
peak LVOT gradient
- -
Serraf (1999) - Recurrence and Reoperation: ↑ Early 
postoperative peak-to-peak LVOT 
gradient, aortic coarctation
-
Brauner (1997) Postoperative AR progression: ↑ 
preoperative peak LVOT gradient
Recurrence: ↓ Age, preoperative 
gradient, residual end-operative peak 
LVOT gradient >10 mmHg, tunnel- 
type stenosis.
•	 	Only	in	DSS:	↑ preoperative peak 
LVOT gradient.
Late reoperation: ↑ preoperative peak 
LVOT gradient
40 mmHg peak
aOnly in patients who underwent previous cardiac operations.
AV: aortic valve; AR: aortic regurgitation; LVOT(O): left ventricle outflow tract (obstruction); MR: mitral regur-
gitation; MV: mitral valve; CoA: coarctation of the aorta.
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Discussion
This systematic review provides an overview of published data on the natural history 
of paediatric SAS and outcome after surgery, and identifies several determinants of 
prognosis in paediatric cases of SAS, including factors that are helpful in establishing 
surgical indications in these patients.
natural history
This systematic review shows that SAS usually presents before the age of 10 years and 
60% concerns males. Associated cardiac anomalies appear to be less common than pre-
viously reported.3, 4 The progressive nature of the disease is underlined by the common 
need for surgery in half of the included patients. Mortality rates are slightly higher than 
in the age- and gender-matched general population.
Left ventricular outflow tract gradient
Five of the seven included natural history studies 8, 13-15, 17 confirm that a higher LVOT gra-
dient at diagnosis is an independent predictor of various adverse outcomes such as AR, 
faster AR progression, faster progression of LVOT obstruction and surgical intervention. 
One of the other studies 16 found that the peak LVOT gradient was significantly higher 
in patients with progressive AR than in those whose AR showed no signs of progression, 
but did not perform multivariable analyses on their data. The observation that LVOT 
outflow tract obstruction severity is correlated with AR progression provides important 
information for prognostication and clinical decision-making.
Valve-to-membrane distance
Although the sub-valvular obstruction may be a complex 3D structure that does not 
necessarily encircle the LVOT, a level can often be identified to allow measurement of 
its distance to the AV. Interestingly, two studies 8, 15 found a longer distance of the sub-
valvular obstruction from the base of the AV to be associated with less progressive LVOT 
obstruction and potentially predictive of being a low-risk patient (no DSAS surgery, no 
AR, peak LVOT gradient ≤30 mmHg). However, based on the earlier echocardiographic 
studies on this factor reporting contradictory findings, the prognostic role of this factor 
remains controversial.34, 35
surgical outcome
The patient characteristics of the surgical population were similar to those of the natural 
history cohort with respect to age at presentation, gender distribution and the relatively 
low incidence of concomitant cardiac anomalies when compared with earlier reports 3, 4. 
On average, the patients underwent surgery ~3 years after diagnosis with low operative 
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mortality and late mortality rates slightly higher than in the age- and gender-matched 
general population, but with a significant reoperation rate.
Left ventricular outflow tract gradient
In 7 of the 19 surgical (sub)cohorts,9, 19, 20, 24, 26, 28 higher LVOT gradient (at diagnosis, 
pre- and postoperative) was identified as an independent predictor of various adverse 
postoperative outcomes such as postoperative AR, faster AR progression, MR, postop-
erative residual LVOT gradient, faster progression of LVOT obstruction, recurrence and 
reoperation. Two additional studies 21, 25 found a higher LVOT gradient to be associated 
with a worse outcome. However, in these studies, these associations did not reach sta-
tistical significance in multivariable analysis.
In short, a higher LVOT gradient has serious consequences, in both medically and surgi-
cally managed patients, which negatively affect the prognosis and are often irreversible. 
Our review confirms the general consensus of the LVOT gradient being an important 
criterion, when considering surgical treatment of SAS.
There is an ongoing discussion on which LVOT gradient can best be used as a cut-off 
value to discriminate between low- and high-risk patients. Among the included studies, 
the used cut-off value ranged from 30 to 80 mmHg. Brauner et al.,19 for instance, used 
a cut-off value of 40 mmHg in their statistical analyses, but retrospectively conducted 
an ROC sensitivity analysis to determine LVOT gradients that best predicted outcome. 
They found the best preoperative peak LVOT gradient cut-off values in prediction of 
recurrence, reoperation and late progression of AV disease to be 45, 46 and 46 mmHg, 
respectively. Based on these results, further collaborative studies are needed to evaluate 
the optimal cut-off value in the use of LVOT gradient as an indication for surgery.
Aortic regurgitation
One study 20 showed that the presence of AR, regardless of severity, in SAS patients, 
either at diagnosis, preoperatively or at early or late follow-up, was a significant predic-
tor of AR at a later point in the follow-up. One natural history study 13 found that the 
presence of AR preoperatively was predictive of surgical intervention. Thus, AR is a major 
sequela in SAS patients with significant prognostic implications and should therefore 
play an integral role in the surgical decision-making process.
Valve-to-membrane distance
The prognostic relevance of the valve-to-membrane distance was illustrated by the 
aforementioned natural history studies. However, we came upon a dilemma in the 
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potential use of the valve-to-membrane distance as a prognostic marker. Paul et al. 22 
found a longer valve to-membrane distance to be predictive of MR.
On the contrary, Geva et al. 24 and the two natural history studies 8, 15 found a shorter 
valve-to-membrane distance to be prognostically unfavourable, which would suggest 
earlier surgical intervention be considered in patients with a shorter valve-to-membrane 
distance, as opposed to the results reported by Paul et al. 22 However, none of these 
three studies looked into MV function, as Paul et al. 22 did.
On the basis of these contradicting findings, we are unable to formulate clear surgical 
advice with regard to the valve-to-membrane distance, as both high and low values of 
this variable seem to have adverse effects on the course of the disease. Further scientific 
studies on the precise prognostic impact of the valve-to-membrane distance are war-
ranted, as they may clarify the value of this potentially relevant factor.
Other than these foremost prognostic indicators, there are many other factors to con-
sider when contemplating surgical intervention such as patient age, MV involvement, 
AV/MV annulus size, thickness of the AV leaflets and concomitant cardiac anomalies. 
As our results show, all of these factors further influence outcome in SAS patients and 
should, therefore, beweighed into the decision-making process.
study limitations
This is a systematic review of retrospective observational studies. As such, the inherent 
limitations of combining data from retrospective observational studies should be taken 
into consideration.36-38 For this reason, no sub-group analyses or meta-regression was 
attempted.
conclusions
This systematic review underlines the importance of LVOT gradient in surgical decision-
making in paediatric SAS patients; the majority of the included studies found a higher 
LVOT gradient to be associated with adverse outcome. The presence of AR and the 
valve-to-membrane distance should also be taken into consideration as prognostic 
determinants in these patients. Given the small sample size of most series, there is need 
for collaborative effort to further study the optimal timing of surgery based on LVOT 
gradient, the presence of AR and to further investigate the predictive role of the valve-
to-membrane distance.
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aBstract
Background
Despite an increasing interest in pediatric aortic valve repair, aortic valve replacement 
in children may be unavoidable. The evidence on outcome after pediatric aortic valve 
replacement is limited and usually reported in small case series. This systematic review 
and meta-analysis aims to provide an overview of reported outcome of pediatric pa-
tients after aortic valve replacement.
Methods
A systematic literature search for publications reporting outcome after pediatric aortic 
valve replacement published between January 1990 and May 2015 was conducted. 
Studies written in English with a study size of more than 30 patients were included.
results
Thirty-four publications reporting on 42 cohorts were included in this review: 26 con-
cerning the Ross procedure (n = 2409), 13 concerning mechanical prosthesis aortic valve 
replacement (n = 696), and 3 concerning homograft aortic valve replacement (n = 224). 
There were no studies on bioprostheses that met our inclusion criteria. The pooled mean 
patient age was 9.4 years, 12.8 years, and 8.9 years for Ross, mechanical prosthesis, and 
homograft recipients, respectively. Pooled mean follow-up was 6.6 years. The Ross pro-
cedure was associated with lower early (4.20%; 95% confidence interval [CI], 3.37-5.22 
vs 7.34%; 95% CI, 5.21-10.34 vs 12.82%; 95% CI, 8.91-18.46) and late mortality (0.64%/y; 
95% CI, 0.49-0.84 vs 1.23%/y; 95% CI, 0.85-1.79 vs 1.59%/y; 95% CI, 1.03-2.46) compared 
with mechanical prosthesis aortic valve replacement and homograft aortic valve re-
placement, respectively. No significantly different aortic valve reoperation rates were 
observed between the Ross procedure and mechanical prosthesis aortic valve replace-
ment (1.60%/y; 95% CI, 1.27-2.02 vs 1.07%/y; 95% CI, 0.68-1.68, respectively), whereas 
homograft aortic valve replacement was associated with significantly higher aortic valve 
reoperation rates (5.44%/y; 95% CI, 4.24-6.98). The Ross procedure-associated right ven-
tricular outflow tract reoperation rate was 1.91% per year (95% CI, 1.50-2.44).
conclusions
This systematic review illustrates that all currently available aortic valve substitutes are 
associated with suboptimal results in children, reflecting the urgent need for reliable 
and durable repair techniques and innovative replacement solutions for this challeng-
ing group of patients.
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introDuction
Although pediatric aortic valve repair is rapidly developing and meets great interest, 
aortic valve replacement (AVR) often cannot be avoided. The outcome after AVR in pedi-
atric patients is reported infrequently and usually in small retrospective case series. All 
currently available surgical options in children have certain limitations, and the choice of 
valve substitute is determined by several factors. In addition to the occurrence of valve-
related complications,1 the influence of patient growth has a major impact on valve 
performance in children. In current clinical practice, 4 types of aortic valve substitutes 
can be offered to children who require AVR: the Ross procedure, mechanical prostheses 
(MPs), homografts (HGs), and bioprostheses. The Ross procedure (a pulmonary autograft 
in the aortic valve position and an allograft in the pulmonary position) is considered the 
preferred surgical option for children who require AVR.2,3 It is the only living valve sub-
stitute and has proven to be hemodynamically superior without the need for long-term 
anticoagulation, shows diameter increase along with somatic growth, and is associated 
with a low risk of endocarditis.4,5 Nevertheless, the Ross procedure is a complex surgi-
cal procedure, and both the pulmonary autograft and the valve substitute in the right 
ventricular outflow tract (RVOT) may require reintervention.6 The primary advantage of 
MPs is long-term performance. However, in addition to bleeding complications due to 
lifelong anticoagulation, prosthesis-patient mismatch (PPM) can cause deterioration of 
ventricular function in growing children.7-11 Furthermore, female patients with mechani-
cal heart valves face a substantial risk of serious complications during future pregnan-
cies.12 HGs have a low thrombogenicity and favorable tissue characteristics that allow for 
complex reconstruction of the aortic root, but have a limited durability because of early 
calcifications and may not be readily available.8,13,14 Bioprostheses have the advantage 
of commercial availability and assumingly perform similar to HGs; however, high rates 
of early degeneration, calcification, and structural failure have been reported in young 
recipients.8,9,15-18
The balance of the risks and benefits of the various pediatric AVR alternatives remains 
a point of discussion, and an overview of reported outcomes is lacking. Therefore, the 
aim of this systematic literature review and metaanalysis is to provide an overview of 
the published evidence reporting outcomes after contemporary pediatric AVR with 
pulmonary autografts, MPs, HGs, and bioprostheses.
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search strategy
To establish an overview of published evidence on outcome after pediatric AVR, we 
conducted a systematic review according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses guidelines.19 On March 19, 2015, PubMed and Embase 
were searched (Supplement 1). The search was limited to studies that included 30 or 
more patients, were conducted in humans, were published after January 1, 1990, and 
were written in English. We also applied a limit on mean patient age (<18 years) and 
maximum patient age (<21 years) at the time of surgery. All results were screened for 
study design and outcome (early and late mortality, reoperations, and complications). 
Only the most recent or most complete study was included in case study populations 
were overlapping. A second independent reviewer (MMM) assessed whether inclusion 
and exclusion were performed correctly. In case of disagreement, an agreement was ne-
gotiated. References of selected articles were cross-checked for other relevant studies.
Data extraction
Microsoft Office Excel 2011 (Microsoft Corp, Redmond, Wash) was used for data extrac-
tion. Publications were categorized by prosthetic valve type: Ross procedure, MP AVR, 
HG AVR, and bioprosthetic AVR. Studies describing more than 1 type of AVR procedure 
were included as separate cohorts according to the type of AVR procedure performed. 
Studies that included only infants and neonates were pooled separately. Year of pub-
lication, number of patients, study design, and follow-up (patient-years and mean/
median follow-up) were recorded as study characteristics. If follow-up was not reported 
in patient-years, mean or median follow-up was multiplied by the reported number of 
patients. The following baseline patient characteristics were recorded: mean age at time 
of AVR, gender, indication for AVR surgery, previous cardiac interventions, concomitant 
procedures, and annular enlargement procedures. The indication for surgery was catego-
rized by cause of valve disease (eg, congenital, rheumatic, and endocarditis). Morbidity 
and mortality were documented according to the guidelines as described by Akins and 
colleagues.20 The following events were documented: early mortality (%), late mortality 
(%/year), reoperation (%/year), and complications (%/year). Early mortality was defined 
as death within 30 days after AVR, and late mortality was defined as death after 30 days 
postoperatively. All reoperations after initial AVR, including percutaneous interventions, 
were registered. Reoperations were divided into aortic valve reoperations and for the 
Ross procedure RVOT reoperations. A distinction was made between all-cause reop-
erations and reoperations for structural valve deterioration (SVD)/ nonstructural valve 
dysfunction (NSVD). Reoperations for neoaortic root dilatation/aneurysm after the Ross 
procedure were recorded as reoperations for SVD/NSVD. The following complications 
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occurring more than 30 days after AVR were documented: thromboembolism (TE)/valve 
thrombosis (VT), bleeding, and endocarditis.20 Functional health status measured by the 
New York Heart Association (NYHA) classification was registered when described in the 
study.
statistical analyses
Weighted pooled baseline patient characteristics were calculated for each prosthetic 
valve type group. The Student t test and the chi-square test were used to test for differ-
ences in continuous and categoric baseline characteristics, respectively. Early mortality 
risk and linearized occurrence rates of late mortality, sudden unexpected and unex-
plained death, reoperations, and complications after AVR were calculated and pooled 
with the use of inverse variance weighting on a logarithmic scale, because the Shapiro-
Wilk test revealed a significantly skewed distribution among the included studies in the 
majority of outcome measures. When the number of studies was sufficiently large to 
reliably estimate the tau-squared statistic (≥4 studies), a random effects model was used 
to estimate pooled effects. When estimating pooled effects from less than 4 studies, a 
fixed effects model was used. In case a particular event was reported not to occur in an 
individual study, then for the purpose of the analyses it was assumed that 0.5 patient 
experienced an event. The Cochran Q statistic and the I2 test were used to assess hetero-
geneity. Potential causes of heterogeneity were explored by investigating the effect of 
year of first inclusion, mean follow-up duration, and case mix. Funnel plots were used 
to investigate publication bias. Statistical analyses were performed in Microsoft Office 
Excel 2011 (Microsoft Corp), IBM SPSS Statistics (version 21.0.0.1. IBM Corp, Armonk, NY), 
and the R statistical software (version 3.1.0. R Development Core Team, R Foundation for 
Statistical Computing, Vienna, Austria) using the metafor package. The authors had full 
access to and take full responsibility for the integrity of the data.
results
The search resulted in 1218 publications after removal of duplicates. After applying in-
clusion and exclusion criteria, a total of 34 publications were included in the systematic 
review, reporting on 42 cohorts: 26 concerning the Ross procedure (n = 2409),11,13,16,21-43 
13 concerning MP-AVR (n = 696),15,16,23,31,44-52 and 3 concerning HG-AVR (n = 224)13,23,53 
(Figure 1). There were no studies on bioprosthetic AVR that met our inclusion criteria, 
because all of them had a sample size of less than 20 patients. This systematic review 
encompasses a total of 3329 patients with 21,110 patient-years of follow-up.
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study characteristics and baseline patient characteristics
Table 1 provides an overview of the publications included in the present study. Pooled 
mean follow-up was 6.6 years. Indication for AVR was mainly congenital heart disease. 
By excluding studies that included only neonates and infants, the pooled mean age was 
9.5 ± 4.9 years (range, 5.17-14.0 years) for the Ross procedure, 12.8 ± 3.6 years (range, 
9.0-16.6 years) for MP-AVR, and 8.9 ± 4.1 years (range, 4.9-12.5 years) for HG-AVR.
When comparing patients undergoing the Ross procedure (excluding studies that 
included only neonates and infants) with patients undergoing MP-AVR, patients un-
dergoing the Ross procedure were significantly younger (P<.001), less frequently had 
rheumatic valve disease (19.2% vs 36.1%, P <.001), and more frequently had undergone 
previous cardiac interventions (56.8%vs 47.6%, P = .001), whereas the number of con-
comitant procedures (27.7% vs 26.0%, P = .480) and annular enlargement procedures 
(19.3% vs 16.5%, P = .127) was comparable between the 2 groups. Paucity of baseline 
patient data in the HG-AVR group precluded pooled analysis.
study outcomes
Pooled outcome measures (mortality, reoperations, and complications) after the Ross 
procedure in the general pediatric patient population are shown in Table 2, and for neo-
nates and infants, these are shown in Table 3. Pooled outcome measures after MP-AVR 
and HG-AVR are shown in Tables 4 and 5, respectively. In studies reporting on postopera-
tive NYHA functional class (n = 13),11,21,28,31,32,34,36,37,41,42,45,47,49 93% of the patients were in 
NYHA class I at last follow-up.
Heterogeneity and publication bias
Significant heterogeneity was found in the pooling of reoperation rates after the Ross 
procedure and MP-AVR and endocarditis rates after the Ross procedure.With regard to 
reoperations on the aortic valve after the Ross procedure, an outlier in mean follow-up22 
was identified as an isolated source of heterogeneity. Likewise, an outlier in inclusion 
period13 caused heterogeneity in endocarditis rates after the Ross procedure. Heteroge-
neity in aortic valve reoperation rates after MP-AVR was also caused by a single outlier,48 
although we were unable to identify any explanatory study or patient characteristics. 
Exploratory exclusion of these studies eliminated significant heterogeneity but did not 
cause a major change in the pooled estimates.
We were unable to identify the cause of heterogeneity in RVOT reoperations after the 
Ross procedure. The funnel plots showed evidence of possible publication bias in all 
outcome measures (Supplement 2). Smaller studies with relatively high event rate esti-
mates seemed less likely to be published.
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theNewYorkHeart Association (NYHA) classificationwas registeredwhen
described in the study.
Statistical Analyses
Weighted pooled baseline patient characteristics were calculated for
each prosthetic valve type group. The Student t test and the chi-square
test were used to test for differences in continuous and categoric baseline
characteristics, respectively. Early mortality risk and linearized occurrence
rates of late mortality, sudden unexpected and unexplained death,
reoperations, and complications after AVR were calculated and pooled
with the use of inverse variance weighting on a logarithmic scale, because
the Shapiro–Wilk test revealed a significantly skewed distribution among
the included studies in the majority of outcome measures. When the
number of studies was sufficiently large to reliably estimate the tau-
squared statistic (�4 studies), a random effects model was used to estimate
pooled effects. When estimating pooled effects from less than 4 studies, a
fixed effects model was used. In case a particular event was reported not to
occur in an individual study, then for the purpose of the analyses it was
assumed that 0.5 patient experienced an event. The Cochran Q statistic
and the I2 test were used to assess heterogeneity. Potential causes of
heterogeneity were explored by investigating the effect of year of first
inclusion, mean follow-up duration, and case mix. Funnel plots were
used to investigate publication bias. Statistical analyses were performed
in Microsoft Office Excel 2011 (Microsoft Corp), IBM SPSS Statistics
(version 21.0.0.1. IBM Corp, Armonk, NY), and the R statistical software
(version 3.1.0. R Development Core Team, R Foundation for Statistical
Computing, Vienna, Austria) using the metafor package. The authors had
full access to and take full responsibility for the integrity of the data.
RESULTS
The search resulted in 1218 publications after removal of
duplicates. After applying inclusion and exclusion criteria,
a total of 34 publications were included in the systematic
review, reporting on 42 cohorts: 26 concerning the Ross
procedure (n ¼ 2409),11,13,16,21-43 13 concerning MP-AVR
(n ¼ 696),15,16,23,31,44-52 and 3 concerning HG-AVR
(n ¼ 224)13,23,53 (Figure 1). There were no studies on
bioprosthetic AVR that met our inclusion criteria, because
all of them had a sample size of less than 20 patients.
This systematic review encompasses a total of 3329 patients
with 21,110 patient-years of follow-up.
Study Characteristics and Baseline Patient
Characteristics
Table 1 provides an overview of the publications included
in the present study. Pooled mean follow-up was 6.6 years.
Indication for AVRwas mainly congenital heart disease. By
excluding studies that included only neonates and infants,
the pooled mean age was 9.5 � 4.9 years (range,
5.17-14.0 years) for the Ross procedure, 12.8 � 3.6 years
(range, 9.0-16.6 years) for MP-AVR, and 8.9 � 4.1 years
(range, 4.9-12.5 years) for HG-AVR.
When comparing patients undergoing the Ross procedure
(excluding studies that included only neonates and infants)
with patients undergoing MP-AVR, patients undergoing the
Ross procedure were significantly younger (P<.001), less
frequently had rheumatic valve disease (19.2% vs 36.1%,
P < .001), and more frequently had undergone previous
cardiac interventions (56.8% vs 47.6%, P¼ .001), whereas
the number of concomitant procedures (27.7% vs 26.0%,
P ¼ .480) and annular enlargement procedures (19.3% vs
16.5%, P ¼ .127) was comparable between the 2 groups.
Paucity of baseline patient data in the HG-AVR group
precluded pooled analysis.
Study Outcomes
Pooled outcome measures (mortality, reoperations, and
complications) after the Ross procedure in the general
pediatric patient population are shown in Table 2, and
for neonates and infants, these are shown in Table 3.
Pooled outcome measures after MP-AVR and HG-AVR
are shown in Tables 4 and 5, respectively. In studies
reporting on postoperative NYHA functional class
(n ¼ 13),11,21,28,31,32,34,36,37,41,42,45,47,49 93% of the
patients were in NYHA class I at last follow-up.
Heterogeneity and Publication Bias
Significant heterogeneity was found in the pooling of
reoperation rates after the Ross procedure and MP-AVR
FIGURE 1. Flowchart of study selection.
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ross procedure
Gerosa 1991 43 Retrospective 6.9 14 - 34.9 14.0 -
Reddy 1998 41 Retrospective 2.6 7.8# Congenital 80.5 56.1 29.3
Elkins 2001 178 Retrospective 5.2# 9.6 - 51.1 23.0 6.2
Simon 2001 30 Retrospective 4.3 11.3 Congenital - - 0.0
Hazekamp 2005 53 Retrospective 5.5 9.2 Congenital 69.8 24.5 5.7
Bohm 2006 60 Retrospective 3.5 12.6 Congenital 65.0 21.7 6.7
Kalavrouziotis 2006 35 Retrospective 4.1 10.6 - 85.7 - 0.0
Ruzmetov 2006 81 Retrospective 5.3 5.3 - - - -
Stewart 2007 46 Retrospective 5.4 12.9 Congenital - 15.2 0.0
Kadner 2008 52 Retrospective 3.6# 5.2 - 65.4 21.2 30.8
Alsoufi 2009 215 Retrospective 5.7 11.4 Rheumatic - - 14.9
El Behery 2009 41 Retrospective 6 10.2 Congenital - 24.4 -
Piccardo 2009 55 Retrospective 5.5 10 Congenital - 12.7 16.4
Charitos 2012 263 Prospective 6.9 8 Congenital 53.6 - -
Talwar 2012 36 Retrospective 7.9 11.3 - - 27.8 -
Woods (age<1 y) 2012 145 Retrospective - - (<1) - - - -
Elder (age<1 y) 2013 34 Retrospective 10.6 0.5 Congenital - - -
Khan 2013 68 Retrospective 6.7 5.9# - - - 23.5
Ruzmetov 2013 78 Retrospective 8.8 11.1 Congenital - 29.5 23.1
Tan Tanny 2013 100 Retrospective 7.3 8.6 Congenital - 29.0 29.0
Luciani 2014 305 Retrospective 8.4 9.4 - 30.4 29.2 23.9
Luciani (age<1 y) 2014 37 Retrospective 8.4 0.3 - - 54.1 70.3
Bansal 2015 210 Retrospective 5.0 8.1 - - 37.1 -
Bansal (age<1 y) 2015 41 Retrospective 6.1 0.3 - - - -
Nelson 2015 240 Retrospective 10.8 - Congenital 73.8 - 32.5
Nelson (age<1 y) 2015 44 Retrospective 9.8 - Congenital 75.0 - 68.2
total 2409
Mechanical prosthesis
Abid 1992 64 Retrospective 7 12 Rheumatic - 28.1 10.9
Cabalka 1995 36 Retrospective 3.3 - (<18) Congenital 58.3 - -
Yamak 1995 37 Retrospective 2.9 16.6 Rheumatic - 24.3 10.8
Champsaur 1997 54 Retrospective 5.8 12.8 Congenital 51.9 46.3 16.7
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Mazzitelli 1998 30 Retrospective 6.6 - (<18) - - - -
Lupinetti 1999 50 Retrospective 5.4 12.1 Congenital 62.0 10.0 12.0
Alexiou 2000 56 Retrospective 7.3 11.2 Congenital 64.3 26.8 50.0
Shanmugam 2005 55 Retrospective 13 13 Congenital - 18.2 21.8
Ruzmetov 2006 47 Retrospective 7.7 7.7 - - - -
Burczynski 2007 55 Retrospective 6.4 12.8 Congenital - 20.0 0.0
Masuda 2008 45 Retrospective 9.2 9 - 44.4 33.3 55.6
Alsoufi 2009 131 Retrospective 8.3 14 Rheumatic 31.3 - 2.3
Khan 2013 36 Retrospective 4.6 14.0# - - - 5.6
total 696
Homograft
Gerosa 1991 103 Retrospective 8.4 12.5 - 43.7 - -
Clarke 1993 47 Retrospective 2.3 7.1 - 89.4 - 76.6
Khan 2013 74 Retrospective 4 4.9# - - - 12.2
total 224
‘‘-’’ = variable not reported. *Number of patients. ꭞNumber of procedures (excluding annular enlargement 
procedures). #Median.
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table 2. Pooled outcome estimates after the Ross procedure (excluding studies that concerned only neo-
nates and infants)
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
rvot
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Gerosa (1991) 11.63 (5.10-26.51) 1.68 (0.71-4.01) - 1.68 (0.71-4.01) 0.34 (0.05-2.38) 0.34 (0.05-2.38) 0.17 (0.01-2.69) - 1.68 (0.71-4.01)
Reddy (1998) 2.44 (0.35-16.90) 0.47 (0.03-7.50) 0.47 (0.03-7.50) 1.89 (0.48-7.45) 0.47 (0.03-7.50) 1.89 (0.48-7.45) - - -
Elkins (2001) 4.49 (2.28-8.85) 0.31 (0.10-0.95) - 1.23 (0.70-2.16) 0.92 (0.48-1.77) 1.95 (1.25-3.05) 0.05 (0.00-0.82) - 0.21 (0.05-0.82)
Simon (2001) 1.67 (0.11-26.04) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.39 (0.02-6.16) 0.39 (0.02-6.16)
Hazekamp (2005) 5.66 (1.89-16.99) 1.03 (0.33-3.17) 0.17 (0.01-2.74) 1.72 (0.72-4.09) 1.03 (0.33-3.17) 2.74 (1.39-5.44) - - -
Bohm (2006) 0.83 (0.05-13.17) 0.95 (0.24-3.78) 0.24 (0.01-3.79) 0.24 (0.01-3.79) 4.76 (2.60-8.72) 4.76 (2.60-8.72) 0.24 (0.01-3.79) 0.24 (0.01-3.79) 0.24 (0.01-3.79)
Kalavrouziotis (2006) 1.43 (0.09-22.39) 0.70 (0.10-4.91) 0.35 (0.02-5.54) 0.35 (0.02-5.54) 1.39 (0.35-5.52) 1.39 (0.35-5.52) - - -
Ruzmetov (2006) 1.23 (0.18-8.66) 0.23 (0.03-1.65) 0.12 (0.01-1.86) 1.63 (0.78-3.40) 1.40 (0.63-3.09) 3.03 (1.77-5.17) 0.12 (0.01-1.86) 0.12 (0.01-1.86) 0.12 (0.01-1.86)
Stewart (2007) 1.09 (0.07-17.12) 0.20 (0.01-3.20) 0.20 (0.01-3.20) 2.81 (1.35-5.83) 0.40 (0.06-2.84) 3.21 (1.62-6.35) 0.20 (0.01-3.20) 0.20 (0.01-3.20) -
Kadner (2008) 9.62 (4.18-22.12) 1.61 (0.52-4.95) 0.27 (0.02-4.27) 1.07 (0.27-4.26) 3.22 (1.47-7.08) 4.29 (2.18-8.46) 0.27 (0.02-4.27) - 0.27 (0.02-4.27)
Alsoufi (2009) 2.33 (0.98-5.53) 0.04 (0.00-0.65) 0.04 (0.00-0.65) 2.28 (1.58-3.29) - - 0.04 (0.00-0.65) 0.04 (0.00-0.65) 0.16 (0.04-0.65)
El Behery (2009) 4.88 (1.26-18.85) 0.20 (0.01-3.24) 0.20 (0.01-3.24) 0.20 (0.01-3.24) 1.63 (0.62-4.30) 0.81 (0.20-3.23) - - 0.81 (0.20-3.23)
Piccardo (2009) 1.82 (0.26-12.68) 0.66 (0.17-2.63) 0.17 (0.01-2.64) 0.99 (0.32-3.06) 0.99 (0.32-3.06) 0.66 (0.17-2.63) - - 0.33 (0.05-2.34)
Charitos (2012) 3.42 (1.80-6.50) 0.58 (0.30-1.12) 0.13 (0.03-0.52) 0.91 (0.54-1.53) 2.72 (2.02-3.67) 2.98 (2.24-3.96) 0.58 (0.30-1.12) 0.03 (0.00-0.52) 0.65 (0.35-1.20)
Talwar (2012) 2.78 (0.40-19.19) 1.40 (0.53-3.71) 0.18 (0.01-2.80) 1.75 (0.74-4.18) 0.70 (0.18-2.79) - 0.18 (0.01-2.80) 0.18 (0.01-2.80) 0.70 (0.18-2.79)
Khan (2013) 1.47 (0.21-10.29) 0.44 (0.11-1.75) - 0.66 (0.21-2.03) 3.51 (2.17-5.68) - - - -
Ruzmetov (2013) 3.85 (1.27-11.67) 0.58 (0.22-1.55) 0.29 (0.07-1.16) 2.91 (1.89-4.49) 2.33 (1.44-3.78) 5.24 (3.82-7.21) - - -
Tan Tanny (2013) 6.00 (2.76-13.03) 0.55 (0.21-1.46) 0.14 (0.02-0.97) 1.23 (0.64-2.36) 2.74 (1.78-4.22) - - - -
Luciani (2014) 3.28 (1.78-6.03) 0.47 (0.27-0.82) 0.02 (0.00-0.31) 1.44 (1.05-1.99) 1.44 (1.05-1.99) 2.77 (2.20-3.49) 0.08 (0.02-0.31) 0.02 (0.00-0.31) 0.08 (0.02-0.31)
Bansal (2015) 4.29 (2.26-8.12) 0.05 (0.00-0.76) 0.05 (0.00-0.76) - - - - - -
Nelson (2015) 4.17 (2.27-7.64) 0.66 (0.41-1.05) - 2.66 (2.11-3.36) 2.20 (1.70-2.84) - - - -
Pooled (random effects) 4.20 (3.37-5.22) 0.64 (0.49-0.84) 0.16 (0.09-0.29) 1.60 (1.27-2.02) 1.91 (1.50-2.44) 2.75 (2.13-3.53) 0.22 (0.11-0.43) 0.10 (0.04-0.27) 0.40 (0.22-0.73)
Heterogeneity test χ2 20.78 (P = .41)
I2 = 3%
χ2 23.77 (P = .25)
I2 = 16%
χ2 6.32 (P = .98)
I2 = 0%
χ2 40.97 (P = .00)
I2 = 54%
χ2 44.49 (P = .00)
I2 = 59%
χ2 35.59 (P = .00)
I2 = 60%
χ2 12.09 (P = .27)
I2 = 17%
χ2 4.08 (P = .77)
I2 = 0%
χ2 21.60 (P = .03)
I2 = 49%
Data expressed as percentage (95% CI). ‘‘-’’=variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, un-
expected, unexplained death; AV, aortic valve; RVOT, right ventricular outflow tract; SVD, structural valve 
deterioration; NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve thrombosis.
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table 2. Pooled outcome estimates after the Ross procedure (excluding studies that concerned only neo-
nates and infants)
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
rvot
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Gerosa (1991) 11.63 (5.10-26.51) 1.68 (0.71-4.01) - 1.68 (0.71-4.01) 0.34 (0.05-2.38) 0.34 (0.05-2.38) 0.17 (0.01-2.69) - 1.68 (0.71-4.01)
Reddy (1998) 2.44 (0.35-16.90) 0.47 (0.03-7.50) 0.47 (0.03-7.50) 1.89 (0.48-7.45) 0.47 (0.03-7.50) 1.89 (0.48-7.45) - - -
Elkins (2001) 4.49 (2.28-8.85) 0.31 (0.10-0.95) - 1.23 (0.70-2.16) 0.92 (0.48-1.77) 1.95 (1.25-3.05) 0.05 (0.00-0.82) - 0.21 (0.05-0.82)
Simon (2001) 1.67 (0.11-26.04) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.78 (0.11-5.46) 0.39 (0.02-6.16) 0.39 (0.02-6.16) 0.39 (0.02-6.16)
Hazekamp (2005) 5.66 (1.89-16.99) 1.03 (0.33-3.17) 0.17 (0.01-2.74) 1.72 (0.72-4.09) 1.03 (0.33-3.17) 2.74 (1.39-5.44) - - -
Bohm (2006) 0.83 (0.05-13.17) 0.95 (0.24-3.78) 0.24 (0.01-3.79) 0.24 (0.01-3.79) 4.76 (2.60-8.72) 4.76 (2.60-8.72) 0.24 (0.01-3.79) 0.24 (0.01-3.79) 0.24 (0.01-3.79)
Kalavrouziotis (2006) 1.43 (0.09-22.39) 0.70 (0.10-4.91) 0.35 (0.02-5.54) 0.35 (0.02-5.54) 1.39 (0.35-5.52) 1.39 (0.35-5.52) - - -
Ruzmetov (2006) 1.23 (0.18-8.66) 0.23 (0.03-1.65) 0.12 (0.01-1.86) 1.63 (0.78-3.40) 1.40 (0.63-3.09) 3.03 (1.77-5.17) 0.12 (0.01-1.86) 0.12 (0.01-1.86) 0.12 (0.01-1.86)
Stewart (2007) 1.09 (0.07-17.12) 0.20 (0.01-3.20) 0.20 (0.01-3.20) 2.81 (1.35-5.83) 0.40 (0.06-2.84) 3.21 (1.62-6.35) 0.20 (0.01-3.20) 0.20 (0.01-3.20) -
Kadner (2008) 9.62 (4.18-22.12) 1.61 (0.52-4.95) 0.27 (0.02-4.27) 1.07 (0.27-4.26) 3.22 (1.47-7.08) 4.29 (2.18-8.46) 0.27 (0.02-4.27) - 0.27 (0.02-4.27)
Alsoufi (2009) 2.33 (0.98-5.53) 0.04 (0.00-0.65) 0.04 (0.00-0.65) 2.28 (1.58-3.29) - - 0.04 (0.00-0.65) 0.04 (0.00-0.65) 0.16 (0.04-0.65)
El Behery (2009) 4.88 (1.26-18.85) 0.20 (0.01-3.24) 0.20 (0.01-3.24) 0.20 (0.01-3.24) 1.63 (0.62-4.30) 0.81 (0.20-3.23) - - 0.81 (0.20-3.23)
Piccardo (2009) 1.82 (0.26-12.68) 0.66 (0.17-2.63) 0.17 (0.01-2.64) 0.99 (0.32-3.06) 0.99 (0.32-3.06) 0.66 (0.17-2.63) - - 0.33 (0.05-2.34)
Charitos (2012) 3.42 (1.80-6.50) 0.58 (0.30-1.12) 0.13 (0.03-0.52) 0.91 (0.54-1.53) 2.72 (2.02-3.67) 2.98 (2.24-3.96) 0.58 (0.30-1.12) 0.03 (0.00-0.52) 0.65 (0.35-1.20)
Talwar (2012) 2.78 (0.40-19.19) 1.40 (0.53-3.71) 0.18 (0.01-2.80) 1.75 (0.74-4.18) 0.70 (0.18-2.79) - 0.18 (0.01-2.80) 0.18 (0.01-2.80) 0.70 (0.18-2.79)
Khan (2013) 1.47 (0.21-10.29) 0.44 (0.11-1.75) - 0.66 (0.21-2.03) 3.51 (2.17-5.68) - - - -
Ruzmetov (2013) 3.85 (1.27-11.67) 0.58 (0.22-1.55) 0.29 (0.07-1.16) 2.91 (1.89-4.49) 2.33 (1.44-3.78) 5.24 (3.82-7.21) - - -
Tan Tanny (2013) 6.00 (2.76-13.03) 0.55 (0.21-1.46) 0.14 (0.02-0.97) 1.23 (0.64-2.36) 2.74 (1.78-4.22) - - - -
Luciani (2014) 3.28 (1.78-6.03) 0.47 (0.27-0.82) 0.02 (0.00-0.31) 1.44 (1.05-1.99) 1.44 (1.05-1.99) 2.77 (2.20-3.49) 0.08 (0.02-0.31) 0.02 (0.00-0.31) 0.08 (0.02-0.31)
Bansal (2015) 4.29 (2.26-8.12) 0.05 (0.00-0.76) 0.05 (0.00-0.76) - - - - - -
Nelson (2015) 4.17 (2.27-7.64) 0.66 (0.41-1.05) - 2.66 (2.11-3.36) 2.20 (1.70-2.84) - - - -
Pooled (random effects) 4.20 (3.37-5.22) 0.64 (0.49-0.84) 0.16 (0.09-0.29) 1.60 (1.27-2.02) 1.91 (1.50-2.44) 2.75 (2.13-3.53) 0.22 (0.11-0.43) 0.10 (0.04-0.27) 0.40 (0.22-0.73)
Heterogeneity test χ2 20.78 (P = .41)
I2 = 3%
χ2 23.77 (P = .25)
I2 = 16%
χ2 6.32 (P = .98)
I2 = 0%
χ2 40.97 (P = .00)
I2 = 54%
χ2 44.49 (P = .00)
I2 = 59%
χ2 35.59 (P = .00)
I2 = 60%
χ2 12.09 (P = .27)
I2 = 17%
χ2 4.08 (P = .77)
I2 = 0%
χ2 21.60 (P = .03)
I2 = 49%
Data expressed as percentage (95% CI). ‘‘-’’=variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, un-
expected, unexplained death; AV, aortic valve; RVOT, right ventricular outflow tract; SVD, structural valve 
deterioration; NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve thrombosis.
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table 3. Pooled outcome estimates after the Ross procedure in neonates and infants
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
rvot
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Woods (2012) 15.86 (10.90-23.08) - - - - - - - -
Elder (2013) 11.76 (4.69-29.54) 0.14 (0.01-2.21) 0.14 (0.01-2.21) 0.28 (0.04-1.96) 4.16 (2.54-6.83) - - - 0.28 (0.04-1.96)
Luciani (2014) 21.62 (11.71-39.93) 2.57 (1.30-5.10) - 1.93 (0.87-4.26) - - - - -
Bansal (2015) 17.07 (8.70-33.52) 0.20 (0.01-3.19) 0.20 (0.01-3.19) - - - - - -
Nelson (2015) 18.18 (9.71-34.03) 0.70 (0.23-2.15) - 0.46 (0.12-1.85) 4.41 (2.84-6.84) - - - -
Pooled 16.88 (13.12-21.73)* 0.76 (0.21-2.78)* 0.17 (0.02-1.18)ꭞ 1.14 (0.60-2.18)ꭞ 4.30 (3.09-5.97)ꭞ - - - 0.28 (0.04-1.96)ꭞ
Heterogeneity test χ2 1.38 (P = .85)
I2 = 0%
χ2 9.05 (P = .03)
I2 = 67%
χ2 0.03 (P = .85)
I2 = 0%
χ2 5.32 (P = .07)
I2 = 62%
χ2 0.03 (P = .87)
I2 = 0%
- - - -
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; RVOT, right ventricular outflow tract; SVD, structural valve de-
terioration; NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve thrombosis. *Random 
effects. ꭞFixed effects.
table 4. Pooled outcome estimates after aortic valve replacement with mechanical prosthesis
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Abid (1992) 12.50 (6.54-23.90) 2.60 (1.41-4.79) 0.13 (0.01-2.07) 1.30 (0.54-3.10) 0.78 (0.25-2.41) 1.30 (0.54-3.10) 0.52 (0.13-2.07) 0.78 (0.25-2.41)
Cabalka (1995) 5.56 (1.44-21.36) 0.85 (0.12-6.02) - 0.43 (0.03-6.79) 0.43 (0.03-6.79) 0.85 (0.12-6.02) 1.71 (0.43-6.75) 0.43 (0.03-6.79)
Yamak (1995) 8.11 (2.74-23.99) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83)
Champsaur (1997) 12.96 (6.49-25.87) 2.30 (1.04-5.07) 0.19 (0.01-3.05) 1.15 (0.37-3.54) 1.15 (0.37-3.54) 0.77 (0.19-3.05) 0.38 (0.05-2.71) -
Mazzitelli (1998) 1.67 (0.11-26.04) 1.52 (0.49-4.66) 0.25 (0.02-4.02) 2.53 (1.06-6.00) 1.52 (0.49-4.66) 1.01 (0.25-4.01) 0.51 (0.07-3.57) -
Lupinetti (1999) 10.00 (4.35-22.97) 1.48 (0.56-3.91) 0.18 (0.01-2.94) 3.69 (2.01-6.78) 2.58 (1.24-5.37) 1.11 (0.36-3.41) 0.18 (0.01-2.94) 0.74 (0.19-2.94)
Alexiou (2000) 5.36 (1.78-16.11) 0.74 (0.24-2.29) 0.12 (0.01-1.97) 0.74 (0.24-2.29) 0.49 (0.12-1.97) 0.49 (0.12-1.97) 0.12 (0.01-1.97) 0.12 (0.01-1.97)
Shanmugam (2005) 0.91 (0.06-14.35) 0.15 (0.02-1.07) 0.08 (0.00-1.20) 0.60 (0.23-1.60) 0.45 (0.15-1.40) 0.08 (0.00-1.20) 0.15 (0.02-1.07) 0.30 (0.08-1.20)
Ruzmetov (2006) 6.38 (2.14-19.08) 0.83 (0.27-2.56) 0.14 (0.01-2.20) 1.38 (0.58-3.30) 0.83 (0.27-2.56) 0.14 (0.01-2.20) 0.14 (0.01-2.20) 0.55 (0.14-2.20)
Burczynski (2007) 0.91 (0.06-14.35) 0.57 (0.14-2.26) 0.14 (0.01-2.26) 0.28 (0.04-2.01) 0.14 (0.01-2.26) 0.57 (0.14-2.26) 0.14 (0.01-2.26) 0.57 (0.14-2.26)
Masuda (2008) 2.22 (0.32-15.43) 0.48 (0.12-1.93) 0.24 (0.03-1.71) 0.48 (0.12-1.93) 0.24 (0.03-1.71) 0.97 (0.36-2.56) - 0.24 (0.03-1.71)
Alsoufi (2009) 6.11 (3.12-11.95) 1.75 (1.12-2.73) - 0.74 (0.37-1.47) - 0.37 (0.14-0.98) 0.28 (0.09-0.85) 0.09 (0.01-0.65)
Khan (2013) 1.39 (0.09-21.78) 0.60 (0.09-4.26) - 0.60 (0.09-4.26) - 1.21 (0.30-4.79) - -
Pooled (random effects) 7.34 (5.21-10.34) 1.23 (0.85-1.79) 0.18 (0.08-0.41) 1.07 (0.68-1.68) 0.86 (0.53-1.42) 0.76 (0.53-1.09) 0.39 (0.22-0.68) 0.45 (0.27-0.75)
Heterogeneity test χ2 14.78 (P = .32)
I2 = 18%
χ2 18.79 (P = .13)
I2 = 36%
χ2 1.22 (P = 1.00)
I2 = 0%
χ2 25.57 (P = .01)
I2 = 53%
χ2 14.81 (P = .19)
I2 = 32%
χ2 9.62 (P = .72)
I2 = 0%
χ2 7.97 (P = .72)
I2 = 0%
χ2 5.67 (P = .84)
I2 = 0%
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; SVD, structural valve deterioration; NSVD, nonstructural valve 
dysfunction; TE, thromboembolism; VT, valve thrombosis.
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table 3. Pooled outcome estimates after the Ross procedure in neonates and infants
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
rvot
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Woods (2012) 15.86 (10.90-23.08) - - - - - - - -
Elder (2013) 11.76 (4.69-29.54) 0.14 (0.01-2.21) 0.14 (0.01-2.21) 0.28 (0.04-1.96) 4.16 (2.54-6.83) - - - 0.28 (0.04-1.96)
Luciani (2014) 21.62 (11.71-39.93) 2.57 (1.30-5.10) - 1.93 (0.87-4.26) - - - - -
Bansal (2015) 17.07 (8.70-33.52) 0.20 (0.01-3.19) 0.20 (0.01-3.19) - - - - - -
Nelson (2015) 18.18 (9.71-34.03) 0.70 (0.23-2.15) - 0.46 (0.12-1.85) 4.41 (2.84-6.84) - - - -
Pooled 16.88 (13.12-21.73)* 0.76 (0.21-2.78)* 0.17 (0.02-1.18)ꭞ 1.14 (0.60-2.18)ꭞ 4.30 (3.09-5.97)ꭞ - - - 0.28 (0.04-1.96)ꭞ
Heterogeneity test χ2 1.38 (P = .85)
I2 = 0%
χ2 9.05 (P = .03)
I2 = 67%
χ2 0.03 (P = .85)
I2 = 0%
χ2 5.32 (P = .07)
I2 = 62%
χ2 0.03 (P = .87)
I2 = 0%
- - - -
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; RVOT, right ventricular outflow tract; SVD, structural valve de-
terioration; NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve thrombosis. *Random 
effects. ꭞFixed effects.
table 4. Pooled outcome estimates after aortic valve replacement with mechanical prosthesis
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Abid (1992) 12.50 (6.54-23.90) 2.60 (1.41-4.79) 0.13 (0.01-2.07) 1.30 (0.54-3.10) 0.78 (0.25-2.41) 1.30 (0.54-3.10) 0.52 (0.13-2.07) 0.78 (0.25-2.41)
Cabalka (1995) 5.56 (1.44-21.36) 0.85 (0.12-6.02) - 0.43 (0.03-6.79) 0.43 (0.03-6.79) 0.85 (0.12-6.02) 1.71 (0.43-6.75) 0.43 (0.03-6.79)
Yamak (1995) 8.11 (2.74-23.99) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83) 0.49 (0.03-7.83)
Champsaur (1997) 12.96 (6.49-25.87) 2.30 (1.04-5.07) 0.19 (0.01-3.05) 1.15 (0.37-3.54) 1.15 (0.37-3.54) 0.77 (0.19-3.05) 0.38 (0.05-2.71) -
Mazzitelli (1998) 1.67 (0.11-26.04) 1.52 (0.49-4.66) 0.25 (0.02-4.02) 2.53 (1.06-6.00) 1.52 (0.49-4.66) 1.01 (0.25-4.01) 0.51 (0.07-3.57) -
Lupinetti (1999) 10.00 (4.35-22.97) 1.48 (0.56-3.91) 0.18 (0.01-2.94) 3.69 (2.01-6.78) 2.58 (1.24-5.37) 1.11 (0.36-3.41) 0.18 (0.01-2.94) 0.74 (0.19-2.94)
Alexiou (2000) 5.36 (1.78-16.11) 0.74 (0.24-2.29) 0.12 (0.01-1.97) 0.74 (0.24-2.29) 0.49 (0.12-1.97) 0.49 (0.12-1.97) 0.12 (0.01-1.97) 0.12 (0.01-1.97)
Shanmugam (2005) 0.91 (0.06-14.35) 0.15 (0.02-1.07) 0.08 (0.00-1.20) 0.60 (0.23-1.60) 0.45 (0.15-1.40) 0.08 (0.00-1.20) 0.15 (0.02-1.07) 0.30 (0.08-1.20)
Ruzmetov (2006) 6.38 (2.14-19.08) 0.83 (0.27-2.56) 0.14 (0.01-2.20) 1.38 (0.58-3.30) 0.83 (0.27-2.56) 0.14 (0.01-2.20) 0.14 (0.01-2.20) 0.55 (0.14-2.20)
Burczynski (2007) 0.91 (0.06-14.35) 0.57 (0.14-2.26) 0.14 (0.01-2.26) 0.28 (0.04-2.01) 0.14 (0.01-2.26) 0.57 (0.14-2.26) 0.14 (0.01-2.26) 0.57 (0.14-2.26)
Masuda (2008) 2.22 (0.32-15.43) 0.48 (0.12-1.93) 0.24 (0.03-1.71) 0.48 (0.12-1.93) 0.24 (0.03-1.71) 0.97 (0.36-2.56) - 0.24 (0.03-1.71)
Alsoufi (2009) 6.11 (3.12-11.95) 1.75 (1.12-2.73) - 0.74 (0.37-1.47) - 0.37 (0.14-0.98) 0.28 (0.09-0.85) 0.09 (0.01-0.65)
Khan (2013) 1.39 (0.09-21.78) 0.60 (0.09-4.26) - 0.60 (0.09-4.26) - 1.21 (0.30-4.79) - -
Pooled (random effects) 7.34 (5.21-10.34) 1.23 (0.85-1.79) 0.18 (0.08-0.41) 1.07 (0.68-1.68) 0.86 (0.53-1.42) 0.76 (0.53-1.09) 0.39 (0.22-0.68) 0.45 (0.27-0.75)
Heterogeneity test χ2 14.78 (P = .32)
I2 = 18%
χ2 18.79 (P = .13)
I2 = 36%
χ2 1.22 (P = 1.00)
I2 = 0%
χ2 25.57 (P = .01)
I2 = 53%
χ2 14.81 (P = .19)
I2 = 32%
χ2 9.62 (P = .72)
I2 = 0%
χ2 7.97 (P = .72)
I2 = 0%
χ2 5.67 (P = .84)
I2 = 0%
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; SVD, structural valve deterioration; NSVD, nonstructural valve 
dysfunction; TE, thromboembolism; VT, valve thrombosis.
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Discussion
This is the first study that systematically compiles the available evidence on reported 
outcome after contemporary AVR in the pediatric population into a comprehensive 
overview. It highlights the imperfections of currently available aortic valve substitutes 
in children. It seems that the Ross procedure in children aged more than 1 year is associ-
ated with low early and late mortality rates, lower compared with MP-AVR and HG-AVR. 
However, this study also shows that RVOT reoperations after the Ross procedure are 
required in approximately 20%of the general pediatric patient population and in more 
than 40% of neonates and infants in the first postoperative decade. In addition, the 
results of our study indicate that HG-AVR is associated with a significantly higher rate 
of aortic valve reoperations compared with both the MP-AVR and the Ross procedure. 
The initial search resulted in only 6 studies on bioprostheses, all of which had a sample 
size of less than 20 patients, reflecting the abandonment of their use in pediatric AVR in 
contemporary practice as a result of their high rates of early degeneration, calcification, 
and structural failure in young recipients.8,9,15-17,23,45
early mortality
The observed differences in early mortality risk between the different heart valve substi-
tutes are probably mainly driven by patient-related factors, such as patient age, urgency 
of the procedure, preoperative hemodynamic status, and disease cause.
Differences in patient characteristics, surgical technique, and additional procedures 
performed at the time of MP-AVR may explain the higher early mortality rate in this 
patient group. However, our pooled analysis of patient characteristics and surgical 
details revealed differences that were not consistently in favor of the Ross procedure. 
table 5. Pooled outcome estimates after aortic valve replacement with homograft
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Gerosa (1991) 15.53 (9.90-24.37) 1.62 (0.96-2.72) - 2.77 (1.87-4.12) 2.43 (1.59-3.70) 0.06 (0.00-0.92) 0.06 (0.00-0.92) 0.23 (0.06-0.92)
Clarke (1993) 12.77 (6.05-26.95) 0.93 (0.13-6.51) 0.46 (0.03-7.35) 6.48 (3.16-13.26) 5.55 (2.55-12.08) 0.93 (0.13-6.51) 2.78 (0.91-8.47) 1.85 (0.47-7.30)
Khan (2013) 4.05 (1.34-12.28) 1.69 (0.71-4.03) - 9.12 (6.37-13.07) - - - -
Pooled (fixed effects) 12.82 (8.91-18.46) 1.59 (1.03-2.46) 0.46 (0.03-7.35) 5.44 (4.24-6.98) 2.93 (2.02-4.25) 0.37 (0.07-1.82) 1.62 (0.57-4.55) 0.66 (0.25-1.75)
Heterogeneity test χ2 8.37 (P = .04)
I2 = 76%
χ2 0.51 (P = .91)
I2 = 0%
- χ2 13.89 (P = .00)
I2 = 86%
χ2 0.88 (P = .64)
I2 = 0%
χ2 2.95 (P = .23)
I2 = 66%
χ2 3.14 (P = .21)
I2 = 68%
χ2 1.54 (P = .46)
I2 = 35%
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; SVD, structural valve deterioration; NSVD, nonstructural valve 
dysfunction; TE, thromboembolism; VT, valve thrombosis.
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Whereas rheumatic valve disease was more frequent in patients undergoing MP-AVR, 
patients undergoing the Ross procedure more frequently had undergone previous 
cardiac interventions. The number of concomitant procedures and annular enlarge-
ment procedures was comparable between the 2 groups. The 2 included studies that 
compared the characteristics of patients undergoing the Ross procedure with those of 
mechanical valve recipients further support the differences we found in pooled baseline 
patient characteristics.23,31 Although we did not find conclusive evidence of selection 
bias, residual hidden selection bias may explain the higher mortality rate associated 
with MP-AVR. With regard to the Ross procedure, younger age at the time of operation 
seems to be associated with a less favorable outcome and is most likely representative 
of very complex (critical) aortic stenosis. This is confirmed by our observations in the 
studies concerning the Ross procedure in neonates and infants that showed a substan-
tially higher early mortality risk than the older pediatric patients undergoing the Ross. 
Next to patient-related factors, the era of operation may have influenced early mortality 
risk, analogous to findings in young adults who undergo valve replacement.54 The early 
mortality risks were higher in studies conducted in the early 1990s when compared 
with more recent studies.13,49,50,53 Improved early patient outcome in more recent years 
is most likely the result of improvements in diagnostic workup, surgical timing, intensive 
care, and anesthesia.
late mortality
Similar to observations in young adult patient populations,55 the Ross procedure in 
children is associated with significantly lower late mortality rates compared with MP-
AVR and HG-AVR (0.64%/y vs 1.23%/y vs 1.59%/y, respectively). PPM and suboptimal 
hemodynamic performance of MPs and HGs may have contributed to the observed 
excess mortality, particularly in growing children.
In addition, as with early mortality, the higher late mortality rate in MP-AVR may be 
explained by the fact that children who undergo MP-AVR more often have rheumatic 
table 5. Pooled outcome estimates after aortic valve replacement with homograft
study early mortality
%
late mortality
%/y
suuD
%/y
av
reoperation
%/y
reoperation for
svD/nsvD
%/y
te/vt
%/y
Bleeding
%/y
endocarditis
%/y
Gerosa (1991) 15.53 (9.90-24.37) 1.62 (0.96-2.72) - 2.77 (1.87-4.12) 2.43 (1.59-3.70) 0.06 (0.00-0.92) 0.06 (0.00-0.92) 0.23 (0.06-0.92)
Clarke (1993) 12.77 (6.05-26.95) 0.93 (0.13-6.51) 0.46 (0.03-7.35) 6.48 (3.16-13.26) 5.55 (2.55-12.08) 0.93 (0.13-6.51) 2.78 (0.91-8.47) 1.85 (0.47-7.30)
Khan (2013) 4.05 (1.34-12.28) 1.69 (0.71-4.03) - 9.12 (6.37-13.07) - - - -
Pooled (fixed effects) 12.82 (8.91-18.46) 1.59 (1.03-2.46) 0.46 (0.03-7.35) 5.44 (4.24-6.98) 2.93 (2.02-4.25) 0.37 (0.07-1.82) 1.62 (0.57-4.55) 0.66 (0.25-1.75)
Heterogeneity test χ2 8.37 (P = .04)
I2 = 76%
χ2 0.51 (P = .91)
I2 = 0%
- χ2 13.89 (P = .00)
I2 = 86%
χ2 0.88 (P = .64)
I2 = 0%
χ2 2.95 (P = .23)
I2 = 66%
χ2 3.14 (P = .21)
I2 = 68%
χ2 1.54 (P = .46)
I2 = 35%
Data expressed as percentage (95% CI). ‘‘-’’ = variable not reported. In case an event was reported not to 
occur, for pooling purposes it was assumed that 0.5 patient experienced the event. SUUD, Sudden, unex-
pected, unexplained death; AV, aortic valve; SVD, structural valve deterioration; NSVD, nonstructural valve 
dysfunction; TE, thromboembolism; VT, valve thrombosis.
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valve disease and connective tissue disease, which may have given rise to substantial 
selection bias, although we did not find conclusive evidence thereof.31
In contrast to the high early mortality risk of the Ross procedure in neonates and infants, 
late mortality rates in these patients are low and comparable to late mortality in the 
older pediatric patients undergoing the Ross procedure.
As observed with early mortality, late mortality rates after MP-AVR seem to be depen-
dent on the era of operation, with improved survival in patients undergoing operation 
more recently. The only exception to this time-dependent improved survival was the 
study published by Alsoufi and colleagues.31 This study describes a population of chil-
dren with predominantly rheumatic valves in a developing country with suboptimal 
anticoagulation compliance, which might explain this observation. Late survival after 
the Ross procedure seems to leave little room for improvement in more recent years.
reoperations
The rate of reoperations on the aortic valve was comparable for the Ross procedure and 
MP-AVR, although the indication for aortic valve reoperation differs. Although patients 
with an MP tend to outgrow the prosthetic valve, patients undergoing the Ross pro-
cedure often experience valve insufficiency caused by dilatation of the neoaortic root. 
Compared with both the Ross procedure and MP-AVR, HG-AVR was associated with a 
significantly higher aortic valve reoperation rate, due to both PPM in growing children 
and early degeneration.56,57
One of the major disadvantages of the Ross procedure is that single valve disease is 
treated with double valve replacement, placing both valves at risk of degeneration and 
reoperation. Failure of the pulmonary valve substitute, although usually less life threat-
ening, does pose an additional risk of reoperation or percutaneous reintervention. When 
the additional risk of reoperations on the RVOT associated with the Ross procedure is 
taken into account, the Ross procedure is associated with a higher total reoperation 
rate compared with MP-AVR in the first postoperative decade, with a further increase 
in reoperation rates to be expected in the second postoperative decade.6 This aspect of 
the Ross procedure needs to be addressed clearly to (parents of ) children who are fac-
ing AVR. Of note, for neonates and infants undergoing the Ross procedure, aortic valve 
reoperation rates seem to be lower, whereas RVOT reoperation rates are 2 times higher 
compared with older children after the Ross procedure. The latter can be explained by 
the rapid child growth at a younger age. Studies on outcome after reoperative AVR in 
children and young adults report early and late mortality rates comparable to those we 
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observed after primary AVR, which suggests that reoperations, although challenging, 
are safe.27,58-61
valve-related complications
When evaluating valve-related event occurrence after adult AVR with mechanical 
versus biological valve substitutes, basically the burden of anticoagulation therapy is 
compared with the burden of reoperation. In children, the growth-dependent increase 
in PPM needs to be considered. The present study confirms that the Ross procedure is 
associated with significantly lower TE/VT rates compared with MP-AVR (0.22%/y; 95% 
confidence interval [CI], 0.11-0.43/y vs 0.76%/y; 95% CI, 0.53-1.09/y, respectively), and 
there was a trend toward lower bleeding rates (0.10%/y; 95% CI, 0.04-0.27/y vs 0.39%/y; 
95% CI, 0.22-0.68/y, respectively). Pooled SVD and NSVD rates after the Ross procedure 
are substantially higher compared with MP-AVR.
Of note, the only prospective study in this systematic review reported a very high TE/
VT event rate of 0.58%/y for patients undergoing the Ross27 compared with the other 
retrospective Ross studies. The prospective design of this study is the most likely expla-
nation for this observation because there will have been less recall bias compared with 
retrospective studies.
As expected, pediatric HG-AVR is associated with higher valve deterioration rates than 
both the Ross procedure and MP-AVR. This is in line with earlier reports that show ac-
celerated calcification and degeneration of the HG in the aortic position in children.57
With regard to pooled endocarditis rates, the Ross procedure and MP-AVR were com-
parable, whereas HG-AVR was associated with a higher rate of endocarditis. This may 
be explained by the fact that this finding is based on a single study in which a relatively 
large proportion of patients (89%) had undergone at least 1 previous cardiac interven-
tion, which is known to be associated with prosthetic valve endocarditis.62
functional health status
The majority of studies that reported NYHA functional class reported a large propor-
tion of patients being in NYHA class I at last follow-up. However, the NYHA classification 
has not been designed for children, which most likely explains why preoperative NYHA 
classification was not assessed in most studies. Therefore, it is not possible to determine 
improvement in functional performance after AVR. To determine the effect of AVR on 
functional performance, both preoperative and postoperative functional classification 
should be registered for every patient. Also, questionnaires are needed to provide more 
insight in quality of life in relation to heart valve prostheses. There is some evidence for 
62
better quality of life after the Ross procedure than after MP-AVR in young adult patients, 
but more studies are needed.63
source of heterogeneity
Although heterogeneity was considerable in our meta-analysis and may have led to 
inaccurate results, we pursued a thorough examination of possible sources of hetero-
geneity. The year of operation, ranging from 1964 to 2013 among the included studies, 
may have affected the results because evolution of operative techniques seems to have 
led to lower operative risk. Furthermore, the heterogeneity in RVOT reoperation rates 
after the Ross procedure may be explained by possible interinstitutional variation in 
indications for RVOT reoperation. The cause of the higher aortic valve reoperation rate 
reported by Lupinetti and colleagues48 in comparison with the other included studies 
remains to be elucidated.
Our findings of largely unchanged pooled estimates after exploratory exclusion of the 
identified sources of heterogeneity suggest that the heterogeneity caused by afore-
mentioned studies did not have a substantial impact on the pooled estimates of the 
outcomes discussed and, thus, did not compromise the validity of these estimates.
future perspectives
Recent clinical practice guidelines for adult valvular heart disease recommend the Ross 
procedure to be reserved for patients in whom anticoagulation is contraindicated.64 
Our results show that in particular in younger growing children the Ross procedure 
may be beneficial in a larger group of patients when performed in centers of expertise. 
Although the included studies provide limited insight into the impact of patient char-
acteristics on outcome with the different valve options, the Ross procedure seems to be 
associated with more favorable early and late survival in the first postoperative decade. 
However, the Ross procedure is also associated with a substantial reoperation rate in the 
first postoperative decade, and a further increase in reoperation rates is to be expected 
in the second postoperative decade.6 Unfortunately, no firm conclusions can be drawn 
for individual patients because most of the included publications have a mixed study 
population with regard to patient characteristics and cause of valve disease.
When repair of the aortic valve is not possible or has failed, replacement may be unavoid-
able. In search of the best AVR procedure in children, heart valve tissue engineering is 
a promising development.65-67 Tissue-engineered valve technology is still in its infancy 
but may be a solution in the future with the prospect of a durable living heart valve that 
adapts to the growing child. This innovative technology aims at avoiding reoperations 
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and improving long-term outcome after AVR and hopefully will provide a more durable 
solution for children requiring AVR.
study limitations
The present study is a systematic review and meta-analysis of observational studies, all 
but 1 retrospective in design. As such, the inherent limitations of meta-analyses and 
combining data from retrospective observational studies should be taken into consider-
ation.68 Selection bias may have affected the observed outcomes because unpublished 
data, abstracts, and presentations were not included. Finally, the mean follow-up of the 
included studies does not allow extensions of the observed outcomes beyond the first 
postoperative decade.
conclusions
Despite improvements in diagnostic workup, surgical timing, and expertise in pediatric 
aortic valve repair techniques, AVR may be unavoidable. Results of AVR in children 
remain suboptimal with the currently available valve substitutes. The present study 
illustrates that both the Ross procedure and MP-AVR, although the most commonly 
used procedures for AVR in children, are associated with suboptimal outcome, reflecting 
the urgent need for reliable and durable repair techniques and innovative replacement 
solutions for this challenging group of patients.
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suPPleMentary Material
supplement 1. Literature search query
PubMed (1161 results)
(((((aortic valve replacement OR ross OR (heart valve prosthesis implantation [MeSH] 
AND (aorta OR aortic)))) AND (allograft OR autograft OR mechanical OR prosthetic OR 
homograft OR bioprosthe* OR xenograft OR xenoprosthe* OR porcine OR bovine) AND 
((‘‘1990/01/01’’[PDat] : ‘‘3000/12/31’’[PDat]) AND Humans[Mesh] AND English [lang] AND 
(infant[MeSH] OR child[MeSH] OR adolescent[ MeSH])))))
embase (1181 results)
(aortic AND (‘valve’/exp OR valve) AND replacement OR ross) AND (‘allograft’/exp OR 
allograft OR ‘autograft’/exp OR autograft OR mechanical OR prosthetic OR ‘homograft’/ 
exp OR homograft OR bioprosthe* OR xenograft OR xenoprosthe* OR porcine OR bo-
vine) AND [humans]/lim AND [english]/lim AND [1990-2015]/py AND ([newborn]/ lim 
OR [infant]/lim OR [child]/lim OR [adolescent]/lim)
PubMed as supplied by publisher (122 results)
(((((aortic valve replacement OR ross OR (heart valve prosthesis implantation [MeSH] 
AND (aorta OR aortic)))) AND (allograft OR autograft OR mechanical OR prosthetic OR 
homograft OR bioprosthe* OR xenograft OR xenoprosthe* OR porcine OR bovine) AND 
((‘‘1990/01/ 01’’[PDat] : ‘‘3000/12/31’’[PDat]) AND English[lang])))) AND publisher[sb]
70
supplement 2. Funnel plots on a natural log x-axis. 
Studies that concerned only neonates and infants were excluded from these funnel plots. Studies on ho-
mograft AVR were too few to yield conclusive funnel plots. SE, Standard error; MP, mechanical prosthesis; 
AV (R), aortic valve (replacement); RVOT, right ventricular outflow tract; SVD, structural valve deterioration; 
NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve thrombosis.
FIGURE E1. Funnel plots on a natural log x-axis. Studies that concerned only neonates and infants were excluded from these funnel plots. Studies on
homograft AVR were too few to yield conclusive funnel plots. SE, Standard error; MP, mechanical prosthesis; AV (R), aortic valve (replacement);
RVOT, right ventricular outflow tract; SVD, structural valve deterioration; NSVD, nonstructural valve dysfunction; TE, thromboembolism; VT, valve
thrombosis.
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supplement 2. (continued)
FIGURE E1. (Continued).
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aBstract
Background
To support decision-making regarding prosthetic valve selection in non-elderly adults, 
we aim to provide a detailed overview of outcome after contemporary mechanical 
aortic valve replacement (AVR).
Methods
A systematic review was conducted for papers reporting clinical outcome after AVR 
with bileaflet mechanical valves with a mean patient age ≥18 and ≤55 years, published 
between 1 January 1995 and 31 December 2015. Through meta-analysis outcomes were 
pooled and entered into a microsimulation model to calculate (event-free) life expec-
tancy and lifetime event risk.
results
Twenty-nine publications, encompassing a total of 5728 patients with 32 515 patient-
years of follow-up (pooled mean follow-up: 5.7 years), were included. Pooled mean age 
at surgery was 48.0 years. Pooled early mortality risk was 3.15% (95% confidence interval 
(CI):2.37-4.23), late mortality rate was 1.55%/year (95%CI:1.25-1.92); 38.7% of late deaths 
were valve-related. Pooled thromboembolism rate was 0.90%/year (95%CI:0.68-1.21), 
major bleeding 0.85%/year (95%CI:0.65-1.12), nonstructural valve dysfunction 0.39%/
year (95%CI:0.21-0.76), endocarditis 0.41%/year (95%CI:0.29-0.57), valve thrombosis 
0.14%/year (95%CI:0.08-0.25), structural valve deterioration 0.00%/year (zero events ob-
served), and reintervention 0.51%/year (95%CI:0.37-0.71), mostly due to nonstructural 
valve dysfunction and endocarditis. For a 45-year-old, for example, this translated to an 
estimated life expectancy of 19 years (general population: 34 years) and lifetime risks 
of thromboembolism, bleeding and reintervention of 18%, 15%, and 10%, respectively.
conclusions
This study demonstrates that outcome after mechanical AVR in non-elderly adults is 
characterized by suboptimal survival and considerable lifetime risk of anticoagulation-
related complications, but also reoperation. Non-elderly adult patients who are facing 
prosthetic valve selection are entitled to conveyance of evidence-based estimates of the 
risks and benefits of both mechanical and biological valve options in a shared decision-
making process.
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introDuction
Aortic valve replacement (AVR) is the most widely used surgical treatment for aortic 
valve disease in non-elderly adults. When valve repair is not possible, two types of valve 
substitutes are available: mechanical and biological valves. The primary advantage of 
mechanical valves is their durability. They do, however, require lifelong anticoagulation 
due to their increased thrombogenicity, which gives rise to a substantial risk of throm-
boembolic and bleeding complications that may have an important impact on quality of 
life.1 Furthermore, patients are faced with the hassle of INR regulation, the valve sound 
and, in the case of a woman with pregnancy wishes, the hazards of anticoagulation 
during pregnancy. Biological valves do not require long-term anticoagulation unless 
another indication is present. However, they are subject to valve deterioration over time 
and young patients, in particular, may require a reoperation later in life.2
Since all currently available valve substitutes have important limitations, younger 
patients who require AVR are facing a difficult choice. A mechanical valve is often 
recommended in non-elderly adult patients due to the lower, though not absent, rate 
of reoperation compared with biological valves. Subsequently, most non-elderly adult 
patients will face a lifelong risk of bleeding and thromboembolic events after their 
mechanical AVR. To improve decision-making with regard to prosthetic valve selection 
in non-elderly adults, detailed and up-to-date information on mechanical valve-related 
morbidity and mortality is required. To gain insight in morbidity and mortality after 
contemporary mechanical AVR in non-elderly adults, we aim to provide an overview of 
published evidence by conducting a systematic review and meta-analysis of reported 
outcome. Furthermore, we aim to estimate age-specific life expectancy and lifetime risk 
of valve-related events with the use of a microsimulation model based on the results of 
our meta-analysis.
MetHoDs
This systematic review was conducted according to the PRISMA guidelines.3 This study 
was approved by the institutional review board and informed consent was waived 
(MEC-2015-170).
literature search
On 7 December 2015, a systematic literature search was conducted in Embase, MEDLINE, 
The Cochrane Collaboration andWeb of Science by a biomedical information specialist 
(Supplement 1). All studies were screened by two independent reviewers (NMK, JRGE). 
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Studies reporting survival after contemporary AVR with a mechanical valve in patients 
with a mean age ≥18 and ≤55 years published in English after 1 January 1995 were 
considered for inclusion. Studies were included if >90% of the cohort received bileaflet 
prostheses. Studies limited to patients with pre-existing comorbidities or patients with a 
history of previous AVR were excluded. Studies with a study size ≤20 patients or focusing 
only on certain prosthetic valve sizes or multiple valve replacement were also excluded.
In case of overlapping study populations, only the most recent or most complete study 
was included. In case of disagreement between the reviewers, a consensus was negoti-
ated.
In case a full text publication was not available or information was missing the author 
was contacted by e-mail.
Data extraction
Microsoft Office Excel (details in Supplement 5) was used for data extraction. The same 
pair of reviewers (NMK, JRGE) extracted the data independently. After data extraction, 
each reviewer verified the other reviewer’s data entries. Recorded study characteristics, 
baseline patient and operative characteristics and outcome events are listed in Supple-
ment 5. Morbidity and mortality were documented according to the guidelines.4 Early 
outcome events were defined as occurring within the first 30 postoperative days, regard-
less of the patient’s location, and late outcome events were defined as occurring after 
the first 30 postoperative days. If the total follow-up was not reported, it was calculated 
by multiplying the number of patients with the mean follow-up duration of that study.
Meta-analysis
Continuous variables are presented as mean ± standard deviation. Categorical variables 
are presented as counts and percentages. Linearized event occurrence rates are pre-
sented as percentages per year.
Pooled baseline patient characteristics were calculated with the use of sample size 
weighting. Early mortality risk and linearized occurrence rates of late mortality, reopera-
tions and complications after AVR were calculated and pooled with the use of inverse 
variance weighting on a logarithmic scale, as the Shapiro-Wilk test revealed a significantly 
skewed distribution among the included studies in the majority of outcome measures. 
Inverse variance weighting was conducted according to the number of patients for early 
mortality and according to the number of patientyears of follow-up for late events. In 
case a particular event was reported not to occur in an individual study, then for the 
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purpose of inverse variance weighting it was assumed that 0.5 patient experienced that 
event. A random-effects model was used to estimate pooled effects.
The Cochran Q statistic and the I2 test were used to assess heterogeneity. Potential 
causes of heterogeneity were explored by investigating the effect of year of first 
inclusion, mean follow-up duration, case mix and study design (retrospective versus 
prospective/randomized controlled trial) by means of univariable random-effects meta-
regression. Funnel plots were used to investigate publication bias. To investigate the 
potential influence of publication bias on pooled outcome, sensitivity analyses were 
conducted by temporarily excluding the smallest quartile (by sample size) of included 
studies. Statistical analyses were performed in Microsoft Office Excel, IBM SPSS Statistics 
and R (software details are listed in Supplement 5).
Microsimulation
A microsimulation model based on the pooled outcome estimates of our meta-analysis 
was used to calculate age-specific life expectancy and lifetime risk of valve-related mor-
bidity.5,6 The microsimulation model iteratively simulates individual patient lives after 
surgery, taking into account the morbidity and mortality events that the patient may 
experience. The simulated individual patient life histories are then aggregated to obtain 
estimates of population level outcome. The mortality of a patient is composed of the 
background mortality of the general population, operative mortality, mortality due to 
valve-related events and an additional excess mortality component that is not a direct 
result of valve-related events, but is associated with underlying valve pathology, left 
ventricular function and other associated pathology.
The operative mortality risk, the occurrence rate of each valve-related event and the risk 
of mortality and reintervention as a direct result of each of these valve-related events 
were obtained from our meta-analysis. The occurrence rates of all events were assumed 
to be linear and non-age- dependent. The hazard ratios of the additional excess mortal-
ity not directly resulting from valve-related events have been previously estimated.6 
For patients aged 25, 35, 45, and 55, these hazard ratios were 5.5, 4.4, 2.9, and 1.8 
formales and 7.0, 7.0, 4.2, and 2.8 for females, respectively. The background mortality 
of the general population was obtained from the 1996 USA Life Tables, as 1996 was the 
pooled median year of intervention (assuming a constant incidence rate over time in 
each study) and the majority of the included study population originated from, or was 
comparable to the US population.7
To obtain age-specific estimates of life expectancy and lifetime risk of valve-related 
morbidity, the microsimulation model was run for the ages 25, 35, 45, and 55 years for 
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10 000 iterations each and separately for males and females. The age-specific outcomes 
of both genders were then pooled at the male/female ratio obtained from our meta-
analysis (72.0% male).
For the purposes of internal validation, the model was additionally run for 10 000 itera-
tions at the pooled mean age (48 years) and pooled male/ female ratio of the included 
studies (72.0% male). The actuarial survival curve obtained from this model was then 
plotted against the pooled overall mortality observed in ourmeta-analysis.
figure 1. Flowchart of systematic literature search.
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results
The systematic literature search identified 3100 publications, of which 29 were included 
in the meta-analysis, encompassing a total of 5728 patients with 32 515 patient-years 
of follow-up (pooled mean follow-up: 5.7 years) (Figure 1). Supplement 2 represents 
the characteristics of the included studies (references listed in Supplement 6). Pooled 
baseline patient characteristics are shown in Table 1.
Pooled risks of early mortality and early complications and pooled linearized occurrence 
rates of late mortality and late morbid events are presented in Table 2 (individual study 
estimates are presented in Supplement 3).
Microsimulation-based age-specific estimates of (event-free) life expectancy and life-
time risk of valve-related morbidity are shown in Figure 2. The microsimulation model 
table 1. Pooled pre-operative and peri-operative characteristics
variable Pooled data range included studies (n)
Total number of patients 5728 20-865 29
Mean age (years) 48.0 33.0-54.9 29
Gender Male 72.0% 50.0-91.0% 23
Etiology Degenerative 21.5% 0.0-78.0% 12
Endocarditis 10.0% 0.0-100% 19
Rheumatic 36.4% 0.0-77.8% 12
Congenital 16.5% 0.0-57.0% 10
Prosthetic valve dysfunction 3.8% 0.0-22.0% 14
Other/unknown 11.7% 0.0-66.0% 13
Aortic valve haemodynamics Stenosis 43.5% 0.0-100% 13
Regurgitation 40.4% 0.0-70.0% 13
Combined 16.2% 0.0-30.0% 12
Bicuspid aortic valve 24.5% 1.4-100% 4
Previous cardiac intervention 8.4% 0.0-26.0% 13
Emergency surgery 3.4% 0.0-35.0% 10
Prosthetic valve type Bileaflet 99.9% 96.5-100% 29
Tilting-disc 0.1% 0.0-3.5% 29
Caged-ball 0.0% 0.0-0.0% 29
Concomitant procedures 22.2% 0.0-52.2% 11
CABG 7.1% 0.0-17.5% 21
Aortic surgery 8.6% 0.0-33.0% 11
Multiple valve replacement 2.6% 0.0-24.6% 17
CABG, coronary artery bypass grafting.
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calibrated well with the pooled mortality observed in our meta-analysis over the first 
postoperative decade (see Supplement 7). For a 45-year-old, for example, microsimu-
lation-based estimated life expectancy was 19 years (general population: 34 years) and 
lifetime risks of thromboembolism, bleeding and reintervention were 18%, 15%, and 
10%, respectively.
table 2. Pooled risk of early outcome events and linearized occurrence rates of late outcome events ob-
tained from the meta-analysis
outcome events Pooled estimate Heterogeneitya included studies (n)
early (<30 days)
Early mortality (%) 3.15 (2.37-4.21) I2 = 70% (P < 0.001) 25
Re-exploration for bleeding (%) 5.15 (2.57-11.81) I2 = 87% (P < 0.001) 7
Pacemaker implantation (%) 3.53 (2.47-5.05) I2 = 20% (P = 0.289) 4
Deep sternal infection/mediastinitis (%) 2.48 (1.56-3.94) I2 = 0% (P = 0.409) 5
Endocarditis (%) 0.43 (0.16-1.13) I2 = 0% (P = 0.853) 7
Stroke (%) 1.55 (0.98-2.46) I2 = 15% (P = 0.312) 8
Transient ischemic attack (%) 0.81 (0.38-1.72) I2 = 1% (P = 0.400) 5
Myocardial infarction (%) 0.87 (0.40-1.87) I2 = 0% (P = 0.687) 5
Valve thrombosis (%) 0.30 (0.09-1.05) I2 = 0% (P = 0.782) 5
Peripheral bleeding (%) 0.41 (0.15-1.09) I2 = 0% (P = 0.756) 7
late (>30 days)
Late mortality (%/year) 1.55 (1.25-1.92)c I2 = 83% (P < 0.001) 29
 Cardiac death (%/year) 0.95 (0.71-1.27) I2 = 70% (P < 0.001) 22
 Valve-related death (%/year) 0.60 (0.44-0.81) I2 = 64% (P < 0.001) 24
 SUD (%/year) 0.37 (0.26-0.54) I2 = 47% (P = 0.011) 19
Reintervention (%/year) 0.51 (0.37-0.71) I2 = 47% (P = 0.011) 20
Thromboembolism (%/year) 0.90 (0.68-1.21)d I2 = 79% (P < 0.001) 25
Valve thrombosis (%/year) 0.14 (0.08-0.25) I2 = 62% (P < 0.001) 18
Bleeding (%/year) 0.85 (0.65-1.12)d I2 = 67% (P < 0.001) 26
SVD (%/year) 0.00b - 15
NSVD (%/year) 0.39 (0.21-0.76) I2 = 83% (P < 0.001) 17
Endocarditis (%/year) 0.41 (0.29-0.57) I2 = 34% (P = 0.072) 19
Pooled estimates presented as ‘percentage (95% confidence interval)’.
SUD, sudden unexplained death; SVD, structural valve deterioration; NSVD, nonstructural valve dysfunc-
tion.
aThe reported P-values are the P-values of Cochran’s Q test for heterogeneity.
bThere were zero events of SVD in the 15 studies that reported this outcome.
cThe background mortality rate in the age- and gender-matched United States general population for the 
pooled year of surgery and length of follow-up of our cohort was 0.55%/year.
dThe background rates of thromboembolism and bleeding events in the age- and gender-matched general 
population were 0.12%/year and 0.03%/year, respectively (based on the Oxford Vascular Study8).
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The funnel plots showed evidence of possible publication bias in early mortality, 
late mortality, thromboembolism, and bleeding (Supplement 8). Sensitivity analyses 
showed that this potential publication bias did not substantially influence our pooled 
outcomes, as pooled outcomes remained largely unchanged after temporary exclusion 
of the smallest quartile of studies (before vs. after exclusion: early mortality [3.15% vs. 
3.03%], late mortality [1.55%/year vs. 1.55%/year], thromboembolism [0.90%/year vs. 
0.88%/year], bleeding rates [0.85%/year vs. 0.87%/year]).
Heterogeneity
There was substantial heterogeneity in early mortality, re-exploration for bleeding and 
all late outcome measures with the exception of structural valve deterioration (SVD) and 
endocarditis. Univariable random-effectsmeta-regression (Supplement 4) showed that 
studies with a longer mean follow-up reported lower early mortality (P < 0.001), lower 
reintervention rates (P = 0.010) and lower bleeding rates (P = 0.042), although follow-up 
Figure 2.
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figure 2. Microsimulation-based age-specific life expectancy and lifetime risk of valve-related morbidity. 
AVR, aortic valve replacement.
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duration was moderately negatively correlated with concomitant CABG (r= -0.37) and 
earlier year of first inclusion (r= -0.31).
Etiology was another important factor associated with heterogeneity as a higher pro-
portion of pre-operative endocarditis appeared to be correlated with higher rates of 
late mortality (P= 0.008) and NSVD (P = 0.002), while a higher proportion of rheumatic 
etiology was associated with lower rates of NSVD (P= 0.004). Bleeding and nonstructural 
valve dysfunction (NSVD) rates were higher in cohorts with a higher proportion of aortic 
stenosis (bleeding P= 0.026; NSVD P< 0.001) and, consequently, a lower proportion of 
aortic regurgitation (bleeding P=0.003; NSVD P< 0.001), although there was a moderate-
to-strong negative correlation between preoperative aortic valve stenosis (as opposed 
to regurgitation) and etiology (endocarditis r= -0.71; rheumatic r= -0.37). Lastly, higher 
proportions of emergency surgeries (P = 0.007) and concomitant CABG (P= 0.046) 
were associated with higher rates of NSVD and a higher proportion of concomitant 
procedures was associated with higher reported early mortality risk (P= 0.045).We were 
unable to find any explanatory variables for the heterogeneity in thromboembolism and 
valve thrombosis rates. Differences in study design, year of first inclusion and previous 
cardiac interventions were not associated with heterogeneity in any of the outcome 
measures. Meta-regression was not conducted for re-exploration for bleeding due to 
limited sample size.
Discussion
This study offers an overview of reported mortality and morbidity after mechanical 
AVR in non-elderly adult patients and microsimulation-based age-specific estimates of 
expected lifetime outcome. It confirms the excellent long-term durability of mechanical 
valves in these patients, but also underlines the substantial late cardiovascular death 
and anticoagulation-related complication hazards after mechanical AVR. Although no 
cases of SVD were observed after contemporary AVR with currently available mechani-
cal valves, microsimulation revealed a considerable lifetime risk of reintervention in 
this subgroup that ranged from 15% for patients aged 25 years at surgery to 8% for 
55-year-olds, mostly due to NSVD and endocarditis. Most notably however, the com-
bined lifetime risk of thromboembolism, valve thrombosis and bleeding ranged from 
53% for patients aged 25 years at surgery to 30% for 55-year-olds. Life expectancy is 
substantially impaired in these patients compared with the general population and 
about 40% of deaths are valve-related.
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Mortality
Elective, isolated mechanical AVR has been previously shown to be associated with 
significant excess mortality when compared with the general age-matched population.9 
In our meta-analysis we found a 3.15% early mortality risk and a substantial late mortal-
ity rate of 1.55%/year in patients with a pooled mean age of 48.0 years at the time of 
surgery. Microsimulation-based mean life expectancy after contemporary mechanical 
AVR ranged from 28 years for patients aged 25 years at surgery to 16 years for 55-year-
olds, which is little over half the life expectancy of the age-matched general population. 
When taking the absent risk of SVD and subsequent reintervention associated with con-
temporary mechanical AVR into account, this mortality rate appears to be relatively high 
in comparison with other valve substitutes in non-elderly adults, such as the Ross proce-
dure, which has been reported to be associated with lower late mortality in non-elderly 
adults compared with our pooled results after contemporary mechanical AVR (0.64%/
year vs. 1.55%/year), while early mortality risk was comparable (3.24% vs. 3.15%).10 Pros-
thetic valve-associated hemodynamic factors, such as prosthesis-patient mismatch, may 
play a role in this observed excess mortality.11,12 Furthermore, the higher mortality after 
mechanical AVR may be attributable in part to the required anticoagulation treatment. 
In this regard, optimization of the anticoagulation therapy after mechanical AVR may 
offer a survival benefit in these patients. This is supported by a recent study by Mokhles 
et al., which found that, with optimal self-management anticoagulation, mechanical 
AVR offers excellent late survival, comparable to the general age-matched population 
and also comparable to patients undergoing the Ross procedure.13
The survival differences between mechanical valves and other valve substitutes may be 
further explained by possible differences in patient characteristics, surgical technique 
and concomitant procedures performed at the time of AVR. Rheumatic valve disease 
being the most common etiology in present study (34% of our patients) may represent 
evidence of this possible selection bias.
thromboembolism and bleeding
Present study underlines the burden of thromboembolism and bleeding after mechani-
cal AVR in non-elderly patients as approximately half of patients aged 25 and 1 out of 3 
patients aged 55 at the time of surgery are estimated to experience thromboembolism, 
valve thrombosis or bleeding events during their lifetime. This is most likely an under-
estimate as the included studies were largely retrospective in design, which may have 
given rise to recall bias. Anticoagulation-related complications remain an important 
limitation of mechanical valve prostheses, especially in the young patients in which they 
are generally used, as there are serious implications for life-, career- and pregnancy-
planning in these patients. However, optimizations of the required anticoagulation 
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therapy such as self-management and lower dosing may be promising methods of 
reducing complication rates after mechanical AVR. There is increasing evidence that 
patients with contemporary mechanical valves and no comorbidities may be safely 
managed at a lower INR than currently recommended, subsequently reducing bleeding 
complications without increasing the risk of thromboembolic events.14-16 Furthermore, 
advances in the design of mechanical valves may lead to reduced thrombogenicity. Me-
chanical valves specifically designed with this in mind have emerged, one of which has 
recently received FDA-approval for anticoagulation management at a lower INR than 
recommended by the guidelines.16 Nevertheless, we did not find any evidence in this 
systematic review that thromboembolism and bleeding hazard has decreased in more 
recent years.
Pharmacological advances that provide more stable INR management may further 
reduce complication rates as studies have shown that, in patients treated with currently 
available anticoagulants, 25% of periodically measured INR values lie outside of the 
target range.14
reintervention, nonstructural valve dysfunction, and endocarditis
Our results underline excellent long-term durability as the main advantage of me-
chanical valves, with negligible SVD rates. Although SVD remains a rare complication 
in mechanical valve recipients, depending on age at surgery, approximately 8-15% of 
patients require reintervention during their lifetime, mostly due to NSVD (pannus for-
mation, paravalvular leakage, etc.), valve thrombosis or prosthetic valve endocarditis. 
Although this risk of reintervention is very low compared with other valve substitutes in 
non-elderly adults, it is not absent and should always be taken into consideration and 
discussed with the patient when prosthetic valve selection is addressed.
Prosthetic valve selection
In prosthetic valve selection, mechanical valve-associated thromboembolism and 
bleeding risk is generally weighed against the risk of SVD and subsequent reinterven-
tion associated with biological valve substitutes. In non-elderly patients a mechanical 
valve is often recommended due to the limited durability of biological alternatives. 
However, the durability of modern bioprostheses is improving. These improvements 
as well as improved outcomes in reoperative aortic valve surgery and the prospect of 
transcatheter valve-in-valve replacement of failing bioprostheses has led to an increase 
in their use in younger patients.17-22 Additionally, the Ross procedure represents another 
valuable option in these patients that avoids the need for long-term anticoagulation 
and provides superior long-term survival, excellent hemodynamic performance and a 
low risk of endocarditis in selected patients when performed in centres of expertise. 
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Due to the continued improvements in bioprosthetic AVR and the option of the Ross 
procedure, the substantial risk of mechanical valve-related complications, as delineated 
by our results, will become more prominent in the process of prosthetic valve selection. 
Furthermore, although the risk of reintervention after mechanical AVR is low, it is cer-
tainly not absent and should also be taken into consideration in the process of prosthetic 
valve selection. This also applies to the risk of thromboembolism and bleeding after AVR 
with biological alternatives. Besides clinical factors, the benefits and limitations of each 
option have substantial implications for life-, career- and pregnancy planning in these 
patients. Therefore, conveyance of patient-tailored evidence-based risks and benefits 
of both mechanical and biological valve options in a shared decisionmaking process 
is of great importance.2,23 Innovative solutions such as patient information portals and 
decision aids may prove useful in this setting.24
Heterogeneity
Although heterogeneity was considerable in our meta-analysis and may have poten-
tially influenced the results, we pursued a thorough examination of possible sources 
of heterogeneity. Etiology and concomitant procedures appear to be important factors 
of influence on the reported outcomes, which is in line with expectations based on the 
literature.25,26 Furthermore, we found aortic regurgitation vs. stenosis to be associated 
with more favourable reported outcome with regard to bleeding and NSVD rates, while 
regurgitation has been previously described to be associated with less favourable 
outcome.25 This discrepancy may be explained by the strong correlation we found in 
our meta-regression between aortic valve haemodynamics and etiology (studies with 
a higher proportion of stenosis had lower proportions of endocarditis and rheumatic 
etiology), which may have confounded the results.
Lastly, although there was no consistent evidence thereof in our analyses, the year of 
operation, ranging from 1977-2014 among the included studies, may still have affected 
the results, as case-mix may have changed over the years and evolution of operative 
techniques may have led to lower operative risk.
Although this observed heterogeneity might have introduced uncertainty in our meta-
analysis, with the use of a random-effects model, this uncertainty is incorporated in the 
reported pooled outcome estimates.
Publication bias
The asymmetry we found in our funnel plots may represent evidence of possible publi-
cation bias. However, assessment of publication bias in absolute risk outcomes, as were 
all of our outcomes, is associated with substantial methodological limitations which 
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may in itself give rise to funnel plot asymmetry.27 Our funnel plots should therefore be 
interpreted with caution. Although a conclusive investigation of publication bias may 
not be possible, our sensitivity analyses show that any potential publication bias did not 
substantially influence our pooled outcomes.
limitations
The present study is a systematic review and meta-analysis of observational studies, 
most of which are retrospective in design. As such, the inherent limitations of meta-
analyses and combining data from retrospective observational studies should be taken 
into consideration.28 Selection bias may have affected the observed outcomes, as un-
published data, abstracts and presentations were not included. Among the included 
studies, baseline and surgical characteristics were not reported in sufficient detail 
and consistently enough for us to fully account for all baseline covariates in our meta-
analyses. Direct comparisons with alternative valve prostheses are hampered by the 
lack of published comparative data. Setting a time limit to systematic literature searches 
may introduce potential bias, but we chose to do so in our aim to provide an overview 
of contemporary outcome. Finally, there are some limitations to the microsimulation 
model that should be taken into account. The relationship of the occurrence rates of 
valve-related events after mechanical AVR with age, follow-up duration and history of 
previous valve-related events remains poorly defined and could, thus, not be incorpo-
rated into our microsimulation model. Uncertainty in the parameters within the model 
(second order uncertainty) was also not incorporated in our microsimulation model. 
The model requires assumptions to be made about the evolution of event occurrence 
rates beyond the observed follow-up period, which may have introduced uncertainty. 
Our United States general population-based background mortality estimate should be 
regarded as merely a reference point, as it may not be an ideal reflection of the general 
populationmortality of the different countries that are represented in the individual 
studies in the review.
conclusions
This review shows that the use of mechanical valves in non-elderly adult patients is 
associated with substantial excess mortality over time and considerable lifetime risk of 
anticoagulation-related complications, but also reoperation. This confirms the fact that 
non-elderly adult patients who require AVR are facing a difficult choice between mechani-
cal and biological valves and, therefore, conveyance of patient-tailored evidence-based 
risks and benefits of both mechanical and biological valve options in a shared decision-
making process is of great importance in the setting of prosthetic valve selection.
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supplement 1. Literature search query
embase (embase en Medline): 3181 results
(‘Aorta valve replacement’/de OR ‘Aorta Valve Prosthesis’/exp OR ((‘Aorta Valve’/de OR 
‘Aorta Valve Disease’/exp OR ((aortic OR aorta) NEAR/3 (valve OR valvul* OR stenos* 
OR insufficien* OR regurgitat* OR incompeten*)):ab,ti) AND (‘Transplantation’/de OR 
‘Implantation’/exp OR (replac* OR transplant* OR implant* OR artificial):ab,ti)) OR (AVR 
AND valve):ab,ti) AND (‘Mechanical heart valve’/exp OR (mechanical OR mechano* OR 
ATS OR ‘Bjork Shiley’ OR ‘Bjoerk Shiley’ OR CarboMedic* OR ‘Saint Jude’ OR ‘St Jude’ OR 
‘St. Jude’ OR ‘Starr Edwards’ OR pyrocarbon OR LTIC OR carbon):ab,ti) AND (‘Survival’/exp 
OR ‘Mortality’/exp OR ‘Prognosis’/de OR ‘Treatment outcome’/exp OR ‘Evaluation and 
follow up’/de OR ‘Follow up’/de OR ‘Hazard Assessment’/de OR (surviv* OR mortalit* OR 
death* OR prognos* OR outcome* OR ‘follow up’ OR ‘long term’ OR hazard*):ab,ti) NOT 
([animals]/lim NOT [humans]/lim)
Medline (oviD-sP): 2350 results
(((“Aortic Valve”/ OR exp “Aortic Valve Stenosis”/ OR “Aortic Valve Insufficiency”/ OR 
((aortic OR aorta) ADJ3 (valve OR valvul* OR stenos* OR insufficien* OR regurgitat* OR 
incompeten*)).ab,ti.) AND (“Transplantation”/ OR transplantation.xs. OR “Heart Valve 
Prosthesis Implantation”/ OR (replac* OR transplant* OR implant* OR artifical).ab,ti.)) OR 
(AVR AND valve).ab,ti.) AND (“Carbon”/ OR (mechanical OR mechano* OR ATS OR “Bjork 
Shiley” OR “Bjoerk Shiley” OR Carbomedic* OR “Saint Jude” OR “St Jude” OR “St. Jude” 
OR “Starr Edwards” OR pyrocarbon OR LTIC OR carbon).ab,ti.) AND (“Survival”/ OR exp 
“Mortality”/ OR mortality.xs. OR “Prognosis”/ OR exp “Treatment outcome”/ OR “Follow-
Up Studies”/ OR (surviv* OR mortalit* OR death* OR prognos* OR outcome* OR “follow 
up” OR “long term” OR hazard*).ab,ti.) NOT (animals NOT humans).sh.
cochrane central: 80 results
(((((aortic OR aorta) NEAR/3 (valve OR valvul* OR stenos* OR insufficien* OR regurgitat* 
OR incompeten*)):ab,ti) AND ((replac* OR transplant* OR implant* OR artificial):ab,ti)) 
OR (AVR AND valve):ab,ti) AND ((mechanical OR mechano* OR ATS OR ‘Bjork Shiley’ OR 
‘Bjoerk Shiley’ OR CarboMedic* OR ‘Saint Jude’ OR ‘St Jude’ OR ‘St. Jude’ OR ‘Starr Edwards’ 
OR pyrocarbon OR LTIC OR carbon):ab,ti) AND ((surviv* OR mortalit* OR death* OR prog-
nos* OR outcome* OR ‘follow up’ OR ‘long term’ OR hazard*):ab,ti)
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web of science: 1538 results
TS=(((((aortic OR aorta) NEAR/2 (valve OR valvul* OR stenos* OR insufficien* OR regur-
gitat* OR incompeten*)) AND (replac* OR transplant* OR implant* OR artificial)) OR 
(AVR AND valve)) AND ((mechanical OR mechano* OR ATS OR “Bjork Shiley” OR “Bjoerk 
Shiley” OR CarboMedic* OR “Saint Jude” OR “St Jude” OR “St. Jude” OR “Starr Edwards” 
OR pyrocarbon OR LTIC OR carbon)) AND ((surviv* OR mortalit* OR death* OR prognos* 
OR outcome* OR “follow up” OR “long term” OR hazard*)) NOT ((animal* OR rat OR rats 
OR mouse OR mice OR pigs Or swine OR sheep) NOT (human* OR people OR patient*)))
PubMed as supplied by publisher: 36 results
((((aortic[tiab] OR aorta[tiab]) AND (valve[tiab] OR valvul*[tiab] OR stenos*[tiab] OR 
insufficien*[tiab] OR regurgitat*[tiab] OR incompeten*[tiab])) AND (replac*[tiab] OR 
transplant*[tiab] OR implant*[tiab] OR artificial[tiab])) OR (AVR[tiab] AND valve[tiab])) 
AND ((mechanical[tiab] OR mechano*[tiab] OR ATS[tiab] OR Bjork Shiley*[tiab] OR 
CarboMedic*[tiab] OR Saint Jude*[tiab] OR St Jude*[tiab] OR St. Jude*[tiab] OR Starr 
Edwards*[tiab] OR pyrocarbon[tiab] OR LTIC[tiab] OR carbon[tiab])) AND ((surviv*[tiab] 
OR mortalit*[tiab] OR death*[tiab] OR prognos*[tiab] OR outcome*[tiab] OR follow 
up*[tiab] OR long term*[tiab] OR hazard*[tiab])) NOT ((animal*[tiab] OR rat[tiab] OR 
rats[tiab] OR mouse[tiab] OR mice[tiab] OR pigs[tiab] OR swine[tiab] OR sheep[tiab]) NOT 
(human*[tiab] OR people[tiab] OR patient[tiab] OR patients[tiab])) AND publisher[sb]
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supplement 2. Study characteristics
first author year of publication no. of patients inclusion period
(y)
study type Mean follow-up
(y)
Mean age
(y)
gender
(% male)
Prosthesis model
Nistal 1996 209 1989-1992 Retrospective 2.5 54.1 74.2 Carbomedics
Gaudino 1997 20 1988-1996 Retrospective 2.5 46.5 85.0 Sorin Bicarbon (n=10)/Carbomedics (n=5)/St. Jude (n=3)
Katircioglu 1997 865 1986-1996 Retrospective 3.3 42.9 - St. Jude
Renzulli 1997 305 1982-1994 Retrospective 3.1 50.4 - Carbomedics (n=200)/St. Jude (n=82)/Sorin Bicarbon (n=23)
Natsuaki 1998 37 1985-1997 Retrospective 5.3 52.0 78.4 St. Jude
Jamieson 1999 384 1989-1994 Retrospective 2.5 52.3 74.2 St. Jude/Carbomedics (n=NR)
Chang 2001 256 1988-1997 Retrospective 5.3 43.9 - St. Jude (n=142)/Carbomedics (n=114)
Imanaka 2001 126 1990-1996 Retrospective 6.3 51.2 59.5 Carbomedics
Ozeren 2001 70 1998-2000 Retrospective 1.3 33.8 - ATS
Kuwaki 2002 69 1990-2000 Retrospective 6.5 48.9 68.1 Carbomedics
Aagaard 2003 55 1987-2000 Retrospective 7.6a 33.0a 76.4 Carbomedics
Emery 2003 271 1977-1997 Retrospective 7.2 40.0 74.2 St. Jude
Chang 2005 179 1988-1999 Retrospective 7.9 44.4 - Carbomedics
Concha 2005 62 1997-2003 Prospective 2.5 37.7 75.8 Carbomedics (n=38)/St. Jude (n=24)
Sakamoto 2005 46 1995-2002 Retrospective 6.2 54.0 91.3 St. Jude
Kandemir 2006 174 1992-2004 Retrospective 6.2 47.7 77.6 Carbomedics (n=94)/St. Jude (n=80)
Klieverik 2006 204 1991-2001 Retrospective 6.2 45.0 73.0 St. Jude (n=199)/ATS (n=4)/Björk-Shiley (n=1)
Kilian 2007 147 1990-1998 Retrospective 8.1 54.8 85.0 Sorin Bicarbon
Rodrigues 2009 117 1995-2003 Retrospective 4.0 45.0 69.2 St. Jude
Torella 2010 396 2001-2005 RCT 5.6a 49.7 69.2 Sorin Bicarbon (n=292)/St. Jude (n=92)/Edwards MIRA(n=7)/ Carbomedics (n=5)
Doss 2011 20 - RCT 1.0 48.0 55.0 Edwards MIRA
Weber 2012 103 2000-2009 Prospective 2.8 50.0 84.5 St. Jude/ATS (n=NR)
Cohoon 2013 60 1994-2000 Retrospective 6.6 46.0 83.3 St. Jude
Andreas 2014 173 1991-2008 Retrospective 7.9 41.0 75.1 Carbomedics/Medtronic Hall/On-X/Edwards/St. Jude (n=NR)
McClure 2014 361 1992-2011 Retrospective 6.0a 53.2 70.4 St. Jude (n=318)/On-X (n=23)/Carbomedics (n=19)/Unknown (n=1)
Nazarov 2014 211 2003-2004 Prospective 5.1 52.2 - Cardiamed
Nishida 2014 220 1990-2012 Retrospective 12.0 54.9 72.7 Carbomedics
Bouhout 2015 450 1997-2006 Prospective 9.1 53.0 67.6 Carbomedics (n=402)/St. Jude (n=35)/Medtronic Advantage (n=13)
Nishida 2015 157 1981-2014 Retrospective 11.8 50.6 49.7 St. Jude
aMedian. -, variable not reported; RCT, randomized controlled trial; NR, not reported.
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supplement 2. Study characteristics
first author year of publication no. of patients inclusion period
(y)
study type Mean follow-up
(y)
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(y)
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(% male)
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Chang 2001 256 1988-1997 Retrospective 5.3 43.9 - St. Jude (n=142)/Carbomedics (n=114)
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Emery 2003 271 1977-1997 Retrospective 7.2 40.0 74.2 St. Jude
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Concha 2005 62 1997-2003 Prospective 2.5 37.7 75.8 Carbomedics (n=38)/St. Jude (n=24)
Sakamoto 2005 46 1995-2002 Retrospective 6.2 54.0 91.3 St. Jude
Kandemir 2006 174 1992-2004 Retrospective 6.2 47.7 77.6 Carbomedics (n=94)/St. Jude (n=80)
Klieverik 2006 204 1991-2001 Retrospective 6.2 45.0 73.0 St. Jude (n=199)/ATS (n=4)/Björk-Shiley (n=1)
Kilian 2007 147 1990-1998 Retrospective 8.1 54.8 85.0 Sorin Bicarbon
Rodrigues 2009 117 1995-2003 Retrospective 4.0 45.0 69.2 St. Jude
Torella 2010 396 2001-2005 RCT 5.6a 49.7 69.2 Sorin Bicarbon (n=292)/St. Jude (n=92)/Edwards MIRA(n=7)/ Carbomedics (n=5)
Doss 2011 20 - RCT 1.0 48.0 55.0 Edwards MIRA
Weber 2012 103 2000-2009 Prospective 2.8 50.0 84.5 St. Jude/ATS (n=NR)
Cohoon 2013 60 1994-2000 Retrospective 6.6 46.0 83.3 St. Jude
Andreas 2014 173 1991-2008 Retrospective 7.9 41.0 75.1 Carbomedics/Medtronic Hall/On-X/Edwards/St. Jude (n=NR)
McClure 2014 361 1992-2011 Retrospective 6.0a 53.2 70.4 St. Jude (n=318)/On-X (n=23)/Carbomedics (n=19)/Unknown (n=1)
Nazarov 2014 211 2003-2004 Prospective 5.1 52.2 - Cardiamed
Nishida 2014 220 1990-2012 Retrospective 12.0 54.9 72.7 Carbomedics
Bouhout 2015 450 1997-2006 Prospective 9.1 53.0 67.6 Carbomedics (n=402)/St. Jude (n=35)/Medtronic Advantage (n=13)
Nishida 2015 157 1981-2014 Retrospective 11.8 50.6 49.7 St. Jude
aMedian. -, variable not reported; RCT, randomized controlled trial; NR, not reported.
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supplement 3. Pooled early mortality risk and linearized occurrence rates of 
late outcome events. (including individual study estimates)
early mortality
(%)
late mortality
(%/yr)
cardiac death
(%/yr)
valve-related
death (%/yr)
suD
(%/yr)
reintervention
(%/yr)
thromboembo-
lism
(%/yr)
valve thrombosis
(%/yr) Bleeding
(%/yr)
svD
(%/yr)
nsvD
(%/yr)
endocarditis
(%/yr)
Nistal (1996) 5.26(2.96-9.36) 1.53(0.77-3.05) 1.15(0.52-2.55) 0.96(0.40-2.29) 0.57(0.19-1.78) 0.38(0.10-1.53) 3.07(1.89-4.97) 0.10(0.01-1.53) 1.92(1.04-3.54) 0.10(0.01-1.53) 0.77(0.29-2.03) 0.10(0.01-1.53)
Gaudino (1997) 2.50(0.16-38.60) 5.90(1.97-17.69) 5.90(1.97-17.69) 1.97(0.28-13.70) 0.98(0.06-15.51) 1.97(0.28-13.70) - - - - 5.90(1.97-17.69) 1.97(0.28-13.70)
Katircioglu (1997) 5.90(4.52-7.69) 0.71(0.44-1.14) - - - 1.00(0.67-1.49) 1.50(1.08-2.07) 0.71(0.44-1.14) 1.58(1.15-2.17) - 0.12(0.04-0.39) -
Renzulli (1997) 8.39(5.72-12.31) 0.79(0.38-1.66) 0.57(0.24-1.36) 0.34(0.11-1.05) 0.23(0.06-0.91) - 0.23(0.06-0.91) 0.06(0.00-0.91) 0.91(0.46-1.81) 0.06(0.00-0.91) - -
Natsuaki (1998) - 1.02(0.26-4.05) 0.51(0.07-3.60) 0.25(0.02-4.06) - - 0.25(0.02-4.06) - 0.51(0.07-3.60) - 0.25(0.02-4.06) -
Jamieson (1999) 2.60(1.41-4.80) 1.75(1.09-2.80) 0.72(0.34-1.51) 0.62(0.28-1.37) 0.10(0.01-0.73) - 1.13(0.63-2.04) 0.05(0.00-0.82) 1.54(0.93-2.55) - - -
Chang (2001) 4.69(2.70-8.14) 2.06(1.43-2.98) - - - - - - - 0.04(0.00-0.59) - -
Imanaka (2001) 6.35(3.25-12.42) 1.26(0.68-2.34) 0.63(0.26-1.52) 0.51(0.19-1.34) 0.25(0.06-1.01) - 0.25(0.06-1.01) - 0.25(0.06-1.01) - 0.13(0.02-0.90) 0.13(0.02-0.90)
Ozeren (2001) 1.43(0.20-10.00) 0.58(0.04-9.25) - - - 1.17(0.17-8.19) - 0.58(0.04-9.25) 0.58(0.04-9.25) - 1.17(0.17-8.19) 0.58(0.04-9.25)
Kuwaki (2002) 5.80(2.24-15.01) 1.11(0.47-2.67) 0.89(0.34-2.37) 0.22(0.03-1.58) 0.22(0.03-1.58) 0.67(0.22-2.07) 1.34(0.60-2.96) 0.22(0.03-1.58) 0.45(0.11-1.78) 0.11(0.01-1.78) 1.11(0.47-2.67) 0.22(0.03-1.58)
Aagard (2003) 0.91(0.06-14.35) 0.99(0.37-2.63) 0.74(0.24-2.29) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.50(0.12-1.97) 0.25(0.03-1.75) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.25(0.03-1.75) 0.25(0.03-1.75)
Emery (2003) 1.11(0.36-3.41) 0.92(0.58-1.46) - 0.20(0.08-0.54) - 0.41(0.20-0.82) 0.31(0.14-0.68) 0.10(0.03-0.41) 0.31(0.14-0.68) 0.03(0.00-0.41) 0.31(0.14-0.68) 0.15(0.05-0.47)
Chang (2005) 1.68(0.55-5.15) 1.34(0.86-2.10) 0.99(0.59-1.67) 0.64(0.33-1.22) 0.14(0.04-0.56) 0.07(0.01-0.50) 1.20(0.75-1.93) 0.07(0.01-0.50) 0.92(0.54-1.58) 0.04(0.00-0.57) 0.07(0.01-0.50) 0.42(0.19-0.94)
Concha (2005) 6.45(2.50-16.65) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.64(0.09-4.48) 2.54(0.97-6.69) - 1.27(0.32-5.04) - - 1.91(0.62-5.85)
Sakamoto (2005) 2.17(0.31-15.11) 1.05(0.34-3.24) 0.35(0.05-2.48) 0.35(0.05-2.48) 0.18(0.01-2.80) 0.18(0.01-2.80) 0.81(0.22-2.93) - 0.18(0.01-2.80) - - 0.70(0.18-2.79)
Kandemir (2006) 2.30(0.87-6.06) 1.52(0.93-2.47) 1.33(0.79-2.24) 0.19(0.05-0.76) 0.09(0.01-0.67) - 0.95(0.51-1.76) 0.09(0.01-0.67) 0.66(0.32-1.39) 0.05(0.00-0.76) 0.09(0.01-0.67) -
Klieverik (2006) 1.96(0.74-5.17) 1.58(1.02-2.44) 1.10(0.66-1.86) 0.87(0.48-1.56) 0.47(0.21-1.05) 0.79(0.43-1.46) 0.47(0.21-1.05) 0.24(0.08-0.73) 0.87(0.48-1.56) 0.04(0.00-0.63) 0.32(0.12-0.84) 0.47(0.21-1.05)
Kilian (2007) 4.08(1.86-8.94) 3.52(2.61-4.73) - 1.34(0.82-2.18) - 0.50(0.23-1.12) 1.34(0.82-2.18) - 1.51(0.95-2.38) - - -
Rodrigues (2009) 6.84(3.50-13.35) 1.91(1.00-3.65) 1.49(0.71-3.10) 1.27(0.57-2.82) 0.42(0.11-1.69) 0.21(0.03-1.50) 0.42(0.11-1.69) 0.11(0.01-1.69) 2.33(1.30-4.19) 0.11(0.01-1.69) - 0.21(0.03-1.50)
Torella (2010) - 0.09(0.02-0.36) 0.09(0.02-0.36) 0.09(0.02-0.36) 0.02(0.00-0.36) - 0.18(0.07-0.48) - 0.14(0.04-0.42) - - -
Doss (2011) 2.50(0.16-38.60) 5.00(0.74-33.78) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 5.00(0.74-33.78) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60)
Weber (2012) - 0.71(0.18-2.81) 0.35(0.05-2.50) 0.35(0.05-2.50) 0.18(0.01-2.82) 0.71(0.18-2.81) 2.12(0.96-4.68) - 0.35(0.05-2.50) - - 0.71(0.18-2.81)
Cohoon (2013) - 1.77(0.85-3.68) - - - - - - - - - -
Andreas (2014) 1.16(0.29-4.59) 2.05(1.42-2.96) 1.54(1.01-2.35) 1.39(0.89-2.17) 1.02(0.61-1.72) 0.73(0.39-1.36) 1.10(0.66-1.82) 0.07(0.01-0.52) 1.32(0.83-2.08) - - 0.66(0.34-1.26)
McClure (2014) 1.39(0.58-3.31) 2.28(1.78-2.92) 0.67(0.42-1.07) 0.19(0.08-0.45) 0.02(0.00-0.30) 0.26(0.12-0.55) 0.41(0.23-0.74) - 0.75(0.48-1.16) - - -
Nazarov (2014) 3.32(1.60-6.87) 1.94(1.27-2.97) - - - - 2.13(1.42-3.19) 0.05(0.00-0.74) 0.55(0.25-1.23) 0.05(0.00-0.74) 0.18(0.05-0.74) 0.28(0.09-0.86)
Nishida (2014) 0.91(0.23-3.61) 2.80(2.24-3.51) 2.30(1.79-2.95) 1.00(0.68-1.46) - 0.23(0.10-0.51) 0.80(0.52-1.22) 0.04(0.01-0.27) 0.65(0.40-1.04) 0.02(0.00-0.30) 0.27(0.13-0.56) 0.42(0.23-0.75)
Bouhout (2015) 1.11(0.46-2.66) 1.41(1.10-1.83) 1.00(0.74-1.36) 0.76(0.53-1.07) 0.49(0.32-0.76) 0.63(0.43-0.93) 1.00(0.74-1.36) 0.07(0.02-0.23) 0.93(0.68-1.27) 0.01(0.00-0.19) 0.90(0.65-1.24) 0.24(0.13-0.45)
Nishida (2015) 1.27(0.32-5.05) 2.50(1.88-3.32) 1.10(0.71-1.69) 0.60(0.33-1.08) - 0.27(0.11-0.65) 0.86(0.53-1.40) 0.03(0.00-0.43) 0.65(0.37-1.14) 0.03(0.00-0.43) 0.16(0.05-0.50) 0.16(0.05-0.50)
Pooled 3.15(2.37-4.21) 1.55(1.25-1.92) 0.95(0.71-1.27) 0.60(0.44-0.81) 0.37(0.26-0.54) 0.51(0.37-0.71) 0.90(0.68-1.21) 0.14(0.08-0.25) 0.85(0.65-1.12) 0.00a 0.39(0.21-0.76) 0.41(0.29-0.57)
Heterogeneityb I2=70% (p<0.001) I2=83% (p<0.001) I2=70% (p<0.001) I2=64% (p<0.001) I2=47% (p=0.011) I2=47% (p=0.011) I2=79% (p<0.001) I2=62% (p<0.001) I2=67% (p<0.001) - I2=83% (p<0.001) I2=34% (p=0.0721)
Pooled estimates presented as “percentage (95% confidence interval)”.
-, variable not reported; Yr, year; SUD, sudden, unexplained death; SVD, structural valve deterioration; NSVD, 
nonstructural valve dysfunction.
In case a particular event was reported not to occur in an individual study, then for the purpose of the 
analyses it was assumed that 0.5 patient experienced that event.
aThere were zero events of SVD in the 15 studies that reported this outcome.
bThe reported p-values are the p-values of Cochran’s Q test for heterogeneity.
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supplement 3. Pooled early mortality risk and linearized occurrence rates of 
late outcome events. (including individual study estimates)
early mortality
(%)
late mortality
(%/yr)
cardiac death
(%/yr)
valve-related
death (%/yr)
suD
(%/yr)
reintervention
(%/yr)
thromboembo-
lism
(%/yr)
valve thrombosis
(%/yr) Bleeding
(%/yr)
svD
(%/yr)
nsvD
(%/yr)
endocarditis
(%/yr)
Nistal (1996) 5.26(2.96-9.36) 1.53(0.77-3.05) 1.15(0.52-2.55) 0.96(0.40-2.29) 0.57(0.19-1.78) 0.38(0.10-1.53) 3.07(1.89-4.97) 0.10(0.01-1.53) 1.92(1.04-3.54) 0.10(0.01-1.53) 0.77(0.29-2.03) 0.10(0.01-1.53)
Gaudino (1997) 2.50(0.16-38.60) 5.90(1.97-17.69) 5.90(1.97-17.69) 1.97(0.28-13.70) 0.98(0.06-15.51) 1.97(0.28-13.70) - - - - 5.90(1.97-17.69) 1.97(0.28-13.70)
Katircioglu (1997) 5.90(4.52-7.69) 0.71(0.44-1.14) - - - 1.00(0.67-1.49) 1.50(1.08-2.07) 0.71(0.44-1.14) 1.58(1.15-2.17) - 0.12(0.04-0.39) -
Renzulli (1997) 8.39(5.72-12.31) 0.79(0.38-1.66) 0.57(0.24-1.36) 0.34(0.11-1.05) 0.23(0.06-0.91) - 0.23(0.06-0.91) 0.06(0.00-0.91) 0.91(0.46-1.81) 0.06(0.00-0.91) - -
Natsuaki (1998) - 1.02(0.26-4.05) 0.51(0.07-3.60) 0.25(0.02-4.06) - - 0.25(0.02-4.06) - 0.51(0.07-3.60) - 0.25(0.02-4.06) -
Jamieson (1999) 2.60(1.41-4.80) 1.75(1.09-2.80) 0.72(0.34-1.51) 0.62(0.28-1.37) 0.10(0.01-0.73) - 1.13(0.63-2.04) 0.05(0.00-0.82) 1.54(0.93-2.55) - - -
Chang (2001) 4.69(2.70-8.14) 2.06(1.43-2.98) - - - - - - - 0.04(0.00-0.59) - -
Imanaka (2001) 6.35(3.25-12.42) 1.26(0.68-2.34) 0.63(0.26-1.52) 0.51(0.19-1.34) 0.25(0.06-1.01) - 0.25(0.06-1.01) - 0.25(0.06-1.01) - 0.13(0.02-0.90) 0.13(0.02-0.90)
Ozeren (2001) 1.43(0.20-10.00) 0.58(0.04-9.25) - - - 1.17(0.17-8.19) - 0.58(0.04-9.25) 0.58(0.04-9.25) - 1.17(0.17-8.19) 0.58(0.04-9.25)
Kuwaki (2002) 5.80(2.24-15.01) 1.11(0.47-2.67) 0.89(0.34-2.37) 0.22(0.03-1.58) 0.22(0.03-1.58) 0.67(0.22-2.07) 1.34(0.60-2.96) 0.22(0.03-1.58) 0.45(0.11-1.78) 0.11(0.01-1.78) 1.11(0.47-2.67) 0.22(0.03-1.58)
Aagard (2003) 0.91(0.06-14.35) 0.99(0.37-2.63) 0.74(0.24-2.29) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.50(0.12-1.97) 0.25(0.03-1.75) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.12(0.01-1.98) 0.25(0.03-1.75) 0.25(0.03-1.75)
Emery (2003) 1.11(0.36-3.41) 0.92(0.58-1.46) - 0.20(0.08-0.54) - 0.41(0.20-0.82) 0.31(0.14-0.68) 0.10(0.03-0.41) 0.31(0.14-0.68) 0.03(0.00-0.41) 0.31(0.14-0.68) 0.15(0.05-0.47)
Chang (2005) 1.68(0.55-5.15) 1.34(0.86-2.10) 0.99(0.59-1.67) 0.64(0.33-1.22) 0.14(0.04-0.56) 0.07(0.01-0.50) 1.20(0.75-1.93) 0.07(0.01-0.50) 0.92(0.54-1.58) 0.04(0.00-0.57) 0.07(0.01-0.50) 0.42(0.19-0.94)
Concha (2005) 6.45(2.50-16.65) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.32(0.02-5.06) 0.64(0.09-4.48) 2.54(0.97-6.69) - 1.27(0.32-5.04) - - 1.91(0.62-5.85)
Sakamoto (2005) 2.17(0.31-15.11) 1.05(0.34-3.24) 0.35(0.05-2.48) 0.35(0.05-2.48) 0.18(0.01-2.80) 0.18(0.01-2.80) 0.81(0.22-2.93) - 0.18(0.01-2.80) - - 0.70(0.18-2.79)
Kandemir (2006) 2.30(0.87-6.06) 1.52(0.93-2.47) 1.33(0.79-2.24) 0.19(0.05-0.76) 0.09(0.01-0.67) - 0.95(0.51-1.76) 0.09(0.01-0.67) 0.66(0.32-1.39) 0.05(0.00-0.76) 0.09(0.01-0.67) -
Klieverik (2006) 1.96(0.74-5.17) 1.58(1.02-2.44) 1.10(0.66-1.86) 0.87(0.48-1.56) 0.47(0.21-1.05) 0.79(0.43-1.46) 0.47(0.21-1.05) 0.24(0.08-0.73) 0.87(0.48-1.56) 0.04(0.00-0.63) 0.32(0.12-0.84) 0.47(0.21-1.05)
Kilian (2007) 4.08(1.86-8.94) 3.52(2.61-4.73) - 1.34(0.82-2.18) - 0.50(0.23-1.12) 1.34(0.82-2.18) - 1.51(0.95-2.38) - - -
Rodrigues (2009) 6.84(3.50-13.35) 1.91(1.00-3.65) 1.49(0.71-3.10) 1.27(0.57-2.82) 0.42(0.11-1.69) 0.21(0.03-1.50) 0.42(0.11-1.69) 0.11(0.01-1.69) 2.33(1.30-4.19) 0.11(0.01-1.69) - 0.21(0.03-1.50)
Torella (2010) - 0.09(0.02-0.36) 0.09(0.02-0.36) 0.09(0.02-0.36) 0.02(0.00-0.36) - 0.18(0.07-0.48) - 0.14(0.04-0.42) - - -
Doss (2011) 2.50(0.16-38.60) 5.00(0.74-33.78) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60) 5.00(0.74-33.78) 2.50(0.16-38.60) 2.50(0.16-38.60) 2.50(0.16-38.60)
Weber (2012) - 0.71(0.18-2.81) 0.35(0.05-2.50) 0.35(0.05-2.50) 0.18(0.01-2.82) 0.71(0.18-2.81) 2.12(0.96-4.68) - 0.35(0.05-2.50) - - 0.71(0.18-2.81)
Cohoon (2013) - 1.77(0.85-3.68) - - - - - - - - - -
Andreas (2014) 1.16(0.29-4.59) 2.05(1.42-2.96) 1.54(1.01-2.35) 1.39(0.89-2.17) 1.02(0.61-1.72) 0.73(0.39-1.36) 1.10(0.66-1.82) 0.07(0.01-0.52) 1.32(0.83-2.08) - - 0.66(0.34-1.26)
McClure (2014) 1.39(0.58-3.31) 2.28(1.78-2.92) 0.67(0.42-1.07) 0.19(0.08-0.45) 0.02(0.00-0.30) 0.26(0.12-0.55) 0.41(0.23-0.74) - 0.75(0.48-1.16) - - -
Nazarov (2014) 3.32(1.60-6.87) 1.94(1.27-2.97) - - - - 2.13(1.42-3.19) 0.05(0.00-0.74) 0.55(0.25-1.23) 0.05(0.00-0.74) 0.18(0.05-0.74) 0.28(0.09-0.86)
Nishida (2014) 0.91(0.23-3.61) 2.80(2.24-3.51) 2.30(1.79-2.95) 1.00(0.68-1.46) - 0.23(0.10-0.51) 0.80(0.52-1.22) 0.04(0.01-0.27) 0.65(0.40-1.04) 0.02(0.00-0.30) 0.27(0.13-0.56) 0.42(0.23-0.75)
Bouhout (2015) 1.11(0.46-2.66) 1.41(1.10-1.83) 1.00(0.74-1.36) 0.76(0.53-1.07) 0.49(0.32-0.76) 0.63(0.43-0.93) 1.00(0.74-1.36) 0.07(0.02-0.23) 0.93(0.68-1.27) 0.01(0.00-0.19) 0.90(0.65-1.24) 0.24(0.13-0.45)
Nishida (2015) 1.27(0.32-5.05) 2.50(1.88-3.32) 1.10(0.71-1.69) 0.60(0.33-1.08) - 0.27(0.11-0.65) 0.86(0.53-1.40) 0.03(0.00-0.43) 0.65(0.37-1.14) 0.03(0.00-0.43) 0.16(0.05-0.50) 0.16(0.05-0.50)
Pooled 3.15(2.37-4.21) 1.55(1.25-1.92) 0.95(0.71-1.27) 0.60(0.44-0.81) 0.37(0.26-0.54) 0.51(0.37-0.71) 0.90(0.68-1.21) 0.14(0.08-0.25) 0.85(0.65-1.12) 0.00a 0.39(0.21-0.76) 0.41(0.29-0.57)
Heterogeneityb I2=70% (p<0.001) I2=83% (p<0.001) I2=70% (p<0.001) I2=64% (p<0.001) I2=47% (p=0.011) I2=47% (p=0.011) I2=79% (p<0.001) I2=62% (p<0.001) I2=67% (p<0.001) - I2=83% (p<0.001) I2=34% (p=0.0721)
Pooled estimates presented as “percentage (95% confidence interval)”.
-, variable not reported; Yr, year; SUD, sudden, unexplained death; SVD, structural valve deterioration; NSVD, 
nonstructural valve dysfunction.
In case a particular event was reported not to occur in an individual study, then for the purpose of the 
analyses it was assumed that 0.5 patient experienced that event.
aThere were zero events of SVD in the 15 studies that reported this outcome.
bThe reported p-values are the p-values of Cochran’s Q test for heterogeneity.
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supplement 4. Random effects meta-regression of natural log-transformed 
outcome measures
covariate β 95%ci- 95%ci+ se p-value
Early mortality
Year of first inclusion -0.007 -0.058 0.045 0.026 0.796
Mean fuP (per year) -0.172 -0.261 -0.082 0.046 <0.001
concomitant Procedures 2.479 0.057 4.902 1.236 0.045
Concomitant CABG 3.855 -1.350 9.060 2.656 0.147
AS -1.565 -3.416 0.286 0.945 0.098
AR 1.250 -1.057 3.557 1.177 0.288
Rheumatic 1.250 -0.059 2.560 0.668 0.061
Mean age (per year) -0.006 -0.061 0.049 0.028 0.829
Endocarditis 0.306 -2.544 3.156 1.454 0.834
Emergency 1.542 -6.225 9.310 3.963 0.697
Prospective/RCT study design -0.157 -0.964 0.651 0.412 0.704
Previous cardiac intervention 0.655 -4.494 5.804 2.627 0.803
Late mortality
Year of first inclusion -0.002 -0.036 0.032 0.017 0.911
Mean FUP (per year) 0.063 0.000 0.126 0.032 0.052
Concomitant Procedures -0.154 -1.911 1.602 0.896 0.863
Concomitant CABG 0.293 -3.462 4.047 1.916 0.879
AS 0.989 -0.73 2.708 0.877 0.260
AR -1.502 -3.377 0.373 0.956 0.116
Rheumatic -0.552 -1.317 0.214 0.391 0.158
Mean age (per year) 0.035 -0.001 0.071 0.018 0.054
endocarditis 1.650 0.426 2.874 0.624 0.008
Emergency 2.699 -0.290 5.687 1.525 0.077
Prospective/RCT study design -0.314 -0.821 0.193 0.259 0.225
Previous cardiac intervention 1.368 -0.991 3.727 1.204 0.256
Reintervention
Year of first inclusion 0.018 -0.030 0.067 0.025 0.464
Mean fuP (per year) -0.107 -0.189 -0.026 0.042 0.010
Concomitant Procedures 0.739 -1.542 3.020 1.164 0.526
Concomitant CABG 2.908 -1.772 7.588 2.388 0.223
AS 0.132 -1.087 1.352 0.622 0.831
AR 0.129 -1.637 1.895 0.901 0.886
Rheumatic 0.665 -0.038 1.369 0.359 0.064
Mean age (per year) -0.042 -0.087 0.003 0.023 0.069
Endocarditis 0.635 -1.386 2.657 1.031 0.538
Emergency 2.666 -2.277 7.608 2.522 0.290
Prospective/RCT study design 0.368 -0.359 1.094 0.371 0.321
Previous cardiac intervention -0.111 -3.504 3.281 1.731 0.949
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supplement 4. (continued)
covariate β 95%ci- 95%ci+ se p-value
TE/VT
Year of first inclusion 0.023 -0.023 0.069 0.023 0.321
Mean FUP (per year) -0.062 -0.158 0.034 0.049 0.203
Concomitant Procedures 1.342 -0.669 3.353 1.026 0.191
Concomitant CABG 2.949 -1.601 7.499 2.321 0.204
AS 0.920 -1.046 2.886 1.003 0.359
AR 0.576 -1.513 2.665 1.066 0.589
Rheumatic 0.622 -0.950 2.195 0.802 0.438
Mean age (per year) -0.004 -0.060 0.052 0.029 0.892
Endocarditis -0.754 -6.126 4.619 2.741 0.783
Emergency 1.922 -5.606 9.449 3.841 0.617
Prospective/RCT study design 0.368 -0.307 1.044 0.345 0.286
Previous cardiac intervention 0.994 -3.053 5.042 2.065 0.630
Bleeding
Year of first inclusion 0.000 -0.042 0.041 0.021 0.991
Mean fuP (per year) -0.077 -0.151 -0.003 0.038 0.042
Concomitant Procedures 1.150 -0.092 2.391 0.633 0.070
Concomitant CABG 3.157 -0.696 7.011 1.966 0.108
as 2.235 0.263 4.206 1.006 0.026
ar -3.083 -5.150 -1.016 1.054 0.003
Rheumatic 0.690 -0.633 2.014 0.675 0.307
Mean age (per year) -0.008 -0.057 0.040 0.025 0.742
Endocarditis 0.324 -4.003 4.652 2.208 0.883
Emergency -1.907 -11.833 8.019 5.064 0.707
Prospective/RCT study design -0.338 -0.952 0.277 0.313 0.281
Previous cardiac intervention 0.343 -3.076 3.761 1.744 0.844
NSVD
Year of first inclusion 0.037 -0.049 0.123 0.044 0.401
Mean FUP (per year) -0.146 -0.309 0.016 0.083 0.078
Concomitant Procedures 1.619 -4.787 8.026 3.269 0.620
concomitant caBg -7.148 -14.176 -0.119 3.586 0.046
as 3.128 1.306 4.949 0.929 <0.001
ar -3.770 -5.945 -1.595 1.110 <0.001
rheumatic -3.296 -5.537 -1.055 1.143 0.004
Mean age (per year) -0.002 -0.108 0.104 0.054 0.970
endocarditis 2.718 0.978 4.458 0.888 0.002
emergency 6.612 1.778 11.445 2.466 0.007
Prospective/RCT study design 0.523 -0.922 1.968 0.737 0.478
Previous cardiac intervention 0.367 -6.177 6.911 3.339 0.913
SE, standard error; 95%CI-, 95% confidence interval lower bound; 95%CI+, 95% confidence interval upper 
bound; FUP, follow-up; CABG, coronary artery bypass grafting; AS, aortic stenosis; AR, aortic regurgitation; RCT, 
randomized controlled trial; TE, thromboembolism; VT, valve thrombosis; NSVD, nonstructural valve dysfunction
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supplement 5. Methods
list of recorded variables
Study characteristics:
	 •	 	Study	design
	 •	 	Number	of	patients	included
	 •	 	Inclusion	period
	 •	 	Total	follow-up
Baseline patient and operative characteristics:
	 •	 	Mean	age
	 •	 	Gender
	 •	 	Etiology
	 •	 	Aortic	valve	hemodynamics
	 •	 	Aortic	valve	morphology
	 •	 	Previous	cardiac	interventions	(any	previous	surgical	or	percutaneous	interven-
tion on the heart, thoracic aorta and/or pulmonary trunk)
	 •	 	Urgency	of	the	operation
	 •	 	Type	of	mechanical	valve	(bileaflet,	caged-ball	or	tilting	disc)
  o Prosthesis model
	 •	 Concomitant	procedures
Outcome events
	 •	 	Early	outcome	events	(<30	days	after	surgery)
  o  Early mortality (all-cause mortality within the first 30 postoperative days)
  o  Re-exploration for bleeding
  o  Pacemaker implantation
  o  Deep sternal infection/mediastinitis
  o  Endocarditis
  o  Stroke
  o  Transient ischemic attack
  o  Myocardial infarction
  o  Valve thrombosis
  o  Peripheral bleeding
	 •	 Late	outcome	events	(>30	days	after	surgery)
  o Late mortality
   - Cardiac death
   - Valve related death
   - Sudden, unexplained death (SUD)
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  o Reintervention
  o Thromboembolism
  o Valve thrombosis
  o Bleeding
  o Endocarditis
  o Structural valve deterioration (SVD)
  o Nonstructural valve dysfunction (NSVD)
statistical software used
Statistical analyses were performed in Microsoft Office Excel 2011 (Microsoft Corp., 
Redmond, WA, USA), IBM SPSS Statistics (version 21.0.0.1. IBM Corp., Armonk, NY, USA) 
and in the R statistical software (version 3.1.0. R Development Core Team, R Foundation 
for Statistical Computing, Vienna, Austria) using the metafor package.
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supplement 7. Microsimulation model calibration plot.
The actuarial survival curve obtained from the microsimulation model run for 10,000 iterations at the 
pooled mean age (48 years) and male/female ratio (72.0% male) of the included studies compared to the 
pooled overall mortality observed in our meta-analysis.
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supplement 8. Funnel plots.
Funnel plots on a natural log x-axis. SE, standard error; SVD, structural valve deterioration; NSVD, nonstruc-
tural valve dysfunction.
Supplement 8. Funnel plots.
Funnel plots on a natural log x-axis. SE, standard error; SVD, structural valve deterioration; NSVD, nonstructural valve dysfunction.
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aBstract
Background
To support decision-making in aortic valve replacement in children and adults, we pro-
vide a comprehensive overview of outcomeafter the Ross procedure.
Methods
A systematic search was conducted for publications reporting clinical outcome after the 
Ross procedure, published between January 1, 2000, and November 22, 2017. Reported 
event rates and time-to-event data were pooled and entered into a microsimulation 
model to calculate life expectancy and lifetime event risk. 
results
Ninety-nine publications were included (13 129 patients; total follow-up: 93 408 patient-
years, pooled mean follow-up: 7.9±5.3 years). Pooled mean age at surgery was 9.4±5.5 
years for children and 41.9±11.4 for adults. For children and adults, respectively, pooled 
early mortality risk was 4.19% (95% CI, 3.21-5.46) and 2.01% (95% CI, 1.44-2.82), late 
mortality rate was 0.54%/y (95% CI, 0.42-0.70) and 0.59%/y (95% CI, 0.46-0.76), autograft 
reintervention 1.28%/y (95% CI, 0.99-1.66) and 0.83%/y (95% CI, 0.68-1.01), and right 
ventricular outflow tract reintervention 1.97%/y (95% CI, 1.64-2.36) and 0.47%/y (95% 
CI, 0.37-0.59). Pooled thromboembolism and bleeding rates were low and comparable 
to the general population. Lifetime risks of autograft and right ventricular outflow tract 
reintervention were, respectively, 94% and 100% for children and 49% and 19% for a 
45-year-old. Estimated life expectancy after surgery was 59 years for children (general 
population: 64 years) and 30 years for a 45 years old (general population: 31 years).
conclusions
Through excellent survival and avoidance of the burden of anticoagulation, the Ross 
procedure provides a unique opportunity for patients whose preferences do not align 
with the outcome provided by mechanical valve replacement and for growing children 
who also benefit from autograft diameter increase along with somatic growth. On the 
downside, almost all pediatric and many adult Ross patients will require a reintervention 
in their lifetime.
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introDuction
Replacement of the aortic valve with a pulmonary autograft (the Ross procedure) was 
introduced in the late 1960s by Donald Ross.1 It provides many benefits over other op-
tions for aortic valve replacement (AVR) in children and young adults because of the 
favorable hemodynamic characteristics, low risk of endocarditis, low thrombogenicity, 
avoidance of anticoagulation therapy, and the diameter increase it shows along with 
somatic growth.2 However, the Ross procedure is a technically demanding operation, 
and both the autograft in aortic position and the valve substitute in the right ventricular 
outflow tract (RVOT) are susceptible to valve deterioration and subsequent reinterven-
tion over time.
Reports on outcome after the Ross procedure are scattered, and although survival after 
this procedure is reported almost uniformly as excellent, rates of valve-related morbidity, 
especially autograft and allograft deterioration and reintervention, vary strongly among 
reports. This makes it difficult to draw inferences on what patients can be expected 
to face after the Ross procedure, information essential in guiding decision-making in 
children and young adults requiring AVR.
Since the publication of a prior systematic review on reported outcome after the Ross 
procedure by our group in 2009,2 a wealth of additional patient series has been pub-
lished, substantially longer follow-up has been accrued of the included patients, and our 
group has implemented advanced methods of meta-analysis of time-to-event data and 
microsimulation that allow for a much better insight into long-term outcome in these 
patients. We therefore provide an update of the systematic literature search, applying 
the latest methods of meta-analysis and calculating microsimulationbased estimates of 
age-specific life expectancy and lifetime risk of valve-related events.
MetHoDs
search strategy and selection of studies
This systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines3 and registered in the 
PROSPERO registry (CRD42016039676). The data, analytic methods, and study materials 
will be made available on request to the corresponding author.
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On November 22, 2017, Embase, MEDLINE, Web of Science, The Cochrane Library, and 
Google Scholar were searched by a biomedical information specialist using keywords 
related to the Ross procedure/pulmonary autograft (Supplement 1).
All studies were screened by 2 independent reviewers (J.R.G. Etnel, S.A. Huygens). Ob-
servational studies and randomized controlled trials reporting clinical outcome after the 
Ross procedure published in English after January 1, 2000, were considered for inclusion. 
Studies limited to patients with preexisting comorbidities or a history of previous AVR 
were excluded. Studies with a study size <20 patients or focusing only on certain aortic/ 
pulmonary valve/annulus/root sizes were also excluded. In case of multiple publications 
on overlapping study populations, the publication with the greatest total follow-up in 
patient-years or overall completeness of data was included for each outcome of interest 
separately. In case of disagreement between the reviewers, a consensus was negotiated.
Data extraction
Microsoft Office Excel 2010 (Microsoft Corp, Redmond, WA) was used for data extrac-
tion. Data were extracted independently by 2 reviewers (J.R.G. Etnel, P. Grashuis). After 
data extraction, each reviewer verified the other reviewer’s data entries. Recorded study 
characteristics, baseline patient characteristics, operative characteristics and outcome 
events are listed in Supplement 1. Functional class was defined according to the New 
York Heart Association for adults and Ross4 for children.
Morbidity and mortality were documented according to the 2008 guidelines by Akins 
et al.5 Early outcome events were defined as occurring within the first 30 postoperative 
days, regardless of the patient’s location, and late outcome events were defined as oc-
curring after the first 30 postoperative days. If total follow-up duration in patient-years 
was not reported, it was calculated by multiplying the number of patients with the mean 
follow-up duration of that study.
statistical analyses
Statistical software used is listed in Supplement 1.
Continuous variables are presented as mean±SD. Categorical variables are presented as 
counts and percentages. Linearized event occurrence rates (constant hazard rates over 
time) are presented as percentages per year.
For all analyses, studies were grouped by age: pediatric (reported as concerning only 
children and mean age <18 years), adult (reported as concerning only adults and mean 
age ≥18 years), and all ages (combined pediatric and adult series). Pooled baseline pa-
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tient characteristics were calculated with the use of sample size weighting. Early risks of 
mortality and linearized occurrence rates of late morbidity and mortality were calculated 
for each individual study and pooled with the use of inverse variance weighting in a 
random-effects model according to the DerSimonian and Laird method. Outcomes were 
pooled on a logarithmic scale, as the Shapiro-Wilk test revealed a significantly skewed 
distribution among the included studies in the majority of outcome measures. Inverse 
variance weighting was conducted according to the number of patients for early mortal-
ity and according to the number of patient-years of follow-up for late events. In case a 
particular event was reported not to occur in an individual study, it was assumed that 0.5 
patient experienced that event for the purpose of inverse variance weighting (continuity 
correction). Cochran’s Q statistic and the I2 statistic were used to assess heterogeneity 
between studies. Potential causes of heterogeneity were explored by investigating the 
effect of all baseline patient characteristics and operative details listed in Table 1 as well 
as study design (retrospective versus prospective/ randomized controlled trial) and 
median year of surgery by means of univariable random-effects meta-regression. The 
influence of potential publication bias on pooled outcome was investigated by conduct-
ing sensitivity analyses by temporarily excluding the smallest quartile (by sample size) of 
included studies in the all ages group.
kaplan-Meier meta-analysis
Pooled Kaplan-Meier time-to-event meta-analysis was conducted by extrapolating and 
pooling estimates of individual patient time-to-event data from published Kaplan-Meier 
curves for survival and reintervention. Published Kaplan-Meier curves were digitized, 
and an estimate of the individual patient time-to-event data was then extrapolated 
from the digitized curve coordinates, assuming a constant rate of censorship between 
each time point at which the number of patients at risk was specified.6 If there were no 
Kaplan-Meier curves available, but time points of each event were reported or there 
were no events, the individual patient time-to-event data were manually reconstructed 
up to a maximum follow-up of the mean follow-up +2 SDs, under the same assumption 
of a constant rate of censorship. Reconstructed individual patient time-to-event data of 
each study were then combined.
Microsimulation
A microsimulation model based on the pooled outcome estimates of our meta-analysis 
was used to calculate age-specific life expectancy and lifetime risk of valve-related 
morbidity.7,8 A description of the concept of the microsimulation model and a schematic 
overview of the hypothetical scenario that each simulated patient is run through are 
provided in Supplement 1.
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table 1. Pooled baseline patient characteristics and operative details
all ages Pediatric adult
Data presented as mean±SD or percentage (range). AV indi-
cates aortic valve; AVR, aortic valve replacement; CABG, coro-
nary artery bypass grafting; NYHA, New York Heart Associa-
tion; Preop., preoperative; and RVOT, right ventricular outflow 
tract.
*Twenty-seven pediatric+31 adult+33 unique studies.
Pooled estimate no. of studies Pooled estimate no. of studies Pooled estimate no. of studies
total number of patients 13 129 91* 2743 36 6892 35
follow-up 85 34 31
Mean, y 7.9±5.3 7.4±4.5 8.4±4.7
Total, patient-years 93 408 18 557 49 435
Mean age, y 30.9±11.5 81 9.4±5.5 30 41.9±11.4 30
Male 72.6% (51.0-87.1) 71 70.6% (60.8-91.7) 25 73.0% (51.0-87.1) 26
urgent 4.6% (0.0-50.0) 11 2.3% (0.0-2.6) 2 4.0% (1.1-50.0) 7
Preoperative nyHa/ross class 25 3 17
I/II 62.9% (25.5-100.0) 91.2% (85.7-100.0) 61.8% (30.0-100.0)
III/IV 37.1% (0.0-74.5) 8.8% (0.0-14.3) 38.2% (0.0-70.0)
Hemodynamics 72 25 28
Aortic stenosis 36.5% (11.1-78.3) 29.5% (12.1-76.0) 40.9% (11.1-72.6)
Aortic regurgitation 32.7% (9.0-61.5) 25.9% (7.9-48.0) 33.1% (9.0-61.5)
Combined 30.8% (0.0-75.8) 44.6% (14.3-75.8) 26.0% (0.0-55.1)
Bicuspid av 63.6% (17.5-94.4) 50 61.7% (40.0-80.0) 15 62.9% (34.1-93.5) 21
cause 45 14 18
Congenital 57.3% (0.7-100.0) 80.5% (49.8-100.0) 52.2% (37.9-84.1)
Degenerative/calcification 7.4% (0.0-44.4) 1.6% (0.0-7.1) 8.4% (1.4-44.4)
Rheumatic 14.2% (0.0-52.9) 12.3% (1.0-45.8) 14.4% (1.9-29.7)
Endocarditis 13.3% (0.0-100.0) 3.9% (0.0-10.0) 19.4% (3.9-100.0)
Other/unknown 7.8% (0.0-51.2) 1.8% (0.0-6.7) 5.5% (4.6-18.1)
Previous cardiac intervention 35.5% (7.8-100.0) 41 67.4% (38.0-100.0) 18 12.8% (7.8-72.2) 11
AV intervention 31.4% (0.0-100.0) 60.6% (41.8-80.0) 11.2% (3.1-100.0)
Percutaneous 15.5% (0.0-72.0) 33.1% (9.1-72.0) 3.3% (0.3-38.9)
AV surgery 19.0% (0.0-66.7) 32.3% (0.0-60.0) 8.8% (0.0-66.7)
AVR 3.9% (0.0-13.3) 2.3% (0.0-12.2) 4.3% (0.0-12.8)
technique 67 26 27
Total root replacement 93.9% (46.3-100.0) 97.4% (65.9-100.0) 95.3% (50.0-100.0)
Subcoronary 2.1% (0.0-21.6) 1.6% (0.0-12.3) 0.8% (0.0-19.0)
Inclusion cylinder 3.9% (0.0-42.8) 1.0% (0.0-6.0) 3.8% (0.0-42.8)
rvot conduit 57 20 21
Allograft 89.1% (0.0-100.0) 86.1% (0.0-100.0) 86.0% (0.0-100.0)
Bioprosthesis 10.9% (0.0-78.9) 13.9% (0.0-100.0) 14.0% (0.0-75.7)
concomitant procedures 40 20 18
CABG 4.7% (0.0-44.1) 6.5% (0.0-44.1) 5.1% (0.0-25.9)
Ascending aortic surgery 10.7% (0.0-60.0) 5.1% (0.0-24.3) 15.8% (0.0-60.0)
Annular enlargement procedure 9.6% (0.0-52.9) 18.3% (0.0-42.0) 1.5% (0.0-7.4)
Other valve repair or replacement 5.4% (0.0-40.0) 8.4% (1.7-40.0) 4.8% (0.0-23.3)
Other 8.2% (0.0-38.1) 12.0% (2.6-25.2) 7.3% (0.0-38.1)
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table 1. Pooled baseline patient characteristics and operative details
all ages Pediatric adult
Data presented as mean±SD or percentage (range). AV indi-
cates aortic valve; AVR, aortic valve replacement; CABG, coro-
nary artery bypass grafting; NYHA, New York Heart Associa-
tion; Preop., preoperative; and RVOT, right ventricular outflow 
tract.
*Twenty-seven pediatric+31 adult+33 unique studies.
Pooled estimate no. of studies Pooled estimate no. of studies Pooled estimate no. of studies
total number of patients 13 129 91* 2743 36 6892 35
follow-up 85 34 31
Mean, y 7.9±5.3 7.4±4.5 8.4±4.7
Total, patient-years 93 408 18 557 49 435
Mean age, y 30.9±11.5 81 9.4±5.5 30 41.9±11.4 30
Male 72.6% (51.0-87.1) 71 70.6% (60.8-91.7) 25 73.0% (51.0-87.1) 26
urgent 4.6% (0.0-50.0) 11 2.3% (0.0-2.6) 2 4.0% (1.1-50.0) 7
Preoperative nyHa/ross class 25 3 17
I/II 62.9% (25.5-100.0) 91.2% (85.7-100.0) 61.8% (30.0-100.0)
III/IV 37.1% (0.0-74.5) 8.8% (0.0-14.3) 38.2% (0.0-70.0)
Hemodynamics 72 25 28
Aortic stenosis 36.5% (11.1-78.3) 29.5% (12.1-76.0) 40.9% (11.1-72.6)
Aortic regurgitation 32.7% (9.0-61.5) 25.9% (7.9-48.0) 33.1% (9.0-61.5)
Combined 30.8% (0.0-75.8) 44.6% (14.3-75.8) 26.0% (0.0-55.1)
Bicuspid av 63.6% (17.5-94.4) 50 61.7% (40.0-80.0) 15 62.9% (34.1-93.5) 21
cause 45 14 18
Congenital 57.3% (0.7-100.0) 80.5% (49.8-100.0) 52.2% (37.9-84.1)
Degenerative/calcification 7.4% (0.0-44.4) 1.6% (0.0-7.1) 8.4% (1.4-44.4)
Rheumatic 14.2% (0.0-52.9) 12.3% (1.0-45.8) 14.4% (1.9-29.7)
Endocarditis 13.3% (0.0-100.0) 3.9% (0.0-10.0) 19.4% (3.9-100.0)
Other/unknown 7.8% (0.0-51.2) 1.8% (0.0-6.7) 5.5% (4.6-18.1)
Previous cardiac intervention 35.5% (7.8-100.0) 41 67.4% (38.0-100.0) 18 12.8% (7.8-72.2) 11
AV intervention 31.4% (0.0-100.0) 60.6% (41.8-80.0) 11.2% (3.1-100.0)
Percutaneous 15.5% (0.0-72.0) 33.1% (9.1-72.0) 3.3% (0.3-38.9)
AV surgery 19.0% (0.0-66.7) 32.3% (0.0-60.0) 8.8% (0.0-66.7)
AVR 3.9% (0.0-13.3) 2.3% (0.0-12.2) 4.3% (0.0-12.8)
technique 67 26 27
Total root replacement 93.9% (46.3-100.0) 97.4% (65.9-100.0) 95.3% (50.0-100.0)
Subcoronary 2.1% (0.0-21.6) 1.6% (0.0-12.3) 0.8% (0.0-19.0)
Inclusion cylinder 3.9% (0.0-42.8) 1.0% (0.0-6.0) 3.8% (0.0-42.8)
rvot conduit 57 20 21
Allograft 89.1% (0.0-100.0) 86.1% (0.0-100.0) 86.0% (0.0-100.0)
Bioprosthesis 10.9% (0.0-78.9) 13.9% (0.0-100.0) 14.0% (0.0-75.7)
concomitant procedures 40 20 18
CABG 4.7% (0.0-44.1) 6.5% (0.0-44.1) 5.1% (0.0-25.9)
Ascending aortic surgery 10.7% (0.0-60.0) 5.1% (0.0-24.3) 15.8% (0.0-60.0)
Annular enlargement procedure 9.6% (0.0-52.9) 18.3% (0.0-42.0) 1.5% (0.0-7.4)
Other valve repair or replacement 5.4% (0.0-40.0) 8.4% (1.7-40.0) 4.8% (0.0-23.3)
Other 8.2% (0.0-38.1) 12.0% (2.6-25.2) 7.3% (0.0-38.1)
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The operative mortality risk, the occurrence rate of each valve-related event, and the risk 
of mortality and reintervention as a direct result of each of these valve-related events 
were obtained from our meta-analysis. Separate estimates were obtained for children 
and adults from the respective subgroup analyses of our meta-analysis. The hazard 
of structural valve deterioration of the autograft and RVOT conduit were assumed to 
be time-varying and were modeled by fitting a Gompertz distribution to our pooled 
time-to-event data. The hazards of all other events were assumed to be constant over 
time. Additional excess mortality not directly resulting from valve-related events was es-
timated for the all ages, pediatric and adult subgroups separately using the least squares 
method (details in Supplement 1). The background mortality of the general population 
was obtained for the pooled median year of surgery among included studies (2001, 
assuming a constant incidence rate over time in each study) and for the regions that 
the majority of the included study population originated from (Europe, 52% of patients; 
North America, 34% of patients) from the World Health Organization Global Health Ob-
servatory Data Repository for Europe and from the US Life Tables for North America.9,10
To obtain estimates of life expectancy and lifetime risk of valve-related morbidity, tak-
ing into account both first-order uncertainty (random variability in outcomes between 
identical patients) and second-order uncertainty (uncertainty in the input parameter 
estimates), probabilistic sensitivity analysis was conducted. The microsimulation model 
was run iteratively for 500 simulations with a sample size of 1000 patients per simulation 
(these amounts were based on the methods described by O’Hagan et al11). In each of the 
500 simulations, the values of the input parameters were randomly drawn from distribu-
tions corresponding with each parameter’s point estimate and variance, obtained from 
the meta-analysis as described above. This yielded a complete set of outcome estimates 
for each of the 500 simulated patient populations. For each outcome measure, the mean 
of outcome estimates across all 500 simulated populations was considered the point 
estimate of outcome, and the 2.5th and 97.5th percentile were considered the lower and 
upper limits of the 95% credible interval, respectively.
To obtain age-specific estimates, this process was repeated separately for the pediatric 
group at the pooled mean age and SD of that subgroup (9.4±5.5 years) and also for the 
adults for the specific ages 25, 35, 45, and 55 years and at the male/female ratio obtained 
from our meta-analysis (pediatric 70.6% male, adult 73.0% male).
For the purposes of internal validation, the model was additionally run for 10 000 itera-
tions at the pooled mean age (30.9±11.5 years) and pooled male/female ratio (72.6% 
male) of the all ages group, excluding early mortality. The actuarial survival curve 
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obtained from this model was then plotted against the pooled overall survival curve 
observed in our Kaplan-Meier meta-analysis, excluding early mortality.
results
The systematic literature search identified 4252 publications, of which 99 were included 
in the meta-analysis, encompassing a total of 13 129 patients with 93 408 patient-years 
of follow-up (pooled mean follow-up: 7.9±5.3 years) (Figure 1). Supplement 2 represents 
the characteristics of the included studies (references listed in Supplement 7).
Pooled baseline patient characteristics are shown in Table 1.
Pooled risks of early mortality and pooled linearized occurrence rates of late mortality 
and late morbid events are presented in Table 2 (individual study estimates are presented 
in Supplement 3). Early morbidity was reported too inconsistently to be included in the 
analyses. Pooled Kaplan-Meier curves of freedom from all-cause mortality, autograft 
reintervention, and RVOT reintervention are shown in Figures 2 through 4, respectively.
Microsimulation-based age-specific estimates of lifetime risk of valve-related morbid-
ity and life expectancy are shown in Figures 5 and 6, respectively. The microsimula-
tion model calibrated well with the pooled mortality observed in our meta-analysis 
(Supplement 4). Least squares regression of survival estimates from the microsimulation 
model (excluding early mortality) versus those obtained from the meta-analysis of time-
to-event data (excluding early mortality) revealed that excess mortality, not directly 
related to valve-related events, was zero in the pediatric, adult, and all ages groups alike 
(Supplement 5). For children, life expectancy after surgery (58.9 years; 95% credible in-
terval [CI], 56.9-60.9) was 92.1% of that in the age- and sex-matched general population 
(64.0 years), for a 25-year-old 94.1% (46.3 years [95% CI, 44.6-48.0] versus 49.1 years), 
35-yearold 94.8% (37.8 years [95% CI, 36.4-39.4] versus 39.9 years), 45-year-old 95.4% 
(29.7 years [95% CI, 28.4- 31.1] versus 31.1 years), and 55-year-old 96.1% (22.1 years [95% 
CI, 21.0-23.3] versus 23.0 years)
Sensitivity analyses showed that any eventual publication bias did not substantially 
influence our pooled outcomes, as pooled outcomes remained largely unchanged 
after temporary exclusion of the smallest quartile of studies by sample size (all ages 
group, before versus after exclusion: late mortality [0.50%/y versus 0.48%/y], autograft 
reintervention [1.10%/y versus 1.09%/y], RVOT reintervention [0.91%/y versus 0.89%/y], 
thromboembolism [0.16%/y versus 0.15%/y], and bleeding [0.09%/y versus 0.07%/y]).
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Heterogeneity
There was substantial heterogeneity in early mortality, late mortality, reintervention, 
endocarditis, and bleeding.
Univariable random-effects meta-regression (Supplement 6) in the all ages group 
showed that studies with higher early mortality reported shorter mean follow-up 
(P<0.001), lower mean age at surgery (P=0.003), higher preoperative NYHA/ Ross class 
(P=0.031), more preoperative endocarditis (P=0.003), less frequent use of allografts for 
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encompassing a total of 13 129 patients with 93 408 
patient-years of follow-up (pooled mean follow-up: 
7.9±5.3 years) (Figure  1). Supplement II in the Data 
Supplement represents the characteristics of the includ-
ed studies (references listed in Supplement VII in the 
Data Supplement).
Pooled baseline patient characteristics are shown in 
Table 1.
Pooled risks of early mortality and pooled linearized 
occurrence rates of late mortality and late morbid events 
are presented in Table 2 (individual study estimates are 
presented in Supplement III in the Data Supplement). 
Early morbidity was reported too inconsistently to be 
included in the analyses. Pooled Kaplan-Meier curves of 
freedom from all-cause mortality, autograft reinterven-
tion, and RVOT reintervention are shown in Figures 2 
through 4, respectively.
Microsimulation-based age-specific estimates of life-
time risk of valve-related morbidity and life expectancy 
are shown in Figures 5 and 6, respectively. The microsim-
ulation model calibrated well with the pooled mortality 
observed in our meta-analysis (Supplement IV in the 
Data Supplement). Least squares regression of survival 
estimates from the microsimulation model (excluding 
early mortality) versus those obtained from the meta-
analysis of time-to-event data (excluding early mortal-
ity) revealed that excess mortality, not directly related 
to valve-related events, was zero in the pediatric, adult, 
and all ages groups alike (Supplement V in the Data 
Supplement). For children, life expectancy after surgery 
(58.9 years; 95% credible interval [CI], 56.9–60.9) was 
92.1% of that in the age- and sex-matched general 
population (64.0 years), for a 25-year-old 94.1% (46.3 
years [95% CI, 44.6–48.0] versus 49.1 years), 35-year-
old 94.8% (37.8 years [95% CI, 36.4–39.4] versus 39.9 
years), 45-year-old 95.4% (29.7 years [95% CI, 28.4–
31.1] versus 31.1 years), and 55-year-old 96.1% (22.1 
years [95% CI, 21.0–23.3] versus 23.0 years)
Sensitivity analyses showed that any eventual pub-
lication bias did not substantially influence our pooled 
outcomes, as pooled outcomes remained largely 
unchanged after temporary exclusion of the small-
est quartile of studies by sample size (all ages group, 
before versus after exclusion: late mortality [0.50%/y 
versus 0.48%/y], autograft reintervention [1.10%/y 
versus 1.09%/y], RVOT reintervention [0.91%/y ver-
sus 0.89%/y], thromboembolism [0.16%/y versus 
0.15%/y], and bleeding [0.09%/y versus 0.07%/y]).
Figure 1. Flowchart of study selection.
The sum of the number of studies in the 
subgroups of included studies is greater than 
the total of 99 included studies, because of 
inclusion in multiple subgroups when possible. 
1Including 3 studies with both pediatric and 
adult subgroups. 226 pediatric + 31 adult + 3 
both pediatric and adult subgroups + 31 no 
distinction.
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figure 1. Flowchart of study selection.
The sum of the number of studies in the subgroups of included studies is greater than the total of 99 in-
cluded studies, because of inclusion in multiple subgroups when possible. 1Including 3 studies with both 
pediatric and adult subgroups. 226 pediatric + 31 adult + 3 both pediatric and adult subgroups + 31 no 
distinction.
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of autograft reintervention ranging from 94% for 
children to 32% for 55-year-olds and for the RVOT 
conduit ranging from 100% for children to 14% for 
55-year-olds. RVOT conduit deterioration and sub-
sequent reintervention rates are significantly higher
among children undergoing the Ross procedure com-
pared with adults and represent the predominant indi-
cation for reintervention in these children.
Mortality
Our results show that the Ross procedure is associated 
with low early mortality and excellent late survival with 
15-year actuarial survival of 93.5% for children and
91.9% for adults and life expectancy 90% to 95% of
the age- and sex-matched general population. Excess
mortality not directly related to valve-related events is
very low if not zero in these patients.
This mortality is substantially lower than the mor-
tality reported after mechanical AVR, in children and 
adults alike, despite the considerably higher reinter-
vention rates after the Ross procedure.12,13 The favor-
able hemodynamics of the autograft in comparison 
with mechanical prostheses may play a role in this 
observed difference in mortality.14 Furthermore, the 
higher mortality after mechanical AVR may be attrib-
utable in part to the thrombogenicity of mechanical 
valve prostheses and the subsequent requirement for 
anticoagulation treatment and the associated bleed-
ing risks.15 The often unstable International Nor-
malized Ratio (INR) management may play a major 
role in this anticoagulation-related excess mortality 
risk after mechanical AVR, as a propensity-matched 
study by Mokhles et al16 has previously demonstrat-
ed that, with optimal self-management anticoagu-
lation, mechanical AVR offers excellent late survival 
comparable to the Ross procedure. However, this 
study by Mokhles et al16 also illustrates the chal-
lenges that possible differences in patient selection 
pose in comparisons between the Ross procedure 
and mechanical AVR.
Figure 2. Pooled Kaplan-Meier freedom from all-cause mortality.
Figure 3. Pooled Kaplan-Meier freedom from autograft reintervention.
Figure 4. Pooled Kaplan-Meier freedom from right ventricular outflow 
tract (RVOT) reintervention.
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figure 3. Pooled Kaplan-Meier freedom from autograft reintervention.
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of autograft reintervention ranging from 94% for 
children to 32% for 55-year-olds and for the RVOT 
conduit ranging from 100% for children to 14% for 
55-year-olds. RVOT conduit deterioration and sub-
sequent reintervention rates are significantly higher
among children undergoing the Ross procedure com-
pared with adults and represent the predominant indi-
cation for reintervention in these children.
Mortality
Our results show that the Ross procedure is associated 
with low early mortality and excellent late survival with 
15-year actuarial survival of 93.5% for children and
91.9% for adults and life expectancy 90% to 95% of
the age- and sex-matched general population. Excess
mortality not directly related to valve-related events is
very low if not zero in these patients.
This mortality is substantially lower than the mor-
tality reported after mechanical AVR, in children and 
adults alike, despite the considerably higher reinter-
vention rates after the R ss proce ure.12,13 The favor-
able hemodynamics of the autograft in co parison 
with mechanical prostheses may play a role in this 
observed difference in mort lity.14 Furthermore, the 
higher ort lity after mechanical AVR may be attrib-
utable in part to the thrombogenicity of mechanical 
valve prostheses and the sub equen  requirement for 
a ticoagulati n treatment and the associat d bleed-
ing r sks.15 The ften unstable International Nor-
malized Ratio (INR) management may play a major 
role in this anticoagulation-related excess mortality 
risk after mechanical AVR, as a propensity-matched 
study by Mokhles et al16 has previously demonstrat-
ed that, with optimal self-management anticoagu-
lation, mechanical AVR offers excellent late survival 
comparable to the Ross procedure. However, this 
study by Mokhles et al16 also illustrates the chal-
lenges that possible differences in patient selection 
pose in comparisons between the Ross procedure 
and mechanical AVR.
Figure 2. Pooled Kaplan-Meier freedom from all-cause mortality.
Figure 3. Pooled Kaplan-Meier freedom from autograft reintervention.
Figure 4. Pooled Kaplan-Meier freedom from right ventricular outflow 
tract (RVOT) reintervention.
D
ow
nloaded from
 http://ahajournals.org by on A
pril 23, 2020
figure 2. Pooled Kaplan-Meier freedom from all-cause mortality.
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RVOT reconstruction (P=0.005), more concomitant valve procedures, (P=0.031), and less 
concomitant ascending aortic surgery (P<0.001).
Higher late mortality was associated with shorter mean follow-up (P=0.012), higher 
mean age at surgery (P=0.039), more urgent operations (P<0.001), and more preopera-
tive endocarditis (P<0.001).
Higher reintervention rates were associated with lower mean age at surgery (P<0.001), 
more preoperative combined aortic stenosis and regurgitation (P=0.011), more previ-
ous cardiac interventions (P=0.014), in particular previous aortic valve interventions 
(P<0.001), and more frequent concomitant annular enlargement procedures (P<0.001).
Higher postoperative endocarditis rates were associated with shorter mean follow-up 
(P<0.001), less bicuspid aortic valve (P=0.004), and more frequent use of total root replace-
ment (P=0.007) and more frequent use of bioprostheses for RVOT reconstruction (P=002).
Higher postoperative bleeding rates were associated with shorter mean follow-up 
(P=0.001), higher proportions of preoperative endocarditis (P<0.001), and more con-
comitant valve procedures (P<0.001).
table 2. Pooled outcome estimates
Pooled estimate (95% ci) no. of studies Heterogeneity
all ages Pediatric adult all ages Pediatric adult all ages Pediatric adult
early mortality (%) 2.87 (2.39-3.45) 4.19 (3.21-5.46) 2.01 (1.44-2.82) 78 24 31 I2=50.9% (P<0.001) I2=27.9% (P=0.102) I2=53.6% (P<0.001)
late mortality (%/y) 0.50 (0.44-0.58) 0.54 (0.42-0.70) 0.59 (0.46-0.76) 72 22 26 I2=30.5% (P=0.009) I2=7.3% (P=0.363) I2=57.3% (P<0.001)
Cardiac (%/y) 0.29 (0.24-0.35) 0.41 (0.27-0.63) 0.24 (0.17-0.33) 57 15 22 I2=6.6% (P=0.335) I2=14.0% (P=0.296) I2=17.5% (P=0.227)
Valve-related (%/y) 0.23 (0.19-0.28) 0.36 (0.22-0.57) 0.21 (0.14-0.32) 56 14 23 I2=0.0% (P=0.821) I2=0.0% (P=0.736) I2=26.8% (P=0.117)
SUD (%/y) 0.17 (0.13-0.21) 0.20 (0.11-0.39) 0.16 (0.10-0.25) 56 14 23 I2=0.0% (P=0.926) I2=0.0% (P=0.951) I2=20.7% (P=0.185)
reintervention (%/y) 1.84 (1.49-2.27) 3.04 (2.39-3.87) 1.20 (1.01-1.42) 60 23 24 I2=92.7% (P<0.001) I2=85.5% (P<0.001) I2=57.0% (P<0.001)
Autograft (%/y) 1.10 (0.94-1.29) 1.28 (0.99-1.66) 0.83 (0.68-1.01) 68 26 24 I2=76.3% (P<0.001) I2=66.1% (P<0.001) I2=52.2% (P=0.002)
RVOT (%/y) 0.91 (0.74-1.12) 1.97 (1.64-2.36) 0.47 (0.37-0.59) 67 26 24 I2=84.3% (P<0.001) I2=52.1% (P=0.001) I2=45.5% (P=0.009)
endocarditis (%/y) 0.29 (0.21-0.41) 0.27 (0.15-0.48) 0.27 (0.16-0.45) 31 6 15 I2=61.2% (P<0.001) I2=0.0% (P=0.770) I2=71.8% (P<0.001)
Autograft (%/y) 0.21 (0.13-0.35) 0.15 (0.04-0.61) 0.18 (0.09-0.39) 25 3 12 I2=64.3% (P<0.001) I2=0.0% (P=0.877) I2=74.0% (P<0.001)
RVOT (%/y) 0.17 (0.13-0.22) 0.21 (0.06-0.71) 0.14 (0.09-0.21) 24 3 11 I2=0.0% (P=0.977) I2=0.0% (P=0.727) I2=0.0% (P=0.867)
thromboembolism (%/y) 0.16 (0.12-0.22) 0.11 (0.04-0.30) 0.17 (0.11-0.27) 21 5 7 I2=0.0% (P=0.793) I2=0.0% (P=0.935) I2=0.0% (P=0.565)
valve thrombosis (%/y) 0.06 (0.03-0.12) 0.14 (0.03-0.71) 0.03 (0.01-0.09) 12 3 7 I2=0.0% (P=0.840) I2=0.0% (P=0.957) I2=0.0% (P=0.958)
Bleeding (%/y) 0.09 (0.02-0.36) 0.10 (0.03-0.41) 0.10 (0.01-0.67) 15 4 9 I2=87.4% (P<0.001) I2=0.0% (P=0.609) I2=91.6% (P<0.001)
Pacemaker implantation (%/y) 0.30 (0.20-0.44) 0.33 (0.21-0.51) 0.25 (0.05-1.17) 12 9 4 I2=0.0% (P=0.712) I2=0.0% (P=0.607) I2=44.5% (P=0.144)
Data presented as percentage (95% confidence interval) or linearized occurrence rate (95% confidence interval).
RVOT indicates right ventricular outflow tract; and SUD, sudden unexplained death.
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table 2. Pooled outcome estimates
Pooled estimate (95% ci) no. of studies Heterogeneity
all ages Pediatric adult all ages Pediatric adult all ages Pediatric adult
early mortality (%) 2.87 (2.39-3.45) 4.19 (3.21-5.46) 2.01 (1.44-2.82) 78 24 31 I2=50.9% (P<0.001) I2=27.9% (P=0.102) I2=53.6% (P<0.001)
late mortality (%/y) 0.50 (0.44-0.58) 0.54 (0.42-0.70) 0.59 (0.46-0.76) 72 22 26 I2=30.5% (P=0.009) I2=7.3% (P=0.363) I2=57.3% (P<0.001)
Cardiac (%/y) 0.29 (0.24-0.35) 0.41 (0.27-0.63) 0.24 (0.17-0.33) 57 15 22 I2=6.6% (P=0.335) I2=14.0% (P=0.296) I2=17.5% (P=0.227)
Valve-related (%/y) 0.23 (0.19-0.28) 0.36 (0.22-0.57) 0.21 (0.14-0.32) 56 14 23 I2=0.0% (P=0.821) I2=0.0% (P=0.736) I2=26.8% (P=0.117)
SUD (%/y) 0.17 (0.13-0.21) 0.20 (0.11-0.39) 0.16 (0.10-0.25) 56 14 23 I2=0.0% (P=0.926) I2=0.0% (P=0.951) I2=20.7% (P=0.185)
reintervention (%/y) 1.84 (1.49-2.27) 3.04 (2.39-3.87) 1.20 (1.01-1.42) 60 23 24 I2=92.7% (P<0.001) I2=85.5% (P<0.001) I2=57.0% (P<0.001)
Autograft (%/y) 1.10 (0.94-1.29) 1.28 (0.99-1.66) 0.83 (0.68-1.01) 68 26 24 I2=76.3% (P<0.001) I2=66.1% (P<0.001) I2=52.2% (P=0.002)
RVOT (%/y) 0.91 (0.74-1.12) 1.97 (1.64-2.36) 0.47 (0.37-0.59) 67 26 24 I2=84.3% (P<0.001) I2=52.1% (P=0.001) I2=45.5% (P=0.009)
endocarditis (%/y) 0.29 (0.21-0.41) 0.27 (0.15-0.48) 0.27 (0.16-0.45) 31 6 15 I2=61.2% (P<0.001) I2=0.0% (P=0.770) I2=71.8% (P<0.001)
Autograft (%/y) 0.21 (0.13-0.35) 0.15 (0.04-0.61) 0.18 (0.09-0.39) 25 3 12 I2=64.3% (P<0.001) I2=0.0% (P=0.877) I2=74.0% (P<0.001)
RVOT (%/y) 0.17 (0.13-0.22) 0.21 (0.06-0.71) 0.14 (0.09-0.21) 24 3 11 I2=0.0% (P=0.977) I2=0.0% (P=0.727) I2=0.0% (P=0.867)
thromboembolism (%/y) 0.16 (0.12-0.22) 0.11 (0.04-0.30) 0.17 (0.11-0.27) 21 5 7 I2=0.0% (P=0.793) I2=0.0% (P=0.935) I2=0.0% (P=0.565)
valve thrombosis (%/y) 0.06 (0.03-0.12) 0.14 (0.03-0.71) 0.03 (0.01-0.09) 12 3 7 I2=0.0% (P=0.840) I2=0.0% (P=0.957) I2=0.0% (P=0.958)
Bleeding (%/y) 0.09 (0.02-0.36) 0.10 (0.03-0.41) 0.10 (0.01-0.67) 15 4 9 I2=87.4% (P<0.001) I2=0.0% (P=0.609) I2=91.6% (P<0.001)
Pacemaker implantation (%/y) 0.30 (0.20-0.44) 0.33 (0.21-0.51) 0.25 (0.05-1.17) 12 9 4 I2=0.0% (P=0.712) I2=0.0% (P=0.607) I2=44.5% (P=0.144)
Data presented as percentage (95% confidence interval) or linearized occurrence rate (95% confidence interval).
RVOT indicates right ventricular outflow tract; and SUD, sudden unexplained death.
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of autograft reintervention ranging from 94% for 
children to 32% for 55-year-olds and for the RVOT 
conduit ranging from 100% for children to 14% for 
55-year-olds. RVOT conduit deterioration and sub-
sequent reintervention rates are significantly higher
among children undergoing the Ross procedure com-
pared with adults and represent the predominant indi-
cation for reintervention in these children.
Mortality
Our results show that the Ross procedure is associated 
with low early mortality and excellent late survival with 
15-year actuarial survival of 93.5% for children and
91.9% for adults and life expectancy 90% to 95% of
the age- and sex-matched general population. Excess
mortality not directly related to valve-related events is
very low if not zero in these patients.
This mortality is substantially lower than the mor-
tality reported after mechanical AVR, in children and 
adults alike, despite the considerably higher reinter-
vention rates after the Ross procedure.12,13 The favor-
able hemodynamics of the autograft in comparison 
with mechanical prostheses may play a role in this 
observed difference in mortality.14 Furthermore, the 
higher mortality after mechanical AVR may be attrib-
utable in part to the thrombogenicity of mechanical 
valve prostheses and the subsequent requirement for 
anticoagulation treatment and the associated bleed-
ing risks.15 The often unstable International Nor-
malized Ratio (INR) management may play a major 
role in this anticoagulation-related excess mortality 
risk after mechanical AVR, as a propensity-matched 
study by Mokhles et al16 has previously demonstrat-
ed that, with optimal self-management anticoagu-
lation, mechanical AVR offers excellent late survival 
comparable to the Ross procedure. However, this 
study by Mokhles et al16 also illustrates the chal-
lenges that possible differences in patient selection 
pose in comparisons between the Ross procedure 
and mechanical AVR.
Figure 2. Pooled Kaplan-Meier freedom from all-cause mortality.
Figure 3. Pooled Kaplan-Meier freedom from autograft reintervention.
Figure 4. Pooled Kaplan-Meier freedom from right ventricular outflow 
tract (RVOT) reintervention.
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figure 4. Pooled Kaplan-Meier freedom from right ventricular outflow tract (RVOT) reintervention.
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Discussion
This study shows that the Ross procedure, when applied in a broad population of 
children and young adults, is associated with low early and late mortality, with a life 
expectancy after surgery of ≈90% to 95% of the life expectancy in the age- and sex-
matched general population, depending on patient age at surgery. Thromboembolism, 
bleeding, and endocarditis rates are low. However, it also underlines the most important 
drawback of the Ross procedure: substantial late structural valve deterioration of both 
the autograft and the RVOT conduit, and subsequently high age-dependent reinterven-
tion rates, with lifetime risk of autograft reintervention ranging from 94% for children 
to 32% for 55-year-olds and for the RVOT conduit ranging from 100% for children to 
14% for 55-year-olds. RVOT conduit deterioration and subsequent reintervention rates 
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Thus, when comparing survival differences between 
the Ross procedure and other valve substitutes, possible 
differences in patient characteristics and concomitant 
procedures performed at the time of surge y should 
be take  into acc unt. Compared with published data 
on children and adults undergoing mechanical AVR, 
patients undergoing the Ross procedure are on aver-
age slightly younger, less frequently have rheumatic or 
degenerative disease and more frequently have con-
genital disease, but also have more frequently under-
gone prior cardiac interventions and undergo concomi-
tant procedures slightly more often.12,13
Furthermore, the difference in life expectancy 
between patients after the Ross procedure and the gen-
eral population appears to be slightly greater in children 
than in adults, although it should be taken into consid-
eration that a large proportion of the mortality in the 
pediatric population may be attributable to neonates 
and infants rather than older children, as has been pre-
viously demonstrated.12
Autograft Deterioration
Both the autograft and RVOT conduit are subject to 
structural valve deterioration over time.
Subsequently, almost all patients that undergo the 
Ross procedure at age 25 or younger are projected to 
undergo autograft reintervention at some point dur-
ing their lifetime, predominantly because of structural 
valve deterioration. For older adults, this lifetime risk 
lies between 32% and 68%, decreasing with increas-
ing age at surgery.
After autograft root replacement, the main mecha-
nism of autograft deterioration is progressive autograft 
regurgitation because of dilatation of the neoaortic root 
and may be explained by factors such as age, preop-
erative aortic regurgitation, preoperative aortic annulus 
dilatation, and underlying cause of disease.17–20
Considering the strong influence of these patient-
related factors on outcome, careful patient selection 
and patient-tailored decision-making are essential in 
achieving optimal outcome after the Ross procedure.
Given the technical complexity of the procedure, 
variation in surgical technique and surgeon and center 
volume may also affect long-term autograft function. 
For instance, subcoronary implantation, the inclusion 
technique, external prosthetic or pericardial support, 
and annuloplasty have all been proposed to provide a 
mechanically more durable result than full unsupported 
root replacement, with less neoaortic dilatation and 
subsequent regurgitation.21–23 However, these tech-
niques are only applied in a few centers. The techni-
cally demanding nature of these techniques and subse-
quent risk of distortion of the neoaortic valve apparatus 
remains a concern, particularly among surgeons less 
familiar with these techniques.24
Furthermore, the acute increase in mechanical 
stress on the autograft associated with transplanting 
the pulmonary valve apparatus from the pulmonary to 
the systemic circulation is also thought to play a role 
in autograft dilatation and deterioration.25 In this light, 
strict postoperative systemic blood pressure control, 
especially in the first few months postoperative before 
any remodeling has occurred, has been proposed as a 
means to further reduce allograft dilation. The effec-
tiveness thereof remains to be elucidated.
Figure 5. Microsimulation-based age-specific lifetime risks of valve-
related morbidity after the Ross procedure.  
Error bars represent 95% credible intervals. If no error bars are displayed, the 
entire credible interval lies above 100%, because of a high probability of that 
particular event occurring multiple times sequentially in the same patient. The 
hazard of structural valve deterioration of the autograft and right ventricular 
outflow tract (RVOT) conduit were assumed to be time-varying and were 
modeled by fitting a Gompertz distribution to our pooled time-to-event data. 
The hazards of all other events were assumed to be constant over time. NSVD 
indicates nonstructural valve dysfunction; and SVD, structural valve deterioration.
Figure 6. Microsimulation-based age-specific mean life expectancy 
after the Ross procedure compared with the age- and sex-matched 
general population.  
Error bars represent 95% credible intervals. The hazard of structural valve de-
terioration of the autograft and right ventricular outflow tract (RVOT) conduit 
were assumed to be time-varying and were modeled by fitting a Gompertz 
distribution to our pooled time-to-event data. The hazards of all other events 
were assumed to be constant over time.
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figure 5. Microsimulation-based age-specific lifetime risks of valve-related morbidity after the Ross pro-
cedure.
Erro  bars represent 95% credibl  in ervals. If no error bars are displayed, the entire credible interval lies 
above 100%, because of a high probability of that particular event occurring multiple times sequentially in 
the same patient. The hazard of structural valve deterioration of the autograft and right ventricular outflow 
tract (RVOT) conduit were assumed to be time-varying and were modeled by fitting a Gompertz distribu-
tion to our pooled time-to-event data. The hazards of all other events were assumed to be constant over 
time. NSVD indicates nonstructural valve dysfunction; and SVD, structural valve deterioration.
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are significantly higher among children undergoing the Ross procedure compared with 
adults and represent the predominant indication for reintervention in these children.
Mortality
Our results show that the Ross procedure is associated with low early mortality and 
excellent late survival with 15-year actuarial survival of 93.5% for children and 91.9% for 
adults and life expectancy 90% to 95% of the age- and sex-matched general population. 
Excess mortality not directly related to valve-related events is very low if not zero in 
these patients.
This mortality is substantially lower than the mortality reported after mechanical AVR, 
in children and adults alike, despite the considerably higher reintervention rates after 
the Ross procedure.12,13 The favorable hemodynamics of the autograft in comparison 
with mechanical prostheses may play a role in this observed difference in mortality.14 
Furthermore, the higher mortality after mechanical AVR may be attributable in part to 
the thrombogenicity of mechanical valve prostheses and the subsequent requirement 
for anticoagulation treatment and the associated bleeding risks.15 The often unstable In-
ternational Normalized Ratio (INR) management may play a major role in this anticoagu-
lation-related excess mortality risk after mechanical AVR, as a propensity-matched study 
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Thus, when comparing survival differences between 
the Ross procedure and other valve substitutes, possible 
differences in patient characteristics and concomitant 
procedures performed at the time of surgery should 
be taken into account. Compared with published data 
on children and adults undergoing mechanical AVR, 
patients undergoing the Ross procedure are on aver-
age slightly younger, less frequently have rheumatic or 
degenerative disease and more frequently have con-
genital disease, but also have more frequently under-
gone prior cardiac interventions and undergo concomi-
tant procedures slightly more often.12,13
Furthermore, the difference in life expectancy 
between patients after the Ross procedure and the gen-
eral population appears to be slightly greater in children 
than in adults, although it should be taken into consid-
eration that a large proportion of the mortality in the 
pediatric population may be attributable to neonates 
and infants rather than older children, as has been pre-
viously demonstrated.12
Autograft Deterioration
Both the autograft and RVOT conduit are subject to 
structural valve deterioration over time.
Subsequently, almost all patients that undergo the 
Ross procedure at age 25 or younger are projected to 
undergo autograft reintervention at some point dur-
ing their lifetime, predominantly because of structural 
valve deterioration. For older adults, this lifetime risk 
lies between 32% and 68%, decr as ng ith increas-
ing age at surgery.
After autograft root replacement, the main mecha-
nism of autograft deterioration is progressive autograft 
regurgitation because of dilatation of the neoaortic root 
and may be explained by factors such as age, preop-
erative aortic regurgitation, preoperative aortic annulus 
dilatation, and underlying cause of disease.17–20
Consid ring the strong influence of these patient-
r lated factors on outcome, careful patient selection 
and patient-tailored decision-making are essential in 
achieving optimal outcome after the Ross procedure.
Given the technical complexity of the procedure, 
variation in surgical technique and surgeon and center 
volume may also affect long-term autograft function. 
For instance, subcoronary implantation, the inclusion 
technique, external prosthetic or pericardial support, 
and annuloplasty have all been proposed to provide a 
mechanically more durable result than full unsupported 
root replacement, with less neoaortic dilatation and 
subsequent regurgitation.21–23 However, these tech-
niques are only applied in a few centers. The techni-
cally demanding nature of these techniques and subse-
quent risk of distortion of the neoaortic valve apparatus 
remains a concern, particularly among surgeons less 
familiar with these techniques.24
Furthermore, the acute increase in mechanical 
stress on the autograft associated with transplanting 
the pulmonary valve apparatus from the pulmonary to 
the systemic circulation is also thought to play a role 
in autograft dilatation and deterioration.25 In this light, 
strict postoperative systemic blood pressure control, 
especially in the first few months postoperative before 
any remodeling has occurred, has been proposed as a 
means to further reduce allograft dilation. The effec-
tiveness thereof remains to be elucidated.
Figure 5. Microsimulation-based age-specific lifetime risks of valve-
related morbidity after the Ross procedure.  
Error bars represent 95% credible intervals. If no error bars are displayed, the 
entire credible interval lies above 100%, because of a high probability of that 
particular event occurring multiple times sequentially in the same patient. The 
hazard of structural valve deterioration of the autograft and right ventricular 
outflow tract (RVOT) conduit were assumed to be time-varying and were 
modeled by fitting a Gompertz distribution to our pooled time-to-event data. 
The hazards of all other events were assumed to be constant over time. NSVD 
indicates nonstructural valve dysfunction; and SVD, structural valve deterioration.
Figure 6. Microsimulation-based age-specific mean life expectancy 
after the Ross procedure compared with the age- and sex-matched 
general population.  
Error bars represent 95% credible intervals. The hazard of structural valve de-
terioration of the autograft and right ventricular outflow tract (RVOT) conduit 
were assumed to be time-varying and were modeled by fitting a Gompertz 
distribution to our pooled time-to-event data. The hazards of all other events 
were assumed to be constant over time.
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figure 6. Microsimulation-based age-specific mean life expectancy after the Ross procedure compared 
with the age- and sex-matched general population.
Error bars represent 95% credible intervals. The hazard of structural valve de-terioration of the autograft 
and right ventricular outflow tract (RVOT) conduit were assumed to be time-varying and were modeled 
by fitting a Gompertz distribution to our pooled time-to-event data. The hazards of all other events were 
assumed to be constant over time.
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by Mokhles et al16 has previously demonstrated that, with optimal self-management 
anticoagulation, mechanical AVR offers excellent late survival comparable to the Ross 
procedure. However, this study by Mokhles et al16 also illustrates the challenges that 
possible differences in patient selection pose in comparisons between the Ross proce-
dure and mechanical AVR.
Thus, when comparing survival differences between the Ross procedure and other valve 
substitutes, possible differences in patient characteristics and concomitant procedures 
performed at the time of surgery should be taken into account. Compared with pub-
lished data on children and adults undergoing mechanical AVR, patients undergoing 
the Ross procedure are on average slightly younger, less frequently have rheumatic or 
degenerative disease and more frequently have congenital disease, but also have more 
frequently undergone prior cardiac interventions and undergo concomitant procedures 
slightly more often.12,13
Furthermore, the difference in life expectancy between patients after the Ross proce-
dure and the general population appears to be slightly greater in children than in adults, 
although it should be taken into consideration that a large proportion of the mortality in 
the pediatric population may be attributable to neonates and infants rather than older 
children, as has been previously demonstrated.12
autograft deterioration
Both the autograft and RVOT conduit are subject to structural valve deterioration over 
time.
Subsequently, almost all patients that undergo the Ross procedure at age 25 or younger 
are projected to undergo autograft reintervention at some point during their lifetime, 
predominantly because of structural valve deterioration. For older adults, this lifetime 
risk lies between 32% and 68%, decreasing with increasing age at surgery.
After autograft root replacement, the main mechanism of autograft deterioration is pro-
gressive autograft regurgitation because of dilatation of the neoaortic root and may be 
explained by factors such as age, preoperative aortic regurgitation, preoperative aortic 
annulus dilatation, and underlying cause of disease.17-20
Considering the strong influence of these patient-related factors on outcome, careful 
patient selection and patient-tailored decision-making are essential in achieving opti-
mal outcome after the Ross procedure.
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Given the technical complexity of the procedure, variation in surgical technique and 
surgeon and center volume may also affect long-term autograft function. For instance, 
subcoronary implantation, the inclusion technique, external prosthetic or pericar-
dial support, and annuloplasty have all been proposed to provide a mechanically more 
durable result than full unsupported root replacement, with less neoaortic dilatation 
and subsequent regurgitation.21-23 However, these techniques are only applied in a few 
centers. The technically demanding nature of these techniques and subsequent risk 
of distortion of the neoaortic valve apparatus remains a concern, particularly among 
surgeons less familiar with these techniques.24
Furthermore, the acute increase in mechanical stress on the autograft associated with 
transplanting the pulmonary valve apparatus from the pulmonary to the systemic 
circulation is also thought to play a role in autograft dilatation and deterioration.25 In 
this light, strict postoperative systemic blood pressure control, especially in the first 
few months postoperative before any remodeling has occurred, has been proposed 
as a means to further reduce allograft dilation. The effectiveness thereof remains to be 
elucidated.
Although reintervention remains a concern, continued improvements in surgical tech-
niques and perioperative management have led to vast improvements in the safety of 
reoperative aortic valve surgery over the years. Subsequently, reoperations can currently 
be successfully performed with low mortality.23 Unfortunately, when patients undergo 
autograft reintervention, the advantages of the Ross procedure are often lost because 
the autograft is often replaced with a mechanical valve.23 However, in cases of autograft 
dysfunction because of root dilatation with intact autograft valve leaflets or in cases 
in which the valve leaflets can be successfully repaired, the increasing experience with 
valve-sparing autograft reinterventions provides increasing opportunities for long-term 
preservation of the benefits of the Ross procedure.26
rvot conduit deterioration
Although usually less life-threatening, deterioration of the RVOT conduit does pose a 
substantial additional reintervention hazard, especially in children.
Structural RVOT conduit deterioration is a complex multifactorial process that is not 
yet well defined. Contrary to the predominant regurgitation seen in autografts, dete-
rioration of the RVOT conduit, most commonly an allograft, is characterized mostly by 
progressive stenosis.27
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In allografts, immunologic factors are thought to play a role in RVOT conduit degen-
eration, as host immune response and AB0 blood group and human leukocyte antigen 
patient-donor mismatch have been demonstrated to be associated with increased 
structural RVOT allograft failure.28,29 In response, decellularization techniques have been 
developed that aim to reduce immune response and promote autologous cell repopula-
tion by removing donor cells from the allograft while maintaining an intact extracellular 
matrix. There is some early clinical experience with the application of such allografts in 
the Ross procedure that demonstrates satisfactory hemodynamic function.40-44 However, 
longer follow-up and accumulation of larger patient series is required to produce more 
definitive evidence on the hypothesized effect of decellularization.
Age is another important factor related to RVOT conduit degeneration, with younger age 
being associated with higher rates of valve degeneration. This is also clearly reflected by 
our results, with significantly higher RVOT reintervention rates in the pediatric subgroup 
compared with the adult subgroup. Even higher rates of RVOT reintervention have been 
previously reported in neonates and infants (4.30%/y) compared with our pediatric 
subgroup which also includes older children.12 Although the exact mechanism that 
underlies the effect of age on RVOT conduit degeneration is not entirely understood, 
age-related differences in calcium metabolism, immune activity, somatic growth, and 
hemodynamics are hypothesized to play a role.45-48
Although the additional reintervention risk imposed by substituting single valve for 
double valve disease in the Ross procedure is substantial, the advancement of percuta-
neous reinterventions on the RVOT presents a promising solution for delaying surgical 
reinterventions in selected patients.
thromboembolism, bleeding, and endocarditis
One of the most important advantages of the Ross procedure is its low thrombogenicity 
and avoidance of anticoagulation therapy. This is reflected by our results of exceedingly 
low rates of thromboembolism and bleeding, comparable to the age- and sex-matched 
general population.30 Endocarditis rates are also low, approximately half the endocardi-
tis rates previously reported for mechanical AVR in patient populations with comparable 
proportions of preoperative endocarditis.12,13
valve selection and implications for practice
In prosthetic valve selection, the risk of valve deterioration and subsequent reinterven-
tion associated with biological valve substitutes, such as the Ross procedure, is generally 
weighed against mechanical valve-associated thromboembolism and bleeding risk. In 
growing children, the Ross procedure is often considered the preferred surgical option 
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as it is the only living valve substitute and shows diameter increase along with somatic 
growth.31 However, in older adolescents and nonelderly adults, a mechanical valve is 
often recommended because of its superior durability, despite the relatively high risk of 
thromboembolic and bleeding events, inferior hemodynamics, substantial excess mor-
tality, and subsequent implications for pregnancy and lifestyle.13 The 2017 US guidelines 
for the management of adult valvular heart disease propose the Ross procedure to be 
reserved for patients in whom anticoagulation is contraindicated, and the 2017 Euro-
pean guidelines do not even mention the Ross procedure at all.32,33 However, our results 
suggest that the Ross procedure may be beneficial to a larger group of selected patients 
when performed in centers of expertise. Owing to its excellent hemodynamics and 
long-term survival, low risks of thromboembolism, bleeding and endocarditis, absence 
of valve sounds, avoidance of the inconvenience and risks of anticoagulation therapy, 
and continuous improvements in the safety and outcome of reinterventions, the Ross 
procedure provides an outcome profile in stark contrast to that of mechanical AVR. This 
provides a unique opportunity for patients whose preferences, lifestyles, and life plan-
ning do not align with the outcome profile of mechanical AVR. In this light, conveyance 
of patient-tailored evidence-based risks and benefits of all treatment options in a shared 
decision- making process is of great importance.32,33 Innovative solutions such as patient 
information portals and decision aids may prove useful in this setting.34,35
Also, although the risk of reintervention after mechanical AVR is low, it is certainly not 
absent and should also be taken into consideration in the process of prosthetic valve 
selection. This also applies to the risk of thromboembolism and bleeding after AVR with 
biological alternatives.
Continuous advances in the design of bioprostheses are hypothesized to improve the 
durability of modern bioprostheses. This has led to an increase in their use in younger 
patients. Further development and studies on their long-term performance in young 
adult patients are required to shed light on their potential as a valve substitute in young 
adults.
Lastly, continuous improvements in aortic valve repair techniques may increasingly 
provide options for native valve preservation in young adult patients, avoiding or post-
poning the need for valve replacement.36
Our outcomes provide a unique insight into what patients can be expected to face during 
the course of their lives after undergoing the Ross procedure, which represents valuable 
information to patients and clinicians in a meaningful format. This provides the opportu-
nity to provide patients the essential information they need to support decision-making 
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and improve treatment adherence, follow-up compliance, health behaviors, and quality 
of life.34 Our methodology also provides the basis for patient-tailored decision-making 
by allowing for the possibility to generate patient-tailored outcome estimates. Although 
we were currently only able to tailor our outcome estimates to age, further studies on the 
relationship between other patient-related factors and outcomes will make it possible 
to further tailor outcome estimates, taking other factors into account such as underlying 
cause of disease, hemodynamics, symptoms, medical history, and concomitant diseases. 
This may aid clinicians and patients in more accurately selecting the optimal treatment 
for each individual patient. This methodology may also provide similar opportunities 
in other areas of cardiovascular medicine in which long-term outcome modeling and 
subsequent evidence-based decision-making remain a challenge.
Furthermore, because of continuous improvements in long-term survival, quality of life 
(as opposed to length of life) is increasingly coming into focus. Our outcomes show that, 
while life expectancy after the Ross procedure approaches the life expectancy of the 
general population, patients may face numerous valve-related events during their lives. 
How these valve-related events impact quality of life in these patients remains to be 
elucidated, although the Ross procedure has been previously shown to be associated 
with superior quality of life compared with mechanical AVR and comparable to aortic 
valve repair.37 The lifetime event occurrence estimates provided by our methodology 
may provide the basis for estimating long-term quality of life in these patients and may 
inform efforts aimed at improving this.
strengths and limitations
To our knowledge, this is the first and only systematic review on this subject to use our 
advanced methods of meta-analysis of time-to-event data and microsimulation. These 
methods in conjunction with the large sample size allow us to provide robust long-term 
outcome estimates and age-specific estimates of life expectancy and lifetime event risk, 
allowing for a much better insight into long-term outcome in these patients and provid-
ing information that is crucial in decision-making and patient information.
This study has several limitations. It is a systematic review and meta-analysis of ob-
servational studies, many of which are retrospective in design. As such, the inherent 
limitations of meta-analyses and pooling data from retrospective observational studies 
should be taken into consideration.38 Selection bias may have affected the observed 
outcomes, as unpublished data, abstracts, and presentations were not included. Funnel 
plots could not be used to investigate publication bias, as funnel plots do not allow 
for meaningful interpretation in case of absolute risk outcomes (as are all of our out-
comes) because of substantial methodological limitations which may in itself give rise 
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to funnel plot asymmetry.39 Direct comparisons with alternative valve prostheses are 
hampered by the lack of published comparative data. Finally, there are limitations to the 
microsimulation model that should be taken into account. The relationship between the 
occurrence rates of valve-related events after the Ross procedure and age and history 
of previous valve-related events remains poorly defined and could, thus, not be incor-
porated into our microsimulation model. The model requires assumptions to be made 
about the evolution of event occurrence rates beyond the observed follow-up period, 
which may have introduced uncertainty, although this uncertainty is incorporated in the 
95% credible intervals of our outcome estimates.
conclusions
Outcome after the Ross procedure is characterized by excellent survival and low 
postoperative rates of thromboembolism, bleeding, and endocarditis. Lifetime risk of 
reintervention is high, mainly because of age-dependent structural valve deterioration 
of both the autograft and allograft. The Ross procedure provides a unique opportunity 
for patients whose preferences, lifestyles, and life planning do not align with the out-
come provided by mechanical valve replacement and for growing children who also 
benefit from autograft diameter increase along with somatic growth. Thus, patients 
who are facing AVR are entitled to conveyance of evidence-based estimates of the risks 
and benefits of all treatment options in a shared decision-making process. Our results 
warrant reintroduction of the Ross procedure as a valuable option on the surgical menu 
for selected patients.
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supplement 1. Supplementary methods
1. search query
embase: 3777 results
(‘pulmonary valve replacement’/de OR ‘pulmonary valve prosthesis’/de OR ‘Ross pro-
cedure’/de OR ((‘heart valve prosthesis’/de OR ‘heart valve bioprosthesis’/exp OR ‘heart 
valve replacement’/exp OR bioprosthesis/de OR xenograft/de OR allograft/de OR allo-
transplantation/de OR ‘cardiovascular surgery’/de) AND (‘pulmonary valve’/de OR ‘pul-
monary valve disease’/exp )) OR (((pulmon* OR lung) NEAR/6 (valv*) NEAR/6 (replace* 
OR transplant* OR allotransplant* OR allograft* OR homotransplant* OR homograft* OR 
xenotransplant* OR xenograft* OR heterotransplant* OR heterograft* OR prosthe* OR 
bioprosthe* OR stent* OR implant* OR substitut* OR conduit* OR melod* OR mechani-
cal* OR insert*)) OR ((conduit OR reconstruct*) NEAR/15 (right OR pulm*) NEAR/6 ven-
tric*) OR (reconstruct* NEAR/3 pulmon* NEAR/3 tract*) OR (rvot NEAR/3 reconstruct*) 
OR (Ross NEAR/3 (procedure* OR operation*)) OR (pulmonar* NEAR/3 autograft*)):ab,ti) 
NOT ([animals]/lim NOT [humans]/lim) AND [english]/lim NOT ([Conference Abstract]/
lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim ) NOT (‘case report’/de OR ((case 
NEXT/1 report*)):ab,ti)
Medline: 3815 results
(((Heart Valve Prosthesis/ OR Heart Valve Prosthesis Implantation/ OR bioprosthesis/ 
OR heterograft/ OR allografts/ OR “Transplantation, Homologous”/ OR Cardiovascular 
Surgical Procedures/ ) AND (pulmonary valve/ OR Pulmonary Valve Insufficiency/ OR 
Pulmonary Valve Stenosis/ OR pulmonary artery/)) OR (((pulmon* OR lung) ADJ6 (valv*) 
ADJ6 (replace* OR transplant* OR allotransplant* OR allograft* OR homotransplant* OR 
homograft* OR xenotransplant* OR xenograft* OR heterotransplant* OR heterograft* OR 
prosthe* OR bioprosthe* OR stent* OR implant* OR substitut* OR conduit* OR melod* 
OR mechanical* OR insert*)) OR ((conduit OR reconstruct*) ADJ15 (right OR pulm*) ADJ6 
ventric*) OR (reconstruct* ADJ3 pulmon* ADJ3 tract*) OR (rvot ADJ3 reconstruct*) OR 
(Ross ADJ3 (procedure* OR operation*)) OR (pulmonar* ADJ3 autograft*)).ab,ti.) NOT 
(exp animals/ NOT humans/) AND english.la. NOT (letter OR news OR comment OR edi-
torial OR congresses OR abstracts).pt. NOT (“case reports”/ OR ((case ADJ report*)).ab,ti.)
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web of science: 3094 results
TS=(((((pulmon* OR lung) NEAR/5 (valv*) NEAR/5 (replace* OR transplant* OR allotrans-
plant* OR allograft* OR homotransplant* OR homograft* OR xenotransplant* OR xeno-
graft* OR heterotransplant* OR heterograft* OR prosthe* OR bioprosthe* OR stent* OR 
implant* OR substitut* OR conduit* OR melod* OR mechanical* OR insert*)) OR ((conduit 
OR reconstruct*) NEAR/15 (right OR pulm*) NEAR/5 ventric*) OR (reconstruct* NEAR/2 
pulmon* NEAR/2 tract*) OR (rvot NEAR/2 reconstruct*) OR (Ross NEAR/2 (procedure* OR 
operation*)) OR (pulmonar* NEAR/2 autograft*))) NOT (((case NEAR/1 report*)))) AND 
LA=(english) AND DT=(article)
cochrane: 138 results
((((pulmon* OR lung) NEAR/6 (valv*) NEAR/6 (replace* OR transplant* OR allotransplant* 
OR allograft* OR homotransplant* OR homograft* OR xenotransplant* OR xenograft* 
OR heterotransplant* OR heterograft* OR prosthe* OR bioprosthe* OR stent* OR im-
plant* OR substitut* OR conduit* OR melod* OR mechanical* OR insert*)) OR ((conduit 
OR reconstruct*) NEAR/15 (right OR pulm*) NEAR/6 ventric*) OR (reconstruct* NEAR/3 
pulmon* NEAR/3 tract*) OR (rvot NEAR/3 reconstruct*) OR (Ross NEAR/3 (procedure* OR 
operation*)) OR (pulmonar* NEAR/3 autograft*)):ab,ti) NOT (((case NEXT/1 report*)):ab,ti)
google scholar: 200 results
“pulmonary valve replacement|transplantation|allotransplantation|allograft|homotran
splantation|homograft|xenotransplantation|xenograft|heterotransplantation|heterogra
ft|prosthesis|bioprosthesis|implant|conduit”|”Ross procedure|operation”
2. list of recorded variables
study characteristics:
	 •	 Study	design
	 •	 Number	of	patients	included
	 •	 Inclusion	period
	 •	 Total	follow-up
Baseline patient and operative characteristics:
	 •	 Mean	age
	 •	 Sex
	 •	 Etiology
	 •	 Aortic	valve	hemodynamics
	 •	 Aortic	valve	morphology
	 •	 	Previous	cardiac	interventions	(any	previous	surgical	or	percutaneous	interven-
tion on the heart, thoracic aorta and/or pulmonary trunk)
	 •	 New	York	Heart	Association/Ross	functional	class
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	 •	 Urgency	of	the	operation
	 •	 	Technique	(total	root	replacement,	subcoronary	implantation	or	inclusion	cylin-
der)
	 •	 	Type	 of	 right	 ventricular	 outflow	 tract	 prosthesis	 (allograft,	 bioprosthesis	 or	
other)
	 •	 Concomitant	procedures
outcome events:
	 •	 Early	outcome	events	(<30	days	after	surgery)
  o Early mortality (all-cause mortality within the first 30 postoperative days)
  o Re-exploration for bleeding
  o Pacemaker implantation
  o Deep sternal infection/mediastinitis
  o Endocarditis
  o Stroke
  o Transient ischemic attack
  o Myocardial infarction
  o Valve thrombosis
  o Peripheral bleeding
	 •	 Late	outcome	events	(>30	days	after	surgery)
  o Late mortality
   - Cardiac death
   - Valve related death
   - Sudden, unexplained death (SUD)
  o Reintervention
   - Autograft
   - Right ventricular outflow tract (RVOT)
  o Thromboembolism
  o Valve thrombosis
  o Bleeding
  o Endocarditis
   - Autograft
   - Right ventricular outflow tract (RVOT)
  o Structural valve deterioration (SVD)
   - Autograft
   - Right ventricular outflow tract (RVOT)
  o Nonstructural valve dysfunction (NSVD)
   - Autograft
   - Right ventricular outflow tract (RVOT)
  o Pacemaker implantation
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3. statistical software used
Meta-analysis of baseline patient and study characteristics and event risks and linear-
ized occurrence rates were performed in Microsoft Office Excel 2011 (Microsoft Corp., 
Redmond, WA, USA). Published Kaplan-Meier curves were digitized using Engauge Digi-
tizer (version 10.3, http://markummitchell.github.io/engauge-digitizer). Extrapolation of 
estimated individual patient time-to-event data from the digitized curves, meta-analysis 
thereof, microsimulation and meta-regression were performed in R statistical software 
(version 3.3.2, R Development Core Team, R Foundation for Statistical Computing, Vi-
enna, Austria).
4. Microsimulation model: concept
The microsimulation model iteratively simulates individual patient lives after surgery, 
taking into account the morbidity and mortality events that the patient may experience. 
The simulated individual patient life histories are then aggregated to obtain estimates 
of population level outcome. The mortality of a patient is composed of the background 
mortality of the general population, operative mortality, mortality due to valve-related 
events and an additional excess mortality component that is not a direct result of 
valve-related events, but is associated with underlying valve pathology, left ventricular 
function and other associated pathology.
4. Microsimulation model: schematic overview (each simulated patient is run through 
this hypothetical scenario)
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5. Microsimulation model: estimation of excess mortality
For estimation of the hazard ratios of the additional excess mortality not directly re-
sulting from valve-related events relative to background mortality, a microsimulation 
model containing only background mortality and mortality due to valve-related events 
(excluding early mortality) was run for 10,000 iterations at the mean age of the adult 
and pediatric subgroups separately. Subsequently, the hazard ratios were estimated by 
fitting the survival output of this microsimulation model to the survival observed in our 
meta-analysis of time-to-event data (excluding early mortality) using the least squares 
method.
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supplement 2. Individual study characteristics. 
“-“=variable not reported. FUP=follow-up. Studies included only in the Kaplan-Meier meta-analysis due 
to overlapping study populations (Brown 2007, “All ages” and “Pediatric” groups; Frigiola 2010, “All awges” 
and “Pediatric” groups; Sievers 2010, “All ages”, “Pediatric” and “Adult” groups; Brancaccio 2014, “All ages” 
and “Pediatric” groups) are not included in this overview.
all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Sharoni 2000 - Middle East 40 1996-1999 1.0 -(0.7-41.0) - - -
Sirvydis 2000 Prospective EU 45 1993-1999 2.5 11.5(4.0-45.0) 100.0% 0.0% 0.0%
Solowiejczyk 2000 - North America 40 1988-1996 2.0 8.3(0.0-19.0) 100.0% 0.0% 0.0%
Carr-White 2001 - EU 144 1993-2000 4.0 31.0(0.2-64.0) 100.0% 0.0% 0.0%
Laudito 2001 Retrospective North America 72 1993-2000 3.5 9.1(0.0-39.6) - - -
Oswalt 2001 Prospective North America 191 1990-2000 4.9 39.0(0.0-69.0) 100.0% 0.0% 0.0%
Phillips 2001 - North America 31 1993-1998 1.7 28.0(5.0-60.0) - - -
Xie 2001 - North America 49 1991-1996 3.0 36.0(16.0-66.0) 100.0% 0.0% 0.0%
Schmid 2002 Retrospective EU 51 1997-2002 3.0 43.2(-) 100.0% 0.0% 0.0%
Svensson 2002 - EU 77 1995-1999 - 44.0(17.0-66.0) 100.0% 0.0% 0.0%
Fullerton 2003 - North America 44 1997-2002 3.2 49.0(19.0-71.0) 100.0% 0.0% 0.0%
Lupinetti 2003 - North America 78 1994-2001 3.4 10.7(0.2-22.3) 100.0% 0.0% 0.0%
Alphonso 2004 Retrospective EU 60 1991-2002 5.8 15.0(0.5-67.0) - - -
Kouchoukos 2004 - North America 119 1998-2002 4.4 31.0(4.0-56.0) 100.0% 0.0% 0.0%
Matalanis 2004 - Oceania 31 1994-2002 2.4 42.0(24.0-61.0) 100.0% 0.0% 0.0%
Raja 2004 Retrospective EU 38 1996-2003 2.8 13.1(1.4-29.7) 100.0% 0.0% 0.0%
Chotivatanapong 2005 - Asia 30 1997-2002 1.4 36.3(17.0-60.0) 100.0% 0.0% 0.0%
Kumar 2005 - Asia 153 1993-2003 6.4 28.0(0.7-65.0) 100.0% 0.0% 0.0%
Settepani 2005 Retrospective EU 103 1991-2003 6.0 35.2(17.0-65.0) 100.0% 0.0% 0.0%
Pitsis 2006 - EU 21 1998-2004 4.0 42.0(16.0-55.0) 81.0% 19.0% 0.0%
Wang 2006 Prospective Oceania 30 1995-2005 5.4 23.0(13.0-49.0) 100.0% 0.0% 0.0%
Klieverik 2007 Prospective EU 94 1988-2005 8.7 30.4(16.0-52.0) 93.6% 6.4% 0.0%
Pasquali 2007 Retrospective North America 121 1995-2004 6.5 8.2(0.0-34.0) - - -
Salehi 2007 - Middle East 80 2001-2004 1.4 27.6(11.0-56.0) - - -
Elkins 2008 Prospective North America 487 1986-2002 - 24.0(0.0-62.0) 83.6% 5.3% 11.1%
Frigiola 2008 Retrospective EU 110 1994-2007 6.8 30.2(17.0-65.0) 100.0% 0.0% 0.0%
Kadner 2008 Retrospective EU 52 1993-2004 3.6 3.6(0.0-15.0) 100.0% 0.0% 0.0%
El Behery 2009 Retrospective EU 41 1991-2003 6.0 10.2(0.5-18.3) 95.1% 0.0% 4.9%
Goldberg 2009 Retrospective North America 32 2003-2007 1.6 5.4(0.0-20.0) - - -
Al Rashidi 2010 Prospective EU 26 2003-- 2.9 37.0(31.0-41.0) - - -
Alsoufi 2010 Retrospective Middle East 227 1991-2004 7.8 12.1(0.0-18.0) 100.0% 0.0% 0.0%
Coskun 2010 Retrospective EU 23 2000-2008 2.3 12.6(0.0-40.0) - - -
El-Hamamsy 2010 RCT EU 108 1994-2001 10.2 38.0(19.0-66.0) - - -
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supplement 2. Individual study characteristics. 
“-“=variable not reported. FUP=follow-up. Studies included only in the Kaplan-Meier meta-analysis due 
to overlapping study populations (Brown 2007, “All ages” and “Pediatric” groups; Frigiola 2010, “All awges” 
and “Pediatric” groups; Sievers 2010, “All ages”, “Pediatric” and “Adult” groups; Brancaccio 2014, “All ages” 
and “Pediatric” groups) are not included in this overview.
all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Sharoni 2000 - Middle East 40 1996-1999 1.0 -(0.7-41.0) - - -
Sirvydis 2000 Prospective EU 45 1993-1999 2.5 11.5(4.0-45.0) 100.0% 0.0% 0.0%
Solowiejczyk 2000 - North America 40 1988-1996 2.0 8.3(0.0-19.0) 100.0% 0.0% 0.0%
Carr-White 2001 - EU 144 1993-2000 4.0 31.0(0.2-64.0) 100.0% 0.0% 0.0%
Laudito 2001 Retrospective North America 72 1993-2000 3.5 9.1(0.0-39.6) - - -
Oswalt 2001 Prospective North America 191 1990-2000 4.9 39.0(0.0-69.0) 100.0% 0.0% 0.0%
Phillips 2001 - North America 31 1993-1998 1.7 28.0(5.0-60.0) - - -
Xie 2001 - North America 49 1991-1996 3.0 36.0(16.0-66.0) 100.0% 0.0% 0.0%
Schmid 2002 Retrospective EU 51 1997-2002 3.0 43.2(-) 100.0% 0.0% 0.0%
Svensson 2002 - EU 77 1995-1999 - 44.0(17.0-66.0) 100.0% 0.0% 0.0%
Fullerton 2003 - North America 44 1997-2002 3.2 49.0(19.0-71.0) 100.0% 0.0% 0.0%
Lupinetti 2003 - North America 78 1994-2001 3.4 10.7(0.2-22.3) 100.0% 0.0% 0.0%
Alphonso 2004 Retrospective EU 60 1991-2002 5.8 15.0(0.5-67.0) - - -
Kouchoukos 2004 - North America 119 1998-2002 4.4 31.0(4.0-56.0) 100.0% 0.0% 0.0%
Matalanis 2004 - Oceania 31 1994-2002 2.4 42.0(24.0-61.0) 100.0% 0.0% 0.0%
Raja 2004 Retrospective EU 38 1996-2003 2.8 13.1(1.4-29.7) 100.0% 0.0% 0.0%
Chotivatanapong 2005 - Asia 30 1997-2002 1.4 36.3(17.0-60.0) 100.0% 0.0% 0.0%
Kumar 2005 - Asia 153 1993-2003 6.4 28.0(0.7-65.0) 100.0% 0.0% 0.0%
Settepani 2005 Retrospective EU 103 1991-2003 6.0 35.2(17.0-65.0) 100.0% 0.0% 0.0%
Pitsis 2006 - EU 21 1998-2004 4.0 42.0(16.0-55.0) 81.0% 19.0% 0.0%
Wang 2006 Prospective Oceania 30 1995-2005 5.4 23.0(13.0-49.0) 100.0% 0.0% 0.0%
Klieverik 2007 Prospective EU 94 1988-2005 8.7 30.4(16.0-52.0) 93.6% 6.4% 0.0%
Pasquali 2007 Retrospective North America 121 1995-2004 6.5 8.2(0.0-34.0) - - -
Salehi 2007 - Middle East 80 2001-2004 1.4 27.6(11.0-56.0) - - -
Elkins 2008 Prospective North America 487 1986-2002 - 24.0(0.0-62.0) 83.6% 5.3% 11.1%
Frigiola 2008 Retrospective EU 110 1994-2007 6.8 30.2(17.0-65.0) 100.0% 0.0% 0.0%
Kadner 2008 Retrospective EU 52 1993-2004 3.6 3.6(0.0-15.0) 100.0% 0.0% 0.0%
El Behery 2009 Retrospective EU 41 1991-2003 6.0 10.2(0.5-18.3) 95.1% 0.0% 4.9%
Goldberg 2009 Retrospective North America 32 2003-2007 1.6 5.4(0.0-20.0) - - -
Al Rashidi 2010 Prospective EU 26 2003-- 2.9 37.0(31.0-41.0) - - -
Alsoufi 2010 Retrospective Middle East 227 1991-2004 7.8 12.1(0.0-18.0) 100.0% 0.0% 0.0%
Coskun 2010 Retrospective EU 23 2000-2008 2.3 12.6(0.0-40.0) - - -
El-Hamamsy 2010 RCT EU 108 1994-2001 10.2 38.0(19.0-66.0) - - -
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all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Valeske 2010 Retrospective EU 98 1996-2008 5.0 11.0(0.1-25.0) 99.0% 1.0% 0.0%
Brown 2011 Retrospective North America 230 1994-2010 7.8 42.4(20.0-68.0) 100.0% 0.0% 0.0%
Clark 2011 Retrospective North America 54 1992-2007 6.4 13.5(0.5-35.0) 83.3% 0.0% 16.7%
Kalfa 2011 Retrospective EU 107 1993-2009 5.7 22.0(0.2-67.0) 100.0% 0.0% 0.0%
Kitamura 2011 - Asia 21 - 9.9 22.0(6.0-47.0) 100.0% 0.0% 0.0%
Ryan 2011 Prospective North America 160 1994-2008 5.4 42.0(-) 100.0% 0.0% 0.0%
Brinkman 2012 Prospective North America 160 1994-2008 10.1 -(-) 100.0% 0.0% 0.0%
Charitos 2012 Retrospective/prospective EU 263 - 6.9 8.0(-) - - -
Juthier 2012 Prospective EU 336 1992-2010 6.2 29.4(3.0-55.0) 80.1% 15.5% -
Luciani 2012 Retrospective EU 134 1994-2011 10.8 25.9(0.1-49.0) 46.3% 21.6% 32.1%
McBrien 2012 Retrospective EU 101 1997-2010 4.7 24.8(0.1-53.0) 100.0% - -
Ruzmetov 2012 Retrospective North America 106 1990-2011 7.8 17.9(0.1-40.0) 100.0% 0.0% 0.0%
Goda 2013 Retrospective EU 33 1993-2010 8.8 9.9(0.0-17.0) 100.0% 0.0% 0.0%
Khan 2013 Retrospective North America 68 1995-2011 6.7 5.9(0.0-17.0) 100.0% 0.0% 0.0%
Ruzmetov 2013 Retrospective North America 78 1993-2011 8.8 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Skillington 2013 - Oceania 310 1992-2012 9.4 39.3(16.0-63.0) - - -
Stelzer 2013 Prospective North America 530 1987-2013 - 42.7(-) 100.0% 0.0% 0.0%
Tanny 2013 Retrospective Oceania 100 1995-2012 7.3 8.6(0.0-18.0) 91.0% 3.0% 6.0%
Andreas 2014 Retrospective EU 246 1991-2011 10.0 29.0(-) 100.0% 0.0% 0.0%
Da Costa 2014 - South America 414 1995-2013 8.2 30.8(3.0-60.0) 86.0% 0.0% 14.0%
David 2014 Prospective North America 212 1990-2004 13.8 34.0(-) 50.9% - -
Kallio 2014 Retrospective EU 51 1994-2009 11.5 4.8(0.0-16.0) - - -
Le Guillou 2014 Retrospective EU 28 1997-2011 6.4 42.0(19.0-57.0) 100.0% 0.0% 0.0%
Lehoux 2014 Retrospective North America 25 1997-2008 7.3 7.3(-) 100.0% 0.0% 0.0%
Lo Rito 2014 Retrospective EU 140 1991-2011 10.8 9.9(0.2-35.4) 100.0% 0.0% 0.0%
Luciani 2014 Retrospective EU 305 1990-2014 8.4 9.4(0.0-18.0) 65.9% 5.6% 4.6%
Ruzmetov 2014 Retrospective North America 78 1993-2011 9.9 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Xu 2014 Retrospective Asia 58 1994-2009 8.2 28.3(5.0-56.0) 81.0% 19.0% 0.0%
Zebele 2014 Retrospective EU 91 1998-2011 20.0 20.0(-) 100.0% 0.0% 0.0%
Bansal 2015 Retrospective North America 305 1992-2012 8.2 13.1(0.0-70.3) 96.4% 3.6% 0.0%
Escarain 2015 Retrospective South America 263 1995-2012 7.5 42.0(15.0-67.0) 100.0% 0.0% 0.0%
Jacobsen 2015 Retrospective North America 36 1992-2014 2.2 14.0(11.0-31.0) 100.0% 0.0% 0.0%
Lukyanov 2015 - EU 114 2002-2012 3.9 -(0.0-18.0) 92.1% 12.3% 0.0%
Mastrobuoni 2015 Prospective EU 306 1991-2014 10.6 41.7(-) 54.9% 2.3% 42.8%
Nelson 2015 Retrospective North America 240 1991-2013 10.7 -(0.0-18.0) 100.0% 0.0% 0.0%
Sievers 2015 Retrospective/Prospective EU 1779 - 8.3 44.7(-) - - -
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supplement 2. (continued)
all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Valeske 2010 Retrospective EU 98 1996-2008 5.0 11.0(0.1-25.0) 99.0% 1.0% 0.0%
Brown 2011 Retrospective North America 230 1994-2010 7.8 42.4(20.0-68.0) 100.0% 0.0% 0.0%
Clark 2011 Retrospective North America 54 1992-2007 6.4 13.5(0.5-35.0) 83.3% 0.0% 16.7%
Kalfa 2011 Retrospective EU 107 1993-2009 5.7 22.0(0.2-67.0) 100.0% 0.0% 0.0%
Kitamura 2011 - Asia 21 - 9.9 22.0(6.0-47.0) 100.0% 0.0% 0.0%
Ryan 2011 Prospective North America 160 1994-2008 5.4 42.0(-) 100.0% 0.0% 0.0%
Brinkman 2012 Prospective North America 160 1994-2008 10.1 -(-) 100.0% 0.0% 0.0%
Charitos 2012 Retrospective/prospective EU 263 - 6.9 8.0(-) - - -
Juthier 2012 Prospective EU 336 1992-2010 6.2 29.4(3.0-55.0) 80.1% 15.5% -
Luciani 2012 Retrospective EU 134 1994-2011 10.8 25.9(0.1-49.0) 46.3% 21.6% 32.1%
McBrien 2012 Retrospective EU 101 1997-2010 4.7 24.8(0.1-53.0) 100.0% - -
Ruzmetov 2012 Retrospective North America 106 1990-2011 7.8 17.9(0.1-40.0) 100.0% 0.0% 0.0%
Goda 2013 Retrospective EU 33 1993-2010 8.8 9.9(0.0-17.0) 100.0% 0.0% 0.0%
Khan 2013 Retrospective North America 68 1995-2011 6.7 5.9(0.0-17.0) 100.0% 0.0% 0.0%
Ruzmetov 2013 Retrospective North America 78 1993-2011 8.8 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Skillington 2013 - Oceania 310 1992-2012 9.4 39.3(16.0-63.0) - - -
Stelzer 2013 Prospective North America 530 1987-2013 - 42.7(-) 100.0% 0.0% 0.0%
Tanny 2013 Retrospective Oceania 100 1995-2012 7.3 8.6(0.0-18.0) 91.0% 3.0% 6.0%
Andreas 2014 Retrospective EU 246 1991-2011 10.0 29.0(-) 100.0% 0.0% 0.0%
Da Costa 2014 - South America 414 1995-2013 8.2 30.8(3.0-60.0) 86.0% 0.0% 14.0%
David 2014 Prospective North America 212 1990-2004 13.8 34.0(-) 50.9% - -
Kallio 2014 Retrospective EU 51 1994-2009 11.5 4.8(0.0-16.0) - - -
Le Guillou 2014 Retrospective EU 28 1997-2011 6.4 42.0(19.0-57.0) 100.0% 0.0% 0.0%
Lehoux 2014 Retrospective North America 25 1997-2008 7.3 7.3(-) 100.0% 0.0% 0.0%
Lo Rito 2014 Retrospective EU 140 1991-2011 10.8 9.9(0.2-35.4) 100.0% 0.0% 0.0%
Luciani 2014 Retrospective EU 305 1990-2014 8.4 9.4(0.0-18.0) 65.9% 5.6% 4.6%
Ruzmetov 2014 Retrospective North America 78 1993-2011 9.9 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Xu 2014 Retrospective Asia 58 1994-2009 8.2 28.3(5.0-56.0) 81.0% 19.0% 0.0%
Zebele 2014 Retrospective EU 91 1998-2011 20.0 20.0(-) 100.0% 0.0% 0.0%
Bansal 2015 Retrospective North America 305 1992-2012 8.2 13.1(0.0-70.3) 96.4% 3.6% 0.0%
Escarain 2015 Retrospective South America 263 1995-2012 7.5 42.0(15.0-67.0) 100.0% 0.0% 0.0%
Jacobsen 2015 Retrospective North America 36 1992-2014 2.2 14.0(11.0-31.0) 100.0% 0.0% 0.0%
Lukyanov 2015 - EU 114 2002-2012 3.9 -(0.0-18.0) 92.1% 12.3% 0.0%
Mastrobuoni 2015 Prospective EU 306 1991-2014 10.6 41.7(-) 54.9% 2.3% 42.8%
Nelson 2015 Retrospective North America 240 1991-2013 10.7 -(0.0-18.0) 100.0% 0.0% 0.0%
Sievers 2015 Retrospective/Prospective EU 1779 - 8.3 44.7(-) - - -
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all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Tierney 2005 Retrospective North America 26 1989-2003 5.2 3.4(-) - - -
Boethig 2007 Retrospective EU 109 1985-2005 5.0 31.5(0.0-69.5) - - -
Franke 2015 - EU 136 2007-2013 3.0 50.0(20.0-67.0) 100.0% 0.0% 0.0%
Ruzmetov 2015 Retrospective North America 72 1993-2012 11.0 11.9(0.3-18.0) - - -
Baird 2016 Retrospective North America 50 2000-2014 4.4 4.5(-) 98.0% 2.0% 0.0%
Brown 2016 Retrospective North America 115 1993-2015 7.8 11.4(0.1-18.0) 100.0% 0.0% 0.0%
Carrel 2016 Prospective EU 22 2006-- 5.0 -(-) 100.0% 0.0% 0.0%
Karaskov 2016 Retrospective EU 741 1998-2014 5.8 47.4(18.0-67.0) 100.0% 0.0% 0.0%
Mazine 2016 Prospective North America 208 1990-2014 13.6 37.3(16.0-63.0) 50.0% - -
Popelová 2016 - EU 33 2005-2015 - -(-) - - -
Zimmermann 2016 Retrospective EU 76 1993-2011 5.2 15.9(0.4-58.4) 100.0% 0.0% 0.0%
Bouhout 2017 Retrospective North America 200 2011-2016 - 46.0(--65.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 107 1997-2009 11.0 30.0(3.0-54.0) - - -
Martin 2017 Prospective North America 310 1990-2014 15.1 40.8(18.0--) 83.5% 5.8% 10.6%
Ratschiller 2017 Retrospective EU 190 1991-2017 12.0 28.0(0.0-61.7) 89.5% 0.0% 10.5%
Schneider 2017 Retrospective EU 154 1994-2016 10.0 12.0(19.0-48.0) 97.4% 1.3% 1.3%
Skoglund 2017 Retrospective EU 77 --2015 15.9 22.7(-) - - -
Tran 2017 Retrospective EU 75 1998-2012 5.2 10.2(0.4-18.0) 100.0% 0.0% 0.0%
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supplement 2. (continued)
all ages
study design origin Patients (n) inclusion period Mean/median fuP Mean/median age at surgery 
(range)
technique
  total root replacement subcoronary inclusion
Tierney 2005 Retrospective North America 26 1989-2003 5.2 3.4(-) - - -
Boethig 2007 Retrospective EU 109 1985-2005 5.0 31.5(0.0-69.5) - - -
Franke 2015 - EU 136 2007-2013 3.0 50.0(20.0-67.0) 100.0% 0.0% 0.0%
Ruzmetov 2015 Retrospective North America 72 1993-2012 11.0 11.9(0.3-18.0) - - -
Baird 2016 Retrospective North America 50 2000-2014 4.4 4.5(-) 98.0% 2.0% 0.0%
Brown 2016 Retrospective North America 115 1993-2015 7.8 11.4(0.1-18.0) 100.0% 0.0% 0.0%
Carrel 2016 Prospective EU 22 2006-- 5.0 -(-) 100.0% 0.0% 0.0%
Karaskov 2016 Retrospective EU 741 1998-2014 5.8 47.4(18.0-67.0) 100.0% 0.0% 0.0%
Mazine 2016 Prospective North America 208 1990-2014 13.6 37.3(16.0-63.0) 50.0% - -
Popelová 2016 - EU 33 2005-2015 - -(-) - - -
Zimmermann 2016 Retrospective EU 76 1993-2011 5.2 15.9(0.4-58.4) 100.0% 0.0% 0.0%
Bouhout 2017 Retrospective North America 200 2011-2016 - 46.0(--65.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 107 1997-2009 11.0 30.0(3.0-54.0) - - -
Martin 2017 Prospective North America 310 1990-2014 15.1 40.8(18.0--) 83.5% 5.8% 10.6%
Ratschiller 2017 Retrospective EU 190 1991-2017 12.0 28.0(0.0-61.7) 89.5% 0.0% 10.5%
Schneider 2017 Retrospective EU 154 1994-2016 10.0 12.0(19.0-48.0) 97.4% 1.3% 1.3%
Skoglund 2017 Retrospective EU 77 --2015 15.9 22.7(-) - - -
Tran 2017 Retrospective EU 75 1998-2012 5.2 10.2(0.4-18.0) 100.0% 0.0% 0.0%
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PeDiatric
study design origin Patients (n) inclusion period Mean/median
fuP
Mean/median age at 
surgery (range)
technique
  total root 
replacement
subcoronary inclusion
Solowiejczyk 2000 - North America 40 1988-1996 2.0 8.3(0.0-19.0) 100.0% 0.0% 0.0%
Pigula 2001 Retrospective North America 34 1995-2000 1.4 10.0(0.3-18.0) 100.0% 0.0% 0.0%
Lupinetti 2003 - North America 78 1994-2001 3.4 10.7(0.2-22.3) 100.0% 0.0% 0.0%
Hazekamp 2005 - EU 53 1994-2003 5.5 9.2(0.0-17.7) 100.0% 0.0% 0.0%
Kalavrouziotis 2006 - EU 35 1996-2004 4.1 10.6(0.0-18.0) 100.0% 0.0% 0.0%
Kadner 2008 Retrospective EU 52 1993-2004 3.6 3.6(0.0-15.0) 100.0% 0.0% 0.0%
El Behery 2009 Retrospective EU 41 1991-2003 6.0 10.2(0.5-18.3) 95.1% 0.0% 4.9%
Goldberg 2009 Retrospective North America 32 2003-2007 1.6 5.4(0.0-20.0) - - -
Alsoufi 2010 Retrospective Middle East 227 1991-2004 7.8 12.1(0.0-18.0) 100.0% 0.0% 0.0%
Valeske 2010 Retrospective EU 98 1996-2008 5.0 11.0(0.1-25.0) 99.0% 1.0% 0.0%
Charitos 2012 Retrospective/prospective EU 263 - 6.9 8.0(-) - - -
Oda 2012 Retrospective Asia 38 1997-2011 6.4 6.6(-) 100.0% 0.0% 0.0%
Talwar 2012 Retrospective Asia 36 1992-2009 7.9 11.3(0.8-11.0) 100.0% 0.0% 0.0%
Goda 2013 Retrospective EU 33 1993-2010 8.8 9.9(0.0-17.0) 100.0% 0.0% 0.0%
Khan 2013 Retrospective North America 68 1995-2011 6.7 5.9(0.0-17.0) 100.0% 0.0% 0.0%
Ruzmetov 2013 Retrospective North America 78 1993-2011 8.8 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Tanny 2013 Retrospective Oceania 100 1995-2012 7.3 8.6(0.0-18.0) 91.0% 3.0% 6.0%
Andreas 2014 Retrospective EU 70 1991-2011 10.0 10.0(-) 100.0% 0.0% 0.0%
Kallio 2014 Retrospective EU 51 1994-2009 11.5 4.8(0.0-16.0) - - -
Lehoux 2014 Retrospective North America 25 1997-2008 7.3 7.3(-) 100.0% 0.0% 0.0%
Lo Rito 2014 Retrospective EU 140 1991-2011 10.8 9.9(0.2-35.4) 100.0% 0.0% 0.0%
Luciani 2014 Retrospective EU 305 1990-2014 8.4 9.4(0.0-18.0) 65.9% 5.6% 4.6%
Ruzmetov 2014 Retrospective North America 78 1993-2011 9.9 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Lukyanov 2015 - EU 114 2002-2012 3.9 -(0.0-18.0) 92.1% 12.3% 0.0%
Nelson 2015 Retrospective North America 240 1991-2013 10.7 -(0.0-18.0) 100.0% 0.0% 0.0%
Piccardo 2009 Retrospective EU 55 1993-2006 5.5 10.0(0.3-18.0) 100.0% 0.0% 0.0%
Tierney 2005 Retrospective North America 26 1989-2003 5.2 3.4(-) - - -
Ruzmetov 2015 Retrospective North America 72 1993-2012 11.0 11.9(0.3-18.0) - - -
Baird 2016 Retrospective North America 50 2000-2014 4.4 4.5(-) 98.0% 2.0% 0.0%
Brown 2016 Retrospective North America 115 1993-2015 7.8 11.4(0.1-18.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 21 1997-2009 11.0 12.0(6.0-17.0) - - -
Tran 2017 Retrospective EU 75 1998-2012 5.2 10.2(0.4-18.0) 100.0% 0.0% 0.0%
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PeDiatric
study design origin Patients (n) inclusion period Mean/median
fuP
Mean/median age at 
surgery (range)
technique
  total root 
replacement
subcoronary inclusion
Solowiejczyk 2000 - North America 40 1988-1996 2.0 8.3(0.0-19.0) 100.0% 0.0% 0.0%
Pigula 2001 Retrospective North America 34 1995-2000 1.4 10.0(0.3-18.0) 100.0% 0.0% 0.0%
Lupinetti 2003 - North America 78 1994-2001 3.4 10.7(0.2-22.3) 100.0% 0.0% 0.0%
Hazekamp 2005 - EU 53 1994-2003 5.5 9.2(0.0-17.7) 100.0% 0.0% 0.0%
Kalavrouziotis 2006 - EU 35 1996-2004 4.1 10.6(0.0-18.0) 100.0% 0.0% 0.0%
Kadner 2008 Retrospective EU 52 1993-2004 3.6 3.6(0.0-15.0) 100.0% 0.0% 0.0%
El Behery 2009 Retrospective EU 41 1991-2003 6.0 10.2(0.5-18.3) 95.1% 0.0% 4.9%
Goldberg 2009 Retrospective North America 32 2003-2007 1.6 5.4(0.0-20.0) - - -
Alsoufi 2010 Retrospective Middle East 227 1991-2004 7.8 12.1(0.0-18.0) 100.0% 0.0% 0.0%
Valeske 2010 Retrospective EU 98 1996-2008 5.0 11.0(0.1-25.0) 99.0% 1.0% 0.0%
Charitos 2012 Retrospective/prospective EU 263 - 6.9 8.0(-) - - -
Oda 2012 Retrospective Asia 38 1997-2011 6.4 6.6(-) 100.0% 0.0% 0.0%
Talwar 2012 Retrospective Asia 36 1992-2009 7.9 11.3(0.8-11.0) 100.0% 0.0% 0.0%
Goda 2013 Retrospective EU 33 1993-2010 8.8 9.9(0.0-17.0) 100.0% 0.0% 0.0%
Khan 2013 Retrospective North America 68 1995-2011 6.7 5.9(0.0-17.0) 100.0% 0.0% 0.0%
Ruzmetov 2013 Retrospective North America 78 1993-2011 8.8 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Tanny 2013 Retrospective Oceania 100 1995-2012 7.3 8.6(0.0-18.0) 91.0% 3.0% 6.0%
Andreas 2014 Retrospective EU 70 1991-2011 10.0 10.0(-) 100.0% 0.0% 0.0%
Kallio 2014 Retrospective EU 51 1994-2009 11.5 4.8(0.0-16.0) - - -
Lehoux 2014 Retrospective North America 25 1997-2008 7.3 7.3(-) 100.0% 0.0% 0.0%
Lo Rito 2014 Retrospective EU 140 1991-2011 10.8 9.9(0.2-35.4) 100.0% 0.0% 0.0%
Luciani 2014 Retrospective EU 305 1990-2014 8.4 9.4(0.0-18.0) 65.9% 5.6% 4.6%
Ruzmetov 2014 Retrospective North America 78 1993-2011 9.9 11.1(0.0-18.0) 100.0% 0.0% 0.0%
Lukyanov 2015 - EU 114 2002-2012 3.9 -(0.0-18.0) 92.1% 12.3% 0.0%
Nelson 2015 Retrospective North America 240 1991-2013 10.7 -(0.0-18.0) 100.0% 0.0% 0.0%
Piccardo 2009 Retrospective EU 55 1993-2006 5.5 10.0(0.3-18.0) 100.0% 0.0% 0.0%
Tierney 2005 Retrospective North America 26 1989-2003 5.2 3.4(-) - - -
Ruzmetov 2015 Retrospective North America 72 1993-2012 11.0 11.9(0.3-18.0) - - -
Baird 2016 Retrospective North America 50 2000-2014 4.4 4.5(-) 98.0% 2.0% 0.0%
Brown 2016 Retrospective North America 115 1993-2015 7.8 11.4(0.1-18.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 21 1997-2009 11.0 12.0(6.0-17.0) - - -
Tran 2017 Retrospective EU 75 1998-2012 5.2 10.2(0.4-18.0) 100.0% 0.0% 0.0%
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aDult
study design origin Patients (n) inclusion period Mean/median 
fuP
Mean/median age at 
surgery (range)
technique
  total root 
replacement
subcoronary inclusion
Knott-Craig 2000 Retrospective North America 145 1986-1999 2.5 -(17.0-82.0) 100.0% 0.0% 0.0%
Xie 2001 - North America 49 1991-1996 3.0 36.0(16.0-66.0) 100.0% 0.0% 0.0%
Schmid 2002 Retrospective EU 51 1997-2002 3.0 43.2(-) 100.0% 0.0% 0.0%
Svensson 2002 - EU 77 1995-1999 - 44.0(17.0-66.0) 100.0% 0.0% 0.0%
Fullerton 2003 - North America 44 1997-2002 3.2 49.0(19.0-71.0) 100.0% 0.0% 0.0%
Matalanis 2004 - Oceania 31 1994-2002 2.4 42.0(24.0-61.0) 100.0% 0.0% 0.0%
Chotivatanapong 2005 - Asia 30 1997-2002 1.4 36.3(17.0-60.0) 100.0% 0.0% 0.0%
Settepani 2005 Retrospective EU 103 1991-2003 6.0 35.2(17.0-65.0) 100.0% 0.0% 0.0%
Pitsis 2006 - EU 21 1998-2004 4.0 42.0(16.0-55.0) 81.0% 19.0% 0.0%
Klieverik 2007 Prospective EU 94 1988-2005 8.7 30.4(16.0-52.0) 93.6% 6.4% 0.0%
Frigiola 2008 Retrospective EU 110 1994-2007 6.8 30.2(17.0-65.0) 100.0% 0.0% 0.0%
Al Rashidi 2010 Prospective EU 26 2003-- 2.9 37.0(31.0-41.0) - - -
El-Hamamsy 2010 RCT EU 108 1994-2001 10.2 38.0(19.0-66.0) - - -
Brown 2011 Retrospective North America 230 1994-2010 7.8 42.4(20.0-68.0) 100.0% 0.0% 0.0%
Ryan 2011 Prospective North America 160 1994-2008 5.4 42.0(-) 100.0% 0.0% 0.0%
Brinkman 2012 Prospective North America 160 1994-2008 10.1 -(-) 100.0% 0.0% 0.0%
Skillington 2013 - Oceania 310 1992-2012 9.4 39.3(16.0-63.0) - - -
Stelzer 2013 Prospective North America 530 1987-2013 - 42.7(-) 100.0% 0.0% 0.0%
Andreas 2014 Retrospective EU 176 1991-2011 10.0 36.0(-) 100.0% 0.0% 0.0%
David 2014 Prospective North America 212 1990-2004 13.8 34.0(-) 50.9% - -
Le Guillou 2014 Retrospective EU 28 1997-2011 6.4 42.0(19.0-57.0) 100.0% 0.0% 0.0%
Escarain 2015 Retrospective South America 263 1995-2012 7.5 42.0(15.0-67.0) 100.0% 0.0% 0.0%
Jacobsen 2015 Retrospective North America 36 1992-2014 2.2 14.0(11.0-31.0) 100.0% 0.0% 0.0%
Mastrobuoni 2015 Prospective EU 306 1991-2014 10.6 41.7(-) 54.9% 2.3% 42.8%
Sievers 2015 Retrospective/Prospective EU 1779 - 8.3 44.7(-) - - -
Franke 2015 - EU 136 2007-2013 3.0 50.0(20.0-67.0) 100.0% 0.0% 0.0%
Carrel 2016 Prospective EU 22 2006-- 5.0 -(-) 100.0% 0.0% 0.0%
Karaskov 2016 Retrospective EU 741 1998-2014 5.8 47.4(18.0-67.0) 100.0% 0.0% 0.0%
Mazine 2016 Prospective North America 208 1990-2014 13.6 37.3(16.0-63.0) 50.0% - -
Popelová 2016 - EU 33 2005-2015 - -(-) - - -
Bouhout 2017 Retrospective North America 200 2011-2016 - 46.0(--65.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 86 1997-2009 11.0 34.0(18.0-54.0) - - -
Martin 2017 Prospective North America 310 1990-2014 15.1 40.8(18.0--) 83.5% 5.8% 10.6%
Skoglund 2017 Retrospective EU 77 --2015 15.9 22.7(-) - - -
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aDult
study design origin Patients (n) inclusion period Mean/median 
fuP
Mean/median age at 
surgery (range)
technique
  total root 
replacement
subcoronary inclusion
Knott-Craig 2000 Retrospective North America 145 1986-1999 2.5 -(17.0-82.0) 100.0% 0.0% 0.0%
Xie 2001 - North America 49 1991-1996 3.0 36.0(16.0-66.0) 100.0% 0.0% 0.0%
Schmid 2002 Retrospective EU 51 1997-2002 3.0 43.2(-) 100.0% 0.0% 0.0%
Svensson 2002 - EU 77 1995-1999 - 44.0(17.0-66.0) 100.0% 0.0% 0.0%
Fullerton 2003 - North America 44 1997-2002 3.2 49.0(19.0-71.0) 100.0% 0.0% 0.0%
Matalanis 2004 - Oceania 31 1994-2002 2.4 42.0(24.0-61.0) 100.0% 0.0% 0.0%
Chotivatanapong 2005 - Asia 30 1997-2002 1.4 36.3(17.0-60.0) 100.0% 0.0% 0.0%
Settepani 2005 Retrospective EU 103 1991-2003 6.0 35.2(17.0-65.0) 100.0% 0.0% 0.0%
Pitsis 2006 - EU 21 1998-2004 4.0 42.0(16.0-55.0) 81.0% 19.0% 0.0%
Klieverik 2007 Prospective EU 94 1988-2005 8.7 30.4(16.0-52.0) 93.6% 6.4% 0.0%
Frigiola 2008 Retrospective EU 110 1994-2007 6.8 30.2(17.0-65.0) 100.0% 0.0% 0.0%
Al Rashidi 2010 Prospective EU 26 2003-- 2.9 37.0(31.0-41.0) - - -
El-Hamamsy 2010 RCT EU 108 1994-2001 10.2 38.0(19.0-66.0) - - -
Brown 2011 Retrospective North America 230 1994-2010 7.8 42.4(20.0-68.0) 100.0% 0.0% 0.0%
Ryan 2011 Prospective North America 160 1994-2008 5.4 42.0(-) 100.0% 0.0% 0.0%
Brinkman 2012 Prospective North America 160 1994-2008 10.1 -(-) 100.0% 0.0% 0.0%
Skillington 2013 - Oceania 310 1992-2012 9.4 39.3(16.0-63.0) - - -
Stelzer 2013 Prospective North America 530 1987-2013 - 42.7(-) 100.0% 0.0% 0.0%
Andreas 2014 Retrospective EU 176 1991-2011 10.0 36.0(-) 100.0% 0.0% 0.0%
David 2014 Prospective North America 212 1990-2004 13.8 34.0(-) 50.9% - -
Le Guillou 2014 Retrospective EU 28 1997-2011 6.4 42.0(19.0-57.0) 100.0% 0.0% 0.0%
Escarain 2015 Retrospective South America 263 1995-2012 7.5 42.0(15.0-67.0) 100.0% 0.0% 0.0%
Jacobsen 2015 Retrospective North America 36 1992-2014 2.2 14.0(11.0-31.0) 100.0% 0.0% 0.0%
Mastrobuoni 2015 Prospective EU 306 1991-2014 10.6 41.7(-) 54.9% 2.3% 42.8%
Sievers 2015 Retrospective/Prospective EU 1779 - 8.3 44.7(-) - - -
Franke 2015 - EU 136 2007-2013 3.0 50.0(20.0-67.0) 100.0% 0.0% 0.0%
Carrel 2016 Prospective EU 22 2006-- 5.0 -(-) 100.0% 0.0% 0.0%
Karaskov 2016 Retrospective EU 741 1998-2014 5.8 47.4(18.0-67.0) 100.0% 0.0% 0.0%
Mazine 2016 Prospective North America 208 1990-2014 13.6 37.3(16.0-63.0) 50.0% - -
Popelová 2016 - EU 33 2005-2015 - -(-) - - -
Bouhout 2017 Retrospective North America 200 2011-2016 - 46.0(--65.0) 100.0% 0.0% 0.0%
Pardo González 2017 Prospective EU 86 1997-2009 11.0 34.0(18.0-54.0) - - -
Martin 2017 Prospective North America 310 1990-2014 15.1 40.8(18.0--) 83.5% 5.8% 10.6%
Skoglund 2017 Retrospective EU 77 --2015 15.9 22.7(-) - - -
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supplement 3. Individual study outcome estimates.
1The reported p-values are those of the Cochran’s Q test for heterogeneity. *zero events reported, for the 
purpose of the analyses it was assumed that 0.5 patient experienced that event. “-“=variable not reported. 
Yr=year. SUD=sudden unexplained death. RVOT=right ventricular outflow tract. Studies included only in 
the Kaplan-Meier meta-analysis due to overlapping study populations (Brown 2007, “All ages” and “Pedi-
atric” groups; Frigiola 2010, “All ages” and “Pediatric” groups; Sievers 2010, “All ages”, “Pediatric” and “Adult” 
groups; Brancaccio 2014, “All ages” and “Pediatric” groups) are not included in this overview.
all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Sharoni 2000 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* - - -
Sirvydis 2000 8.89(3.49-22.65) 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)*
Solowiejczyk 2000 - - - - - 1.25(0.18-8.77) 0.63(0.04-9.91)* 1.25(0.18-8.77)
Carr-White 2001 0.35(0.02-5.52)* 0.69(0.26-1.84) - - - - - 0.69(0.26-1.84)
Laudito 2001 0.69(0.04-11.00)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* - 2.75(1.32-5.70) -
Oswalt 2001 5.24(2.86-9.57) 0.53(0.22-1.28) - 0.05(0.00-0.85)* 0.05(0.00-0.85)* 1.60(0.97-2.64) 1.28(0.73-2.24) 0.32(0.10-0.99)
Phillips 2001 9.68(3.30-28.37) - - - - - - -
Xie 2001 4.08(1.05-15.86) 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.68(0.10-4.80) 0.34(0.02-5.41)* 0.68(0.10-4.80)
Schmid 2002 0.98(0.06-15.46)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.64(0.09-4.55)
Svensson 2002 3.90(1.28-11.81) - - - - - - -
Fullerton 2003 6.82(2.29-20.33) 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.72(0.10-5.05) 0.72(0.10-5.05) 0.36(0.02-5.70)*
Lupinetti 2003 3.85(1.27-11.67) 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 1.90(0.80-4.53) 1.52(0.57-4.02) 0.38(0.05-2.69)
Alphonso 2004 0.83(0.05-13.17)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 1.74(0.79-3.84) 1.16(0.44-3.07) 0.58(0.15-2.31)
Kouchoukos 2004 1.68(0.43-6.64) 0.38(0.10-1.52) 0.38(0.10-1.52) 0.19(0.03-1.35) 0.10(0.01-1.52)* 2.86(1.74-4.72) 2.10(1.17-3.77) 0.76(0.29-2.03)
Matalanis 2004 3.23(0.47-22.18) 2.71(0.69-10.62) - 0.68(0.04-10.72)* 0.68(0.04-10.72)* 2.71(0.69-10.62) 1.35(0.19-9.48) 0.68(0.04-10.72)*
Raja 2004 2.63(0.38-18.20) 0.95(0.14-6.69) 0.95(0.14-6.69) 0.48(0.03-7.55)* 0.48(0.03-7.55)* 1.90(0.48-7.51) 0.48(0.03-7.55)* 1.90(0.48-7.51)
Chotivatanapong 2005 13.33(5.35-33.20) 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* - - -
Kumar 2005 6.54(3.59-11.90) 0.87(0.44-1.74) 0.87(0.44-1.74) 0.65(0.29-1.45) - 1.09(0.59-2.02) 0.87(0.44-1.74) 0.05(0.00-0.87)*
Settepani 2005 0.49(0.03-7.71)* 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) 0.08(0.01-1.29)* 0.97(0.44-2.15) 0.81(0.34-1.94) 0.16(0.02-1.15)
Pitsis 2006 4.76(0.70-32.25) 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 2.38(0.61-9.36) 2.38(0.61-9.36) 0.60(0.04-9.44)*
Wang 2006 1.67(0.11-26.04)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 2.46(0.93-6.48) 1.85(0.60-5.66) 0.62(0.09-4.34)
Klieverik 2007 3.19(1.05-9.72) 0.12(0.02-0.87) 0.12(0.02-0.87) 0.06(0.00-0.98)* 0.06(0.00-0.98)* - - -
Pasquali 2007 2.48(0.81-7.58) 0.29(0.07-1.17) 0.29(0.07-1.17) 0.07(0.00-1.17)* 0.07(0.00-1.17)* 4.67(3.33-6.55) 2.19(1.33-3.61) 2.19(1.33-3.61)
Salehi 2007 3.75(1.24-11.38) 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 1.76(0.45-6.95) 1.76(0.45-6.95) 0.44(0.03-6.99)*
Elkins 2008 3.90(2.51-6.06) 0.46(0.28-0.76) 0.25(0.12-0.49) 0.25(0.12-0.49) 0.18(0.08-0.41) - 1.16(0.85-1.60) 1.01(0.72-1.42)
Frigiola 2008 0.45(0.03-7.22)* 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) - 1.06(0.53-2.12) 0.53(0.20-1.41)
Kadner 2008 9.62(4.18-22.12) 1.61(0.52-4.95) 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 4.30(2.18-8.46) 0.54(0.08-3.79) 3.76(1.82-7.78)
El Behery 2009 4.88(1.26-18.85) 0.20(0.01-3.24)* - - - 1.63(0.62-4.30) 0.20(0.01-3.24)* 1.63(0.62-4.30)
Goldberg 2009 15.63(6.98-34.95) 0.99(0.06-15.60)* - - - - - -
Al Rashidi 2010 1.92(0.12-29.93)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 1.32(0.19-9.24) 1.32(0.19-9.24) -
Alsoufi 2010 3.08(1.49-6.39) 0.17(0.05-0.52) - - - 4.86(3.95-5.97) 1.64(1.14-2.35) 1.64(1.14-2.35)
Coskun 2010 4.35(0.64-29.57) 1.02(0.06-16.09)* - - - - - -
149
The Ross procedure
5
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1The reported p-values are those of the Cochran’s Q test for heterogeneity. *zero events reported, for the 
purpose of the analyses it was assumed that 0.5 patient experienced that event. “-“=variable not reported. 
Yr=year. SUD=sudden unexplained death. RVOT=right ventricular outflow tract. Studies included only in 
the Kaplan-Meier meta-analysis due to overlapping study populations (Brown 2007, “All ages” and “Pedi-
atric” groups; Frigiola 2010, “All ages” and “Pediatric” groups; Sievers 2010, “All ages”, “Pediatric” and “Adult” 
groups; Brancaccio 2014, “All ages” and “Pediatric” groups) are not included in this overview.
all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Sharoni 2000 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* 1.25(0.08-19.64)* - - -
Sirvydis 2000 8.89(3.49-22.65) 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)*
Solowiejczyk 2000 - - - - - 1.25(0.18-8.77) 0.63(0.04-9.91)* 1.25(0.18-8.77)
Carr-White 2001 0.35(0.02-5.52)* 0.69(0.26-1.84) - - - - - 0.69(0.26-1.84)
Laudito 2001 0.69(0.04-11.00)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* 0.20(0.01-3.13)* - 2.75(1.32-5.70) -
Oswalt 2001 5.24(2.86-9.57) 0.53(0.22-1.28) - 0.05(0.00-0.85)* 0.05(0.00-0.85)* 1.60(0.97-2.64) 1.28(0.73-2.24) 0.32(0.10-0.99)
Phillips 2001 9.68(3.30-28.37) - - - - - - -
Xie 2001 4.08(1.05-15.86) 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.68(0.10-4.80) 0.34(0.02-5.41)* 0.68(0.10-4.80)
Schmid 2002 0.98(0.06-15.46)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.64(0.09-4.55)
Svensson 2002 3.90(1.28-11.81) - - - - - - -
Fullerton 2003 6.82(2.29-20.33) 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.72(0.10-5.05) 0.72(0.10-5.05) 0.36(0.02-5.70)*
Lupinetti 2003 3.85(1.27-11.67) 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 1.90(0.80-4.53) 1.52(0.57-4.02) 0.38(0.05-2.69)
Alphonso 2004 0.83(0.05-13.17)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 1.74(0.79-3.84) 1.16(0.44-3.07) 0.58(0.15-2.31)
Kouchoukos 2004 1.68(0.43-6.64) 0.38(0.10-1.52) 0.38(0.10-1.52) 0.19(0.03-1.35) 0.10(0.01-1.52)* 2.86(1.74-4.72) 2.10(1.17-3.77) 0.76(0.29-2.03)
Matalanis 2004 3.23(0.47-22.18) 2.71(0.69-10.62) - 0.68(0.04-10.72)* 0.68(0.04-10.72)* 2.71(0.69-10.62) 1.35(0.19-9.48) 0.68(0.04-10.72)*
Raja 2004 2.63(0.38-18.20) 0.95(0.14-6.69) 0.95(0.14-6.69) 0.48(0.03-7.55)* 0.48(0.03-7.55)* 1.90(0.48-7.51) 0.48(0.03-7.55)* 1.90(0.48-7.51)
Chotivatanapong 2005 13.33(5.35-33.20) 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* - - -
Kumar 2005 6.54(3.59-11.90) 0.87(0.44-1.74) 0.87(0.44-1.74) 0.65(0.29-1.45) - 1.09(0.59-2.02) 0.87(0.44-1.74) 0.05(0.00-0.87)*
Settepani 2005 0.49(0.03-7.71)* 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) 0.08(0.01-1.29)* 0.97(0.44-2.15) 0.81(0.34-1.94) 0.16(0.02-1.15)
Pitsis 2006 4.76(0.70-32.25) 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 2.38(0.61-9.36) 2.38(0.61-9.36) 0.60(0.04-9.44)*
Wang 2006 1.67(0.11-26.04)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 0.31(0.02-4.90)* 2.46(0.93-6.48) 1.85(0.60-5.66) 0.62(0.09-4.34)
Klieverik 2007 3.19(1.05-9.72) 0.12(0.02-0.87) 0.12(0.02-0.87) 0.06(0.00-0.98)* 0.06(0.00-0.98)* - - -
Pasquali 2007 2.48(0.81-7.58) 0.29(0.07-1.17) 0.29(0.07-1.17) 0.07(0.00-1.17)* 0.07(0.00-1.17)* 4.67(3.33-6.55) 2.19(1.33-3.61) 2.19(1.33-3.61)
Salehi 2007 3.75(1.24-11.38) 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 1.76(0.45-6.95) 1.76(0.45-6.95) 0.44(0.03-6.99)*
Elkins 2008 3.90(2.51-6.06) 0.46(0.28-0.76) 0.25(0.12-0.49) 0.25(0.12-0.49) 0.18(0.08-0.41) - 1.16(0.85-1.60) 1.01(0.72-1.42)
Frigiola 2008 0.45(0.03-7.22)* 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) - 1.06(0.53-2.12) 0.53(0.20-1.41)
Kadner 2008 9.62(4.18-22.12) 1.61(0.52-4.95) 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 4.30(2.18-8.46) 0.54(0.08-3.79) 3.76(1.82-7.78)
El Behery 2009 4.88(1.26-18.85) 0.20(0.01-3.24)* - - - 1.63(0.62-4.30) 0.20(0.01-3.24)* 1.63(0.62-4.30)
Goldberg 2009 15.63(6.98-34.95) 0.99(0.06-15.60)* - - - - - -
Al Rashidi 2010 1.92(0.12-29.93)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 1.32(0.19-9.24) 1.32(0.19-9.24) -
Alsoufi 2010 3.08(1.49-6.39) 0.17(0.05-0.52) - - - 4.86(3.95-5.97) 1.64(1.14-2.35) 1.64(1.14-2.35)
Coskun 2010 4.35(0.64-29.57) 1.02(0.06-16.09)* - - - - - -
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all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
El-Hamamsy 2010 0.93(0.13-6.51) 0.27(0.09-0.84) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.73(0.36-1.45) 0.09(0.01-0.64) 0.64(0.30-1.33)
Valeske 2010 2.04(0.52-8.05) 0.10(0.01-1.63)* - - - 0.20(0.03-1.45) 0.20(0.03-1.45) 0.10(0.01-1.63)*
Brown 2011 0.87(0.22-3.46) 0.67(0.38-1.18) 0.17(0.05-0.52) - 0.28(0.12-0.67) 1.40(0.95-2.07) 1.12(0.73-1.74) 0.28(0.12-0.67)
Clark 2011 0.93(0.06-14.61)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 2.89(1.57-5.33) 0.29(0.04-2.05) 2.60(1.37-4.96)
Kalfa 2011 0.47(0.03-7.42)* 0.49(0.16-1.52) 0.08(0.01-1.31)* 0.08(0.01-1.31)* 0.08(0.01-1.31)* - - 1.15(0.55-2.40)
Kitamura 2011 2.38(0.15-36.82)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 1.44(0.47-4.44) 0.24(0.02-3.83)* 0.96(0.24-3.82)
Ryan 2011 1.88(0.61-5.75) 0.58(0.24-1.39) 0.12(0.02-0.83) 0.06(0.00-0.93)* 0.06(0.00-0.93)* 1.75(1.06-2.88) - 0.12(0.02-0.83)
Brinkman 2012 - - - - - 1.05(0.66-1.69) 1.05(0.66-1.69) -
Charitos 2012 3.42(1.80-6.50) - - - - 3.63(2.81-4.69) 0.91(0.54-1.53) 2.72(2.02-3.67)
Juthier 2012 3.27(1.83-5.85) 0.44(0.23-0.84) 0.10(0.02-0.39) 0.02(0.00-0.39)* 0.02(0.00-0.39)* 2.29(1.73-3.04) 1.81(1.31-2.49) 0.49(0.26-0.91)
Luciani 2012 1.49(0.38-5.91) 0.14(0.03-0.55) 0.14(0.03-0.55) 0.14(0.03-0.55) 0.07(0.01-0.49) 1.93(1.34-2.79) 1.87(1.28-2.71) 0.07(0.01-0.49)
McBrien 2012 0.50(0.03-7.86)* 0.21(0.03-1.49) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.11(0.01-1.68)* 1.90(0.99-3.62) 1.26(0.57-2.80) 0.63(0.20-1.95)
Ruzmetov 2012 2.83(0.93-8.63) 0.73(0.33-1.61) 0.48(0.18-1.29) 0.24(0.06-0.97) 0.24(0.06-0.97) 4.60(3.37-6.27) 2.18(1.38-3.44) 2.42(1.57-3.73)
Goda 2013 - - - - - - 1.03(0.34-3.18) -
Khan 2013 2.94(0.75-11.52) 0.44(0.11-1.75) - - - 4.17(2.69-6.48) 0.66(0.21-2.03) 3.51(2.17-5.68)
Ruzmetov 2013 - - - - - 5.24(3.82-7.21) - 2.33(1.44-3.78)
Skillington 2013 0.32(0.05-2.28) 0.17(0.07-0.41) 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.51(0.31-0.85) 0.38(0.21-0.68) 0.17(0.07-0.41)
Stelzer 2013 1.13(0.51-2.51) - - - - - - -
Tanny 2013 6.00(2.76-13.03) 0.55(0.21-1.46) 0.41(0.13-1.27) 0.27(0.07-1.09) 0.14(0.02-0.97) 3.70(2.55-5.36) 1.23(0.64-2.36) 2.74(1.78-4.22)
Andreas 2014 1.63(0.62-4.30) 0.16(0.06-0.43) 0.02(0.00-0.32)* 0.02(0.00-0.32)* 0.02(0.00-0.32)* 1.18(0.82-1.69) 0.45(0.25-0.81) 0.69(0.43-1.11)
Da Costa 2014 2.66(1.48-4.76) 0.60(0.39-0.94) 0.45(0.27-0.75) 0.30(0.16-0.56) 0.18(0.08-0.40) 1.21(0.89-1.65) 0.67(0.44-1.01) 0.45(0.27-0.75)
David 2014 0.47(0.07-3.33) 0.31(0.16-0.59) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.85(0.58-1.26) 0.51(0.31-0.85) 0.31(0.16-0.59)
Kallio 2014 9.80(4.26-22.54) 0.51(0.17-1.58) 0.51(0.17-1.58) 0.17(0.02-1.21) 0.09(0.01-1.36)* 3.58(2.35-5.45) 0.68(0.26-1.81) 2.05(1.17-3.58)
Le Guillou 2014 10.71(3.68-31.21) 3.35(1.52-7.35) 0.28(0.02-4.44)* 0.28(0.02-4.44)* 0.28(0.02-4.44)* 2.23(0.85-5.88) 1.12(0.28-4.43) 0.56(0.08-3.94)
Lehoux 2014 - - - - - 2.19(0.83-5.78) 0.27(0.02-4.36)* 1.10(0.28-4.35)
Lo Rito 2014 2.86(1.09-7.51) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.03(0.00-0.53)* 1.72(1.17-2.52) 0.73(0.40-1.31) 0.99(0.60-1.64)
Luciani 2014 3.28(1.78-6.03) 0.47(0.27-0.82) 0.23(0.11-0.52) - - 2.93(2.34-3.66) 1.44(1.05-1.99) 1.44(1.05-1.99)
Ruzmetov 2014 - - - - - - 3.37(2.31-4.91) -
Xu 2014 3.45(0.88-13.46) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)*
Zebele 2014 1.10(0.16-7.72) 0.16(0.05-0.51) 0.05(0.01-0.39) - - 0.88(0.54-1.43) 0.49(0.26-0.95) 0.38(0.18-0.81)
Bansal 2015 3.61(2.02-6.44) 0.52(0.30-0.89) - - - - 1.84(1.38-2.45) -
Escarain 2015 2.66(1.28-5.53) 0.71(0.42-1.20) 0.30(0.14-0.68) 0.30(0.14-0.68) 0.03(0.00-0.41)* 0.91(0.58-1.45) 0.66(0.38-1.13) 0.20(0.08-0.54)
Jacobsen 2015 1.39(0.09-21.78)* 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 5.05(1.94-13.12) 3.79(1.25-11.49) 0.63(0.04-10.01)*
Lukyanov 2015 1.75(0.44-6.93) - - - - - - -
Mastrobuoni 2015 2.29(1.10-4.76) 0.71(0.47-1.09) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.03(0.00-0.24) 1.33(0.97-1.81) 1.23(0.89-1.70) 0.37(0.21-0.68)
Nelson 2015 4.17(2.27-7.64) 0.66(0.41-1.06) - - - 7.75(6.78-8.86) 2.69(2.13-3.39) 2.22(1.72-2.87)
Sievers 2015 1.07(0.68-1.67) 0.68(0.56-0.83) - - - 1.19(1.02-1.37) 0.72(0.59-0.87) 0.62(0.50-0.76)
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all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
El-Hamamsy 2010 0.93(0.13-6.51) 0.27(0.09-0.84) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.73(0.36-1.45) 0.09(0.01-0.64) 0.64(0.30-1.33)
Valeske 2010 2.04(0.52-8.05) 0.10(0.01-1.63)* - - - 0.20(0.03-1.45) 0.20(0.03-1.45) 0.10(0.01-1.63)*
Brown 2011 0.87(0.22-3.46) 0.67(0.38-1.18) 0.17(0.05-0.52) - 0.28(0.12-0.67) 1.40(0.95-2.07) 1.12(0.73-1.74) 0.28(0.12-0.67)
Clark 2011 0.93(0.06-14.61)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 0.14(0.01-2.31)* 2.89(1.57-5.33) 0.29(0.04-2.05) 2.60(1.37-4.96)
Kalfa 2011 0.47(0.03-7.42)* 0.49(0.16-1.52) 0.08(0.01-1.31)* 0.08(0.01-1.31)* 0.08(0.01-1.31)* - - 1.15(0.55-2.40)
Kitamura 2011 2.38(0.15-36.82)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 1.44(0.47-4.44) 0.24(0.02-3.83)* 0.96(0.24-3.82)
Ryan 2011 1.88(0.61-5.75) 0.58(0.24-1.39) 0.12(0.02-0.83) 0.06(0.00-0.93)* 0.06(0.00-0.93)* 1.75(1.06-2.88) - 0.12(0.02-0.83)
Brinkman 2012 - - - - - 1.05(0.66-1.69) 1.05(0.66-1.69) -
Charitos 2012 3.42(1.80-6.50) - - - - 3.63(2.81-4.69) 0.91(0.54-1.53) 2.72(2.02-3.67)
Juthier 2012 3.27(1.83-5.85) 0.44(0.23-0.84) 0.10(0.02-0.39) 0.02(0.00-0.39)* 0.02(0.00-0.39)* 2.29(1.73-3.04) 1.81(1.31-2.49) 0.49(0.26-0.91)
Luciani 2012 1.49(0.38-5.91) 0.14(0.03-0.55) 0.14(0.03-0.55) 0.14(0.03-0.55) 0.07(0.01-0.49) 1.93(1.34-2.79) 1.87(1.28-2.71) 0.07(0.01-0.49)
McBrien 2012 0.50(0.03-7.86)* 0.21(0.03-1.49) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.11(0.01-1.68)* 1.90(0.99-3.62) 1.26(0.57-2.80) 0.63(0.20-1.95)
Ruzmetov 2012 2.83(0.93-8.63) 0.73(0.33-1.61) 0.48(0.18-1.29) 0.24(0.06-0.97) 0.24(0.06-0.97) 4.60(3.37-6.27) 2.18(1.38-3.44) 2.42(1.57-3.73)
Goda 2013 - - - - - - 1.03(0.34-3.18) -
Khan 2013 2.94(0.75-11.52) 0.44(0.11-1.75) - - - 4.17(2.69-6.48) 0.66(0.21-2.03) 3.51(2.17-5.68)
Ruzmetov 2013 - - - - - 5.24(3.82-7.21) - 2.33(1.44-3.78)
Skillington 2013 0.32(0.05-2.28) 0.17(0.07-0.41) 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.51(0.31-0.85) 0.38(0.21-0.68) 0.17(0.07-0.41)
Stelzer 2013 1.13(0.51-2.51) - - - - - - -
Tanny 2013 6.00(2.76-13.03) 0.55(0.21-1.46) 0.41(0.13-1.27) 0.27(0.07-1.09) 0.14(0.02-0.97) 3.70(2.55-5.36) 1.23(0.64-2.36) 2.74(1.78-4.22)
Andreas 2014 1.63(0.62-4.30) 0.16(0.06-0.43) 0.02(0.00-0.32)* 0.02(0.00-0.32)* 0.02(0.00-0.32)* 1.18(0.82-1.69) 0.45(0.25-0.81) 0.69(0.43-1.11)
Da Costa 2014 2.66(1.48-4.76) 0.60(0.39-0.94) 0.45(0.27-0.75) 0.30(0.16-0.56) 0.18(0.08-0.40) 1.21(0.89-1.65) 0.67(0.44-1.01) 0.45(0.27-0.75)
David 2014 0.47(0.07-3.33) 0.31(0.16-0.59) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.85(0.58-1.26) 0.51(0.31-0.85) 0.31(0.16-0.59)
Kallio 2014 9.80(4.26-22.54) 0.51(0.17-1.58) 0.51(0.17-1.58) 0.17(0.02-1.21) 0.09(0.01-1.36)* 3.58(2.35-5.45) 0.68(0.26-1.81) 2.05(1.17-3.58)
Le Guillou 2014 10.71(3.68-31.21) 3.35(1.52-7.35) 0.28(0.02-4.44)* 0.28(0.02-4.44)* 0.28(0.02-4.44)* 2.23(0.85-5.88) 1.12(0.28-4.43) 0.56(0.08-3.94)
Lehoux 2014 - - - - - 2.19(0.83-5.78) 0.27(0.02-4.36)* 1.10(0.28-4.35)
Lo Rito 2014 2.86(1.09-7.51) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.03(0.00-0.53)* 1.72(1.17-2.52) 0.73(0.40-1.31) 0.99(0.60-1.64)
Luciani 2014 3.28(1.78-6.03) 0.47(0.27-0.82) 0.23(0.11-0.52) - - 2.93(2.34-3.66) 1.44(1.05-1.99) 1.44(1.05-1.99)
Ruzmetov 2014 - - - - - - 3.37(2.31-4.91) -
Xu 2014 3.45(0.88-13.46) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)*
Zebele 2014 1.10(0.16-7.72) 0.16(0.05-0.51) 0.05(0.01-0.39) - - 0.88(0.54-1.43) 0.49(0.26-0.95) 0.38(0.18-0.81)
Bansal 2015 3.61(2.02-6.44) 0.52(0.30-0.89) - - - - 1.84(1.38-2.45) -
Escarain 2015 2.66(1.28-5.53) 0.71(0.42-1.20) 0.30(0.14-0.68) 0.30(0.14-0.68) 0.03(0.00-0.41)* 0.91(0.58-1.45) 0.66(0.38-1.13) 0.20(0.08-0.54)
Jacobsen 2015 1.39(0.09-21.78)* 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 5.05(1.94-13.12) 3.79(1.25-11.49) 0.63(0.04-10.01)*
Lukyanov 2015 1.75(0.44-6.93) - - - - - - -
Mastrobuoni 2015 2.29(1.10-4.76) 0.71(0.47-1.09) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.03(0.00-0.24) 1.33(0.97-1.81) 1.23(0.89-1.70) 0.37(0.21-0.68)
Nelson 2015 4.17(2.27-7.64) 0.66(0.41-1.06) - - - 7.75(6.78-8.86) 2.69(2.13-3.39) 2.22(1.72-2.87)
Sievers 2015 1.07(0.68-1.67) 0.68(0.56-0.83) - - - 1.19(1.02-1.37) 0.72(0.59-0.87) 0.62(0.50-0.76)
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all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Tierney 2005 - - - - - - - 2.22(0.72-6.79)
Boethig 2007 0.92(0.13-6.45) 0.36(0.09-1.45) 0.09(0.01-1.45)* 0.09(0.01-1.45)* 0.09(0.01-1.45)* - - -
Franke 2015 0.74(0.10-5.18) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.98(0.37-2.61) 0.74(0.24-2.28) 0.25(0.03-1.74)
Ruzmetov 2015 1.39(0.20-9.73) 0.51(0.19-1.34) - - - - 2.78(1.84-4.19) 2.27(1.44-3.59)
Baird 2016 - 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* - 0.91(0.23-3.60) 4.98(2.80-8.86)
Brown 2016 0.87(0.12-6.12) 0.45(0.17-1.19) 0.22(0.06-0.89) 0.22(0.06-0.89) 0.11(0.02-0.79) 3.57(2.54-5.01) 1.45(0.84-2.49) 1.90(1.18-3.03)
Carrel 2016 2.27(0.15-35.20)* - - - - 0.91(0.13-6.40) 0.91(0.13-6.40) 0.45(0.03-7.22)*
Karaskov 2016 2.97(1.97-4.48) 0.58(0.37-0.93) 0.45(0.27-0.77) 0.36(0.20-0.64) 0.26(0.13-0.52) 1.85(1.43-2.39) 1.20(0.87-1.65) 0.91(0.63-1.31)
Mazine 2016 0.48(0.07-3.40) 0.42(0.24-0.75) 0.11(0.03-0.33) 0.11(0.03-0.33) 0.07(0.02-0.28) 0.74(0.48-1.14) 0.49(0.29-0.83) 0.25(0.12-0.52)
Popelová 2016 1.52(0.10-23.72)* - - - - - - -
Zimmermann 2016 - 0.13(0.01-2.02)* 0.13(0.01-2.02)* 0.13(0.01-2.02)* 0.13(0.01-2.02)* - 1.52(0.69-3.36) -
Bouhout 2017 1.00(0.25-3.97) - - - - - - -
Pardo González 2017 0.93(0.13-6.57) 0.17(0.04-0.68) 0.17(0.04-0.68) 0.17(0.04-0.68) 0.17(0.04-0.68) 1.78(1.17-2.73) 0.93(0.52-1.68) 1.10(0.64-1.90)
Martin 2017 1.29(0.49-3.42) 0.60(0.41-0.87) 0.34(0.21-0.56) 0.09(0.03-0.23) 0.02(0.00-0.15) 1.20(0.92-1.55) 0.68(0.48-0.97) 0.45(0.29-0.69)
Ratschiller 2017 2.11(0.80-5.55) 0.53(0.30-0.93) - - - - - -
Schneider 2017 5.19(2.65-10.20) 0.60(0.32-1.12) 0.42(0.20-0.88) 0.30(0.13-0.72) 0.18(0.06-0.56) - 1.56(1.07-2.29) 1.86(1.32-2.64)
Skoglund 2017 0.65(0.04-10.29)* 0.08(0.01-0.58) - - - - - 0.82(0.44-1.51)
Tran 2017 0.67(0.04-10.56)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 3.08(1.76-5.37) 0.77(0.25-2.37) 1.79(0.86-3.74)
Pooled estimate (95%ci) 2.87(2.39-3.45) 0.50(0.44-0.58) 0.29(0.24-0.35) 0.23(0.19-0.28) 0.17(0.13-0.21) 1.84(1.49-2.27) 1.10(0.94-1.29) 0.91(0.74-1.12)
Heterogeneity I^2=50.9%(p<0.001) I^2=30.5%(p=0.009) I^2=6.6%(p=0.335) I^2=0.0%(p=0.821) I^2=0.0%(p=0.926) I^2=92.7%(p<0.001) I^2=76.3%(p<0.001) I^2=84.3%(p<0.001)
number of studies 78 72 57 56 56 60 68 67
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supplement 3. (continued)
all ages
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Tierney 2005 - - - - - - - 2.22(0.72-6.79)
Boethig 2007 0.92(0.13-6.45) 0.36(0.09-1.45) 0.09(0.01-1.45)* 0.09(0.01-1.45)* 0.09(0.01-1.45)* - - -
Franke 2015 0.74(0.10-5.18) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.98(0.37-2.61) 0.74(0.24-2.28) 0.25(0.03-1.74)
Ruzmetov 2015 1.39(0.20-9.73) 0.51(0.19-1.34) - - - - 2.78(1.84-4.19) 2.27(1.44-3.59)
Baird 2016 - 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* - 0.91(0.23-3.60) 4.98(2.80-8.86)
Brown 2016 0.87(0.12-6.12) 0.45(0.17-1.19) 0.22(0.06-0.89) 0.22(0.06-0.89) 0.11(0.02-0.79) 3.57(2.54-5.01) 1.45(0.84-2.49) 1.90(1.18-3.03)
Carrel 2016 2.27(0.15-35.20)* - - - - 0.91(0.13-6.40) 0.91(0.13-6.40) 0.45(0.03-7.22)*
Karaskov 2016 2.97(1.97-4.48) 0.58(0.37-0.93) 0.45(0.27-0.77) 0.36(0.20-0.64) 0.26(0.13-0.52) 1.85(1.43-2.39) 1.20(0.87-1.65) 0.91(0.63-1.31)
Mazine 2016 0.48(0.07-3.40) 0.42(0.24-0.75) 0.11(0.03-0.33) 0.11(0.03-0.33) 0.07(0.02-0.28) 0.74(0.48-1.14) 0.49(0.29-0.83) 0.25(0.12-0.52)
Popelová 2016 1.52(0.10-23.72)* - - - - - - -
Zimmermann 2016 - 0.13(0.01-2.02)* 0.13(0.01-2.02)* 0.13(0.01-2.02)* 0.13(0.01-2.02)* - 1.52(0.69-3.36) -
Bouhout 2017 1.00(0.25-3.97) - - - - - - -
Pardo González 2017 0.93(0.13-6.57) 0.17(0.04-0.68) 0.17(0.04-0.68) 0.17(0.04-0.68) 0.17(0.04-0.68) 1.78(1.17-2.73) 0.93(0.52-1.68) 1.10(0.64-1.90)
Martin 2017 1.29(0.49-3.42) 0.60(0.41-0.87) 0.34(0.21-0.56) 0.09(0.03-0.23) 0.02(0.00-0.15) 1.20(0.92-1.55) 0.68(0.48-0.97) 0.45(0.29-0.69)
Ratschiller 2017 2.11(0.80-5.55) 0.53(0.30-0.93) - - - - - -
Schneider 2017 5.19(2.65-10.20) 0.60(0.32-1.12) 0.42(0.20-0.88) 0.30(0.13-0.72) 0.18(0.06-0.56) - 1.56(1.07-2.29) 1.86(1.32-2.64)
Skoglund 2017 0.65(0.04-10.29)* 0.08(0.01-0.58) - - - - - 0.82(0.44-1.51)
Tran 2017 0.67(0.04-10.56)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 3.08(1.76-5.37) 0.77(0.25-2.37) 1.79(0.86-3.74)
Pooled estimate (95%ci) 2.87(2.39-3.45) 0.50(0.44-0.58) 0.29(0.24-0.35) 0.23(0.19-0.28) 0.17(0.13-0.21) 1.84(1.49-2.27) 1.10(0.94-1.29) 0.91(0.74-1.12)
Heterogeneity I^2=50.9%(p<0.001) I^2=30.5%(p=0.009) I^2=6.6%(p=0.335) I^2=0.0%(p=0.821) I^2=0.0%(p=0.926) I^2=92.7%(p<0.001) I^2=76.3%(p<0.001) I^2=84.3%(p<0.001)
number of studies 78 72 57 56 56 60 68 67
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all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Sharoni 2000 - - - - - - -
Sirvydis 2000 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* - 0.44(0.03-7.06)* -
Solowiejczyk 2000 - - - - - - -
Carr-White 2001 - - - - - - -
Laudito 2001 - - - - - - -
Oswalt 2001 - - - - - - -
Phillips 2001 - - - - - - -
Xie 2001 - - - - - - -
Schmid 2002 - - - - - - -
Svensson 2002 - - - - - - -
Fullerton 2003 - - - - - - 0.36(0.02-5.70)*
Lupinetti 2003 0.19(0.01-3.03)* - - - - 0.19(0.01-3.03)* -
Alphonso 2004 - - - - - - -
Kouchoukos 2004 0.10(0.01-1.52)* - - 0.19(0.03-1.35) - - -
Matalanis 2004 0.68(0.04-10.72)* - - 0.68(0.04-10.72)* - - 1.35(0.19-9.48)
Raja 2004 - 0.48(0.03-7.55)* - 0.48(0.03-7.55)* 0.48(0.03-7.55)* - -
Chotivatanapong 2005 - - - - - 11.99(5.27-27.29) -
Kumar 2005 0.44(0.16-1.16) 0.44(0.16-1.16) 0.05(0.00-0.87)* 0.05(0.00-0.87)* - - -
Settepani 2005 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) - - - -
Pitsis 2006 1.19(0.17-8.35) 1.19(0.17-8.35) 0.60(0.04-9.44)* - - - -
Wang 2006 0.62(0.09-4.34) - - - - - -
Klieverik 2007 - - - - 0.06(0.00-0.98)* 0.06(0.00-0.98)* -
Pasquali 2007 - - - - - - -
Salehi 2007 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* - - -
Elkins 2008 0.31(0.17-0.57) 0.15(0.06-0.37) 0.12(0.05-0.33) 0.03(0.00-0.22) - - -
Frigiola 2008 - - - - - - -
Kadner 2008 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* - - 0.27(0.02-4.28)*
El Behery 2009 - - - - - - -
Goldberg 2009 - - - - - - -
Al Rashidi 2010 - - - - - - -
Alsoufi 2010 - - - - - - -
Coskun 2010 - - - - - - -
El-Hamamsy 2010 0.18(0.05-0.73) 0.05(0.00-0.73)* 0.18(0.05-0.73) - - - -
Valeske 2010 - - - 0.10(0.01-1.63)* 0.10(0.01-1.63)* - -
Brown 2011 0.17(0.05-0.52) 0.17(0.05-0.52) - 0.06(0.01-0.40) 0.03(0.00-0.45)* 0.03(0.00-0.45)* -
Clark 2011 0.29(0.04-2.05) 0.29(0.04-2.05) 0.29(0.04-2.05) - - - -
Kalfa 2011 - - 0.16(0.02-1.16) - - - -
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all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Sharoni 2000 - - - - - - -
Sirvydis 2000 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* 0.44(0.03-7.06)* - 0.44(0.03-7.06)* -
Solowiejczyk 2000 - - - - - - -
Carr-White 2001 - - - - - - -
Laudito 2001 - - - - - - -
Oswalt 2001 - - - - - - -
Phillips 2001 - - - - - - -
Xie 2001 - - - - - - -
Schmid 2002 - - - - - - -
Svensson 2002 - - - - - - -
Fullerton 2003 - - - - - - 0.36(0.02-5.70)*
Lupinetti 2003 0.19(0.01-3.03)* - - - - 0.19(0.01-3.03)* -
Alphonso 2004 - - - - - - -
Kouchoukos 2004 0.10(0.01-1.52)* - - 0.19(0.03-1.35) - - -
Matalanis 2004 0.68(0.04-10.72)* - - 0.68(0.04-10.72)* - - 1.35(0.19-9.48)
Raja 2004 - 0.48(0.03-7.55)* - 0.48(0.03-7.55)* 0.48(0.03-7.55)* - -
Chotivatanapong 2005 - - - - - 11.99(5.27-27.29) -
Kumar 2005 0.44(0.16-1.16) 0.44(0.16-1.16) 0.05(0.00-0.87)* 0.05(0.00-0.87)* - - -
Settepani 2005 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) - - - -
Pitsis 2006 1.19(0.17-8.35) 1.19(0.17-8.35) 0.60(0.04-9.44)* - - - -
Wang 2006 0.62(0.09-4.34) - - - - - -
Klieverik 2007 - - - - 0.06(0.00-0.98)* 0.06(0.00-0.98)* -
Pasquali 2007 - - - - - - -
Salehi 2007 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* 0.44(0.03-6.99)* - - -
Elkins 2008 0.31(0.17-0.57) 0.15(0.06-0.37) 0.12(0.05-0.33) 0.03(0.00-0.22) - - -
Frigiola 2008 - - - - - - -
Kadner 2008 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* - - 0.27(0.02-4.28)*
El Behery 2009 - - - - - - -
Goldberg 2009 - - - - - - -
Al Rashidi 2010 - - - - - - -
Alsoufi 2010 - - - - - - -
Coskun 2010 - - - - - - -
El-Hamamsy 2010 0.18(0.05-0.73) 0.05(0.00-0.73)* 0.18(0.05-0.73) - - - -
Valeske 2010 - - - 0.10(0.01-1.63)* 0.10(0.01-1.63)* - -
Brown 2011 0.17(0.05-0.52) 0.17(0.05-0.52) - 0.06(0.01-0.40) 0.03(0.00-0.45)* 0.03(0.00-0.45)* -
Clark 2011 0.29(0.04-2.05) 0.29(0.04-2.05) 0.29(0.04-2.05) - - - -
Kalfa 2011 - - 0.16(0.02-1.16) - - - -
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all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Kitamura 2011 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* - -
Ryan 2011 - - - - - - -
Brinkman 2012 - - - - - - -
Charitos 2012 - - - - - - -
Juthier 2012 0.15(0.05-0.45) - - - - - -
Luciani 2012 - - - - - - -
McBrien 2012 1.69(0.85-3.35) 1.26(0.57-2.80) 0.42(0.11-1.68) - - - 0.42(0.11-1.68)
Ruzmetov 2012 - - - - - - 0.36(0.12-1.12)
Goda 2013 - - - - - - -
Khan 2013 - - - - - - 0.22(0.03-1.55)
Ruzmetov 2013 - - - - - - 0.29(0.07-1.16)
Skillington 2013 0.14(0.05-0.37) 0.07(0.02-0.27) 0.10(0.03-0.32) - - - -
Stelzer 2013 - - - - - - -
Tanny 2013 - - - - - - 0.55(0.21-1.46)
Andreas 2014 0.37(0.19-0.70) - - 0.04(0.01-0.29) - - 0.12(0.04-0.38)
Da Costa 2014 0.24(0.12-0.48) 0.03(0.00-0.21) 0.21(0.10-0.44) 0.24(0.12-0.48) - 0.06(0.02-0.24) -
David 2014 0.14(0.05-0.36) 0.02(0.00-0.27)* 0.14(0.05-0.36) 0.14(0.05-0.36) - 0.02(0.00-0.27)* -
Kallio 2014 - - - - - - -
Le Guillou 2014 1.12(0.28-4.43) 0.56(0.08-3.94) 0.56(0.08-3.94) - - - -
Lehoux 2014 - - - - - - -
Lo Rito 2014 - - - - - - -
Luciani 2014 0.20(0.08-0.47) - - 0.08(0.02-0.31) - 0.02(0.00-0.31)* 0.20(0.08-0.47)
Ruzmetov 2014 - - - - - - -
Xu 2014 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)* -
Zebele 2014 - - - - - - -
Bansal 2015 - - - - - - -
Escarain 2015 0.15(0.05-0.47) 0.10(0.03-0.41) 0.10(0.03-0.41) 0.03(0.00-0.41)* 0.03(0.00-0.41)* 0.03(0.00-0.41)* -
Jacobsen 2015 - - - - - - -
Lukyanov 2015 - - - - - - -
Mastrobuoni 2015 0.10(0.03-0.32) 0.07(0.02-0.27) 0.07(0.02-0.27) - 0.02(0.00-0.27)* 0.14(0.05-0.36) -
Nelson 2015 - - - - - - -
Sievers 2015 - - - - - - -
Tierney 2005 - - - - - - -
Boethig 2007 - - - - - - -
Franke 2015 0.74(0.24-2.28) 0.74(0.24-2.28) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)*
Ruzmetov 2015 - - - - - - -
Baird 2016 - - - - - - -
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supplement 3. (continued)
all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Kitamura 2011 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* 0.24(0.02-3.83)* - -
Ryan 2011 - - - - - - -
Brinkman 2012 - - - - - - -
Charitos 2012 - - - - - - -
Juthier 2012 0.15(0.05-0.45) - - - - - -
Luciani 2012 - - - - - - -
McBrien 2012 1.69(0.85-3.35) 1.26(0.57-2.80) 0.42(0.11-1.68) - - - 0.42(0.11-1.68)
Ruzmetov 2012 - - - - - - 0.36(0.12-1.12)
Goda 2013 - - - - - - -
Khan 2013 - - - - - - 0.22(0.03-1.55)
Ruzmetov 2013 - - - - - - 0.29(0.07-1.16)
Skillington 2013 0.14(0.05-0.37) 0.07(0.02-0.27) 0.10(0.03-0.32) - - - -
Stelzer 2013 - - - - - - -
Tanny 2013 - - - - - - 0.55(0.21-1.46)
Andreas 2014 0.37(0.19-0.70) - - 0.04(0.01-0.29) - - 0.12(0.04-0.38)
Da Costa 2014 0.24(0.12-0.48) 0.03(0.00-0.21) 0.21(0.10-0.44) 0.24(0.12-0.48) - 0.06(0.02-0.24) -
David 2014 0.14(0.05-0.36) 0.02(0.00-0.27)* 0.14(0.05-0.36) 0.14(0.05-0.36) - 0.02(0.00-0.27)* -
Kallio 2014 - - - - - - -
Le Guillou 2014 1.12(0.28-4.43) 0.56(0.08-3.94) 0.56(0.08-3.94) - - - -
Lehoux 2014 - - - - - - -
Lo Rito 2014 - - - - - - -
Luciani 2014 0.20(0.08-0.47) - - 0.08(0.02-0.31) - 0.02(0.00-0.31)* 0.20(0.08-0.47)
Ruzmetov 2014 - - - - - - -
Xu 2014 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.21(0.03-1.49) 0.11(0.01-1.68)* 0.11(0.01-1.68)* 0.11(0.01-1.68)* -
Zebele 2014 - - - - - - -
Bansal 2015 - - - - - - -
Escarain 2015 0.15(0.05-0.47) 0.10(0.03-0.41) 0.10(0.03-0.41) 0.03(0.00-0.41)* 0.03(0.00-0.41)* 0.03(0.00-0.41)* -
Jacobsen 2015 - - - - - - -
Lukyanov 2015 - - - - - - -
Mastrobuoni 2015 0.10(0.03-0.32) 0.07(0.02-0.27) 0.07(0.02-0.27) - 0.02(0.00-0.27)* 0.14(0.05-0.36) -
Nelson 2015 - - - - - - -
Sievers 2015 - - - - - - -
Tierney 2005 - - - - - - -
Boethig 2007 - - - - - - -
Franke 2015 0.74(0.24-2.28) 0.74(0.24-2.28) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)*
Ruzmetov 2015 - - - - - - -
Baird 2016 - - - - - - -
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all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Brown 2016 0.22(0.06-0.89) 0.11(0.02-0.79) 0.11(0.02-0.79) - - - 0.33(0.11-1.04)
Carrel 2016 - - - - - - -
Karaskov 2016 0.81(0.55-1.20) 0.71(0.47-1.08) 0.10(0.03-0.30) 0.23(0.11-0.48) 0.03(0.00-0.23) 0.10(0.03-0.30) -
Mazine 2016 0.25(0.12-0.52) 0.07(0.02-0.28) 0.18(0.07-0.42) 0.18(0.07-0.42) 0.02(0.00-0.28)* 0.02(0.00-0.28)* -
Popelová 2016 - - - - - - -
Zimmermann 2016 - - - - - - -
Bouhout 2017 - - - - - - -
Pardo González 2017 - - - - - - -
Martin 2017 0.06(0.02-0.20) - - - - - -
Ratschiller 2017 - - - - - - -
Schneider 2017 - 0.03(0.00-0.48)* 0.24(0.09-0.64) 0.12(0.03-0.48) 0.03(0.00-0.48)* 0.03(0.00-0.48)* -
Skoglund 2017 - - - - - - -
Tran 2017 - - - - - - -
Pooled estimate (95%ci) 0.29(0.21-0.41) 0.21(0.13-0.35) 0.17(0.13-0.22) 0.16(0.12-0.22) 0.06(0.03-0.12) 0.09(0.02-0.36) 0.30(0.20-0.44)
Heterogeneity I^2=61.2%(p<0.001) I^2=64.3%(p<0.001) I^2=0.0%(p=0.977) I^2=0.0%(p=0.793) I^2=0.0%(p=0.840) I^2=87.4%(p<0.001) I^2=0.0%(p=0.712)
number of studies 31 25 24 21 12 15 12
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supplement 3. (continued)
all ages (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker 
implantation (%/yr)
Brown 2016 0.22(0.06-0.89) 0.11(0.02-0.79) 0.11(0.02-0.79) - - - 0.33(0.11-1.04)
Carrel 2016 - - - - - - -
Karaskov 2016 0.81(0.55-1.20) 0.71(0.47-1.08) 0.10(0.03-0.30) 0.23(0.11-0.48) 0.03(0.00-0.23) 0.10(0.03-0.30) -
Mazine 2016 0.25(0.12-0.52) 0.07(0.02-0.28) 0.18(0.07-0.42) 0.18(0.07-0.42) 0.02(0.00-0.28)* 0.02(0.00-0.28)* -
Popelová 2016 - - - - - - -
Zimmermann 2016 - - - - - - -
Bouhout 2017 - - - - - - -
Pardo González 2017 - - - - - - -
Martin 2017 0.06(0.02-0.20) - - - - - -
Ratschiller 2017 - - - - - - -
Schneider 2017 - 0.03(0.00-0.48)* 0.24(0.09-0.64) 0.12(0.03-0.48) 0.03(0.00-0.48)* 0.03(0.00-0.48)* -
Skoglund 2017 - - - - - - -
Tran 2017 - - - - - - -
Pooled estimate (95%ci) 0.29(0.21-0.41) 0.21(0.13-0.35) 0.17(0.13-0.22) 0.16(0.12-0.22) 0.06(0.03-0.12) 0.09(0.02-0.36) 0.30(0.20-0.44)
Heterogeneity I^2=61.2%(p<0.001) I^2=64.3%(p<0.001) I^2=0.0%(p=0.977) I^2=0.0%(p=0.793) I^2=0.0%(p=0.840) I^2=87.4%(p<0.001) I^2=0.0%(p=0.712)
number of studies 31 25 24 21 12 15 12
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PeDiatric
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related 
(%/yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Solowiejczyk 2000 - - - - - 1.25(0.18-8.77) 0.63(0.04-9.91)* 1.25(0.18-8.77)
Pigula 2001 1.47(0.09-23.04)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 4.14(1.07-16.09) 1.04(0.07-16.32)* 1.04(0.07-16.32)*
Lupinetti 2003 3.85(1.27-11.67) 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 1.90(0.80-4.53) 1.52(0.57-4.02) 0.38(0.05-2.69)
Hazekamp 2005 5.66(1.89-16.99) 1.03(0.33-3.17) 1.03(0.33-3.17) 1.03(0.33-3.17) 0.34(0.05-2.43) 2.74(1.39-5.44) 1.72(0.72-4.09) 1.03(0.33-3.17)
Kalavrouziotis 2006 1.43(0.09-22.39)* 0.70(0.10-4.91) 0.70(0.10-4.91) 0.70(0.10-4.91) 0.70(0.10-4.91) 1.39(0.35-5.52) 0.35(0.02-5.54)* 1.39(0.35-5.52)
Kadner 2008 9.62(4.18-22.12) 1.61(0.52-4.95) 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 4.30(2.18-8.46) 0.54(0.08-3.79) 3.76(1.82-7.78)
El Behery 2009 4.88(1.26-18.85) 0.20(0.01-3.24)* - - - 1.63(0.62-4.30) 0.20(0.01-3.24)* 1.63(0.62-4.30)
Goldberg 2009 15.63(6.98-34.95) 0.99(0.06-15.60)* - - - - - -
Alsoufi 2010 3.08(1.49-6.39) 0.17(0.05-0.52) - - - 4.86(3.95-5.97) 1.64(1.14-2.35) 1.64(1.14-2.35)
Valeske 2010 2.04(0.52-8.05) 0.10(0.01-1.63)* - - - 0.20(0.03-1.45) 0.20(0.03-1.45) 0.10(0.01-1.63)*
Charitos 2012 3.42(1.80-6.50) - - - - 3.63(2.81-4.69) 0.91(0.54-1.53) 2.72(2.02-3.67)
Oda 2012 5.26(1.37-20.28) 0.21(0.01-3.28)* 0.21(0.01-3.28)* 0.21(0.01-3.28)* 0.21(0.01-3.28)* 1.23(0.40-3.80) 0.21(0.01-3.28)* 1.23(0.40-3.80)
Talwar 2012 2.78(0.40-19.19) 1.40(0.53-3.71) 1.40(0.53-3.71) 0.70(0.18-2.79) 0.18(0.01-2.80)* 2.46(1.18-5.11) 1.75(0.74-4.18) 0.70(0.18-2.79)
Goda 2013 - - - - - - 1.03(0.34-3.18) -
Khan 2013 2.94(0.75-11.52) 0.44(0.11-1.75) - - - 4.17(2.69-6.48) 0.66(0.21-2.03) 3.51(2.17-5.68)
Ruzmetov 2013 - - - - - 5.24(3.82-7.21) - 2.33(1.44-3.78)
Tanny 2013 6.00(2.76-13.03) 0.55(0.21-1.46) 0.41(0.13-1.27) 0.27(0.07-1.09) 0.14(0.02-0.97) 3.70(2.55-5.36) 1.23(0.64-2.36) 2.74(1.78-4.22)
Andreas 2014 - - - - - - - -
Kallio 2014 9.80(4.26-22.54) 0.51(0.17-1.58) 0.51(0.17-1.58) 0.17(0.02-1.21) 0.09(0.01-1.36)* 3.58(2.35-5.45) 0.68(0.26-1.81) 2.05(1.17-3.58)
Lehoux 2014 - - - - - 2.19(0.83-5.78) 0.27(0.02-4.36)* 1.10(0.28-4.35)
Lo Rito 2014 2.86(1.09-7.51) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.03(0.00-0.53)* 1.72(1.17-2.52) 0.73(0.40-1.31) 0.99(0.60-1.64)
Luciani 2014 3.28(1.78-6.03) 0.47(0.27-0.82) 0.23(0.11-0.52) - - 2.93(2.34-3.66) 1.44(1.05-1.99) 1.44(1.05-1.99)
Ruzmetov 2014 - - - - - - 3.37(2.31-4.91) -
Lukyanov 2015 1.75(0.44-6.93) - - - - - - -
Nelson 2015 4.17(2.27-7.64) 0.66(0.41-1.06) - - - 7.75(6.78-8.86) 2.69(2.13-3.39) 2.22(1.72-2.87)
Piccardo 2009 1.82(0.26-12.68) 0.66(0.17-2.63) 0.33(0.05-2.34) 0.33(0.05-2.34) 0.17(0.01-2.64)* 1.65(0.69-3.94) 0.66(0.17-2.63) 0.99(0.32-3.06)
Tierney 2005 - - - - - - - 2.22(0.72-6.79)
Ruzmetov 2015 1.39(0.20-9.73) 0.51(0.19-1.34) - - - - 2.78(1.84-4.19) 2.27(1.44-3.59)
Baird 2016 - 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* - 0.91(0.23-3.60) 4.98(2.80-8.86)
Brown 2016 0.87(0.12-6.12) 0.45(0.17-1.19) 0.22(0.06-0.89) 0.22(0.06-0.89) 0.11(0.02-0.79) 3.57(2.54-5.01) 1.45(0.84-2.49) 1.90(1.18-3.03)
Pardo González 2017 4.76(0.70-32.25) - - - - - - -
Tran 2017 0.67(0.04-10.56)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 3.08(1.76-5.37) 0.77(0.25-2.37) 1.79(0.86-3.74)
Pooled estimate (95%ci) 4.19(3.21-5.46) 0.54(0.42-0.70) 0.41(0.27-0.63) 0.36(0.22-0.57) 0.20(0.11-0.39) 3.04(2.39-3.87) 1.28(0.99-1.66) 1.97(1.64-2.36)
Heterogeneity I^2=27.9%(p=0.102) I^2=7.3%(p=0.363) I^2=14.0%(p=0.296) I^2=0.0%(p=0.736) I^2=0.0%(p=0.951) I^2=85.5%(p<0.001) I^2=66.1%(p<0.001) I^2=52.1%(p=0.001)
number of studies 24 22 15 14 14 23 26 26
161
The Ross procedure
5
supplement 3. (continued)
PeDiatric
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related 
(%/yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Solowiejczyk 2000 - - - - - 1.25(0.18-8.77) 0.63(0.04-9.91)* 1.25(0.18-8.77)
Pigula 2001 1.47(0.09-23.04)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 1.04(0.07-16.32)* 4.14(1.07-16.09) 1.04(0.07-16.32)* 1.04(0.07-16.32)*
Lupinetti 2003 3.85(1.27-11.67) 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 0.19(0.01-3.03)* 1.90(0.80-4.53) 1.52(0.57-4.02) 0.38(0.05-2.69)
Hazekamp 2005 5.66(1.89-16.99) 1.03(0.33-3.17) 1.03(0.33-3.17) 1.03(0.33-3.17) 0.34(0.05-2.43) 2.74(1.39-5.44) 1.72(0.72-4.09) 1.03(0.33-3.17)
Kalavrouziotis 2006 1.43(0.09-22.39)* 0.70(0.10-4.91) 0.70(0.10-4.91) 0.70(0.10-4.91) 0.70(0.10-4.91) 1.39(0.35-5.52) 0.35(0.02-5.54)* 1.39(0.35-5.52)
Kadner 2008 9.62(4.18-22.12) 1.61(0.52-4.95) 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 4.30(2.18-8.46) 0.54(0.08-3.79) 3.76(1.82-7.78)
El Behery 2009 4.88(1.26-18.85) 0.20(0.01-3.24)* - - - 1.63(0.62-4.30) 0.20(0.01-3.24)* 1.63(0.62-4.30)
Goldberg 2009 15.63(6.98-34.95) 0.99(0.06-15.60)* - - - - - -
Alsoufi 2010 3.08(1.49-6.39) 0.17(0.05-0.52) - - - 4.86(3.95-5.97) 1.64(1.14-2.35) 1.64(1.14-2.35)
Valeske 2010 2.04(0.52-8.05) 0.10(0.01-1.63)* - - - 0.20(0.03-1.45) 0.20(0.03-1.45) 0.10(0.01-1.63)*
Charitos 2012 3.42(1.80-6.50) - - - - 3.63(2.81-4.69) 0.91(0.54-1.53) 2.72(2.02-3.67)
Oda 2012 5.26(1.37-20.28) 0.21(0.01-3.28)* 0.21(0.01-3.28)* 0.21(0.01-3.28)* 0.21(0.01-3.28)* 1.23(0.40-3.80) 0.21(0.01-3.28)* 1.23(0.40-3.80)
Talwar 2012 2.78(0.40-19.19) 1.40(0.53-3.71) 1.40(0.53-3.71) 0.70(0.18-2.79) 0.18(0.01-2.80)* 2.46(1.18-5.11) 1.75(0.74-4.18) 0.70(0.18-2.79)
Goda 2013 - - - - - - 1.03(0.34-3.18) -
Khan 2013 2.94(0.75-11.52) 0.44(0.11-1.75) - - - 4.17(2.69-6.48) 0.66(0.21-2.03) 3.51(2.17-5.68)
Ruzmetov 2013 - - - - - 5.24(3.82-7.21) - 2.33(1.44-3.78)
Tanny 2013 6.00(2.76-13.03) 0.55(0.21-1.46) 0.41(0.13-1.27) 0.27(0.07-1.09) 0.14(0.02-0.97) 3.70(2.55-5.36) 1.23(0.64-2.36) 2.74(1.78-4.22)
Andreas 2014 - - - - - - - -
Kallio 2014 9.80(4.26-22.54) 0.51(0.17-1.58) 0.51(0.17-1.58) 0.17(0.02-1.21) 0.09(0.01-1.36)* 3.58(2.35-5.45) 0.68(0.26-1.81) 2.05(1.17-3.58)
Lehoux 2014 - - - - - 2.19(0.83-5.78) 0.27(0.02-4.36)* 1.10(0.28-4.35)
Lo Rito 2014 2.86(1.09-7.51) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.13(0.03-0.53) 0.03(0.00-0.53)* 1.72(1.17-2.52) 0.73(0.40-1.31) 0.99(0.60-1.64)
Luciani 2014 3.28(1.78-6.03) 0.47(0.27-0.82) 0.23(0.11-0.52) - - 2.93(2.34-3.66) 1.44(1.05-1.99) 1.44(1.05-1.99)
Ruzmetov 2014 - - - - - - 3.37(2.31-4.91) -
Lukyanov 2015 1.75(0.44-6.93) - - - - - - -
Nelson 2015 4.17(2.27-7.64) 0.66(0.41-1.06) - - - 7.75(6.78-8.86) 2.69(2.13-3.39) 2.22(1.72-2.87)
Piccardo 2009 1.82(0.26-12.68) 0.66(0.17-2.63) 0.33(0.05-2.34) 0.33(0.05-2.34) 0.17(0.01-2.64)* 1.65(0.69-3.94) 0.66(0.17-2.63) 0.99(0.32-3.06)
Tierney 2005 - - - - - - - 2.22(0.72-6.79)
Ruzmetov 2015 1.39(0.20-9.73) 0.51(0.19-1.34) - - - - 2.78(1.84-4.19) 2.27(1.44-3.59)
Baird 2016 - 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* 0.23(0.01-3.61)* - 0.91(0.23-3.60) 4.98(2.80-8.86)
Brown 2016 0.87(0.12-6.12) 0.45(0.17-1.19) 0.22(0.06-0.89) 0.22(0.06-0.89) 0.11(0.02-0.79) 3.57(2.54-5.01) 1.45(0.84-2.49) 1.90(1.18-3.03)
Pardo González 2017 4.76(0.70-32.25) - - - - - - -
Tran 2017 0.67(0.04-10.56)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 0.13(0.01-2.05)* 3.08(1.76-5.37) 0.77(0.25-2.37) 1.79(0.86-3.74)
Pooled estimate (95%ci) 4.19(3.21-5.46) 0.54(0.42-0.70) 0.41(0.27-0.63) 0.36(0.22-0.57) 0.20(0.11-0.39) 3.04(2.39-3.87) 1.28(0.99-1.66) 1.97(1.64-2.36)
Heterogeneity I^2=27.9%(p=0.102) I^2=7.3%(p=0.363) I^2=14.0%(p=0.296) I^2=0.0%(p=0.736) I^2=0.0%(p=0.951) I^2=85.5%(p<0.001) I^2=66.1%(p<0.001) I^2=52.1%(p=0.001)
number of studies 24 22 15 14 14 23 26 26
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PeDiatric (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker implantation (%/yr)
Solowiejczyk 2000 - - - - - - -
Pigula 2001 - - - - - - 2.07(0.30-14.41)
Lupinetti 2003 0.19(0.01-3.03)* - - - - 0.19(0.01-3.03)* -
Hazekamp 2005 - - - - - - -
Kalavrouziotis 2006 - - - - - - -
Kadner 2008 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* - - 0.27(0.02-4.28)*
El Behery 2009 - - - - - - -
Goldberg 2009 - - - - - - -
Alsoufi 2010 - - - - - - -
Valeske 2010 - - - 0.10(0.01-1.63)* 0.10(0.01-1.63)* - -
Charitos 2012 - - - - - - -
Oda 2012 - - - - - - -
Talwar 2012 0.70(0.18-2.79) - - 0.18(0.01-2.80)* 0.18(0.01-2.80)* 0.18(0.01-2.80)* -
Goda 2013 - - - - - - -
Khan 2013 - - - - - - 0.22(0.03-1.55)
Ruzmetov 2013 - - - - - - 0.29(0.07-1.16)
Tanny 2013 - - - - - - 0.55(0.21-1.46)
Andreas 2014 - - - - - - 0.29(0.07-1.14)
Kallio 2014 - - - - - - -
Lehoux 2014 - - - - - - -
Lo Rito 2014 - - - - - - -
Luciani 2014 0.20(0.08-0.47) - - 0.08(0.02-0.31) - 0.02(0.00-0.31)* 0.20(0.08-0.47)
Ruzmetov 2014 - - - - - - -
Lukyanov 2015 - - - - - - -
Nelson 2015 - - - - - - -
Piccardo 2009 0.33(0.05-2.34) 0.17(0.01-2.64)* 0.33(0.05-2.34) 0.17(0.01-2.64)* 0.17(0.01-2.64)* 0.17(0.01-2.64)* 0.17(0.01-2.64)*
Tierney 2005 - - - - - - -
Ruzmetov 2015 - - - - - - -
Baird 2016 - - - - - - -
Brown 2016 0.22(0.06-0.89) 0.11(0.02-0.79) 0.11(0.02-0.79) - - - 0.33(0.11-1.04)
Pardo González 2017 - - - - - - -
Tran 2017 - - - - - - -
Pooled estimate (95%ci) 0.27(0.15-0.48) 0.15(0.04-0.61) 0.21(0.06-0.71) 0.11(0.04-0.30) 0.14(0.03-0.71) 0.10(0.03-0.41) 0.33(0.21-0.51)
Heterogeneity I^2=0.0%(p=0.770) I^2=0.0%(p=0.877) I^2=0.0%(p=0.727) I^2=0.0%(p=0.935) I^2=0.0%(p=0.957) I^2=0.0%(p=0.609) I^2=0.0%(p=0.607)
number of studies 6 3 3 5 3 4 9
163
The Ross procedure
5
supplement 3. (continued)
PeDiatric (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker implantation (%/yr)
Solowiejczyk 2000 - - - - - - -
Pigula 2001 - - - - - - 2.07(0.30-14.41)
Lupinetti 2003 0.19(0.01-3.03)* - - - - 0.19(0.01-3.03)* -
Hazekamp 2005 - - - - - - -
Kalavrouziotis 2006 - - - - - - -
Kadner 2008 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* 0.27(0.02-4.28)* - - 0.27(0.02-4.28)*
El Behery 2009 - - - - - - -
Goldberg 2009 - - - - - - -
Alsoufi 2010 - - - - - - -
Valeske 2010 - - - 0.10(0.01-1.63)* 0.10(0.01-1.63)* - -
Charitos 2012 - - - - - - -
Oda 2012 - - - - - - -
Talwar 2012 0.70(0.18-2.79) - - 0.18(0.01-2.80)* 0.18(0.01-2.80)* 0.18(0.01-2.80)* -
Goda 2013 - - - - - - -
Khan 2013 - - - - - - 0.22(0.03-1.55)
Ruzmetov 2013 - - - - - - 0.29(0.07-1.16)
Tanny 2013 - - - - - - 0.55(0.21-1.46)
Andreas 2014 - - - - - - 0.29(0.07-1.14)
Kallio 2014 - - - - - - -
Lehoux 2014 - - - - - - -
Lo Rito 2014 - - - - - - -
Luciani 2014 0.20(0.08-0.47) - - 0.08(0.02-0.31) - 0.02(0.00-0.31)* 0.20(0.08-0.47)
Ruzmetov 2014 - - - - - - -
Lukyanov 2015 - - - - - - -
Nelson 2015 - - - - - - -
Piccardo 2009 0.33(0.05-2.34) 0.17(0.01-2.64)* 0.33(0.05-2.34) 0.17(0.01-2.64)* 0.17(0.01-2.64)* 0.17(0.01-2.64)* 0.17(0.01-2.64)*
Tierney 2005 - - - - - - -
Ruzmetov 2015 - - - - - - -
Baird 2016 - - - - - - -
Brown 2016 0.22(0.06-0.89) 0.11(0.02-0.79) 0.11(0.02-0.79) - - - 0.33(0.11-1.04)
Pardo González 2017 - - - - - - -
Tran 2017 - - - - - - -
Pooled estimate (95%ci) 0.27(0.15-0.48) 0.15(0.04-0.61) 0.21(0.06-0.71) 0.11(0.04-0.30) 0.14(0.03-0.71) 0.10(0.03-0.41) 0.33(0.21-0.51)
Heterogeneity I^2=0.0%(p=0.770) I^2=0.0%(p=0.877) I^2=0.0%(p=0.727) I^2=0.0%(p=0.935) I^2=0.0%(p=0.957) I^2=0.0%(p=0.609) I^2=0.0%(p=0.607)
number of studies 6 3 3 5 3 4 9
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aDult
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Knott-Craig 2000 - 1.66(0.75-3.66) - 0.83(0.27-2.55) - 2.21(1.11-4.38) 0.83(0.27-2.55) 1.38(0.58-3.29)
Xie 2001 4.08(1.05-15.86) 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.68(0.10-4.80) 0.34(0.02-5.41)* 0.68(0.10-4.80)
Schmid 2002 0.98(0.06-15.46)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.64(0.09-4.55)
Svensson 2002 3.90(1.28-11.81) - - - - - - -
Fullerton 2003 6.82(2.29-20.33) 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.72(0.10-5.05) 0.72(0.10-5.05) 0.36(0.02-5.70)*
Matalanis 2004 3.23(0.47-22.18) 2.71(0.69-10.62) - 0.68(0.04-10.72)* 0.68(0.04-10.72)* 2.71(0.69-10.62) 1.35(0.19-9.48) 0.68(0.04-10.72)*
Chotivatanapong 2005 13.33(5.35-33.20) 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* - - -
Settepani 2005 0.49(0.03-7.71)* 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) 0.08(0.01-1.29)* 0.97(0.44-2.15) 0.81(0.34-1.94) 0.16(0.02-1.15)
Pitsis 2006 4.76(0.70-32.25) 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 2.38(0.61-9.36) 2.38(0.61-9.36) 0.60(0.04-9.44)*
Klieverik 2007 3.19(1.05-9.72) 0.12(0.02-0.87) 0.12(0.02-0.87) 0.06(0.00-0.98)* 0.06(0.00-0.98)* - - -
Frigiola 2008 0.45(0.03-7.22)* 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) - 1.06(0.53-2.12) 0.53(0.20-1.41)
Al Rashidi 2010 1.92(0.12-29.93)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 1.32(0.19-9.24) 1.32(0.19-9.24) -
El-Hamamsy 2010 0.93(0.13-6.51) 0.27(0.09-0.84) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.73(0.36-1.45) 0.09(0.01-0.64) 0.64(0.30-1.33)
Brown 2011 0.87(0.22-3.46) 0.67(0.38-1.18) 0.17(0.05-0.52) - 0.28(0.12-0.67) 1.40(0.95-2.07) 1.12(0.73-1.74) 0.28(0.12-0.67)
Ryan 2011 1.88(0.61-5.75) 0.58(0.24-1.39) 0.12(0.02-0.83) 0.06(0.00-0.93)* 0.06(0.00-0.93)* 1.75(1.06-2.88) - 0.12(0.02-0.83)
Brinkman 2012 - - - - - 1.05(0.66-1.69) 1.05(0.66-1.69) -
Skillington 2013 0.32(0.05-2.28) 0.17(0.07-0.41) 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.51(0.31-0.85) 0.38(0.21-0.68) 0.17(0.07-0.41)
Stelzer 2013 1.13(0.51-2.51) - - - - - - -
Andreas 2014 - - - - - - - -
David 2014 0.47(0.07-3.33) 0.31(0.16-0.59) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.85(0.58-1.26) 0.51(0.31-0.85) 0.31(0.16-0.59)
Le Guillou 2014 10.71(3.68-31.21) 3.35(1.52-7.35) 0.28(0.02-4.44)* 0.28(0.02-4.44)* 0.28(0.02-4.44)* 2.23(0.85-5.88) 1.12(0.28-4.43) 0.56(0.08-3.94)
Escarain 2015 2.66(1.28-5.53) 0.71(0.42-1.20) 0.30(0.14-0.68) 0.30(0.14-0.68) 0.03(0.00-0.41)* 0.91(0.58-1.45) 0.66(0.38-1.13) 0.20(0.08-0.54)
Jacobsen 2015 1.39(0.09-21.78)* 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 5.05(1.94-13.12) 3.79(1.25-11.49) 0.63(0.04-10.01)*
Mastrobuoni 2015 2.29(1.10-4.76) 0.71(0.47-1.09) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.03(0.00-0.24) 1.33(0.97-1.81) 1.23(0.89-1.70) 0.37(0.21-0.68)
Sievers 2015 1.07(0.68-1.67) 0.68(0.56-0.83) - - - 1.19(1.02-1.37) 0.72(0.59-0.87) 0.62(0.50-0.76)
Franke 2015 0.74(0.10-5.18) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.98(0.37-2.61) 0.74(0.24-2.28) 0.25(0.03-1.74)
Carrel 2016 2.27(0.15-35.20)* - - - - 0.91(0.13-6.40) 0.91(0.13-6.40) 0.45(0.03-7.22)*
Karaskov 2016 2.97(1.97-4.48) 0.58(0.37-0.93) 0.45(0.27-0.77) 0.36(0.20-0.64) 0.26(0.13-0.52) 1.85(1.43-2.39) 1.20(0.87-1.65) 0.91(0.63-1.31)
Mazine 2016 0.48(0.07-3.40) 0.42(0.24-0.75) 0.11(0.03-0.33) 0.11(0.03-0.33) 0.07(0.02-0.28) 0.74(0.48-1.14) 0.49(0.29-0.83) 0.25(0.12-0.52)
Popelová 2016 1.52(0.10-23.72)* - - - - - - -
Bouhout 2017 1.00(0.25-3.97) - - - - - - -
Pardo González 2017 0.58(0.04-9.22)* - - - - - - -
Martin 2017 1.29(0.49-3.42) 0.60(0.41-0.87) 0.34(0.21-0.56) 0.09(0.03-0.23) 0.02(0.00-0.15) 1.20(0.92-1.55) 0.68(0.48-0.97) 0.45(0.29-0.69)
Skoglund 2017 0.65(0.04-10.29)* 0.08(0.01-0.58) - - - - - 0.82(0.44-1.51)
Pooled estimate (95%ci) 2.01(1.44-2.82) 0.59(0.46-0.76) 0.24(0.17-0.33) 0.21(0.14-0.32) 0.16(0.10-0.25) 1.20(1.01-1.42) 0.83(0.68-1.01) 0.47(0.37-0.59)
Heterogeneity I^2=53.6%(p<0.001) I^2=57.3%(p<0.001) I^2=17.5%(p=0.227) I^2=26.8%(p=0.117) I^2=20.7%(p=0.185) I^2=57.0%(p<0.001) I^2=52.2%(p=0.002) I^2=45.5%(p=0.009)
number of studies 31 26 22 23 23 24 24 24
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aDult
early mortality (%) late mortality (%/yr)  -Cardiac (%/yr)  -Valve-related (%/
yr)
 - SUD (%/yr) reintervention (%/yr)  -Autograft (%/yr)  -Allograft (%/yr)
Knott-Craig 2000 - 1.66(0.75-3.66) - 0.83(0.27-2.55) - 2.21(1.11-4.38) 0.83(0.27-2.55) 1.38(0.58-3.29)
Xie 2001 4.08(1.05-15.86) 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.34(0.02-5.41)* 0.68(0.10-4.80) 0.34(0.02-5.41)* 0.68(0.10-4.80)
Schmid 2002 0.98(0.06-15.46)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.32(0.02-5.13)* 0.64(0.09-4.55) 0.32(0.02-5.13)* 0.64(0.09-4.55)
Svensson 2002 3.90(1.28-11.81) - - - - - - -
Fullerton 2003 6.82(2.29-20.33) 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.36(0.02-5.70)* 0.72(0.10-5.05) 0.72(0.10-5.05) 0.36(0.02-5.70)*
Matalanis 2004 3.23(0.47-22.18) 2.71(0.69-10.62) - 0.68(0.04-10.72)* 0.68(0.04-10.72)* 2.71(0.69-10.62) 1.35(0.19-9.48) 0.68(0.04-10.72)*
Chotivatanapong 2005 13.33(5.35-33.20) 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* 1.20(0.08-18.85)* - - -
Settepani 2005 0.49(0.03-7.71)* 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) 0.08(0.01-1.29)* 0.97(0.44-2.15) 0.81(0.34-1.94) 0.16(0.02-1.15)
Pitsis 2006 4.76(0.70-32.25) 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 0.60(0.04-9.44)* 2.38(0.61-9.36) 2.38(0.61-9.36) 0.60(0.04-9.44)*
Klieverik 2007 3.19(1.05-9.72) 0.12(0.02-0.87) 0.12(0.02-0.87) 0.06(0.00-0.98)* 0.06(0.00-0.98)* - - -
Frigiola 2008 0.45(0.03-7.22)* 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) 0.13(0.02-0.94) - 1.06(0.53-2.12) 0.53(0.20-1.41)
Al Rashidi 2010 1.92(0.12-29.93)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 0.66(0.04-10.45)* 1.32(0.19-9.24) 1.32(0.19-9.24) -
El-Hamamsy 2010 0.93(0.13-6.51) 0.27(0.09-0.84) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.09(0.01-0.64) 0.73(0.36-1.45) 0.09(0.01-0.64) 0.64(0.30-1.33)
Brown 2011 0.87(0.22-3.46) 0.67(0.38-1.18) 0.17(0.05-0.52) - 0.28(0.12-0.67) 1.40(0.95-2.07) 1.12(0.73-1.74) 0.28(0.12-0.67)
Ryan 2011 1.88(0.61-5.75) 0.58(0.24-1.39) 0.12(0.02-0.83) 0.06(0.00-0.93)* 0.06(0.00-0.93)* 1.75(1.06-2.88) - 0.12(0.02-0.83)
Brinkman 2012 - - - - - 1.05(0.66-1.69) 1.05(0.66-1.69) -
Skillington 2013 0.32(0.05-2.28) 0.17(0.07-0.41) 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.02(0.00-0.27)* 0.51(0.31-0.85) 0.38(0.21-0.68) 0.17(0.07-0.41)
Stelzer 2013 1.13(0.51-2.51) - - - - - - -
Andreas 2014 - - - - - - - -
David 2014 0.47(0.07-3.33) 0.31(0.16-0.59) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.85(0.58-1.26) 0.51(0.31-0.85) 0.31(0.16-0.59)
Le Guillou 2014 10.71(3.68-31.21) 3.35(1.52-7.35) 0.28(0.02-4.44)* 0.28(0.02-4.44)* 0.28(0.02-4.44)* 2.23(0.85-5.88) 1.12(0.28-4.43) 0.56(0.08-3.94)
Escarain 2015 2.66(1.28-5.53) 0.71(0.42-1.20) 0.30(0.14-0.68) 0.30(0.14-0.68) 0.03(0.00-0.41)* 0.91(0.58-1.45) 0.66(0.38-1.13) 0.20(0.08-0.54)
Jacobsen 2015 1.39(0.09-21.78)* 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 1.26(0.18-8.85) 5.05(1.94-13.12) 3.79(1.25-11.49) 0.63(0.04-10.01)*
Mastrobuoni 2015 2.29(1.10-4.76) 0.71(0.47-1.09) 0.10(0.03-0.32) 0.10(0.03-0.32) 0.03(0.00-0.24) 1.33(0.97-1.81) 1.23(0.89-1.70) 0.37(0.21-0.68)
Sievers 2015 1.07(0.68-1.67) 0.68(0.56-0.83) - - - 1.19(1.02-1.37) 0.72(0.59-0.87) 0.62(0.50-0.76)
Franke 2015 0.74(0.10-5.18) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.98(0.37-2.61) 0.74(0.24-2.28) 0.25(0.03-1.74)
Carrel 2016 2.27(0.15-35.20)* - - - - 0.91(0.13-6.40) 0.91(0.13-6.40) 0.45(0.03-7.22)*
Karaskov 2016 2.97(1.97-4.48) 0.58(0.37-0.93) 0.45(0.27-0.77) 0.36(0.20-0.64) 0.26(0.13-0.52) 1.85(1.43-2.39) 1.20(0.87-1.65) 0.91(0.63-1.31)
Mazine 2016 0.48(0.07-3.40) 0.42(0.24-0.75) 0.11(0.03-0.33) 0.11(0.03-0.33) 0.07(0.02-0.28) 0.74(0.48-1.14) 0.49(0.29-0.83) 0.25(0.12-0.52)
Popelová 2016 1.52(0.10-23.72)* - - - - - - -
Bouhout 2017 1.00(0.25-3.97) - - - - - - -
Pardo González 2017 0.58(0.04-9.22)* - - - - - - -
Martin 2017 1.29(0.49-3.42) 0.60(0.41-0.87) 0.34(0.21-0.56) 0.09(0.03-0.23) 0.02(0.00-0.15) 1.20(0.92-1.55) 0.68(0.48-0.97) 0.45(0.29-0.69)
Skoglund 2017 0.65(0.04-10.29)* 0.08(0.01-0.58) - - - - - 0.82(0.44-1.51)
Pooled estimate (95%ci) 2.01(1.44-2.82) 0.59(0.46-0.76) 0.24(0.17-0.33) 0.21(0.14-0.32) 0.16(0.10-0.25) 1.20(1.01-1.42) 0.83(0.68-1.01) 0.47(0.37-0.59)
Heterogeneity I^2=53.6%(p<0.001) I^2=57.3%(p<0.001) I^2=17.5%(p=0.227) I^2=26.8%(p=0.117) I^2=20.7%(p=0.185) I^2=57.0%(p<0.001) I^2=52.2%(p=0.002) I^2=45.5%(p=0.009)
number of studies 31 26 22 23 23 24 24 24
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supplement 3. (continued)
aDult (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker implantation (%/yr)
Knott-Craig 2000 0.28(0.04-1.95) - - - - - -
Xie 2001 - - - - - - -
Schmid 2002 - - - - - - -
Svensson 2002 - - - - - - -
Fullerton 2003 - - - - - - 0.36(0.02-5.70)*
Matalanis 2004 0.68(0.04-10.72)* - - 0.68(0.04-10.72)* - - 1.35(0.19-9.48)
Chotivatanapong 2005 - - - - - 11.99(5.27-27.29) -
Settepani 2005 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) - - - -
Pitsis 2006 1.19(0.17-8.35) 1.19(0.17-8.35) 0.60(0.04-9.44)* - - - -
Klieverik 2007 - - - - 0.06(0.00-0.98)* 0.06(0.00-0.98)* -
Frigiola 2008 - - - - - - -
Al Rashidi 2010 - - - - - - -
El-Hamamsy 2010 0.18(0.05-0.73) 0.05(0.00-0.73)* 0.18(0.05-0.73) - - - -
Brown 2011 0.17(0.05-0.52) 0.17(0.05-0.52) - 0.06(0.01-0.40) 0.03(0.00-0.45)* 0.03(0.00-0.45)* -
Ryan 2011 - - - - - - -
Brinkman 2012 - - - - - - -
Skillington 2013 0.14(0.05-0.37) 0.07(0.02-0.27) 0.10(0.03-0.32) - - - -
Stelzer 2013 - - - - - - -
Andreas 2014 - - - - - - 0.06(0.01-0.40)
David 2014 0.14(0.05-0.36) 0.02(0.00-0.27)* 0.14(0.05-0.36) 0.14(0.05-0.36) - 0.02(0.00-0.27)* -
Le Guillou 2014 1.12(0.28-4.43) 0.56(0.08-3.94) 0.56(0.08-3.94) - - - -
Escarain 2015 0.15(0.05-0.47) 0.10(0.03-0.41) 0.10(0.03-0.41) 0.03(0.00-0.41)* 0.03(0.00-0.41)* 0.03(0.00-0.41)* -
Jacobsen 2015 - - - - - - -
Mastrobuoni 2015 0.10(0.03-0.32) 0.07(0.02-0.27) 0.07(0.02-0.27) - 0.02(0.00-0.27)* 0.14(0.05-0.36) -
Sievers 2015 - - - - - - -
Franke 2015 0.74(0.24-2.28) 0.74(0.24-2.28) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)*
Carrel 2016 - - - - - - -
Karaskov 2016 0.81(0.55-1.20) 0.71(0.47-1.08) 0.10(0.03-0.30) 0.23(0.11-0.48) 0.03(0.00-0.23) 0.10(0.03-0.30) -
Mazine 2016 0.25(0.12-0.52) 0.07(0.02-0.28) 0.18(0.07-0.42) 0.18(0.07-0.42) 0.02(0.00-0.28)* 0.02(0.00-0.28)* -
Popelová 2016 - - - - - - -
Bouhout 2017 - - - - - - -
Pardo González 2017 - - - - - - -
Martin 2017 0.06(0.02-0.20) - - - - - -
Skoglund 2017 - - - - - - -
Pooled estimate (95%ci) 0.27(0.16-0.45) 0.18(0.09-0.39) 0.14(0.09-0.21) 0.17(0.11-0.27) 0.03(0.01-0.09) 0.10(0.01-0.67) 0.25(0.05-1.17)
Heterogeneity I^2=71.8%(p<0.001) I^2=74.0%(p<0.001) I^2=0.0%(p=0.867) I^2=0.0%(p=0.565) I^2=0.0%(p=0.958) I^2=91.6%(p<0.001) I^2=44.5%(p=0.144)
number of studies 15 12 11 7 7 9 4
167
The Ross procedure
5
supplement 3. (continued)
aDult (continued)
endocarditis (%/yr)  -Autograft (%/yr)  -Allograft (%/yr) thromboembolism (%/yr) valve thrombosis (%/yr) Bleeding (%/yr) Pacemaker implantation (%/yr)
Knott-Craig 2000 0.28(0.04-1.95) - - - - - -
Xie 2001 - - - - - - -
Schmid 2002 - - - - - - -
Svensson 2002 - - - - - - -
Fullerton 2003 - - - - - - 0.36(0.02-5.70)*
Matalanis 2004 0.68(0.04-10.72)* - - 0.68(0.04-10.72)* - - 1.35(0.19-9.48)
Chotivatanapong 2005 - - - - - 11.99(5.27-27.29) -
Settepani 2005 0.32(0.08-1.29) 0.16(0.02-1.15) 0.16(0.02-1.15) - - - -
Pitsis 2006 1.19(0.17-8.35) 1.19(0.17-8.35) 0.60(0.04-9.44)* - - - -
Klieverik 2007 - - - - 0.06(0.00-0.98)* 0.06(0.00-0.98)* -
Frigiola 2008 - - - - - - -
Al Rashidi 2010 - - - - - - -
El-Hamamsy 2010 0.18(0.05-0.73) 0.05(0.00-0.73)* 0.18(0.05-0.73) - - - -
Brown 2011 0.17(0.05-0.52) 0.17(0.05-0.52) - 0.06(0.01-0.40) 0.03(0.00-0.45)* 0.03(0.00-0.45)* -
Ryan 2011 - - - - - - -
Brinkman 2012 - - - - - - -
Skillington 2013 0.14(0.05-0.37) 0.07(0.02-0.27) 0.10(0.03-0.32) - - - -
Stelzer 2013 - - - - - - -
Andreas 2014 - - - - - - 0.06(0.01-0.40)
David 2014 0.14(0.05-0.36) 0.02(0.00-0.27)* 0.14(0.05-0.36) 0.14(0.05-0.36) - 0.02(0.00-0.27)* -
Le Guillou 2014 1.12(0.28-4.43) 0.56(0.08-3.94) 0.56(0.08-3.94) - - - -
Escarain 2015 0.15(0.05-0.47) 0.10(0.03-0.41) 0.10(0.03-0.41) 0.03(0.00-0.41)* 0.03(0.00-0.41)* 0.03(0.00-0.41)* -
Jacobsen 2015 - - - - - - -
Mastrobuoni 2015 0.10(0.03-0.32) 0.07(0.02-0.27) 0.07(0.02-0.27) - 0.02(0.00-0.27)* 0.14(0.05-0.36) -
Sievers 2015 - - - - - - -
Franke 2015 0.74(0.24-2.28) 0.74(0.24-2.28) 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)* 0.12(0.01-1.96)*
Carrel 2016 - - - - - - -
Karaskov 2016 0.81(0.55-1.20) 0.71(0.47-1.08) 0.10(0.03-0.30) 0.23(0.11-0.48) 0.03(0.00-0.23) 0.10(0.03-0.30) -
Mazine 2016 0.25(0.12-0.52) 0.07(0.02-0.28) 0.18(0.07-0.42) 0.18(0.07-0.42) 0.02(0.00-0.28)* 0.02(0.00-0.28)* -
Popelová 2016 - - - - - - -
Bouhout 2017 - - - - - - -
Pardo González 2017 - - - - - - -
Martin 2017 0.06(0.02-0.20) - - - - - -
Skoglund 2017 - - - - - - -
Pooled estimate (95%ci) 0.27(0.16-0.45) 0.18(0.09-0.39) 0.14(0.09-0.21) 0.17(0.11-0.27) 0.03(0.01-0.09) 0.10(0.01-0.67) 0.25(0.05-1.17)
Heterogeneity I^2=71.8%(p<0.001) I^2=74.0%(p<0.001) I^2=0.0%(p=0.867) I^2=0.0%(p=0.565) I^2=0.0%(p=0.958) I^2=91.6%(p<0.001) I^2=44.5%(p=0.144)
number of studies 15 12 11 7 7 9 4
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supplement 4. Calibration plot of the microsimulation model. Microsimula-
tion-based actuarial survival is plotted against observed pooled Kaplan-Meier 
survival rates in the all ages group (age- and sex-matched), excluding early 
mortality.
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supplement 5. Least squares regression of modeled survival vs. observed 
survival for estimation of excess mortality not directly related to valve-related 
events.
Hazard ratio1 sum of squared residuals2
all ages Pediatric adult
1.00 359.3 173.8 7063.2
1.05 417.2 208.4 8085.1
1.10 822.8 204.7 8605.5
1.20 1280.9 259.8 12633.2
Bold print indicates the selected model.
1Hazard ratio of background mortality + excess mortality relative to background mortality.
2Sum of squared residuals between microsimulation-based survival and survival observed in our meta-
analysis of Kaplan-Meier freedom from all-cause mortality.
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supplement 6. Univariable random effects meta-regression of natural log-
transformed outcome measures.
early mortality late mortality reintervention endocarditis Bleeding
β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value
study design (prospective/rct) -0.36(-0.86 - 0.14) 0.155 0.03(-0.35 - 0.41) 0.878 -0.38(-0.95 - 0.20) 0.197 -0.50(-1.31 - 0.31) 0.225 -1.59(-4.42 - 1.24) 0.270
Median year of surgery -0.04(-0.09 - 0.01) 0.105 0.03(-0.02 - 0.07) 0.303 0.02(-0.06 - 0.09) 0.636 0.06(-0.03 - 0.16) 0.179 -0.10(-0.44 - 0.24) 0.570
Mean follow-up (/year increase) -0.10(-0.15 - -0.04) <0.001 -0.05(-0.09 - -0.01) 0.012 -0.04(-0.10 - 0.02) 0.242 -0.17(-0.25 - -0.09) <0.001 -0.39(-0.62 - -0.15) 0.001
Mean age at surgery (/year increase) -0.02(-0.03 - -0.01) 0.003 0.01(0.00 - 0.02) 0.039 -0.03(-0.04 - -0.02) <0.001 0.00(-0.03 - 0.03) 0.814 0.00(-0.10 - 0.11) 0.940
Male -1.47(-4.38 - 1.44) 0.323 0.08(-2.17 - 2.34) 0.942 -1.00(-4.58 - 2.58) 0.585 2.51(-3.89 - 8.90) 0.442 *
urgent 2.23(-0.62 - 5.08) 0.125 3.71(1.77 - 5.65) <0.001 1.06(-2.26 - 4.37) 0.532 3.63(-0.26 - 7.52) 0.067 *
Preoperative nyHa/ross class
I/II -1.59(-3.03 - -0.14) 0.031 -1.35(-2.73 - 0.02) 0.053 -0.55(-1.55 - 0.45) 0.283 -1.72(-3.59 - 0.15) 0.071 -6.55(-13.90 - 0.81) 0.081
III/IV 1.59(0.15 - 3.03) 0.031 1.36(-0.02 - 2.74) 0.053 0.57(-0.45 - 1.58) 0.272 1.76(-0.09 - 3.61) 0.063 6.87(-0.17 - 13.90) 0.056
Hemodynamics
Aortic stenosis -0.70(-1.86 - 0.47) 0.243 0.40(-0.37 - 1.18) 0.308 -1.02(-2.18 - 0.13) 0.082 -1.08(-3.29 - 1.13) 0.339 0.75(-2.60 - 4.10) 0.660
Aortic regurgitation 0.06(-1.46 - 1.58) 0.940 -0.35(-1.43 - 0.73) 0.527 -0.92(-2.48 - 0.64) 0.248 -1.79(-4.87 - 1.28) 0.253 -2.35(-9.80 - 5.11) 0.537
Combined 0.60(-0.44 - 1.63) 0.258 0.00(-0.70 - 0.69) 0.998 1.39(0.31 - 2.46) 0.011 1.30(-0.83 - 3.43) 0.231 2.41(-2.53 - 7.34) 0.339
Bicuspid av -0.94(-2.23 - 0.35) 0.155 -0.24(-1.17 - 0.69) 0.611 -0.01(-1.82 - 1.80) 0.992 -2.17(-3.63 - -0.70) 0.004 -2.42(-6.87 - 2.03) 0.286
etiology
Congenital 0.08(-0.49 - 0.65) 0.788 -0.11(-0.62 - 0.40) 0.668 0.29(-1.09 - 1.66) 0.683 -0.22(-1.60 - 1.16) 0.754 -0.23(-2.27 - 1.81) 0.822
Degenerative/calcification -3.10(-5.94 - -0.26) 0.033 0.27(-1.55 - 2.09) 0.771 -1.05(-6.03 - 3.93) 0.681 -1.08(-6.30 - 4.14) 0.685 6.38(-4.26 - 17.02) 0.240
Rheumatic 0.58(-1.04 - 2.19) 0.485 0.46(-0.53 - 1.45) 0.362 0.50(-1.73 - 2.72) 0.661 1.99(-0.36 - 4.34) 0.096 1.61(-14.60 - 17.83) 0.845
Endocarditis 1.50(0.52 - 2.48) 0.003 1.75(0.95 - 2.55) <0.001 0.21(-1.45 - 1.88) 0.800 1.87(-0.13 - 3.88) 0.067 6.26(5.00 - 7.51) <0.001
Other/unknown -0.42(-2.08 - 1.24) 0.618 -0.07(-1.09 - 0.96) 0.895 -1.48(-5.13 - 2.16) 0.425 -0.14(-5.09 - 4.80) 0.955 -1.49(-4.79 - 1.81) 0.377
Previous cardiac intervention 0.44(-0.20 - 1.08) 0.180 -0.22(-0.70 - 0.26) 0.372 0.76(0.16 - 1.37) 0.014 1.22(-0.97 - 3.40) 0.275 0.92(-1.80 - 3.65) 0.506
AV intervention 0.40(-0.37 - 1.17) 0.309 0.07(-0.57 - 0.71) 0.830 1.53(0.77 - 2.29) <0.001 -0.30(-2.80 - 2.19) 0.812 -1.64(-5.42 - 2.14) 0.394
Percutaneous 0.17(-1.22 - 1.56) 0.815 0.62(-0.47 - 1.72) 0.266 1.43(0.19 - 2.67) 0.024 -1.59(-6.28 - 3.10) 0.507 -4.14(-12.42 - 4.14) 0.327
AV surgery 0.59(-1.00 - 2.18) 0.466 -0.04(-1.55 - 1.46) 0.955 1.77(-0.06 - 3.59) 0.057 -1.75(-5.84 - 2.33) 0.400 -1.47(-7.66 - 4.72) 0.642
AVR -3.02(-9.76 - 3.72) 0.380 0.25(-6.87 - 7.37) 0.946 -0.81(-10.40 - 8.79) 0.869 -3.82(-19.14 - 11.49) 0.625 -10.18(-32.97 - 12.61) 0.381
technique
Total root replacement 1.21(-0.14 - 2.56) 0.078 0.59(-0.34 - 1.52) 0.216 0.90(-0.49 - 2.29) 0.205 2.34(0.65 - 4.03) 0.007 3.57(-3.42 - 10.55) 0.317
Subcoronary -0.77(-4.39 - 2.85) 0.678 -3.40(-7.09 - 0.28) 0.070 -0.82(-5.49 - 3.85) 0.729 -2.76(-9.19 - 3.67) 0.399 -5.12(-33.98 - 23.74) 0.728
Inclusion cylinder -1.19(-3.21 - 0.83) 0.247 0.03(-1.59 - 1.64) 0.973 -0.59(-3.11 - 1.93) 0.647 -3.64(-6.59 - -0.68) 0.016 -0.61(-13.18 - 11.96) 0.924
rvot conduit
Allograft -1.18(-2.02 - -0.35) 0.005 -0.59(-1.42 - 0.24) 0.167 -0.18(-1.58 - 1.23) 0.804 -1.23(-3.08 - 0.62) 0.194 *
Bioprosthesis 0.65(-0.44 - 1.74) 0.240 0.56(-0.33 - 1.44) 0.216 0.18(-1.24 - 1.61) 0.801 1.55(0.56 - 2.54) 0.002 *
concomitant procedures -0.26(-2.42 - 1.89) 0.810 0.08(-1.58 - 1.73) 0.929 1.43(-1.07 - 3.92) 0.263 -2.60(-6.68 - 1.48) 0.212 -4.39(-10.92 - 2.14) 0.188
CABG 0.05(-2.85 - 2.95) 0.973 -1.67(-4.60 - 1.26) 0.264 0.78(-2.79 - 4.34) 0.670 -7.92(-28.65 - 12.80) 0.454 -7.35(-82.81 - 68.12) 0.849
Ascending aortic surgery -3.78(-5.87 - -1.68) <0.001 -2.06(-4.44 - 0.32) 0.090 -2.71(-5.93 - 0.52) 0.100 -2.29(-6.52 - 1.93) 0.288 -7.66(-27.55 - 12.23) 0.450
Annular enlargement procedure 0.99(-0.66 - 2.64) 0.239 -0.41(-2.03 - 1.21) 0.617 3.03(1.40 - 4.66) <0.001 -1.10(-7.87 - 5.66) 0.750 -5.17(-22.27 - 11.94) 0.554
Other valve repair or replacement 4.99(0.46 - 9.52) 0.031 -1.65(-6.16 - 2.86) 0.473 5.42(-1.81 - 12.65) 0.142 -13.69(-33.33 - 5.96) 0.172 28.30(22.63 - 33.97) <0.001
Other 1.49(-1.53 - 4.50) 0.334 0.54(-1.92 - 3.01) 0.667 2.52(-0.89 - 5.93) 0.147 2.18(-6.21 - 10.58) 0.610 -5.71(-34.03 - 22.60) 0.693
*Could not be assessed due to insufficient sample size. CI=confidence interval. RCT=randomized 
controlled trial. NYHA=New York Heart Association. AV=aortic valve. AVR=aortic valve replacement. 
RVOT=right ventricular outflow tract. CABG=coronary artery bypass grafting
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supplement 6. Univariable random effects meta-regression of natural log-
transformed outcome measures.
early mortality late mortality reintervention endocarditis Bleeding
β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value
study design (prospective/rct) -0.36(-0.86 - 0.14) 0.155 0.03(-0.35 - 0.41) 0.878 -0.38(-0.95 - 0.20) 0.197 -0.50(-1.31 - 0.31) 0.225 -1.59(-4.42 - 1.24) 0.270
Median year of surgery -0.04(-0.09 - 0.01) 0.105 0.03(-0.02 - 0.07) 0.303 0.02(-0.06 - 0.09) 0.636 0.06(-0.03 - 0.16) 0.179 -0.10(-0.44 - 0.24) 0.570
Mean follow-up (/year increase) -0.10(-0.15 - -0.04) <0.001 -0.05(-0.09 - -0.01) 0.012 -0.04(-0.10 - 0.02) 0.242 -0.17(-0.25 - -0.09) <0.001 -0.39(-0.62 - -0.15) 0.001
Mean age at surgery (/year increase) -0.02(-0.03 - -0.01) 0.003 0.01(0.00 - 0.02) 0.039 -0.03(-0.04 - -0.02) <0.001 0.00(-0.03 - 0.03) 0.814 0.00(-0.10 - 0.11) 0.940
Male -1.47(-4.38 - 1.44) 0.323 0.08(-2.17 - 2.34) 0.942 -1.00(-4.58 - 2.58) 0.585 2.51(-3.89 - 8.90) 0.442 *
urgent 2.23(-0.62 - 5.08) 0.125 3.71(1.77 - 5.65) <0.001 1.06(-2.26 - 4.37) 0.532 3.63(-0.26 - 7.52) 0.067 *
Preoperative nyHa/ross class
I/II -1.59(-3.03 - -0.14) 0.031 -1.35(-2.73 - 0.02) 0.053 -0.55(-1.55 - 0.45) 0.283 -1.72(-3.59 - 0.15) 0.071 -6.55(-13.90 - 0.81) 0.081
III/IV 1.59(0.15 - 3.03) 0.031 1.36(-0.02 - 2.74) 0.053 0.57(-0.45 - 1.58) 0.272 1.76(-0.09 - 3.61) 0.063 6.87(-0.17 - 13.90) 0.056
Hemodynamics
Aortic stenosis -0.70(-1.86 - 0.47) 0.243 0.40(-0.37 - 1.18) 0.308 -1.02(-2.18 - 0.13) 0.082 -1.08(-3.29 - 1.13) 0.339 0.75(-2.60 - 4.10) 0.660
Aortic regurgitation 0.06(-1.46 - 1.58) 0.940 -0.35(-1.43 - 0.73) 0.527 -0.92(-2.48 - 0.64) 0.248 -1.79(-4.87 - 1.28) 0.253 -2.35(-9.80 - 5.11) 0.537
Combined 0.60(-0.44 - 1.63) 0.258 0.00(-0.70 - 0.69) 0.998 1.39(0.31 - 2.46) 0.011 1.30(-0.83 - 3.43) 0.231 2.41(-2.53 - 7.34) 0.339
Bicuspid av -0.94(-2.23 - 0.35) 0.155 -0.24(-1.17 - 0.69) 0.611 -0.01(-1.82 - 1.80) 0.992 -2.17(-3.63 - -0.70) 0.004 -2.42(-6.87 - 2.03) 0.286
etiology
Congenital 0.08(-0.49 - 0.65) 0.788 -0.11(-0.62 - 0.40) 0.668 0.29(-1.09 - 1.66) 0.683 -0.22(-1.60 - 1.16) 0.754 -0.23(-2.27 - 1.81) 0.822
Degenerative/calcification -3.10(-5.94 - -0.26) 0.033 0.27(-1.55 - 2.09) 0.771 -1.05(-6.03 - 3.93) 0.681 -1.08(-6.30 - 4.14) 0.685 6.38(-4.26 - 17.02) 0.240
Rheumatic 0.58(-1.04 - 2.19) 0.485 0.46(-0.53 - 1.45) 0.362 0.50(-1.73 - 2.72) 0.661 1.99(-0.36 - 4.34) 0.096 1.61(-14.60 - 17.83) 0.845
Endocarditis 1.50(0.52 - 2.48) 0.003 1.75(0.95 - 2.55) <0.001 0.21(-1.45 - 1.88) 0.800 1.87(-0.13 - 3.88) 0.067 6.26(5.00 - 7.51) <0.001
Other/unknown -0.42(-2.08 - 1.24) 0.618 -0.07(-1.09 - 0.96) 0.895 -1.48(-5.13 - 2.16) 0.425 -0.14(-5.09 - 4.80) 0.955 -1.49(-4.79 - 1.81) 0.377
Previous cardiac intervention 0.44(-0.20 - 1.08) 0.180 -0.22(-0.70 - 0.26) 0.372 0.76(0.16 - 1.37) 0.014 1.22(-0.97 - 3.40) 0.275 0.92(-1.80 - 3.65) 0.506
AV intervention 0.40(-0.37 - 1.17) 0.309 0.07(-0.57 - 0.71) 0.830 1.53(0.77 - 2.29) <0.001 -0.30(-2.80 - 2.19) 0.812 -1.64(-5.42 - 2.14) 0.394
Percutaneous 0.17(-1.22 - 1.56) 0.815 0.62(-0.47 - 1.72) 0.266 1.43(0.19 - 2.67) 0.024 -1.59(-6.28 - 3.10) 0.507 -4.14(-12.42 - 4.14) 0.327
AV surgery 0.59(-1.00 - 2.18) 0.466 -0.04(-1.55 - 1.46) 0.955 1.77(-0.06 - 3.59) 0.057 -1.75(-5.84 - 2.33) 0.400 -1.47(-7.66 - 4.72) 0.642
AVR -3.02(-9.76 - 3.72) 0.380 0.25(-6.87 - 7.37) 0.946 -0.81(-10.40 - 8.79) 0.869 -3.82(-19.14 - 11.49) 0.625 -10.18(-32.97 - 12.61) 0.381
technique
Total root replacement 1.21(-0.14 - 2.56) 0.078 0.59(-0.34 - 1.52) 0.216 0.90(-0.49 - 2.29) 0.205 2.34(0.65 - 4.03) 0.007 3.57(-3.42 - 10.55) 0.317
Subcoronary -0.77(-4.39 - 2.85) 0.678 -3.40(-7.09 - 0.28) 0.070 -0.82(-5.49 - 3.85) 0.729 -2.76(-9.19 - 3.67) 0.399 -5.12(-33.98 - 23.74) 0.728
Inclusion cylinder -1.19(-3.21 - 0.83) 0.247 0.03(-1.59 - 1.64) 0.973 -0.59(-3.11 - 1.93) 0.647 -3.64(-6.59 - -0.68) 0.016 -0.61(-13.18 - 11.96) 0.924
rvot conduit
Allograft -1.18(-2.02 - -0.35) 0.005 -0.59(-1.42 - 0.24) 0.167 -0.18(-1.58 - 1.23) 0.804 -1.23(-3.08 - 0.62) 0.194 *
Bioprosthesis 0.65(-0.44 - 1.74) 0.240 0.56(-0.33 - 1.44) 0.216 0.18(-1.24 - 1.61) 0.801 1.55(0.56 - 2.54) 0.002 *
concomitant procedures -0.26(-2.42 - 1.89) 0.810 0.08(-1.58 - 1.73) 0.929 1.43(-1.07 - 3.92) 0.263 -2.60(-6.68 - 1.48) 0.212 -4.39(-10.92 - 2.14) 0.188
CABG 0.05(-2.85 - 2.95) 0.973 -1.67(-4.60 - 1.26) 0.264 0.78(-2.79 - 4.34) 0.670 -7.92(-28.65 - 12.80) 0.454 -7.35(-82.81 - 68.12) 0.849
Ascending aortic surgery -3.78(-5.87 - -1.68) <0.001 -2.06(-4.44 - 0.32) 0.090 -2.71(-5.93 - 0.52) 0.100 -2.29(-6.52 - 1.93) 0.288 -7.66(-27.55 - 12.23) 0.450
Annular enlargement procedure 0.99(-0.66 - 2.64) 0.239 -0.41(-2.03 - 1.21) 0.617 3.03(1.40 - 4.66) <0.001 -1.10(-7.87 - 5.66) 0.750 -5.17(-22.27 - 11.94) 0.554
Other valve repair or replacement 4.99(0.46 - 9.52) 0.031 -1.65(-6.16 - 2.86) 0.473 5.42(-1.81 - 12.65) 0.142 -13.69(-33.33 - 5.96) 0.172 28.30(22.63 - 33.97) <0.001
Other 1.49(-1.53 - 4.50) 0.334 0.54(-1.92 - 3.01) 0.667 2.52(-0.89 - 5.93) 0.147 2.18(-6.21 - 10.58) 0.610 -5.71(-34.03 - 22.60) 0.693
*Could not be assessed due to insufficient sample size. CI=confidence interval. RCT=randomized 
controlled trial. NYHA=New York Heart Association. AV=aortic valve. AVR=aortic valve replacement. 
RVOT=right ventricular outflow tract. CABG=coronary artery bypass grafting
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aBstract
Background
To support decision-making in aortic valve replacement in nonelderly adults, we aim to 
provide a comprehensive overview of reported outcome after bioprosthetic aortic valve 
replacement and to translate this to age-specific patient outcome estimates.
Methods
A systematic review was conducted for papers reporting clinical outcome after aortic 
valve replacement with currently available bioprostheses in patients with a mean age 
<55 years, published between January 1, 2000, and January 9, 2016. Pooled reported 
event rates and time-to-event data were pooled and entered into a microsimulation 
model to calculate life expectancy and lifetime event risk for the ages of 25, 35, 45, and 
55 years at surgery.
results
Nineteen publications were included, encompassing a total of 2686 patients with 21 117 
patient-years of follow-up (pooled mean follow-up: 7.9±4.2 years). Pooled mean age at 
surgery was 50.7±11.0 years. Pooled early mortality risk was 3.30% (95% CI, 2.39-4.55), 
late mortality rate was 2.39%/y (95% CI, 1.13-2.94), reintervention 1.82%/y (95% CI, 
1.31-2.52), structural valve deterioration 1.59%/y (95% CI, 1.21-2.10), thromboembolism 
0.53%/y (95% CI, 0.42-0.67), bleeding 0.22%/y (95% CI, 0.16-0.32), endocarditis 0.48%/y 
(95% CI, 0.37-0.62), and 20-year pooled actuarial survival was 58.7% and freedom from 
reintervention was 29.0%. Median time to structural valve deterioration was 17.3 years 
and median time to all-cause first reintervention was 16.9 years. For a 45-year-old adult, 
for example, this translated to a microsimulation-based estimated life expectancy of 21 
years (general population: 32 years) and lifetime risk of reintervention of 78%, structural 
valve deterioration 71%, thromboembolism 12%, bleeding 5%, and endocarditis 9%.
conclusions
Aortic valve replacement with bioprostheses in young adults is associated with high 
structural valve deterioration and reintervention rates and low, though not absent, 
hazards of thromboembolism and bleeding. Foremostly, most patients will require one 
or more reinterventions during their lifetime and survival is impaired in comparison with 
the age- and sex-matched general population. Prosthesis durability remains the main 
concern in nonelderly patients.
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introDuction
When valve repair is not possible, surgical aortic valve replacement (AVR) is the most 
widely used treatment for aortic valve disease in nonelderly adults. Two types of valve 
substitutes are available for AVR: mechanical and biological valves. Mechanical valves 
are often recommended in nonelderly adults because of the lower, though not absent, 
rate of reoperation compared with biological valves. They do, however, require lifelong 
anticoagulation because of their increased thrombogenicity, which gives rise to a sub-
stantial risk of thromboembolic and bleeding complications that may have an important 
impact on quality of life.1 Furthermore, patients are faced with International Normalized 
Ratio regulation, valve sound and, in women of childbearing age, the potential hazards 
of anticoagulation during pregnancy. Biological alternatives, such as bioprostheses (ie, 
xenografts) and the Ross procedure, do not require long-term anticoagulation unless 
another indication is present. However, they are subject to valve deterioration over time 
and young patients, in particular, may require a reoperation later in life.
Improvements in the design of bioprostheses with hypothesized durability benefits, 
enthusiasm for the prospect of transcatheter valve-in-valve implantation as an option 
for reintervention and the increasing role of shared decision-making in valve selection 
has led to an increase in the use of bioprostheses in increasingly younger patients. 
However, reports on long-term outcome after bioprosthetic AVR in nonelderly adults 
are scattered. This makes it difficult to draw inferences on what patients can expect after 
bioprosthetic AVR, information essential in guiding decision-making. Furthermore, with 
growing interest in transcatheter aortic valve implantation (TAVI) as a primary interven-
tion in increasingly younger and lower-risk patients, there is an urgent need for insight 
into long-term outcome of the golden standard in nonelderly adult patients (surgical 
AVR) as a benchmark.
In this light, this systematic review and meta-analysis aims to provide a comprehensive 
overview of reported outcome and calculates microsimulation-based agespecific esti-
mates of life expectancy and lifetime risk of valve-related events.
MetHoDs
search strategy and selection of studies
This systematic review was conducted according to the PRISMA guidelines2 and reg-
istered in the PROSPERO registry (CRD42017079929). The data, analytic methods, and 
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study materials will be made available to other researchers for the purposes of repro-
ducing the results or replicating the procedure on request to the corresponding author.
On September 1, 2016, Embase, MEDLINE, Cochrane Central, and Google Scholar data-
bases were searched by a biomedical information specialist using keywords about AVR 
with bioprostheses (Supplement 1).
All studies were screened by 2 independent reviewers (J.R.G. Etnel and S.A. Huygens). 
Observational studies and randomized controlled trials reporting clinical outcome 
after AVR with currently available bioprostheses (ie, xenografts) in patients with a mean 
age ≥18 and ≤55 years published in English after January 1, 2000, were considered for 
inclusion. Studies limited to patients with preexisting comorbidities (dysfunction of 
extracardiac organ systems) or a history of previous AVR were excluded. Studies with a 
study size <20 patients or focusing only on certain prosthesis sizes were also excluded. 
In case of multiple publications on overlapping study populations, the publication 
with the greatest total follow-up in patient-years and overall completeness of data was 
included for each outcome of interest separately. In case of disagreement between the 
reviewers, a consensus was negotiated.
Data extraction
Microsoft Office Excel 2010 (Microsoft Corp, Redmond, WA) was used for data extraction. 
Data were extracted independently by 2 reviewers (P. Grashuis and B. Pekbay). After data 
extraction, each reviewer verified the other reviewer’s data entries and data entries were 
also verified by a third reviewer (J.R.G. Etnel). Recorded study characteristics, baseline 
patient and operative characteristics and outcome events are listed in Supplement 1.
Morbidity and mortality were documented according to the 2008 guidelines by Akins 
et al.3 Early outcome events were defined as occurring within the first 30 postoperative 
days, regardless of the patient’s location, and late outcome events were defined as oc-
curring after the first 30 postoperative days. Structural valve deterioration was defined 
as dysfunction or deterioration intrinsic to the operated valve (exclusive of infection or 
thrombosis), as determined by reoperation, autopsy, or clinical investigation (including 
periodic echocardiographic surveillance). If the total follow-up duration in patient-years 
was not reported, it was calculated by multiplying the number of patients with the mean 
follow-up duration of that study.
statistical analyses
Statistical software used is listed in Supplement 1.
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Continuous variables are presented as mean±SD. Categorical variables are presented as 
counts and percentages. Linearized event occurrence rates are presented as percent-
ages per year.
Pooled baseline patient characteristics were calculated with the use of sample size 
weighting. Early risks of mortality and linearized occurrence rates of late morbidity and 
mortality were calculated for each individual study and pooled with the use of inverse 
variance weighting in a random-effects model according to the DerSimonian and 
Laird method. Outcomes were pooled on a logarithmic scale, as the Shapiro-Wilk test 
revealed a significantly skewed distribution among the included studies in the major-
ity of outcome measures. Inverse variance weighting was conducted according to the 
number of patients for early mortality and according to the number of patient-years 
of follow-up for late events. In case a particular event was reported not to occur in an 
individual study, it was assumed that 0.5 patient experienced that event for the purpose 
of inverse variance weighting. The Cochran Q statistic and I2 statistic were used to assess 
heterogeneity between studies. Potential causes of heterogeneity were explored by 
investigating the effect of all baseline patient characteristics and operative details listed 
in Table 1 as well as study design (retrospective versus prospective/randomized con-
trolled trial) and pooled median year of surgery by means of univariable random-effects 
meta-regression. The influence of potential publication bias on pooled outcome was 
investigated by conducting sensitivity analyses by temporarily excluding the smallest 
quartile (by sample size) of included studies in all ages group.
kaplan-Meier meta-analysis
Pooled Kaplan-Meier time-to-event meta-analysis was conducted by extrapolating and 
pooling estimates of individual patient time-to-event data from published Kaplan-Meier 
curves. Published Kaplan-Meier curves were digitized and an estimate of the individual 
patient time-to-event data was then extrapolated from the digitized curve coordinates, 
assuming a constant rate of censorship between each time point at which the number 
of patients at risk was specified.4 If there were no Kaplan-Meier curves available, but 
time points of each event were reported or there were no events, the individual patient 
time-to-event data was manually reconstructed up to a maximum follow-up of the 
mean follow-up + 2 SDs, under the same assumption of a constant rate of censorship. 
Reconstructed individual patient time-to-event data of each study were then combined.
Microsimulation
A microsimulation model based on the pooled outcome estimates of our meta-analysis 
was used to calculate age-specific life expectancy and lifetime risk of valve-related 
morbidity.5-7
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table 1. Pooled baseline patient characteristics and operative details
Pooled estimate no. of studies
Mean age, y 50.7±11.0 17
Male 53.1% (0.2-84.5) 16
Mean follow-up, y 7.9±4.2 0
emergency 5.9% (0.0-20.6) 5
Preoperative nyHa class
I/II 56.1% (24.8-79.5) 11
III/IV 43.9% (20.5-81.0) 11
Hemodynamics
Aortic stenosis 41.2% (19.6-77.1) 9
Aortic regurgitation 39.6% (24.6-51.8) 10
Combined 19.2% (11.9-49.1) 8
atrial fibrillation 6.1% (0.7-18.9) 8
Bicuspid av 14.7% (13.8-18.9) 2
cause
Congenital 10.7% (0.0-61.9) 7
Degenerative/calcification 36.1% (6.9-84.5) 6
Rheumatic 30.4% (1.6-88.9) 8
Endocarditis 13.2% (0.0-11.3) 13
Other/Unknown 9.6% (0.0-30.4) 6
Previous cardiac intervention 8.0% (0.0-13.0) 8
AV intervention 4.9% (0.0-9.8) 5
AVR 2.7% (0.0-9.8) 4
Prosthesis
Porcine 52.0% (0.0-100.0) 18
Bovine pericardial 47.9% (0.0-100.0) 18
Stented 78.2% (0.0-100.0) 18
Stentless 21.7% (0.0-100.0) 18
concomitant procedures
CABG 11.8% (0.0-27.0) 16
Ascending aortic surgery 8.2% (0.0-17.5) 9
Annular enlargement procedure 7.5% (0.0-19.7) 6
Other valve repair or replacement 11.9% (0.0-26.9) 12
Other 7.3% (0.0-21.1) 8
Data presented as mean±SD or percentage (range). The number of studies represents the number of stud-
ies in which each respective variable was reported. AV indicates aortic valve; AVR, aortic valve replacement; 
CABG, coronary artery bypass grafting; and NYHA, New York Heart Association.
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The operative mortality risk, the occurrence rate of each valve-related event and the 
risk of mortality and reintervention as a direct result of each of these valve-related 
events were obtained from our meta-analysis. The occurrence rate of structural valve 
deterioration was modeled by fitting a Weibull distribution to our pooled time-to-event 
data, for bleeding a log-normal distribution was used, and for thromboembolism and 
endocarditis a gamma distribution. The occurrence rates of all other events were as-
sumed to be linear. Additional excess mortality not directly resulting from valve-related 
events was estimated separately for the age groups 20 to 40, 40 to 50, and 50 to 60 
years, based on previously published age-specific survival after bioprosthetic AVR, using 
the least squares method (details in Supplement 1).8,9 The background mortality of the 
general population was obtained for the pooled median year of intervention among 
included studies (1998, assuming a constant incidence rate over time in each study) 
and for the regions that the majority of the included study population originated from 
(North America, 41% of patients and Europe, 30% of patients).10,11
To obtain estimates of life expectancy and lifetime risk of valve-related morbidity, tak-
ing into account both first-order uncertainty (random variability in outcomes between 
identical patients) and second-order uncertainty (uncertainty in the input parameter 
estimates), probabilistic sensitivity analysis was conducted. The microsimulation model 
was run iteratively for 500 simulations with a sample size of 1000 patients per simulation 
(these amounts were based on the method described by O’Hagan et al12). In each of the 
500 simulations, the values of the input parameters were randomly drawn from distribu-
tions corresponding with each parameter’s point estimate and variance, obtained from 
the meta-analysis as described above. This yielded a complete set of outcome estimates 
for each of the 500 simulated patient populations. For each outcome measure, the mean 
of outcome estimates across all 500 simulated populations was considered the point 
estimate of outcome, and the 2.5th and 97.5th percentile were considered the lower and 
upper limits of the 95% credible interval, respectively. To obtain age-specific estimates, 
this process was repeated separately for the specific ages 25, 35, 45, and 55 years and at 
the male/female ratio obtained from our meta-analysis (53.1% male).
For the purposes of internal validation, the model was additionally run for 10 000 itera-
tions at the pooled mean age (50.7 years) and pooled male/female ratio (53.1% male) 
from our meta-analysis. The actuarial survival curve obtained from this model was then 
plotted against the pooled overall survival curve observed in our Kaplan-Meier meta-
analysis, excluding early mortality.
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software
Meta-analysis of baseline patient and study characteristics and event risks and linear-
ized occurrence rates were performed in Microsoft Office Excel 2011 (Microsoft Corp, 
Redmond, WA). Published Kaplan-Meier curves were digitized using Engauge Digitizer 
(version 10.3, http://markummitchell. github.io/engauge-digitizer). Extrapolation of 
estimated individual patient time-to-event data from the digitized curves, meta-analysis 
thereof, microsimulation and metaregression were performed in R statistical software 
(version 3.3.2, R Development Core Team, R Foundation for Statistical Computing, Vi-
enna, Austria).
results
The systematic literature search identified 4105 publications, of which 19 were included 
in the meta-analysis, encompassing a total of 2686 patients with 21 117 patient-years of 
follow-up (pooled mean follow- up: 7.9±4.2 years; Figure 1).13-31 Supplement 2 represents 
the characteristics of the included studies.
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and endocarditis a gamma distribution. The occurrence rates 
of all other events were assumed to be linear. Additional ex-
cess mortality not directly resulting from valve-related events 
was estimated separately for the age groups 20 to 40, 40 to 
50, and 50 to 60 years, based on previously published age-spe-
cific survival after bioprosthetic AVR, using the least squares 
method (details in Methods in the Data Supplement).8,9 The 
background mortality of the general population was obtained 
for the pooled median year of intervention among included 
studies (1998, assuming a constant incidence rate over time 
in each study) and for the regions that the majority of the 
included study population originated from (North America, 
41% of patients and Europe, 30% of patients).10,11
To obtain estimates of life expectancy and lifetime risk of 
valve-related morbidity, taking into account both first-order 
uncertainty (random variability in outcomes between iden-
tical patients) and second-order uncertainty (uncertainty in 
the input parameter estimates), probabilistic sensitivity anal-
ysis was conducted. The microsimulation model was run itera-
tively for 500 simulations with a sample size of 1000 patients 
per simulation (these mounts were ba ed o  th  method 
described by O’Hagan et al12). In each of th 500 simulations, 
the values of the input param ters were randomly dr wn
from distributions corresponding with e ch param ter’s point 
estimate and variance, obtained fro  the meta-analysis as 
described above. This yielded a complete set of outcome 
estimates for each of the 500 simulated patient populations. 
For each outcome measure, the mean of outcome estimates 
across all 500 simulated populations was considered the point 
estimate of outcome, and the 2.5th and 97.5th percentile 
were considered the lower and upper limits of the 95% cred-
ible interval, respectively. To obtain age-specific estimates, this 
process was repeated separately for the specific ages 25, 35, 
45, and 55 years and at the male/female ratio obtained from 
our meta-analysis (53.1% m le).
F r the purposes of internal v lidation, the model was ad-
di ionally run for 10 000 it rations at the pooled mean age 
(50.7 years) and pooled male/female ratio (53.1% male) from 
our meta-analysis. The actuarial survival curve obtained from 
this model was then plotted against the pooled overall sur-
vival curve observed in our Kaplan–Meier meta-analysis, ex-
cluding early mortality.
Software
Meta-analysis of baseline patient and study characteristics and 
event risks and linearized occurrence rates were performed 
in Microsoft Office Excel 2011 (Microsoft Corp, Redmond, 
WA). Published Kaplan–Meier curves were digitized using 
Engauge Digitizer (version 10.3, http://markummitchell.
github.io/engauge-digitizer). Extrapolation of estimated 
individual patient time-to-event data from the digitized 
curves, meta-analysis thereof, microsimulation and meta-
regression were performed in R statistical software (version 
3.3.2, R Development Core Team, R Foundation for Statistical 
Computing, Vienna, Austria).
RESULTS
The systematic literature search identified 4105 pub-
lications, of which 19 were included in the meta-
analysis, encompassing a total of 2686 patients with 
21 117 patient-years of follow-up (pooled mean fol-
low-up: 7.9±4.2 years; Figure  1).13–31 Table  1 in the 
Data Supplement represents the characteristics of the 
included studies.
Pooled baseline patient characteristics are shown in 
Table 1.
Pooled risks of early mortality and pooled linear-
ized occurrence rates of late mortality and late morbid 
events are presented in Table 2 (individual study esti-
mates are presented in Table 2 in the Data Supplement). 
Early morbidity, with the exception of reexploration for 
bleeding and thromboembolism, as well as late pace-
maker implantation were not reported consistently 
across >1 study and could thus not be included in the 
analyses. Pooled Kaplan–Meier curves of freedom from 
all-cause mortality and morbidity are shown in Fig-
ures 2 through 5. Median time to structural valve dete-
rioration was 17.3 years, and median time to all-cause 
first reintervention was 16.9 years.
Microsimulation-based age-specific estimates of 
lifetime risk of valve-related morbidity and life expec-
tancy are shown in Figures 6 and 7, respectively. The 
microsimulation model calibrated well with the pooled 
mortality observed in our meta-analysis (Figure 1 in the 
Data Supplement).
Excess mortality not directly related to valve-related 
events was considerable; for patients aged 20 to 40 
years at surgery the hazard ratio for background + ex-
cess mortality versus background mortality was 3.6, for 
40- to 50-year-olds hazard ratio=2.7, and for 50- to
60-year-olds hazard ratio=1.7 (Table 3 in the Data Sup-
plement). For a 25-year-old, life expectancy (32.5 years)Figure 1. Flowchart of study selection.
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figure 1. Flowchart of study selection.
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Pooled baseline patient characteristics are shown in Table 1.
Pooled risks of early mortality and pooled linearized occurrence rates of late mortality 
and late morbid events are presented in Table 2 (individual study estimates are pre-
sented in Supplement 3). Early morbidity, with the exception of reexploration for bleed-
ing and thromboembolism, as well as late pacemaker implantation were not reported 
consistently across >1 study and could thus not be included in the analyses. Pooled 
Kaplan-Meier curves of freedom from all-cause mortality and morbidity are shown in 
Figures 2 through 5. Median time to structural valve deterioration was 17.3 years, and 
median time to all-cause first reintervention was 16.9 years.
Microsimulation-based age-specific estimates of lifetime risk of valve-related morbidity 
and life expectancy are shown in Figures 6 and 7, respectively. The microsimulation model 
calibrated well with the pooled mortality observed in our meta-analysis (Supplement 4).
Excess mortality not directly related to valve-related events was considerable; for pa-
tients aged 20 to 40 years at surgery the hazard ratio for background + excess mortality 
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although limited sample size did not allow for inclusion 
of all covariates in the analysis.
DISCUSSION
This study shows that AVR with bioprostheses in young 
adults is associated with high rates of structural valve de-
terioration and reintervention, with almost all patients 
aged 20 to 40 years at surgery projected to undergo one 
or more reinterventions during their lifetime and ≈60% 
to 75% of patients aged 40 to 60 years at surgery. Al-
though early mortality is low, long-term survival is im-
paired, with a life expectancy of ≈60% to 75% of the life 
expectancy in the age- and sex-matched general popu-
lation. Thromboembolism and bleeding rates are lower 
than after mechanical AVR, but not zero, with a lifetime 
thromboembolism risk of ≈10% to 20% and bleeding 
risk of 5% to 10%, depending on age at surgery.
Figure 2. Pooled Kaplan–Meier freedom from all-cause mortality of the 
study population compared with the age- and sex-matched general 
population.  
AVR indicates aortic valve replacement.
Figure 3. Pooled Kaplan–Meier freedom from reintervention and struc-
tural valve deterioration (SVD).  
AVR indicates aortic valve replacement.
Figure 4. Pooled Kaplan–Meier freedom from thromboembolism and 
bleeding.  
AVR indicates aortic valve replacement.
Figure 5. Pooled Kaplan–Meier freedom from endocarditis.  
AVR indicates aortic valve replacement.
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figure 2. Pooled Kaplan-Meier freedom from all-cause mortality of the study population compared with 
the age- and sex-matched general population.
AVR indicates aortic valve replacement.
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versus background mortality was 3.6, for 40- to 50-year-olds hazard ratio=2.7, and for 
50- to 60-year-olds hazard ratio=1.7 (Supplement 5). For a 25-year-old, life expectancy 
(32.5 years) was 64.1% of that in the age- and sex-matched general population (50.7 
years), for a 35-year-old 61.6% (25.5 versus 41.3 years), 45-year-old 64.9% (21.0 versus 
32.3 years), and 55-year-old 75.0% (23.9 versus 23.9 years).
Sensitivity analyses showed that any eventual publication bias did not substantially 
influence our pooled outcomes, as pooled outcomes remained largely unchanged after 
temporary exclusion of the smallest quartile of studies by sample size (before versus after 
exclusion: early mortality [3.30% versus 3.13%], late mortality [2.39%/y versus 2.31%/y], 
reintervention [1.82%/y versus 1.66%/y], structural valve deterioration [1.59%/y versus 
1.25%/y], endocarditis [0.48%/y versus 0.48%/y], thromboembolism [0.53%/y versus 
0.50%/y], and bleeding [0.22%/y versus 0.20%/y]).
Sensitivity analysis including only studies with a mean age ≤50 years (n=9; Supplement 
6), compared with our main analyses of all studies with a mean age of ≤55 years (n=19), 
revealed higher early mortality (4.59% versus 3.30%, respectively), lower late mortal-
ity (1.61%/y versus 2.39%/y) and comparable rates of reintervention (1.69%/y versus 
table 2. Pooled Outcome Estimates
Pooled estimate (95%ci) Heterogeneity no. of studies
early outcome
Early mortality (%) 3.30 (2.39-4.55) I2=41.7% (P=0.051) 14
Reexploration for bleeding (%) 4.08 (1.96-8.51) I2=71.4% (P=0.007) 5
Thromboembolism (%) 1.60 (0.89-2.87) I2=0.0% (P=0.930) 4
late outcome
Late mortality (%/y) 2.39 (1.13-2.94) I2=75.0% (P<0.001) 15
 Cardiac (%/y) 0.96 (0.71-1.29) I2=52.4% (P=0.017) 12
 Valve-related (%/y) 0.60 (0.37-0.98) I2=55.5% (P=0.017) 10
 SUD (%/y) 0.30 (0.12-0.76) I2=66.0% (P=0.004) 8
Reintervention (%/y) 1.82 (1.31-2.52) I2=88.9% (P<0.001) 17
SVD (%/y) 1.59 (1.21-2.10) I2=74.4% (P<0.001) 15
NSVD (%/y) 0.24 (0.10-0.58) I2=0.0% (P=0.749) 2
Endocarditis (%/y) 0.48 (0.37-0.62) I2=0.0% (P=0.535) 9
Thromboembolism (%/y) 0.53 (0.42-0.67) I2=7.5% (P=0.372) 12
Valve thrombosis (%/y) 0.07 (0.02-0.20) I2=0.0% (P=0.545) 5
Bleeding (%/y) 0.22 (0.16-0.32) I2=0.0% (P=0.619) 10
Data presented as percentage (95% CI) or linearized occurrence rate (95% CI). The number of studies repre-
sents the number of studies in which each respective variable was reported. NSVD indicates nonstructural 
valve dysfunction; SUD, sudden unexplained death; and SVD, structural valve degeneration.
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1.82%/y), structural valve deterioration (1.28%/y versus 1.59%/y), endocarditis (0.43%/y 
versus 0.48%/y), thromboembolism (0.50%/y versus 0.53%/y), and bleeding (0.19%/y 
versus 0.22%/y). Studies with a lower mean age had an earlier median year of surgery 
(Pearson r=0.60), more rheumatic cause (Pearson r=−0.89), higher preoperative New 
York Heart Association class (Pearson r=−0.66), more concomitant annular enlargement 
procedures (Pearson r=−0.78).
Heterogeneity
There was substantial heterogeneity in reexploration for bleeding, late mortality, rein-
tervention, and structural valve deterioration.
Univariable random-effects meta-regression (Supplement 7) showed that studies re-
porting higher late mortality rates included cohorts with a higher mean age (P=0.006), 
a higher proportion of congenital cause (P=0.001; moderate correlation with higher 
proportion of prior surgery, Pearson r=0.44), more frequent use of bovine pericardial 
prostheses as opposed to porcine prostheses (P=0.048; moderate correlation with higher 
age, Pearson r=0.48), and less frequent annular enlargement procedures (P<0.001).
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although limited sample size did not allow for inclusion 
of all covariates in the analysis.
DISCUSSION
This study shows that AVR with bioprostheses in young 
adults is associated with high rates of structural valve de-
terioration and reintervention, with almost all patients 
aged 20 to 40 years at surgery projected to undergo one 
or more reinterventions during their lifetime and ≈60% 
to 75% of patients aged 40 to 60 years at surgery. Al-
though early mortality is low, long-term survival is im-
paired, with a life expectancy of ≈60% to 75% of the life 
expectancy in the age- and sex-matched general popu-
lation. Thromboembolism and bleeding rates are lower 
than after mechanical AVR, but not zero, with a lifetime 
thromboembolism risk of ≈10% to 20% and bleeding 
risk of 5% to 10%, depending on age at surgery.
Figure 2. Pooled Kaplan–Meier freedom from all-cause mortality of the 
study population compared with the age- and sex-matched general 
population.  
AVR indicates aortic valve replacement.
Figure 3. Pooled Kaplan–Meier freedom from reintervention and struc-
tural valve deterioration (SVD).  
AVR indicates aortic valve replacement.
Figure 4. Pooled Kaplan–Meier freedom from thromboembolism and 
bleeding.  
AVR indicates aortic valve replacement.
Figure 5. Pooled Kaplan–Meier freedom from endocarditis.  
AVR indicates aortic valve replacement.
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figure 3. Pooled Kaplan-Meier freedom from reintervention and struc-tural valve deterioration (SVD).
AVR indicates aortic valve replacement.
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although limited sample size did not allow for inclusion 
of all covariates in the analysis.
DISCUSSION
This study shows that AVR with bioprostheses in young 
adults is associated with high rates of structural valve de-
terioration and reintervention, with almost all patients 
aged 20 to 40 years at surgery projected to undergo one 
or more reinterventions during their lifetime and ≈60% 
to 75% of patients aged 40 to 60 years at surgery. Al-
though early mortality is low, long-term survival is im-
paired, with a life expectancy of ≈60% to 75% of the life 
expectancy in the age- and sex-matched general popu-
lation. Thromboembolism and bleeding rates are lower 
than after mechanical AVR, but not zero, with a lifetime 
thromboembolism risk of ≈10% to 20% and bleeding 
risk of 5% to 10%, depending on age at surgery.
Figure 2. Pooled Kaplan–Meier freedom from all-cause mortality of the 
study population compared with the age- and sex-matched general 
population.  
AVR indicates aortic valve replacement.
Figure 3. Pooled Kaplan–Meier freedom from reintervention and struc-
tural valve deterioration (SVD).  
AVR indicates aortic valve replacement.
Figure 4. Pooled Kaplan–Meier freedom from thromboembolism and 
bleeding.  
AVR indicates aortic valve replacement.
Figure 5. Pooled Kaplan–Meier freedom from endocarditis.  
AVR indicates aortic valve replacement.
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figure 5. Pooled Kaplan-Meier freedom from endocarditis.
AVR indicates aortic valve replacement.
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although limited sample size did not allow for inclusion 
of all covariates in the analysis.
DISCUSSION
This study shows that AVR with bioprostheses in young 
adults is associated with high rates of structural valve de-
terioration and reintervention, with almost all patients 
aged 20 to 40 years at surgery projected to undergo one 
or more reinterventions during their lifetime and ≈60% 
to 75% of patients aged 40 to 60 years at surgery. Al-
though early mortality is low, long-term survival is im-
paired, with a life expectancy of ≈60% to 75% of the life 
expectancy in the age- and sex-matched general popu-
lation. Thromboembolism and bleeding rates are lower 
than after mechanical AVR, but not zero, with a lifetime 
thromboembolism risk of ≈10% to 20% and bleeding 
risk of 5% to 10%, depending on age at surgery.
Figure 2. Pooled Kaplan–Meier freedom from all-cause mortality of the 
study population compared with the age- and sex-matched general 
population.  
AVR indicates aortic valve replacement.
Figure 3. Pooled Kaplan–Meier freedom from reintervention and struc-
tural valve deterioration (SVD).  
AVR indicates aortic valve replacement.
Figure 4. Pooled Kaplan–Meier freedom from thromboembolism and 
bleeding.  
AVR indicates aortic valve replacement.
Figure 5. Pooled Kaplan–Meier freedom from endocarditis.  
AVR indicates aortic valve replacement.
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figure 4. Pooled Kaplan-Meier freedom from thromboembolism and bleeding.
AVR indicates aortic valve replacement.
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Studies reporting higher late reintervention rates included cohorts with a lower propor-
tion of rheumatic cause (P=0.014).
Studies reporting higher rates of structural valve deterioration included cohorts with an 
earlier year of surgery (P=0.03), longer mean follow-up (P=0.007), a higher proportion of 
degenerative/calcific cause (P=0.037), and lower preoperative New York Heart Associa-
tion class (P=0.012; strong correlation with higher proportion of degenerative/calcific 
cause, Pearson r=−0.92).
Differences in study design, sex, urgency, hemodynamics, and previous interventions 
were not associated with heterogeneity in any of these outcome measures.
No associations were found between study/baseline patient characteristics and reex-
ploration for bleeding, although limited sample size did not allow for inclusion of all 
covariates in the analysis.
Etnel et al; Bioprosthetic AVR in Nonelderly Adul s
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Mortality
Our results show that bioprosthetic AVR in young adults 
is associated with low early mortality (3.30%), although 
late mortality is high (2.39%/y) and thus life expectancy 
is impaired compared with the general population. This 
late mortality is higher than the late mortality previ-
ously reported for the Ross procedure (0.64%/y) and 
mechanical AVR (1.55%/y) in young adults.1,32
This may be explained in part by bioprosthetic AVR 
having the highest overall reintervention rates of the 
3 in combination with higher thromboembolism and 
bleeding rates than after the Ross procedure, with a 
subsequently higher valve-related mortality.
Besides higher valve-related mortality, excess mor-
tality not directly related to valve-related events is also 
higher than after the Ross procedure.33 The less favora-
ble hemodynamics of bioprostheses may play a role in 
this observed difference.34 Differences in preoperative 
patient characteristics should also be taken into account. 
Compared with adults undergoing the Ross procedure, 
bioprosthetic AVR patients are on average slightly older, 
more frequently have degenerative and rheumatic valve 
disease, and more frequently undergo concomitant pro-
cedures, but on the contrary, also have had less prior 
surgery, and undergo less concomitant aortic surgery.33
Comparison of our findings with mortality after aor-
tic valve repair is difficult, because of a sparsity of avail-
able outcome data, disparity in indications and a lack of 
standardization in data reporting.35 Collaborative initia-
tives, such as the AVIATOR registry, may shed more light 
on whether the benefits of native valve-preservation 
translate to a survival advantage.35
Structural Valve Deterioration and 
Reintervention
The most important drawback of bioprostheses is their 
susceptibility to structural valve deterioration over time, 
particularly in younger patients.19,27,28,36 This is reflected 
by our findings of structural valve deterioration rates of 
1.59%/y, considerably higher than previously reported 
for middle-aged and elderly patients (0.60%/y).37 This 
translates to all patients younger than 40 years of age 
at surgery projected to undergo one or more reinter-
ventions during their lifetime and ≈60% to 75% of 
patients aged 40 to 60 years. Overall reintervention 
rates are higher than after the Ross procedure, even af-
ter taking right ventricular outflow tract reinterventions 
associated with the Ross procedure into account.32 The 
reintervention rate is also higher than previously re-
ported for aortic valve repair in selected patients and 
for mechanical AVR.1,35
The exact mechanism of the age-related nature of 
structural valve deterioration is not yet fully under-
stood. Increased immune competence, more active 
calcium metabolism and hemodynamics have all been 
previously proposed to play a role, however, definitive 
evidence is lacking.36,38,39 In light of the increasingly rec-
ognized relationship between hemodynamics and valve 
durability, technical considerations aimed at avoid-
ing patient-prosthesis mismatch may prove useful in 
improving outcome.36
Many improvements in the design of modern bio-
prostheses have been proposed to improve durability 
and hemodynamics, however, clinical evidence of the 
hypothesized benefits provided by these modifications 
is inconclusive.40–42
Valve-in-valve TAVI is emerging as a prospective 
option for reintervention of failing bioprostheses in 
high-risk elderly patients although there are considera-
ble risks of device malposition, high gradients, arrhyth-
mias, and coronary obstruction.43 However, its effec-
tiveness in younger, lower-risk patients, the feasibility 
of multiple sequential valve-in-valve TAVIs and medium-
to-long-term outcome remain to be investigated.
Figure 6. Microsimulation-based age-specific lifetime risks of valve-
related morbidity bioprosthetic aortic valve replacement (AVR).  
Error bars represent 95% credible intervals. NSVD indicates non-SVD; and 
SVD, structural valve deterioration.
Figure 7. Microsimulation-based age-specific mean life expectancy 
after bioprosthetic AVR compared with the age- and sex-matched 
general population.  
Error bars represent 95% credible intervals.
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figure 6. Microsimulation-based age-specific lifetime risks of valve-related morbidity bioprosthetic aortic 
valve replacement (AVR).
E ror bars represent 95% credible intervals. NSVD indicates non-SVD; and SVD, struc ural valve deterioration.
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Discussion
This study shows that AVR with bioprostheses in young adults is associated with high 
rates of structural valve deterioration and reintervention, with almost all patients aged 
20 to 40 years at surgery projected to undergo one or more reinterventions during their 
lifetime and ≈60% to 75% of patients aged 40 to 60 years at surgery. Although early 
mortality is low, long-term survival is impaired, with a life expectancy of ≈60% to 75% of 
the life expectancy in the age- and sex-matched general population. Thromboembolism 
and bleeding rates are lower than after mechanical AVR, but not zero, with a lifetime 
thromboembolism risk of ≈10% to 20% and bleeding risk of 5% to 10%, depending on 
age at surgery.
Mortality
Our results show that bioprosthetic AVR in young adults is associated with low early 
mortality (3.30%), although late mortality is high (2.39%/y) and thus life expectancy is 
impaired compared with the general population. This late mortality is higher than the 
late mortality previously reported for the Ross procedure (0.64%/y) and mechanical AVR 
(1.55%/y) in young adults.1,32
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is impaired compared with the general population. This 
late mortality is higher than the late mortality previ-
ously reported for the Ross procedure (0.64%/y) and 
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Comparison of our findings with mortality after aor-
tic valve repair is difficult, because of a sparsity of avail-
able outcome data, disparity in indications and a lack of 
standardization in data reporting.35 Collaborative initia-
tives, such as the AVIATOR registry, may shed more light 
on whether the benefits of native valve-preservation 
translate to a survival advantage.35
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translates to all patients younger than 40 years of age 
at surgery projected to undergo one or more reinter-
ventions during their lifetime and ≈60% to 75% of 
patients aged 40 to 60 years. Overall reintervention 
rates are higher than after the Ross procedure, even af-
ter taking right ventricular outflow tract reinterventions 
associated with the Ross procedure into account.32 The 
reintervention rate is also higher than previously re-
ported for aortic valve repair in selected patients and 
for mechanical AVR.1,35
The exact mechanism of the age-related nature of 
structural valve deterioration is not yet fully under-
stood. Increased immune competence, more active 
calcium metabolism and hemodynamics have all been 
previously proposed to play a role, however, definitive 
evidence is lacking.36,38,39 In light of the increasingly rec-
ognized relationship between hemodynamics and valve 
durability, technical considerations aimed at avoid-
ing patient-prosthesis mismatch may prove useful in 
improving outcome.36
Many improvements in the design of modern bio-
prostheses have been proposed to improve durability 
and hemodynamics, however, clinical evidence of the 
hypothesized benefits provided by these modifications 
is inconclusive.40–42
Valve-in-valve TAVI is emerging as a prospective 
option for reintervention of failing bioprostheses in 
high-risk elderly patients although there are considera-
ble risks of device malposition, high gradients, arrhyth-
mias, and coronary obstruction.43 However, its effec-
tiveness in younger, lower-risk patients, the feasibility 
of multiple sequential valve-in-valve TAVIs and medium-
to-long-term outcome remain to be investigated.
Figure 6. Microsimulation-based age-specific lifetime risks of valve-
related morbidity bioprosthetic aortic valve replacement (AVR).  
Error bars represent 95% credible intervals. NSVD indicates non-SVD; and 
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figure 7. Microsimulation-based age-specific mean life expectancy after bioprosthetic AVR compared with 
the age- and sex-matched general popul tion.
Error bars represent 95% credible intervals.
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This may be explained in part by bioprosthetic AVR having the highest overall reinter-
vention rates of the 3 in combination with higher thromboembolism and bleeding rates 
than after the Ross procedure, with a subsequently higher valve-related mortality.
Besides higher valve-related mortality, excess mortality not directly related to valve-
related events is also higher than after the Ross procedure.33 The less favorable hemo-
dynamics of bioprostheses may play a role in this observed difference.34 Differences 
in preoperative patient characteristics should also be taken into account. Compared 
with adults undergoing the Ross procedure, bioprosthetic AVR patients are on average 
slightly older, more frequently have degenerative and rheumatic valve disease, and 
more frequently undergo concomitant procedures, but on the contrary, also have had 
less prior surgery, and undergo less concomitant aortic surgery.33
Comparison of our findings with mortality after aortic valve repair is difficult, because of 
a sparsity of available outcome data, disparity in indications and a lack of standardiza-
tion in data reporting.35 Collaborative initiatives, such as the AVIATOR registry, may shed 
more light on whether the benefits of native valve-preservation translate to a survival 
advantage.35
structural valve deterioration and reintervention
The most important drawback of bioprostheses is their susceptibility to structural valve 
deterioration over time, particularly in younger patients.19,27,28,36 This is reflected by our 
findings of structural valve deterioration rates of 1.59%/y, considerably higher than 
previously reported for middle-aged and elderly patients (0.60%/y).37 This translates to 
all patients younger than 40 years of age at surgery projected to undergo one or more 
reinterventions during their lifetime and ≈60% to 75% of patients aged 40 to 60 years. 
Overall reintervention rates are higher than after the Ross procedure, even after taking 
right ventricular outflow tract reinterventions associated with the Ross procedure into 
account.32 The reintervention rate is also higher than previously reported for aortic valve 
repair in selected patients and for mechanical AVR.1,35
The exact mechanism of the age-related nature of structural valve deterioration is not 
yet fully understood. Increased immune competence, more active calcium metabolism 
and hemodynamics have all been previously proposed to play a role, however, definitive 
evidence is lacking.36,38,39 In light of the increasingly recognized relationship between 
hemodynamics and valve durability, technical considerations aimed at avoiding patient-
prosthesis mismatch may prove useful in improving outcome.36
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Many improvements in the design of modern bioprostheses have been proposed to 
improve durability and hemodynamics, however, clinical evidence of the hypothesized 
benefits provided by these modifications is inconclusive.40-42
Valve-in-valve TAVI is emerging as a prospective option for reintervention of failing 
bioprostheses in high-risk elderly patients although there are considerable risks of 
device malposition, high gradients, arrhythmias, and coronary obstruction.43 However, 
its effectiveness in younger, lower-risk patients, the feasibility of multiple sequential 
valve-in-valve TAVIs and medium-to-long-term outcome remain to be investigated.
thromboembolism and bleeding
Our study shows that thromboembolism (0.53%/y) and bleeding (0.22%/y) rates are far 
lower than reported for mechanical AVR in young adults (0.90%/y and 0.85%/y, respec-
tively).1 However, these risks are not zero. We found thromboembolism and bleeding 
rates higher than in the general population and higher than reported after the Ross 
procedure (thromboembolism and bleeding combined 0.36%/y) and aortic valve repair, 
although bioprosthetic AVR, the Ross procedure and valve repair similarly aim to avoid 
the need for anticoagulation.32,35,44
Besides possible differences in baseline patient characteristics, the observed difference 
in thromboembolism and bleeding rates may also be due in part to indications for an-
ticoagulation arising during follow-up. Two of the included studies reported that at the 
end of follow-up (mean ≈10 years), 25% to 30% of patients required oral anticoagulation 
therapy, mostly because of atrial fibrillation.15,20 In this light, further studies on preopera-
tive factors associated with postoperative development of indications for anticoagula-
tion may aid in selecting patients that stand to benefit most from bioprosthetic AVR.
endocarditis
We found an endocarditis rate after bioprosthetic AVR (0.48%/y) comparable to me-
chanical AVR (0.41%/y), but higher than after the Ross procedure (autograft 0.18%/y, 
right ventricular outflow tract 0.14%/y, total 0.27%/y) and aortic valve repair (0.16%/y) 
in young adults.1,35,45 This may be a manifestation of the increased susceptibility to infec-
tion of prosthetic material as opposed to autologous tissue, which should always be 
taken into account.46
valve selection/future perspectives
The 2017 United States and European guidelines for the management of valvular heart 
disease both recommend mechanical prostheses over biological alternatives for AVR in 
adults younger than 50 to 60 years old. If anticoagulation is contraindicated or if the 
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patient prefers a biological alternative, both guidelines recommend bioprostheses, and 
only the United States guidelines indicate that the Ross procedure may be considered.47,48
Improvements in the design of bioprostheses with hypothesized hemodynamic and 
durability benefits, continuous improvements in the safety and outcome of reinterven-
tions and enthusiasm for the prospect of transcatheter valve-in-valve replacement 
as an option for reintervention have led to an increase in the use of bioprostheses in 
increasingly younger patients.14,23,31,49 However, there is little clinical evidence to support 
the notion that durability of modern bioprostheses is improving and the future role of 
transcatheter valve-in-valve replacement in these young patients remains uncertain. 
This along with the higher rates of thromboembolism, bleeding, reintervention, and 
mortality than after the Ross procedure calls into question the value of bioprostheses as 
a biological alternative in these young patients. However, their wide availability and ease 
of implantation in contrast to the technically challenging nature of the Ross procedure 
make bioprostheses an attractive alternative in centers with limited access to expertise 
on the Ross procedure and in patients who are not candidates for the Ross procedure.
In light of the limitations of all currently available valve substitutes, the currently ongo-
ing technical advances and expanding indications in aortic valve repair are promising 
and may provide the option of native valve preservation in an increasing number of 
patients in the future.35,50
In any case, conveyance of patient-tailored evidence- based risks and benefits of all 
treatment options in a shared decision-making process is of great importance.47,48 Inno-
vative solutions such as patient information portals and decision aids may prove useful 
in this setting.51,52
Furthermore, with growing interest in TAVI as a primary intervention in increasingly 
younger and lowerrisk patients, our findings provide a valuable insight into long-term 
outcome of the golden standard in nonelderly adult patients (surgical AVR) as a bench-
mark. However, the potential role of TAVI in these patients remains to be elucidated.
limitations
First, the inherent limitations of meta-analyses of predominantly retrospective obser-
vational studies should be taken into consideration.53 Selection bias may have affected 
the observed outcomes, as unpublished data, abstracts and presentations were not 
included. Funnel plots could not be used to investigate publication bias, as funnel plots 
do not allow for meaningful interpretation in case of absolute risk outcomes.54 Direct 
comparisons with alternative valve prostheses are hampered by the lack of published 
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comparative data. Heterogeneity may have introduced uncertainty in our outcomes, 
although this uncertainty is reflected in our 95% confidence/credible intervals due to 
the use of random-effects models. The microsimulation model requires assumptions to 
be made about the evolution of event occurrence rates beyond the observed follow-up 
period, which may have introduced uncertainty. Comparison of our microsimulation 
results with previously published microsimulation studies on mechanical AVR is difficult 
due to differences in methodology.1
conclusions
Bioprosthetic AVR in young adults is associated with high overall reintervention rates, 
mainly because of high age-dependent structural valve deterioration. Through avoid-
ance of thrombogenicity and the burden of anticoagulation, bioprosthetic AVR in 
young adults is associated with low thromboembolism and bleeding rates. However, 
these risks are not absent and considerably higher than previously reported for the 
Ross procedure, although comparative data is lacking. Late mortality is high and life 
expectancy is impaired compared with the general population. In conclusion, outcome 
after bioprosthetic AVR in young adults is suboptimal, although it succeeds in provid-
ing a biological option for patients whose preferences do not align with the outcome 
provided by mechanical valve replacement and who are not candidates for the Ross 
procedure. Patients who are facing AVR are entitled to conveyance of evidence- based 
estimates of the risks and benefits of all treatment options in a shared decision-making 
process.
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supplement 1. Supplemental methods
1. Search query
Embase: 3621 results
(‘aorta valve replacement’/de OR ‘aorta valve prosthesis’/de OR (‘heart valve prosthesis’/
de AND ‘aorta valve’/de) OR (aort* AND (valve*) NEAR/6 (replace* OR transplant* OR 
xenotransplant* OR xenograft* OR heterotransplant* OR heterograft* OR prosthe* OR 
bioprosthe* OR stent*)):ab,ti) AND (xenograft/de OR (xenograft* OR xenotransplant* OR 
heterograft* OR heterotransplant* OR ((xeno* OR hetero* OR porcine* OR swine OR pig 
OR bovine* OR nonhuman OR animal OR calf OR cow OR ‘Carpentier-Edwards’ OR Shiley 
OR hancock) NEAR/6 (graft* OR transplant* OR prosthe* OR bioprosthe* OR valve* OR 
aort*))):ab,ti) OR (‘heart valve bioprosthesis’/de OR ‘Carpentier Edwards bioprosthesis’/
de OR ‘Hancock valve prosthesis’/de OR ‘Mosaic bioprosthesis’/de OR ((‘Carpentier-
Edwards’ OR Shiley OR hancock OR freestyle* OR mosaic OR ‘3f enable’ OR biocor OR ‘to-
ronto spv’) NEAR/6 (valve* OR bioprosthe* OR prosthe*)):ab,ti) NOT ([animals]/lim NOT 
[humans]/lim) AND (‘clinical study’/de OR ‘case control study’/exp OR ‘clinical article’/de 
OR ‘clinical trial’/exp OR ‘intervention study’/de OR ‘longitudinal study’/exp OR ‘major 
clinical study’/de OR ‘prospective study’/de OR ‘retrospective study’/de OR mortality/de 
OR ‘cardiovascular mortality’/de OR ‘surgical mortality’/de OR ‘treatment outcome’/exp 
OR survival/exp OR ‘graft survival’/de OR ‘quality of life’/de OR ‘follow up’/de OR ‘evalu-
ation study’/de OR ‘comparative effectiveness’/de OR reoperation/de OR (clinical* OR 
trial* OR prospect* OR retrospect* OR longitudin* OR mortali* OR outcome* OR failure* 
OR surviv* OR (quality NEAR/3 life) OR result* OR (follow* NEXT/1 up*) OR ‘long term’ OR 
longterm OR death OR evaluat* OR effectiv* OR reoperat*):ab,ti) AND [english]/lim NOT 
([Conference Abstract]/lim OR [Conference Paper]/lim OR [Letter]/lim OR [Note]/lim OR 
[Editorial]/lim OR [Conference Review]/lim)
Medline: 2350 results
((“heart valve prosthesis”/ AND “aortic valve”/) OR (aort* ADJ6 (valve*) ADJ6 (replace* 
OR transplant* OR xenotransplant* OR xenograft* OR heterotransplant* OR heterograft* 
OR prosthe* OR bioprosthe* OR stent*)).ab,ti.) AND (heterografts/ OR (xenograft* OR 
xenotransplant* OR heterograft* OR heterotransplant* OR ((xeno* OR hetero* OR 
porcine* OR swine OR pig OR bovine* OR nonhuman OR animal OR calf OR cow OR 
“Carpentier-Edwards” OR Shiley OR hancock) ADJ6 (graft* OR transplant* OR prosthe* 
OR bioprosthe* OR valve* OR aort*))).ab,ti.) OR (((“Carpentier-Edwards” OR Shiley OR 
hancock OR freestyle* OR mosaic OR “3f enable” OR biocor OR “toronto spv”) ADJ3 (valve* 
OR bioprosthe* OR prosthe*)).ab,ti.) NOT (exp animals/ NOT humans/) AND (“Clinical 
Trial”.pt. OR exp “Case-Control Studies”/ OR “Intervention Studies”/ OR exp “Longitudinal 
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Studies”/ OR exp mortality/ OR mortality.xs. OR exp “treatment outcome”/ OR survival/ 
OR “graft survival”/ OR “quality of life”/ OR (clinical* OR trial* OR prospect* OR retrospect* 
OR longitudin* OR mortali* OR outcome* OR failure* OR surviv* OR (quality ADJ3 life) 
OR result* OR (follow* ADJ up*) OR “long term” OR longterm OR death OR evaluat* OR 
effectiv* OR reoperat*).ab,ti.) AND english.la. NOT (congresses OR Letters OR Notes OR 
Editorials).pt.
Cochrane: 113 results
((aort* AND (valve*) NEAR/6 (replace* OR transplant* OR xenotransplant* OR xenograft* 
OR heterotransplant* OR heterograft* OR prosthe* OR bioprosthe* OR stent*)):ab,ti) 
AND ((xenograft* OR xenotransplant* OR heterograft* OR heterotransplant* OR ((xeno* 
OR hetero* OR porcine* OR swine OR pig OR bovine* OR nonhuman OR animal OR calf 
OR cow OR ‘Carpentier-Edwards’ OR Shiley OR hancock) NEAR/6 (graft* OR transplant* 
OR prosthe* OR bioprosthe* OR valve* OR aort*))):ab,ti) OR (((‘Carpentier-Edwards’ OR 
Shiley OR hancock OR freestyle* OR mosaic OR ‘3f enable’ OR biocor OR ‘toronto spv’) 
NEAR/3 (valve* OR bioprosthe* OR prosthe*)):ab,ti) AND ((clinical* OR trial* OR pros-
pect* OR retrospect* OR longitudin* OR mortali* OR outcome* OR failure* OR surviv* OR 
(quality NEAR/3 life) OR result* OR (follow* NEXT/1 up*) OR ‘long term’ OR longterm OR 
death OR evaluat* OR effectiv* OR reoperat*):ab,ti)
Google scholar: 200 results
“aorta|aortic valve replacement|prosthesis|transplantation” xenograft|xenotransplanta
tion|heterograft|heterotransplantation|”Carpentier-Edwards”|hancock clinical|trial|inte
rvention|longitudinal|prospective|retrospective|mortality|outcome|survival|follow-up
2. List of recorded variables
Study characteristics:
	 •	 Study	design
	 •	 Number	of	patients	included
	 •	 Inclusion	period
	 •	 Total	follow-up
Baseline patient and operative characteristics:
	 •	 Mean	age
	 •	 Gender
	 •	 Etiology
	 •	 Aortic	valve	hemodynamics
	 •	 Aortic	valve	morphology
	 •	 	Previous	cardiac	interventions	(any	previous	surgical	or	percutaneous	interven-
tion on the heart, thoracic aorta and/or pulmonary trunk)
206
	 •	 New	York	Heart	Association	functional	class
	 •	 Urgency	of	the	operation
	 •	 Type	of	prosthesis	(porcine	vs.	bovine	pericardial,	stented	vs.	stentless)
	 •	 Concomitant	procedures
Outcome events
	 •	 Early	outcome	events	(<30	days	after	surgery)
  o Early mortality (all-cause mortality within the first 30 postoperative days)
  o Re-exploration for bleeding
  o Pacemaker implantation
  o Deep sternal infection/mediastinitis
  o Endocarditis
  o Stroke
  o Transient ischemic attack
  o Myocardial infarction
  o Valve thrombosis
  o Peripheral bleeding
•	 Late	outcome	events	(>30	days	after	surgery)
  o Late mortality
   - Cardiac death
   - Valve related death
   - Sudden, unexplained death (SUD)
  o Reintervention
  o Thromboembolism
  o Valve thrombosis
  o Bleeding
  o Endocarditis
  o Structural valve deterioration (SVD)
  o Nonstructural valve dysfunction (NSVD)
  o Pacemaker implantation
3. Microsimulation model: concept
The microsimulation model iteratively simulates individual patient lives after surgery, 
taking into account the morbidity and mortality events that the patient may experience. 
The simulated individual patient life histories are then aggregated to obtain estimates 
of population level outcome. The mortality of a patient is composed of the background 
mortality of the general population, operative mortality, mortality due to valve-related 
events and an additional excess mortality component that is not a direct result of 
valve-related events, but is associated with underlying valve pathology, left ventricular 
function and other associated pathology.
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4. Microsimulation model: estimation of excess mortality
For estimation of the hazard ratios of the additional excess mortality not directly result-
ing from valve-related events relative to background mortality, a microsimulation model 
containing only background mortality and mortality due to valve-related events (ex-
cluding early mortality) was run for 10,000 iterations each at the ages of 25, 35, 45 and 
55 for the age groups 20-40, 40-50 and 50-60, respectively. Subsequently, the hazard 
ratios were estimated by fitting the survival output of these microsimulation models 
to the survival observed for the same age groups in the studies by Schnittman et al. 
2018 and Goldstone et al. 2017 (references 9 &10) using the least squares method and 
excluding early mortality.
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supplement 2. Individual study characteristics.
study design origin Patients (n) inclusion period Mean/median fuP fuP completeness Mean/median age (range) Prosthesis
  -Porcine -Bovine pericardial -stented -stentless
Anantha Narayanan 2015 Retrospective North America 63 2004-2011 2.1 - 51.1(18.0-60.0) 0.0% 100.0% 100.0% 0.0%
Bach 2007 Retrospective North America 57 1992-2004 8.5 82.0% 54.5(36.0-60.0) 100.0% 0.0% 0.0% 100.0%
Bourguignon 2015 Retrospective EU 383 1984-2008 8.6 95.3% 51.0(16.0-60.0) 0.0% 100.0% 100.0% 0.0%
McClure 2014 Prospective North America 361 1992-2013 6.5 - 53.9(-65.0) 11.9% 87.8% 100.0% 0.0%
Chan 2011 Prospective North America 147 1976-2010 5.8 - -(-40.0) - - - -
Forcillo 2014 Retrospective North America 144 1991-2011 10.0 95.0% 51.0(18.0-60.0) 0.0% 100.0% 100.0% 0.0%
Christ 2013 Retrospective EU 188 1993-2001 8.8 90.4% 53.1(24.0-60.0) 100.0% 0.0% 0.0% 100.0%
Minakata 2015 Retrospective Asia 53 1986-2001 9.5 84.9% 52.8(21.0-64.0) 0.0% 100.0% 100.0% 0.0%
Wang 2015 Retrospective Asia 112 2002-2009 8.7 95.1% 50.3(--60.0) 100.0% 0.0% 100.0% 0.0%
Vrandecic 2002 Retrospective South America 247 1990-2001 5.9 98.0% 47.3(30.0-79.0) 100.0% 0.0% 0.0% 100.0%
Une 2014 - North America 304 1982-2008 14.2 97.0% 49.2(17.0-59.0) 100.0% 0.0% 100.0% 0.0%
Von Oppell 2001 Prospective South Africa 52 1994-1998 - - 44.0(-) 100.0% 0.0% 0.0% 100.0%
Ruggieri 2012 Retrospective EU 36 1983-1994 13.7 - 43.9(24.0-59.0) 100.0% 0.0% 100.0% 0.0%
Weber 2012 Retrospective EU 103 2000-2009 2.8 97.0% 55.0(46.0-59.0) 0.0% 100.0% 100.0% 0.0%
Banbury 2001 - North America 27 1981-1984 12.0 - -(21.0-50.0) 0.0% 100.0% 100.0% 0.0%
Nishida 2014 Retrospective Asia 51 1981-2013 9.0 - 46.9(-60.0) 0.0% 100.0% 100.0% 0.0%
Wei 2010 - Asia 72 1989-2002 - 96.5% 46.6(35.0-64.0) 100.0% 0.0% 100.0% 0.0%
Vrandecic 2000 Retrospective South America 202 1990-1999 4.4 - 48.1(-) 100.0% 0.0% 100.0% 0.0%
Niclauss 2013 Retrospective EU 84 2000-2010 4.5 100% 54.7(22.0-64.0) 8.6% 91.4% 91.4% 8.6%
 “-“=variable not reported. FUP=follow-up.
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supplement 2. Individual study characteristics.
study design origin Patients (n) inclusion period Mean/median fuP fuP completeness Mean/median age (range) Prosthesis
  -Porcine -Bovine pericardial -stented -stentless
Anantha Narayanan 2015 Retrospective North America 63 2004-2011 2.1 - 51.1(18.0-60.0) 0.0% 100.0% 100.0% 0.0%
Bach 2007 Retrospective North America 57 1992-2004 8.5 82.0% 54.5(36.0-60.0) 100.0% 0.0% 0.0% 100.0%
Bourguignon 2015 Retrospective EU 383 1984-2008 8.6 95.3% 51.0(16.0-60.0) 0.0% 100.0% 100.0% 0.0%
McClure 2014 Prospective North America 361 1992-2013 6.5 - 53.9(-65.0) 11.9% 87.8% 100.0% 0.0%
Chan 2011 Prospective North America 147 1976-2010 5.8 - -(-40.0) - - - -
Forcillo 2014 Retrospective North America 144 1991-2011 10.0 95.0% 51.0(18.0-60.0) 0.0% 100.0% 100.0% 0.0%
Christ 2013 Retrospective EU 188 1993-2001 8.8 90.4% 53.1(24.0-60.0) 100.0% 0.0% 0.0% 100.0%
Minakata 2015 Retrospective Asia 53 1986-2001 9.5 84.9% 52.8(21.0-64.0) 0.0% 100.0% 100.0% 0.0%
Wang 2015 Retrospective Asia 112 2002-2009 8.7 95.1% 50.3(--60.0) 100.0% 0.0% 100.0% 0.0%
Vrandecic 2002 Retrospective South America 247 1990-2001 5.9 98.0% 47.3(30.0-79.0) 100.0% 0.0% 0.0% 100.0%
Une 2014 - North America 304 1982-2008 14.2 97.0% 49.2(17.0-59.0) 100.0% 0.0% 100.0% 0.0%
Von Oppell 2001 Prospective South Africa 52 1994-1998 - - 44.0(-) 100.0% 0.0% 0.0% 100.0%
Ruggieri 2012 Retrospective EU 36 1983-1994 13.7 - 43.9(24.0-59.0) 100.0% 0.0% 100.0% 0.0%
Weber 2012 Retrospective EU 103 2000-2009 2.8 97.0% 55.0(46.0-59.0) 0.0% 100.0% 100.0% 0.0%
Banbury 2001 - North America 27 1981-1984 12.0 - -(21.0-50.0) 0.0% 100.0% 100.0% 0.0%
Nishida 2014 Retrospective Asia 51 1981-2013 9.0 - 46.9(-60.0) 0.0% 100.0% 100.0% 0.0%
Wei 2010 - Asia 72 1989-2002 - 96.5% 46.6(35.0-64.0) 100.0% 0.0% 100.0% 0.0%
Vrandecic 2000 Retrospective South America 202 1990-1999 4.4 - 48.1(-) 100.0% 0.0% 100.0% 0.0%
Niclauss 2013 Retrospective EU 84 2000-2010 4.5 100% 54.7(22.0-64.0) 8.6% 91.4% 91.4% 8.6%
 “-“=variable not reported. FUP=follow-up.
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supplement 3. Individual study outcome estimates.
1The reported p-values are those of the Cochran’s Q test for heterogeneity. *zero events reported, for the pur-
pose of the analyses it was assumed that 0.5 patient experienced that event. “-“=variable not reported. Yr=year. 
SUD=sudden unexplained death. SVD=structural valve degeneration. NSVD=nonstructural valve dysfunction.
early outcoMe late outcoMe
early mortality (%)
reexploration
for bleeding (%)
thromboembolism
(%)
late mortality
(%/yr)  -cardiac (%/yr)
 -valve-related 
(%/yr)  -suD (%/yr)
reintervention
(%/yr) svD (%/yr)
Anantha Narayanan 2015 0.79(0.05-12.55)* 0.79(0.05-12.55)* 1.59(0.23-11.09) 4.58(2.10-10.00) - - - 4.58(2.10-10.00) 1.53(0.39-6.04)
Bach 2007 - - - 3.08(1.87-5.07) 0.62(0.20-1.91) 0.21(0.03-1.46) - 1.44(0.69-3.00) 0.62(0.20-1.91)
Bourguignon 2015 1.31(0.55-3.12) - 1.31(0.55-3.12) 2.58(2.09-3.18) 1.21(0.89-1.65) 0.70(0.46-1.05) 0.52(0.32-0.83) 2.67(2.17-3.28) 2.36(1.90-2.94)
McClure 2014 1.94(0.93-4.04) 2.49(1.31-4.75) - 2.37(1.87-3.02) 0.58(0.36-0.95) - - 0.84(0.56-1.26) -
Chan 2011 - - - - - - - 6.80(5.31-8.72) -
Forcillo 2014 0.69(0.10-4.90) 9.03(5.38-15.16) 2.08(0.68-6.38) 2.85(2.11-3.85) 1.46(0.95-2.23) 0.42(0.19-0.93) 0.14(0.03-0.55) 2.57(1.87-3.53) 2.01(1.40-2.89)
Christ 2013 3.19(1.45-7.01) - - 3.68(2.88-4.71) - - - 2.53(1.88-3.42) 2.11(1.52-2.93)
Minakata 2015 3.77(0.97-14.70) - - 3.97(2.59-6.10) 1.19(0.54-2.64) 0.60(0.19-1.84) 0.10(0.01-1.59)* 2.38(1.36-4.17) 2.38(1.36-4.17)
Wang 2015 3.57(1.36-9.35) 1.79(0.45-7.05) 1.79(0.45-7.05) 1.13(0.63-2.04) 0.82(0.41-1.64) 0.21(0.05-0.82) 0.05(0.00-0.82)* 0.93(0.48-1.78) 0.62(0.28-1.37)
Vrandecic 2002 4.05(2.21-7.43) - - 1.08(0.65-1.78) 0.29(0.11-0.76) 0.04(0.00-0.57)* 0.04(0.00-0.57)* 0.22(0.07-0.67) 0.14(0.04-0.57)
Une 2014 1.97(0.89-4.36) - - 1.46(1.14-1.86) - - - 2.32(1.91-2.81) 1.97(1.60-2.43)
Von Oppell 2001 5.77(1.92-17.31) - - 1.75(0.44-6.93) 1.75(0.44-6.93) 1.75(0.44-6.93) 0.88(0.12-6.17) 1.75(0.44-6.93) 2.63(0.86-8.04)
Ruggieri 2012 - - - - - - - 3.85(2.48-5.99) 4.06(2.64-6.23)
Weber 2012 4.85(2.06-11.41) 6.80(3.32-13.90) - 3.53(1.92-6.49) 2.12(0.96-4.68) 2.12(0.96-4.68) 1.77(0.74-4.21) 0.18(0.01-2.82)* -
Banbury 2001 - - - - - - - - -
Nishida 2014 - - - - - - - - 2.18(1.18-4.03)
Wei 2010 8.33(3.87-17.93) - - 2.06(1.18-3.60) 1.20(0.57-2.51) 0.51(0.17-1.59) 0.09(0.01-1.37)* 0.51(0.17-1.59) 0.51(0.17-1.59)
Vrandecic 2000 5.45(3.07-9.67) - - 2.31(1.42-3.75) 0.72(0.30-1.73) 0.58(0.22-1.53) - 1.15(0.58-2.30) 0.29(0.07-1.15)
Niclauss 2013 2.38(0.61-9.36) - - 2.10(1.06-4.17) 0.26(0.04-1.86) - - 1.31(0.55-3.14) 1.05(0.40-2.78)
Pooled estimate (95%ci) 3.30(2.39-4.55) 4.08(1.96-8.51) 1.60(0.89-2.87) 2.39(1.13-2.94) 0.96(0.71-1.29) 0.60(0.37-0.98) 0.30(0.12-0.76) 1.82(1.31-2.52) 1.59(1.21-2.10)
Heterogeneity1 I^2=41.7%(p=0.051) I^2=71.4%(p=0.007) I^2=0.0%(p=0.930) I^2=75.0%(p<0.001) I^2=52.4%(p=0.017) I^2=55.5%(p=0.017) I^2=66.0%(p=0.004) I^2=88.9%(p<0.001) I^2=74.4%(p<0.001)
number of studies 14 5 4 15 12 10 8 17 15
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supplement 3. Individual study outcome estimates.
1The reported p-values are those of the Cochran’s Q test for heterogeneity. *zero events reported, for the pur-
pose of the analyses it was assumed that 0.5 patient experienced that event. “-“=variable not reported. Yr=year. 
SUD=sudden unexplained death. SVD=structural valve degeneration. NSVD=nonstructural valve dysfunction.
early outcoMe late outcoMe
early mortality (%)
reexploration
for bleeding (%)
thromboembolism
(%)
late mortality
(%/yr)  -cardiac (%/yr)
 -valve-related 
(%/yr)  -suD (%/yr)
reintervention
(%/yr) svD (%/yr)
Anantha Narayanan 2015 0.79(0.05-12.55)* 0.79(0.05-12.55)* 1.59(0.23-11.09) 4.58(2.10-10.00) - - - 4.58(2.10-10.00) 1.53(0.39-6.04)
Bach 2007 - - - 3.08(1.87-5.07) 0.62(0.20-1.91) 0.21(0.03-1.46) - 1.44(0.69-3.00) 0.62(0.20-1.91)
Bourguignon 2015 1.31(0.55-3.12) - 1.31(0.55-3.12) 2.58(2.09-3.18) 1.21(0.89-1.65) 0.70(0.46-1.05) 0.52(0.32-0.83) 2.67(2.17-3.28) 2.36(1.90-2.94)
McClure 2014 1.94(0.93-4.04) 2.49(1.31-4.75) - 2.37(1.87-3.02) 0.58(0.36-0.95) - - 0.84(0.56-1.26) -
Chan 2011 - - - - - - - 6.80(5.31-8.72) -
Forcillo 2014 0.69(0.10-4.90) 9.03(5.38-15.16) 2.08(0.68-6.38) 2.85(2.11-3.85) 1.46(0.95-2.23) 0.42(0.19-0.93) 0.14(0.03-0.55) 2.57(1.87-3.53) 2.01(1.40-2.89)
Christ 2013 3.19(1.45-7.01) - - 3.68(2.88-4.71) - - - 2.53(1.88-3.42) 2.11(1.52-2.93)
Minakata 2015 3.77(0.97-14.70) - - 3.97(2.59-6.10) 1.19(0.54-2.64) 0.60(0.19-1.84) 0.10(0.01-1.59)* 2.38(1.36-4.17) 2.38(1.36-4.17)
Wang 2015 3.57(1.36-9.35) 1.79(0.45-7.05) 1.79(0.45-7.05) 1.13(0.63-2.04) 0.82(0.41-1.64) 0.21(0.05-0.82) 0.05(0.00-0.82)* 0.93(0.48-1.78) 0.62(0.28-1.37)
Vrandecic 2002 4.05(2.21-7.43) - - 1.08(0.65-1.78) 0.29(0.11-0.76) 0.04(0.00-0.57)* 0.04(0.00-0.57)* 0.22(0.07-0.67) 0.14(0.04-0.57)
Une 2014 1.97(0.89-4.36) - - 1.46(1.14-1.86) - - - 2.32(1.91-2.81) 1.97(1.60-2.43)
Von Oppell 2001 5.77(1.92-17.31) - - 1.75(0.44-6.93) 1.75(0.44-6.93) 1.75(0.44-6.93) 0.88(0.12-6.17) 1.75(0.44-6.93) 2.63(0.86-8.04)
Ruggieri 2012 - - - - - - - 3.85(2.48-5.99) 4.06(2.64-6.23)
Weber 2012 4.85(2.06-11.41) 6.80(3.32-13.90) - 3.53(1.92-6.49) 2.12(0.96-4.68) 2.12(0.96-4.68) 1.77(0.74-4.21) 0.18(0.01-2.82)* -
Banbury 2001 - - - - - - - - -
Nishida 2014 - - - - - - - - 2.18(1.18-4.03)
Wei 2010 8.33(3.87-17.93) - - 2.06(1.18-3.60) 1.20(0.57-2.51) 0.51(0.17-1.59) 0.09(0.01-1.37)* 0.51(0.17-1.59) 0.51(0.17-1.59)
Vrandecic 2000 5.45(3.07-9.67) - - 2.31(1.42-3.75) 0.72(0.30-1.73) 0.58(0.22-1.53) - 1.15(0.58-2.30) 0.29(0.07-1.15)
Niclauss 2013 2.38(0.61-9.36) - - 2.10(1.06-4.17) 0.26(0.04-1.86) - - 1.31(0.55-3.14) 1.05(0.40-2.78)
Pooled estimate (95%ci) 3.30(2.39-4.55) 4.08(1.96-8.51) 1.60(0.89-2.87) 2.39(1.13-2.94) 0.96(0.71-1.29) 0.60(0.37-0.98) 0.30(0.12-0.76) 1.82(1.31-2.52) 1.59(1.21-2.10)
Heterogeneity1 I^2=41.7%(p=0.051) I^2=71.4%(p=0.007) I^2=0.0%(p=0.930) I^2=75.0%(p<0.001) I^2=52.4%(p=0.017) I^2=55.5%(p=0.017) I^2=66.0%(p=0.004) I^2=88.9%(p<0.001) I^2=74.4%(p<0.001)
number of studies 14 5 4 15 12 10 8 17 15
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supplement 3. (continued)
nsvD (%/yr)
endocarditis
(%/yr)
thromboembolism
(%/yr)
valve thrombosis
(%/yr) Bleeding (%/yr)
Anantha Narayanan 2015 - - - - -
Bach 2007 - - - - -
Bourguignon 2015 - 0.52(0.32-0.83) 0.48(0.30-0.79) 0.02(0.00-0.24)* 0.21(0.10-0.44)
McClure 2014 - - 0.58(0.36-0.95) - 0.15(0.05-0.39)
Chan 2011 - - - - -
Forcillo 2014 - 0.49(0.23-1.02) 0.56(0.28-1.11) 0.07(0.01-0.49) -
Christ 2013 - - - - -
Minakata 2015 - 0.10(0.01-1.59)* 0.79(0.30-2.11) - 0.60(0.19-1.84)
Wang 2015 - - 0.52(0.21-1.23) - 0.31(0.10-0.96)
Vrandecic 2002 0.22(0.07-0.67) 0.14(0.04-0.57) 0.04(0.00-0.57)* 0.04(0.00-0.57)* 0.04(0.00-0.57)*
Une 2014 - 0.44(0.28-0.69) 0.37(0.23-0.60) - 0.19(0.09-0.37)
Von Oppell 2001 - 0.88(0.12-6.17) 1.75(0.44-6.93) 0.44(0.03-6.97)* 0.44(0.03-6.97)*
Ruggieri 2012 - - - - -
Weber 2012 - 1.06(0.34-3.26) 1.06(0.34-3.26) - 0.18(0.01-2.82)*
Banbury 2001 - - - - -
Nishida 2014 - - - - -
Wei 2010 - 0.34(0.09-1.37) 0.69(0.26-1.82) - 0.34(0.09-1.37)
Vrandecic 2000 0.29(0.07-1.15) 0.58(0.22-1.53) 0.43(0.14-1.34) 0.07(0.00-1.15)* 0.07(0.00-1.15)*
Niclauss 2013 - - 0.26(0.04-1.86) - -
Pooled estimate (95%ci) 0.24(0.10-0.58) 0.48(0.37-0.62) 0.53(0.42-0.67) 0.07(0.02-0.20) 0.22(0.16-0.32)
Heterogeneity1 I^2=0.0%(p=0.749) I^2=0.0%(p=0.535) I^2=7.5%(p=0.372) I^2=0.0%(p=0.545) I^2=0.0%(p=0.619)
number of studies 2 9 12 5 10
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nsvD (%/yr)
endocarditis
(%/yr)
thromboembolism
(%/yr)
valve thrombosis
(%/yr) Bleeding (%/yr)
Anantha Narayanan 2015 - - - - -
Bach 2007 - - - - -
Bourguignon 2015 - 0.52(0.32-0.83) 0.48(0.30-0.79) 0.02(0.00-0.24)* 0.21(0.10-0.44)
McClure 2014 - - 0.58(0.36-0.95) - 0.15(0.05-0.39)
Chan 2011 - - - - -
Forcillo 2014 - 0.49(0.23-1.02) 0.56(0.28-1.11) 0.07(0.01-0.49) -
Christ 2013 - - - - -
Minakata 2015 - 0.10(0.01-1.59)* 0.79(0.30-2.11) - 0.60(0.19-1.84)
Wang 2015 - - 0.52(0.21-1.23) - 0.31(0.10-0.96)
Vrandecic 2002 0.22(0.07-0.67) 0.14(0.04-0.57) 0.04(0.00-0.57)* 0.04(0.00-0.57)* 0.04(0.00-0.57)*
Une 2014 - 0.44(0.28-0.69) 0.37(0.23-0.60) - 0.19(0.09-0.37)
Von Oppell 2001 - 0.88(0.12-6.17) 1.75(0.44-6.93) 0.44(0.03-6.97)* 0.44(0.03-6.97)*
Ruggieri 2012 - - - - -
Weber 2012 - 1.06(0.34-3.26) 1.06(0.34-3.26) - 0.18(0.01-2.82)*
Banbury 2001 - - - - -
Nishida 2014 - - - - -
Wei 2010 - 0.34(0.09-1.37) 0.69(0.26-1.82) - 0.34(0.09-1.37)
Vrandecic 2000 0.29(0.07-1.15) 0.58(0.22-1.53) 0.43(0.14-1.34) 0.07(0.00-1.15)* 0.07(0.00-1.15)*
Niclauss 2013 - - 0.26(0.04-1.86) - -
Pooled estimate (95%ci) 0.24(0.10-0.58) 0.48(0.37-0.62) 0.53(0.42-0.67) 0.07(0.02-0.20) 0.22(0.16-0.32)
Heterogeneity1 I^2=0.0%(p=0.749) I^2=0.0%(p=0.535) I^2=7.5%(p=0.372) I^2=0.0%(p=0.545) I^2=0.0%(p=0.619)
number of studies 2 9 12 5 10
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supplement 4. Calibration plot of the microsimulation model. Microsimula-
tion-based actuarial survival is plotted against observed pooled Kaplan-Meier 
survival rates in the all ages group (age- and gender-matched).
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supplement 5. Least squares regression of modeled survival vs. observed 
survival for estimation of excess mortality not directly related to valve-related 
events.
Hazard ratio1 sum of squared residuals2
Age at surgery 20-40 years
3.4 296.0
3.5 274.8
3.6 266.4
3.7 270.2
3.8 285.5
Age at surgery 40-50 years
2.5 212.5
2.6 155.9
2.7 148.2
2.8 188.9
2.9 275.2
Age at surgery 50-60 years
1.5 634.7
1.6 284.2
1.7 126.9
1.8 159.7
1.9 378.5
Bold print indicates the selected model.
1Hazard ratio of background mortality + excess mortality relative to background mortality.
2Sum of squared residuals between microsimulation-based survival and survival observed in our meta-
analysis of Kaplan-Meier freedom from all-cause mortality.
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supplement 6. Sensitivity analysis including only studies with a mean age 
≤50 years (n=9)
Pooled estimate (95%ci) Heterogeneity number of studies
early outcome
early mortality (%) 4.59(2.94-7.16) I^2=45.6%(p=0.118) 5
reexploration for bleeding (%) - - 0
thromboembolism (%) - - 0
late outcome
late mortality (%/yr) 1.61(1.26-2.09) I^2=31.6%(p=0.211) 5
 -Cardiac (%/yr) 0.78(0.38-1.60) I^2=55.1%(p=0.083) 4
  -Valve-related (%/yr) 0.56(0.21-1.51) I^2=53.0%(p=0.094) 4
   -SUD (%/yr) 0.17(0.02-1.30) I^2=50.2%(p=0.134) 3
reintervention (%/yr) 1.69(0.87-3.28) I^2=93.2%(p<0.001) 7
svD (%/yr) 1.28(0.69-2.37) I^2=84.1%(p<0.001) 7
nsvD (%/yr) 0.24(0.10-0.58) I^2=0.0%(p=0.749) 2
endocarditis (%/yr) 0.43(0.29-0.62) I^2=0.0%(p=0.497) 5
thromboembolism (%/yr) 0.50(0.25-1.00) I^2=51.8%(p=0.081) 5
valve thrombosis (%/yr) 0.10(0.02-0.52) I^2=0.0%(p=0.433) 3
Bleeding (%/yr) 0.19(0.11-0.34) I^2=0.0%(p=0.572) 5
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supplement 7. Univariable random effects meta-regression of natural log-
transformed outcome measures.
reexploration for 
bleeding late mortality reintervention
structural valve 
deterioration
β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value
study design (prospective/rct) -0.72(-2.20 - 0.76) 0.339 -0.14(-0.77 - 0.50) 0.671 0.27(-0.70 - 1.25) 0.582 0.55(-0.95 - 2.05) 0.475
Median year of surgery -0.25(-0.64 - 0.14) 0.205 0.01(-0.04 - 0.06) 0.718 -0.04(-0.10 - 0.01) 0.136 -0.06(-0.12 - -0.01) 0.030
Mean follow-up (/year increase) 0.06(-0.24 - 0.36) 0.702 -0.03(-0.10 - 0.04) 0.337 0.05(-0.05 - 0.16) 0.329 0.14(0.04 - 0.24) 0.007
Mean age (/year increase) 0.09(-0.39 - 0.57) 0.710 0.09(0.03 - 0.15) 0.006 -0.01(-0.10 - 0.07) 0.742 -0.03(-0.12 - 0.06) 0.472
Male 1.60(-0.69 - 3.90) 0.171 0.06(-0.84 - 0.95) 0.903 0.56(-0.99 - 2.10) 0.480 -0.37(-1.68 - 0.94) 0.580
urgent -9.85(-22.95 - 3.25) 0.140 0.71(-5.29 - 6.71) 0.816 1.28(-5.67 - 8.23) 0.719 -4.47(-11.50 - 2.57) 0.214
Preop. nyHa class
I/II * 0.16(-1.51 - 1.83) 0.850 0.73(-1.90 - 3.36) 0.587 2.67(-0.36 - 5.70) 0.084
III/IV * -0.66(-1.99 - 0.68) 0.335 -1.47(-3.72 - 0.77) 0.199 -3.15(-5.61 - -0.68) 0.012
Hemodynamics
Aortic stenosis * 0.04(-2.04 - 2.11) 0.974 0.94(-0.82 - 2.70) 0.297 0.99(-1.22 - 3.20) 0.380
Aortic regurgitation * -2.29(-6.76 - 2.17) 0.314 -2.54(-6.76 - 1.69) 0.239 -2.54(-7.78 - 2.71) 0.343
Combined * 2.19(-0.81 - 5.20) 0.152 0.87(-3.18 - 4.92) 0.674 0.20(-5.31 - 5.71) 0.944
atrial fibrillation * 3.31(-4.49 - 11.11) 0.406 -5.56(-16.24 - 5.12) 0.307 3.41(-14.99 - 21.81) 0.716
Bicuspid av * * * *
etiology
Congenital * 2.00(0.85 - 3.16) 0.001 1.41(-0.17 - 2.99) 0.080 0.78(-1.46 - 3.02) 0.495
Degenerative/calcification * 0.50(-0.91 - 1.91) 0.487 1.24(-1.01 - 3.50) 0.280 2.51(0.15 - 4.88) 0.037
Rheumatic * -0.66(-1.55 - 0.23) 0.144 -1.68(-3.01 - -0.35) 0.014 -1.27(-2.92 - 0.37) 0.129
Endocarditis * -2.22(-9.14 - 4.71) 0.530 0.29(-9.77 - 10.36) 0.955 3.36(-5.63 - 12.36) 0.463
Other/unknown * -3.84(-5.81 - -1.86) <0.001 -8.41(-13.54 - -3.29) 0.001 -8.93(-15.52 - -2.33) 0.008
Previous cardiac intervention * -0.21(-4.09 - 3.66) 0.914 -6.08(-15.78 - 3.61) 0.219 -1.05(-8.05 - 5.96) 0.770
AV intervention * 0.16(-6.07 - 6.40) 0.959 -9.92(-21.08 - 1.24) 0.081 0.93(-5.25 - 7.11) 0.767
AVR * 3.91(-23.78 - 31.59) 0.782 7.16(-16.52 - 30.84) 0.553 0.81(-6.44 - 8.06) 0.827
Prosthesis
Porcine * -0.43(-0.85 - 0.00) 0.050 -0.33(-0.95 - 0.29) 0.295 -0.47(-1.08 - 0.14) 0.134
Bovine pericardial * 0.43(0.00 - 0.86) 0.048 0.34(-0.28 - 0.96) 0.289 0.47(-0.14 - 1.09) 0.130
Stented * 0.02(-0.48 - 0.52) 0.945 0.33(-0.38 - 1.03) 0.366 0.39(-0.32 - 1.10) 0.283
Stentless * -0.02(-0.52 - 0.48) 0.949 -0.32(-1.03 - 0.38) 0.371 -0.38(-1.09 - 0.33) 0.289
concomitant procedures
CABG * 0.78(-2.32 - 3.89) 0.621 -2.02(-6.04 - 2.01) 0.325 -2.27(-6.00 - 1.47) 0.235
Ascending aortic surgery * 1.11(-5.08 - 7.30) 0.725 0.27(-3.67 - 4.20) 0.894 -0.55(-5.37 - 4.27) 0.823
Annular enlargement procedure * -3.96(-6.08 - -1.84) <0.001 -0.09(-1.49 - 1.31) 0.900 0.45(-2.35 - 3.25) 0.753
Other valve repair or replacement * -0.59(-4.38 - 3.20) 0.759 -1.58(-6.53 - 3.37) 0.531 -0.58(-6.09 - 4.93) 0.837
Other * 1.57(-2.07 - 5.21) 0.397 1.89(-3.46 - 7.25) 0.489 0.64(-6.26 - 7.55) 0.855
*Could not be assessed due to insufficient sample size. CI=confidence interval. RCT=randomized con-
trolled trial. Preop.=preoperative. NYHA=New York Heart Association. AV=aortic valve. AVR=aortic valve 
replacement. CABG=coronary artery bypass grafting.
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supplement 7. Univariable random effects meta-regression of natural log-
transformed outcome measures.
reexploration for 
bleeding late mortality reintervention
structural valve 
deterioration
β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value β (95%ci) p-value
study design (prospective/rct) -0.72(-2.20 - 0.76) 0.339 -0.14(-0.77 - 0.50) 0.671 0.27(-0.70 - 1.25) 0.582 0.55(-0.95 - 2.05) 0.475
Median year of surgery -0.25(-0.64 - 0.14) 0.205 0.01(-0.04 - 0.06) 0.718 -0.04(-0.10 - 0.01) 0.136 -0.06(-0.12 - -0.01) 0.030
Mean follow-up (/year increase) 0.06(-0.24 - 0.36) 0.702 -0.03(-0.10 - 0.04) 0.337 0.05(-0.05 - 0.16) 0.329 0.14(0.04 - 0.24) 0.007
Mean age (/year increase) 0.09(-0.39 - 0.57) 0.710 0.09(0.03 - 0.15) 0.006 -0.01(-0.10 - 0.07) 0.742 -0.03(-0.12 - 0.06) 0.472
Male 1.60(-0.69 - 3.90) 0.171 0.06(-0.84 - 0.95) 0.903 0.56(-0.99 - 2.10) 0.480 -0.37(-1.68 - 0.94) 0.580
urgent -9.85(-22.95 - 3.25) 0.140 0.71(-5.29 - 6.71) 0.816 1.28(-5.67 - 8.23) 0.719 -4.47(-11.50 - 2.57) 0.214
Preop. nyHa class
I/II * 0.16(-1.51 - 1.83) 0.850 0.73(-1.90 - 3.36) 0.587 2.67(-0.36 - 5.70) 0.084
III/IV * -0.66(-1.99 - 0.68) 0.335 -1.47(-3.72 - 0.77) 0.199 -3.15(-5.61 - -0.68) 0.012
Hemodynamics
Aortic stenosis * 0.04(-2.04 - 2.11) 0.974 0.94(-0.82 - 2.70) 0.297 0.99(-1.22 - 3.20) 0.380
Aortic regurgitation * -2.29(-6.76 - 2.17) 0.314 -2.54(-6.76 - 1.69) 0.239 -2.54(-7.78 - 2.71) 0.343
Combined * 2.19(-0.81 - 5.20) 0.152 0.87(-3.18 - 4.92) 0.674 0.20(-5.31 - 5.71) 0.944
atrial fibrillation * 3.31(-4.49 - 11.11) 0.406 -5.56(-16.24 - 5.12) 0.307 3.41(-14.99 - 21.81) 0.716
Bicuspid av * * * *
etiology
Congenital * 2.00(0.85 - 3.16) 0.001 1.41(-0.17 - 2.99) 0.080 0.78(-1.46 - 3.02) 0.495
Degenerative/calcification * 0.50(-0.91 - 1.91) 0.487 1.24(-1.01 - 3.50) 0.280 2.51(0.15 - 4.88) 0.037
Rheumatic * -0.66(-1.55 - 0.23) 0.144 -1.68(-3.01 - -0.35) 0.014 -1.27(-2.92 - 0.37) 0.129
Endocarditis * -2.22(-9.14 - 4.71) 0.530 0.29(-9.77 - 10.36) 0.955 3.36(-5.63 - 12.36) 0.463
Other/unknown * -3.84(-5.81 - -1.86) <0.001 -8.41(-13.54 - -3.29) 0.001 -8.93(-15.52 - -2.33) 0.008
Previous cardiac intervention * -0.21(-4.09 - 3.66) 0.914 -6.08(-15.78 - 3.61) 0.219 -1.05(-8.05 - 5.96) 0.770
AV intervention * 0.16(-6.07 - 6.40) 0.959 -9.92(-21.08 - 1.24) 0.081 0.93(-5.25 - 7.11) 0.767
AVR * 3.91(-23.78 - 31.59) 0.782 7.16(-16.52 - 30.84) 0.553 0.81(-6.44 - 8.06) 0.827
Prosthesis
Porcine * -0.43(-0.85 - 0.00) 0.050 -0.33(-0.95 - 0.29) 0.295 -0.47(-1.08 - 0.14) 0.134
Bovine pericardial * 0.43(0.00 - 0.86) 0.048 0.34(-0.28 - 0.96) 0.289 0.47(-0.14 - 1.09) 0.130
Stented * 0.02(-0.48 - 0.52) 0.945 0.33(-0.38 - 1.03) 0.366 0.39(-0.32 - 1.10) 0.283
Stentless * -0.02(-0.52 - 0.48) 0.949 -0.32(-1.03 - 0.38) 0.371 -0.38(-1.09 - 0.33) 0.289
concomitant procedures
CABG * 0.78(-2.32 - 3.89) 0.621 -2.02(-6.04 - 2.01) 0.325 -2.27(-6.00 - 1.47) 0.235
Ascending aortic surgery * 1.11(-5.08 - 7.30) 0.725 0.27(-3.67 - 4.20) 0.894 -0.55(-5.37 - 4.27) 0.823
Annular enlargement procedure * -3.96(-6.08 - -1.84) <0.001 -0.09(-1.49 - 1.31) 0.900 0.45(-2.35 - 3.25) 0.753
Other valve repair or replacement * -0.59(-4.38 - 3.20) 0.759 -1.58(-6.53 - 3.37) 0.531 -0.58(-6.09 - 4.93) 0.837
Other * 1.57(-2.07 - 5.21) 0.397 1.89(-3.46 - 7.25) 0.489 0.64(-6.26 - 7.55) 0.855
*Could not be assessed due to insufficient sample size. CI=confidence interval. RCT=randomized con-
trolled trial. Preop.=preoperative. NYHA=New York Heart Association. AV=aortic valve. AVR=aortic valve 
replacement. CABG=coronary artery bypass grafting.
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aBstract
Selecting the optimal surgical treatment strategy in patients below the age of 65 years 
(i.e., non-elderly patients) with aortic valve or aortic root disease remains challenging. 
The objective of the current study is to summarize contemporary research on clinical and 
quality of life outcomes after aortic valve replacement (AVR) and aortic root surgery in 
non-elderly patients. Recent systematic reviews on clinical outcome after biological and 
mechanical AVR, the Ross procedure and aortic root surgery show that event occurrence 
is considerable after any type of AVR or aortic root surgery and—with the exception of 
the Ross procedure— survival is suboptimal. Although thromboembolism and bleeding 
events are more common after mechanical AVR and root surgery, these events are also 
considerably present after biological AVR, the Ross procedure and valve-sparing aortic 
root surgery (VSRR). Similarly, reoperation is more common after biological AVR, the Ross 
procedure and VSRR, but also occurs frequently after mechanical AVR and root replace-
ment. Published evidence in AVR patients points to the direction of better health-related 
quality of life (HRQoL) outcomes with a biological solutions, while the HRQoL after 
aortic root surgery is limited and contradictory. This review illustrates that treatment 
for non-elderly aortic valve and aortic root disease patients needs to be tailored to the 
individual patient, considering both clinical and HRQoL outcomes as crucial factors to 
reach a treatment decision that best reflects the patient’s values and goals in life.
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introDuction
Due to continued improvements in surgical technique and perioperative management, 
morbidity and mortality after aortic valve and aortic root surgery has decreased.1,2 The 
available tools in the tool-box of the cardiac surgeon have expanded. Besides the more 
common surgical procedures (i.e., valve replacement with mechanical or tissue valve 
prosthesis, with or without replacement of the aortic root), techniques that may be 
considered include the Ross procedure 3, valve-sparing root replacement and external 
aortic support [Personalized External Aortic Root Support 4, Florida sleeve 5]. Under-
usage of the more demanding Ross procedure is likely.6 However, not all procedures are 
equally applicable and careful patient selection is required. The choice for the optimal 
treatment strategy in patients aged 18-65 years (i.e., non-elderly patients) with aortic 
valve or aortic root disease is especially challenging. It requires careful weighing of the 
risks associated with the various treatment modalities, life expectancy and preferences 
of these young, mostly active patients. The objective of the current study is to present 
an overview of clinical outcomes and quality of life after aortic valve replacement (AVR) 
and aortic root surgery in non-elderly patients.
avr
To provide an overview of contemporary clinical outcomes after AVR, three recently 
published systematic reviews with meta-analysis and microsimulation analysis will be 
discussed.
Mechanical aortic valve replacement (Mavr)
“Mechanical Aortic Valve Replacement in Non-Elderly Adults: Meta-Analysis and Micro-
simulation” by Korteland et al. 7 is a systematic review and meta-analysis published in 
2017 including studies published between 01/1995- 12/2015 reporting clinical outcome 
after contemporary MAVR in patients with a mean age ≥18 and ≤55 years. Twenty-nine 
papers were included, encompassing 5,728 patients, 32,515 patient-years, and a pooled 
mean follow-up of 5.7 years. A bileaflet mechanical valve was implanted in 99.9% of 
pooled patients.
Bioprosthetic aortic valve replacement (Bavr)
“Bioprosthetic Aortic Valve Replacement in Nonelderly Adults: A Systematic Review, Me-
ta-Analysis and Microsimulation” by Etnel et al. 8 is a systematic review and meta-analysis 
published in 2019 including studies published between 01/2001-09/2016 reporting 
clinical outcome after contemporary BAVR in patients with a mean age between ≥18 
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and ≤55 years. Nineteen papers were included, encompassing 2,686 patients, 21,117 
patient-years, and a pooled mean follow-up of 7.9 years. Fifty-two percent of pooled 
patients received a porcine biological valve, 47.9% received a bovine pericardial valve. 
Seventy-eight point two percent of implanted valves were stented, 21.7% were stentless.
the ross procedure (ross)
“The Ross Procedure: A Systematic Review, Meta-Analysis, and Microsimulation” by Etnel 
et al. 9 is a systematic review and meta-analysis published in 2018 including studies pub-
lished between 01/2001-11/2017 reporting clinical outcome after the Ross procedure in 
adult and/or pediatric patients. Only the adult subgroup was considered in this review, 
including 35 papers, 6,892 patients, 49,435 patient-years and a pooled mean follow-
up of 8.4 years. Ninety-five point three percent of pooled patients received a total root 
replacement (TRR), 3.8% received an inclusion cylinder and 0.8% received a subcoronary 
implantation. The right ventricle outflow tract conduit was an allograft in 86% and a 
bioprosthesis in 14%.
All three papers used a microsimulation model to extrapolate pooled outcome estimates 
from the meta-analyses. Details of the concept of microsimulation have been previously 
published.9-11 In brief, meta-analysis-based estimates of operative and long-term mortal-
ity and surgery-related event rates are entered into the microsimulation model.
Using this data, the model estimates age-specific lifetime event risks, life expectancy, 
event free life expectancy and causes of mortality.
clinical outcome
Table 1 depicts the patient and procedural characteristics of the AVR studies. The clinical 
outcome estimates are depicted in Table 2.
early morbidity and mortality
Early stroke rate in MAVR was comparable to early thromboembolism rate in BAVR. 
Other early events could not be presented due to inconsistent reporting in the included 
studies. Early mortality risks were comparable after MAVR and BAVR. Early mortality was 
slightly lower after Ross compared to MAVR and BAVR. This difference is possibly due to 
the Ross procedure being performed by specialized surgeons.12 Furthermore, a selection 
bias in Ross patients towards a lower pre-operative risk could be present due to high-risk 
patients not being selected for the Ross procedure.
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late morbidity
The valve-related reintervention rate was highest after BAVR and slightly lower after 
the Ross procedure. Valve-related reintervention rate after MAVR was significantly lower 
compared to BAVR and Ross, however, still considerable. The reinterventions after MAVR 
were mostly caused by non-structural valve dysfunction (NSVD), valve thrombosis or 
prosthetic valve endocarditis. As expected, structural valve deterioration (SVD) was 
absent in the MAVR population. In the BAVR population, SVD event rate was 1.59%/y 
table 1. Baseline characteristics—aortic valve replacement
variable Mechanical avr Bioprosthetic avr ross
Pooled
estimate
range Pooled
estimate
range Pooled
estimate
range
total patient number 5,728 20-865 2,686 36-383 6,892 21-1,779
surgical period 1977-2014 1976-2013 1986-2016
total follow-up (patient-years) 32,515 21,117 49,435
Mean follow-up (years) 5.7 1-12 7.9 2.1-14.2 8.4 1.4-15.9
Mean age (years) 48 33-55 51 44-55 42 23-50
Male (%) 72 50-91 53 0.2-85 73 51-87
aortic valve haemodynamics (%)
Stenosis 43 0-100 41 20-77 41 11-73
Regurgitation 40 0-70 40 25-52 33 9-62
Mixed disease 16 0-30 19 12-49 26 0-55
etiology (%)
Degenerative 22 0-78 36 7-85 8 1-44
Endocarditis 10 0-100 13 0-11 19 3-100
Rheumatic 36 0-78 30 2-89 14 2-30
Congenital 17 0-57 10 0-62 52 38-84
Prosthetic valve dysfunction 4 0-22 - - - -
Other/unknown 12 0-66 10 0-30 6 5-18
nyHa class (%)
I/II - - 56 25-80 62 30-100
III/IV - - 44 21-81 38 0-70
Bicuspid aortic valve (%) 25 1-100 15 14-19 63 34-94
Prior cardiac operation (%) 8.4 0-26 8 0-13 13 8-72
emergency/urgent surgery (%) 3 0-35 6 0-21 4 1-50
concomitant surgery (%)
Ascending aorta 9 0-33 8 0-18 16 0-60
CABG 7 0-18 12 0-27 5 0-26
Other valve 3 0-25 12 0-27 5 0-23
AVR, aortic valve replacement; Ross, the Ross procedure; Range, range of the means of included studies; 
NYHA, New York Heart Association; CABG, coronary artery bypass grafting.
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(95% CI, 1.21-2.10%/y). NSVD was comparable between MAVR and BAVR. SVD and NSVD 
rates could not be presented for the Ross population due to insufficient reporting.
Thromboembolism rates were significantly higher after MAVR compared to BAVR and 
Ross. Major bleeding event rates were higher in MAVR compared to BAVR and Ross, due 
table 2. Outcome estimates—aortic valve replacement
variable Mechanical avr Bioprosthetic avr ross
Pooled 
estimate
range Pooled 
estimate
range Pooled 
estimate
range
early <30 days (%)
Mortality 3.15 2.37-4.21 3.3 2.39-4.55 2.01 1.44-2.82
Re-exploration for bleeding 5.15 2.57-11.81 4.08 1.96-8.51
Peripheral bleeding 0.41 0.15-1.09
Thromboembolism 1.6 0.89-2.87
 Stroke 1.55 0.98-2.46
 Transient ischemic attack 0.81 0.38-1.72
Valve thrombosis 0.3 0.09-1.05
Myocardial infarction 0.87 0.40-1.87
Endocarditis 0.43 0.16-1.13
DSI/mediastinitis 2.48 1.56-3.94
Pacemaker implantation 3.53 2.47-5.05
late >30 days (%/y)
Overall mortality 1.55 1.25-1.92 2.39 1.13-2.94 0.59 0.46-0.76
 Cardiac 0.95 0.71-1.27 0.96 0.71-1.29 0.24 0.17-0.33
 Valve-related 0.6 0.44-0.81 0.6 0.37-0.98 0.21 0.14-0.32
 SUUD 0.37 0.26-0.54 0.3 0.12-0.76 0.16 0.10-0.25
Valve-related reoperation 0.51 0.37-0.71 1.82 1.31-2.52 1.2 1.01-1.42
 Ross autograft 0.83 0.68-1.01
 Ross RVOT 0.47 0.37-0.59
Hemorrhage 0.85 0.65-1.12 0.22 0.16-0.32 0.1 0.01-0.67
Thromboembolism 0.9 0.68-1.21 0.53 0.42-0.67 0.17 0.11-0.27
Valve thrombosis 0.14 0.08-0.25 0.07 0.02-0.20 0.03 0.01-0.09
SVD 0.00 0.00-0.00 1.59 1.21-2.10
NSVD 0.39 0.21-0.76 0.24 0.10-0.58
Endocarditis 0.41 0.29-0.57 0.48 0.37-0.62
 Ross autograft 0.18 0.09-0.39
 Ross RVOT 0.14 0.09-0.21
Pacemaker implantation 0.25 0.05-1.17
AVR, aortic valve replacement; Ross, the Ross procedure; CI, confidence interval; DSI, deep sternal wound 
infection; RVOT, right ventricular outflow tract.
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to the use of oral anticoagulant therapy after MAVR. Although lower compared to MAVR, 
anticoagulant therapy related events were considerable in BAVR and Ross and should 
be taken into consideration in prosthetic valve selection. Event risks accumulate during 
the patients’ lifetime and are considerable, especially in young patients. This accumula-
tion of risks (“lifetime event risks”) can be calculated using microsimulation. The lifetime 
event risks for a 45-yearold patient receiving either a MAVR, BAVR or a Ross procedure 
are presented in Figure 1. It is important to note that these estimates should not be 
compared between the populations due to the differences in patient characteristics. Vi-
sualization of lifetime risks using microsimulation provides more comprehensive insight 
into the risks for an individual patient and can aid in decision-making.
late mortality
Late overall mortality rates were highest after BAVR, followed by MAVR. Late overall 
mortality after the Ross procedure was significantly lower compared to mechanical and 
bioprosthetic AVR. Late valve-related mortality rates were comparable between mechani-
cal and bioprosthetic AVR and significantly lower after the Ross procedure. Whether the 
observed difference is due to patient selection or due to the Ross procedure providing the 
patient with a living neo-aortic valve with excellent hemodynamics, is a topic of debate.
376 Gökalp et al. AVR and root surgery in non-elderly
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2019;8(3):372-382 | http://dx.doi.org/10.21037/acs.2019.04.07
using microsimulation. The lifetime event risks for a 45-year-
old patient receiving either a MAVR, BAVR or a Ross 
procedure are presented in Figure 1. It is important to note 
that these estimates should not be compared between the 
populations due to the differences in patient characteristics. 
Visualization of lifetime risks using microsimulation provides 
more comprehensive insight into the risks for an individual 
patient and can aid in decision-making.
Late mortality
Late overall mortality rates were highest after BAVR, 
followed by MAVR. Late overall mortality after the Ross 
procedure was significantly lower compared to mechanical 
and bioprosthetic AVR. Late valve-related mortality rates 
were comparable between mechanical and bioprosthetic 
AVR and significantly lower after the Ross procedure. 
Whether the observed difference is due to patient selection 
or due to the Ross procedure providing the patient with a 
living neo-aortic valve with excellent hemodynamics, is a 
topic of debate.
The higher overall mortality in BAVR patients might 
be due to a worse preoperative profile, including older 
age, larger proportion of female patients and degenerative 
etiology. BAVR patients also undergo concomitant CABG 
and valve procedures more often, suggesting more advanced 
cardiac disease. In addition, BAVR patients might have a 
lower life expectancy due to various reasons and therefore 
receive a BAVR, causing a selection bias. 
The higher overall mortality in BAVR patients is not 
likely to be attributable to the differences in valve-related 
mortality causes, as is shown by the comparable late valve-
related mortality. This is important when considering 
prosthetic valve selection.
Ross patients have lower postoperative endocarditis, 
thromboembolism and bleeding rates, possibly explaining 
the lower late mortality rate. The difference in overall and 
valve-related mortality in Ross patients is small, suggesting 
that there is little excess mortality. This might be due to 
their preoperative profile (i.e., younger patients, lower 
NYHA class, congenital etiology), specialized surgeons 
and excellent hemodynamics following the Ross procedure 
(12,13). In addition, patients receiving the Ross procedure 
might experience better postoperative surveillance due 
to the complexity of the surgery and the specialization of 
institutions in which they are operated. Another factor that 
might contribute is that congenital patients and patients 
with a higher socio-economic status or education level 
might be more involved in their disease and treatment 
decision-making, do more research, and therefore choose 
Figure 1 Microsimulation estimated lifetime event risks for a 45-year-old mechanical AVR, biological AVR or Ross patient. For Ross valve-
related reintervention both autograft and RVOT reinterventions are included: isolated autograft reintervention 43.46%, isolated RVOT 
reintervention 14.09%, concomitant autograft + RVOT reintervention 5.23%. AVR, aortic valve replacement; RVOT, right ventricular 
outflow tract.
Lifetime event risks for a 45-year-old patient
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figure 1. Microsimulation estimated lifetime event risks for a 45-year-old mechanical AVR, biological AVR 
or Ross patient. For Ross valve-related reintervention both autograft and RVOT reinterventions are includ-
ed: isolated autograft reintervention 43.46%, isolated RVOT reintervention 14.09%, concomitant autograft 
+ RVOT reintervention 5.23%. AVR, aortic valve replacement; RVOT, right ventricular outflow tract.
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The higher overall mortality in BAVR patients might be due to a worse preoperative 
profile, including older age, larger proportion of female patients and degenerative 
etiology. BAVR patients also undergo concomitant CABG and valve procedures more 
often, suggesting more advanced cardiac disease. In addition, BAVR patients might have 
a lower life expectancy due to various reasons and therefore receive a BAVR, causing a 
selection bias.
The higher overall mortality in BAVR patients is not likely to be attributable to the differ-
ences in valve-related mortality causes, as is shown by the comparable late valve-related 
mortality. This is important when considering prosthetic valve selection.
Ross patients have lower postoperative endocarditis, thromboembolism and bleeding 
rates, possibly explaining the lower late mortality rate. The difference in overall and 
valve-related mortality in Ross patients is small, suggesting that there is little excess 
mortality. This might be due to their preoperative profile (i.e., younger patients, lower 
NYHA class, congenital etiology), specialized surgeons and excellent hemodynamics fol-
lowing the Ross procedure.12,13 In addition, patients receiving the Ross procedure might 
experience better postoperative surveillance due to the complexity of the surgery and 
the specialization of institutions in which they are operated. Another factor that might 
contribute is that congenital patients and patients with a higher socio-economic status 
or education level might be more involved in their disease and treatment decision-
making, do more research, and therefore choose the Ross procedure more often. This 
type of patient might also be more involved in their postoperative care and thus receive 
better care and in addition might generally live a healthier lifestyle.14,15 This underlines 
the need for more patient involvement and empowerment to improve clinical outcome 
and quality of life.
The meta-analysis based microsimulation estimates of life expectancy for patients un-
dergoing MAVR, BAVR and Ross are presented in Figure 2 alongside the respective gen-
eral population life expectancies. It is important to note that the differences between 
the interventional population estimates cannot be compared as they were derived from 
different study populations.
aortic root surgery
Two recent systematic reviews with meta-analysis give an overview of current available 
evidence for outcomes after mechanical TRR and valve-sparing root replacement.
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total root replacement (trr)
Mookhoek et al. published a meta-analysis of the reported outcomes after mechanical 
Bentall operations.16 They included 46 studies and a total of 7,629 patients, operated 
between 1968-2012. Mean clinical follow-up was 6.4 years (range, 3.0-10.4 years), result-
ing in 49,175 patient-years. The pooled average age was 49.8 years.
valve sparing root replacement (vsrr)
Arabkhani et al. published a meta-analysis of reported outcomes after valve-sparing 
aortic root replacement in 2015.17 Their search resulted in 31 reports over a 14-year pe-
riod [2000-2014], including 4,777 patients, operated between 1988-2012. Mean clinical 
follow-up was 4.4 years (range, 1.5-13.2 years) and 21,716 patients-years. The pooled 
average age was 51.0 years.
clinical outcome
The pooled pre- and perioperative characteristics of both studies are depicted in Table 
3. Table 4 depicts the pooled early and late clinical outcomes.
early mortality
Early morbidity was not reported in the systematic reviews. Pooled early mortality was 
higher after TRR compared to VSRR. This difference can be explained by the higher 
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the Ross procedure more f en. This typ  of patient might 
also be more involved in their postoperative care and thus 
receive better care and in addition might generally live a 
healthier lifestyle (14,15). This underlines the need for 
more patient involvement and empowerment to improve 
clinical outcome and quality of life.
The meta-analysis based microsimulation estimates of 
life expectancy for patients undergoing MAVR, BAVR 
and Ross are presented in Figure 2 alongside the respective 
general population life expectancies. It is important to note 
that the differences between the interventional population 
estimates cannot be compared as they were derived from 
different study populations.
Aortic root surgery
Two recent systematic reviews with meta-analysis give an 
overview of current available evidence for outcomes after 
mechanical TRR and valve-sparing root replacement.
Total root replacement (TRR)
Mookhoek et al. published a meta-analysis of the reported 
outcomes after mechanical Bentall operations (16). They 
included 46 studies and a total of 7,629 patients, operated 
between 1968–2012. Mean clinical follow-up was 6.4 years 
(range, 3.0–10.4 years), resulting in 49,175 patient-years. 
The pooled average age was 49.8 years.
Valve sparing root replacement (VSRR)
Arabkhani et al. published a meta-analysis of reported 
outcomes after valve-sparing aortic root replacement in 
2015 (17). Their search resulted in 31 reports over a 14-year 
period [2000–2014], including 4,777 patients, operated 
b tween 1988–2012. Mean clinical follow-up was 4.4 years 
( ange, 1.5–13.2 years) and 21,716 patients-years. The 
pooled average age was 51.0 years.
Clinical outcome
The pooled pre- and perioperative characteristics of both 
studies are depicted in Table 3. Table 4 depicts the pooled 
early and late clinical outcomes.
Early mortality
Early morbidity was not reported in the systematic reviews. 
Pooled early mortality was higher after TRR compared 
to VSRR. This difference can be explained by the higher 
prevalence of emergency surgery, aortic dissections and 
previous cardiac surgery in the TRR population. 
Figure 2 Microsimulation estimated life expectancy following mechanical AVR, biological AVR and Ross surgery (solid lines) and age- and 
sex-matched general population (dashed lines). AVR, aortic valve replacement.
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prevalence of emergency surgery, aortic dissections and previous cardiac surgery in the 
TRR population.
late morbidity
Reoperation rates were higher after VSRR compared to TRR. Bleeding rates were higher 
after TRR, due to the mandatory use of life-long anticoagulation therapy in TRR.
late mortality
The pooled late mortality rate was lower after VSRR compared to TRR. This difference can 
be explained by the preoperative differences between the populations and the lower 
overall event occurrence in the VSRR population. However, it should be stressed that a 
direct comparison between these two populations cannot be made using these data.
table 3. Baseline characteristics—aortic root surgery
variable trr vsrr
Pooled 
estimate
range Pooled 
estimate
range
total patient number 7,629 40-675 4,777 32-430
surgical period 1968-2012 1988-2012
total follow-up (patient-years) 49,175 21,716
Mean follow-up (years) 6.4 3-10.4 4.4 1.5-13.2
Mean age (years) 50 29-65 51 29-63
Male (%) 76 55-91 71 57-85
aortic valve haemodynamics (%)
Stenosis
Regurgitation 46* 6-100
Mixed disease
etiology (%)
Type A dissection 15 0-39 11 0-33
Endocarditis 2 0-15
Connective tissue disease 23 0-100 24 0-100
Bicuspid aortic valve 25 4-100 14 0-33
Prior cardiac operation (%) 16 1-7 4 2-12
Mechanical valve (%) 93 43-100
concomitant surgery (%)
CABG 12 0-31 9 0-19
Valve surgery 6 0-12 5 0-12
(Hemi)arch 12 0-39 22 0-68
*severe AR is reported. TRR, total root replacement; VSRR, valve-sparing root replacement; Range, range of 
the means of included studies; CABG, coronary artery bypass grafting.
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HealtH relateD Quality of life outcoMes
There is a growing body of observational evidence on quality of life after AVR. The 
landmark paper by Aicher et al. studied quality of life and anxiety and depression after 
mechanical valve implantation, the Ross procedure and aortic valve repair. It found that 
quality of life, including valve-related aspects such as valve sound, frequency of doctor 
visits and fear of potential complications, is influenced by the type of operation. Patients 
who received mechanical prostheses had worse general health, physical functioning 
and mental health and more cardiac-related anxiety.18 These observations have been 
confirmed by several other studies, that all point into the direction of a better QoL with 
a biological solution.19,20
Contemporary evidence on QoL outcomes after aortic root surgery was reviewed by de 
Heer et al. and showed that limited and only observational data with contradicting re-
sults are available.21 Although a study by Olsson et al. in 1999 showed significantly worse 
health-related QoL outcomes for patients after thoracic aortic surgery compared to the 
general population, an updated study in 2013 showed comparable QoL.22,23 This may 
be the result of advances in cardiac surgery and improved cardiovascular care in more 
recent years and is in agreement with other recent studies that report QoL in thoracic 
aortic surgery patients to be comparable to the general population.24-26 There is some 
evidence on differences in QoL between aortic root surgery strategies: observational 
evidence suggests that QoL after surgery is significantly worse in most of the domains of 
the SF-36 in patients after TRR versus VSRR surgery. TRR patients reported to be signifi-
table 4. Outcome estimates—aortic root surgery
variable trr vsrr
Pooled estimate 95% ci Pooled estimate 95% ci
early <30 days (%)
Mortality 5.6 - 2.2 -
late >30 days (%/y)
Overall mortality 2.02 1.77-2.31 1.53 1.19-1.96
 Valve-related 0.46 0.36-0.59
Valve-related reoperation 0.3 0.22-0.41 1.32 1.0-1.74
Root-related reoperation 0.46 0.36-0.59
Hemorrhage 0.64 0.47-0.87 0.23 0.13-0.42
Thromboembolism 0.77 0.60-1.00 0.41 0.22-0.77
Endocarditis 0.39 0.33-0.46 0.23 0.11-0.51
MAVRE 2.66 2.17-3.24 1.66 1.24-2.23
TRR, total root replacement; VSRR, valve-sparing root replacement; CI, confidence interval; %/y, percentage 
per patient-year; MAVRE, major adverse valve-related event.
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cantly more disturbed by valve sound, more afraid that their valve will fail and assigned 
a lower score to their overall condition.27 There is no evidence that there is a difference 
between mechanical versus biological TRR surgery.28
Given these observations, the notion arises that it is important to consider QoL as a 
crucial factor in treatment selection for both AVR and aortic root surgery, in order to 
reach an evidence-based and patient-centered treatment decision that best reflects 
the patient’s values and goals in life. The concept of shared decision-making allows 
physicians and patients to reach such decisions, and is gaining interest throughout the 
world and even in the European and US guidelines for the management of valvular heart 
disease.29,30 There is growing evidence that tools to support shared decision-making in 
prosthetic heart valve selection are indeed effective in reducing anxiety and depression 
and improving mental health and knowledge in patients who are facing heart valve 
replacement.31
future PersPectives
Patient tailored treatment
The continued decline in mortality after aortic valve and aortic root surgery over the 
years calls for a shift in focus in clinical decision-making towards quality of life. As 
demonstrated by the evidence outlined above, all currently available options for aortic 
valve and root surgery remain imperfect. The outcome profiles of the various treatment 
options are in stark contrast to one another, each with different implications for many 
aspects of patients’ lives, both physical and psychosocial.
As treatment decisions have such an important impact on patients’ lives, choosing the 
optimal treatment tailored for each patient with regard for individual values, prefer-
ences and life planning is of utmost importance. Because preferences and treatment 
goals vary between individual patients and also between patients and their physicians, 
involvement of patients in the decision-making process is essential. Although both 
physicians and patients have been found to prefer shared roles in decision-making, 
physicians still experience substantial difficulty in adequately informing and involving 
their patients.32-34 Thus, there is an urgent need for innovative solutions to aid in more 
effectively informing and involving patients. In this light, online patient information 
portals and decision aids present promising opportunities.31,35 Methods for elucidating 
patients’ values, preferences and treatment goals and how these can effectively be 
incorporated in decision-making should be explored.
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The evolution of clinical outcome over the years should also translate to a shift in research 
focus from classical outcome measures such as survival and event occurrence towards 
patient-centered outcomes that better reflect what is valuable and meaningful to pa-
tients. It remains to be elucidated which outcomes patients value most after aortic valve 
and aortic root surgery. In any case, high quality evidence on clinical outcome remains 
indispensable. The AVIATOR initiative of the Heart Valve Society (HVS) is a longitudinal 
multicenter international registry that focuses on patients with aortic valve insufficiency 
and/or a dilated ascending aorta. The wish is to embrace the complete disease trajec-
tory, starting from the diagnoses, including operation and long-time follow-up. Since 
2013 the AVIATOR Adult Surgical Registry is enrolling patients and comprises already 
5,000 cases.36 Furthermore, the HVS started a new initiative to evaluate prosthetic AVR: 
the LEOPARD registry. These multicenter registries should provide a solid evidence 
base, by applying uniform definitions, to evaluate long-term patient outcomes for the 
different treatment strategies for aortic valve root disease in non-elderly patients. The 
addition of quality of life outcomes to the AVIATOR and LEOPARD registries could be of 
great added value.
novel treatment strategies
Unfortunately, “one valve for life” is not yet on the horizon. Research into tissue en-
gineered valves has made great progress, however in vivo use in humans is not yet 
available.37,38 Meanwhile, other novel treatment strategies are available that are possibly 
underutilized.
Advances in aortic valve repair might provide improved outcomes. Furthermore, 
minimally invasive techniques are developing. In the prevention of further aortic root 
dilatation in Marfan patients, a new stabilization technique was introduced: Personal-
ized External Aortic Root Support (PEARS). The individual’s aortic root is replicated by a 
3-dimensional printed model to produce an individualized polymer mesh sleeve, which 
is wrapped around the aorta. Over a 12-year period [2004-2016] more than 60 patients 
were treated with PEARS in six centers.4
With the promise of more durable bioprostheses, the possibility of transcatheter valve-
in-valve procedures might become available for younger patients. However, both the 
prolonged durability of bioprostheses and transcatheter valve-in-valve outcomes are 
not sufficiently researched in non-elderly patients.
If anticoagulation therapy is unavoidable, reducing associated events is of great impor-
tance. New mechanical prostheses are being developed that require lower INR levels.39 
Optimized anticoagulation therapy through self-management can achieve comparable 
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survival between Ross patients and MAVR patients.40 Two studies included in the BAVR 
systematic review reported that at the end of follow-up 25-30% of the BAVR patients 
required oral anticoagulants, mostly due to atrial fibrillation.41,42 In an effort to reduce 
anticoagulation-related events, characteristics that put BAVR patients at risk for atrial 
fibrillation should be explored. Furthermore, research into the use of NOAC’s for atrial 
fibrillation shows this might be a safe treatment strategy in BAVR.43
conclusions
This review provides an overview of current evidence on aortic valve and aortic root re-
placement in non-elderly adults. The differences in clinical outcome between treatment 
options are not a black-and-white issue and this underlines the need for individual pa-
tient tailored treatment and shared decision-making. Involved and empowered patients 
can make informed decisions and consequently experience improved clinical outcome 
and quality of life.
235
Clinical and QoL outcomes after aortic valve and root surgery in non-elderly adults
7
references
 1. Siregar S, de Heer F, Groenwold RH, et al. Trends and outcomes of valve surgery: 16-year results of 
Netherlands Cardiac Surgery National Database. Eur J Cardiothorac Surg 2014;46:386-97; discus-
sion 397.
 2. Fujita B, Ensminger S, Bauer T, et al. Trends in practice and outcomes from 2011 to 2015 for 
surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42 776 
patients. Eur J Cardiothorac Surg 2018;53:552-9.
 3. Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft. Lancet 1967;2:956-
8.
 4. Treasure T, Petrou M, Rosendahl U, et al. Personalized external aortic root support: a review of the 
current status. Eur J Cardiothorac Surg 2016;50:400-4.
 5. Hess PJ Jr, Klodell CT, Beaver TM, et al. The Florida sleeve: a new technique for aortic root remodel-
ing with preservation of the aortic valve and sinuses. Ann Thorac Surg 2005;80:748-50.
 6. Yacoub MH, El-Hamamsy I, Sievers HH, et al. Underuse of the Ross operation--a lost opportunity. 
Lancet 2014;384:559-60.
 7. Korteland NM, Etnel JR, Arabkhani B, et al. Mechanical aortic valve replacement in non-elderly 
adults: metaanalysis and microsimulation. Eur Heart J 2017;38:3370-7.
 8. Etnel JRG, Huygens SA, Grashuis P, et al. Bioprosthetic Aortic Valve Replacement in Nonelderly 
Adults: A Systematic Review, Meta-Analysis, Microsimulation. Circ Cardiovasc Qual Outcomes 
2019;12:e005481.
 9. Etnel JR, Grashuis P, Huygens SA, et al. The Ross Procedure: A Systematic Review, Meta-Analysis, 
and Microsimulation. Circ Cardiovasc Qual Outcomes 2018;11:e004748.
 10. Puvimanasinghe JP, Takkenberg JJ, Edwards MB, et al. Comparison of outcomes after aortic 
valve replacement with a mechanical valve or a bioprosthesis using microsimulation. Heart 
2004;90:1172-8.
 11. Huygens SA, Rutten-van Molken MP, Bekkers JA, et al. Conceptual model for early health technol-
ogy assessment of current and novel heart valve interventions. Open Heart 2016;3:e000500.
 12. Ouzounian M, Mazine A, David TE. The Ross procedure is the best operation to treat aortic steno-
sis in young and middle-aged adults. J Thorac Cardiovasc Surg 2017;154:778-82.
 13. Um KJ, McClure GR, Belley-Cote EP, et al. Hemodynamic outcomes of the Ross procedure versus 
other aortic valve replacement: a systematic review and meta-analysis. J Cardiovasc Surg (Torino) 
2018;59:462-70.
 14. Mosen DM, Schmittdiel J, Hibbard J, et al. Is patient activation associated with outcomes of care 
for adults with chronic conditions? J Ambul Care Manage 2007;30:21-9.
 15. Goossens E, Fieuws S, Van Deyk K, et al. Effectiveness of structured education on knowledge and 
health behaviors in patients with congenital heart disease. J Pediatr 2015;166:1370-6.e1.
 16. Mookhoek A, Korteland NM, Arabkhani B, et al. Bentall Procedure: A Systematic Review and Meta-
Analysis. Ann Thorac Surg 2016;101:1684-9.
236
 17. Arabkhani B, Mookhoek A, Di Centa I, et al. Reported Outcome After Valve-Sparing Aortic Root 
Replacement for Aortic Root Aneurysm: A Systematic Review and Meta-Analysis. Ann Thorac Surg 
2015;100:1126-31.
 18. Aicher D, Holz A, Feldner S, et al. Quality of life after aortic valve surgery: replacement versus 
reconstruction. J Thorac Cardiovasc Surg 2011;142:e19-24.
 19. Ruel M, Kulik A, Lam BK, et al. Long-term outcomes of valve replacement with modern prostheses 
in young adults. Eur J Cardiothorac Surg 2005;27:425-33; discussion 433.
 20. Zacek P, Holubec T, Vobornik M, et al. Quality of life after aortic valve repair is similar to Ross 
patients and superior to mechanical valve replacement: a cross-sectional study. BMC Cardiovasc 
Disord 2016;16:63.
 21. de Heer F, Gokalp AL, Kluin J, et al. Measuring what matters to the patient: health related quality 
of life after aortic valve and thoracic aortic surgery. Gen Thorac Cardiovasc Surg 2019;67:37-43.
 22. Olsson C, Thelin S, Stahle E, et al. Thoracic aortic aneurysm and dissection: increasing prevalence 
and improved outcomes reported in a nationwide populationbased study of more than 14,000 
cases from 1987 to 2002. Circulation 2006;114:2611-8.
 23. Olsson C, Thelin S. Quality of life in survivors of thoracic aortic surgery. Ann Thorac Surg 
1999;67:1262-7.
 24. Jarral OA, Kidher E, Patel VM, et al. Quality of life after intervention on the thoracic aorta. Eur J 
Cardiothorac Surg 2016;49:369-89.
 25. Lohse F, Lang N, Schiller W, et al. Quality of life after replacement of the ascending aorta in pa-
tients with true aneurysms. Tex Heart Inst J 2009;36:104-10.
 26. Stalder M, Staffelbach S, Immer FF, et al. Aortic root replacement does not affect outcome and 
quality of life. Ann Thorac Surg 2007;84:775-80; discussion 780-1.
 27. Franke UF, Isecke A, Nagib R, et al. Quality of life after aortic root surgery: reimplantation tech-
nique versus composite replacement. Ann Thorac Surg 2010;90:1869-75.
 28. Lehr EJ, Wang PZ, Oreopoulos A, et al. Midterm outcomes and quality of life of aortic root replace-
ment: mechanical vs biological conduits. Can J Cardiol 2011;27:262.e15-20.
 29. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular 
heart disease. Eur Heart J 2017;38:2739-91.
 30. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ ACC guideline for the management of pa-
tients with valvular heart disease: a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014;148:e1-132.
 31. Korteland NM, Ahmed Y, Koolbergen DR, et al. Does the Use of a Decision Aid Improve Decision 
Making in Prosthetic Heart Valve Selection? A Multicenter Randomized Trial. Circ Cardiovasc Qual 
Outcomes 2017. doi: 10.1161/CIRCOUTCOMES.116.003178.
 32. Etnel JRG, Helbing WA, Roos-Hesselink JW, et al. Patient and physician view on patient infor-
mation and decision-making in congenital aortic and pulmonary valve surgery. Open Heart 
2018;5:e000872.
237
Clinical and QoL outcomes after aortic valve and root surgery in non-elderly adults
7
 33. Korteland NM, Kluin J, Klautz RJ, et al. Cardiologist and cardiac surgeon view on decision-making 
in prosthetic aortic valve selection: does profession matter? Neth Heart J 2014;22:336-43.
 34. Korteland NM, Bras FJ, van Hout FM, et al. Prosthetic aortic valve selection: current patient experi-
ence, preferences and knowledge. Open Heart 2015;2:e000237.
 35. Etnel JR, van Dijk AP, Kluin J, et al. Development of an Online, Evidence-Based Patient Information 
Portal for Congenital Heart Disease: A Pilot Study. Front Cardiovasc Med 2017;4:25.
 36. de Heer F, Kluin J, Elkhoury G, et al. AVIATOR: An open international registry to evaluate medi-
cal and surgical outcomes of aortic valve insufficiency and ascending aorta aneurysm. J Thorac 
Cardiovasc Surg 2018. [Epub ahead of print].
 37. Hjortnaes J, Bouten CV, Van Herwerden LA, et al. Translating autologous heart valve tissue engi-
neering from bench to bed. Tissue Eng Part B Rev 2009;15:307-17.
 38. Nachlas AL, Li S, Davis ME. Developing a Clinically Relevant Tissue Engineered Heart Valve-A 
Review of Current Approaches. Adv Healthc Mater 2017. doi: 10.1002/adhm.201700918.
 39. Torella M, Aquila I, Chiodini P, et al. Low-dose anticoagulation after isolated mechanical aortic 
valve replacement with Liva Nova Bicarbon prosthesis: A post hoc analysis of LOWERING-IT Trial. 
Sci Rep 2018;8:8405.
 40. Mokhles MM, Kortke H, Stierle U, et al. Survival comparison of the Ross procedure and mechanical 
valve replacement with optimal self-management anticoagulation therapy: propensity-matched 
cohort study. Circulation 2011;123:31-8.
 41. Forcillo J, El Hamamsy I, Stevens LM, et al. The perimount valve in the aortic position: twenty-year 
experience with patients under 60 years old. Ann Thorac Surg 2014;97:1526-32.
 42. Minakata K, Tanaka S, Takahara Y, et al. Long-term durability of pericardial valves in the aortic posi-
tion in younger patients: when does reoperation become necessary? J Card Surg 2015;30:405-13.
 43. Andrade JG, Meseguer E, Didier R, et al. Non-vitamin K antagonist oral anticoagulants in atrial 
fibrillation patients with bioprosthetic valves. Expert Rev Cardiovasc Ther 2018. [Epub ahead of 
print]

8
Decellularized versus standard pulmonary 
allografts in the Ross procedure: 
propensity-matched analysis
Francisco D.A. da Costa*, Jonathan R.G. Etnel*, Efstratios I. Charitos, Hans-Hinrich 
Sievers, Ulrich Stierle, Daniele Fornazari, Johanna J.M. Takkenberg, Ad J.J.C. Bogers, 
and M. Mostafa Mokhles
*Shared first authorship
Ann Thorac Surg. 2018 Apr;105(4):1205-1213.
240
aBstract
Background
It is hypothesized that decellularization of allografts used for right ventricular outflow 
tract reconstruction may result in decreased valve deterioration. This study compared 
the durability of fresh decellularized pulmonary allografts with standard cryopreserved 
pulmonary allografts in patients undergoing the Ross procedure.
Methods
The Ross procedure was performed in 144 patients with decellularized allografts (DA) 
from 2005 to 2014 and in 619 with standard cryopreserved allografts (SCA) from 1990 
to 2014. Propensity score matching was used to compare early and midterm clinical 
outcome and echocardiographic allograft function over time between the two groups.
results
We matched 94 DA patients (79.3% male; median age, 34.0 years; mean follow-up, 2.4 
± 1.9 years) to 94 SCA patients (78.3% male; median age, 35.0 years; mean follow-up, 
9.4 ± 4.2 years). There were no significant differences in baseline characteristics after 
matching. The matched DA vs SCA groups, respectively, were comparable in actuarial 
5-year freedom from allograft dysfunction (85.6% [95% confidence interval {CI}, 53.9% to 
96.2%] vs 93.3% [95% CI, 85.7% to 96.9%], p = 0.892), freedom from allograft reinterven-
tion (98.8% [95% CI, 91.7% to 99.8%] vs 95.5% [95% CI, 88.5% to 98.3%], p = 0.383), sur-
vival (95.3% [95% CI, 87.8% to 98.2%] vs 97.7% [95% CI, 91.3% to 99.4%], p = 0.323), and 
event-free survival (83.5% [95% CI, 70.6% to 91.1%] vs 84.5% [95% CI, 75.2% to 90.5%], p 
= 0.515). Longitudinal echocardiographic analyses showed a similarly modest increase 
in allograft gradient and regurgitation grades over time in both groups, although direct 
statistical comparison was not possible.
conclusions
Up to 5 years of follow-up, DA and SCA used for right ventricular outflow tract recon-
struction in the Ross procedure are associated with comparably excellent clinical and 
hemodynamic outcome. Longer follow-up and dedicated echocardiographic studies 
will shed light on the long-term performance of DAs.
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introDuction
Replacement of the aortic valve with a pulmonary autograft (the Ross procedure) was 
introduced in the late 1960s 1 and is considered the preferred option for aortic valve 
replacement in children and young adults by many experts owing to the favorable 
hemodynamic characteristics, low risk of endocarditis, low thrombogenicity, avoidance 
of anticoagulation therapy, and its growth potential.2, 3 However, this procedure requires 
reconstruction of the right ventricular outflow tract (RVOT) from which the pulmonary 
autograft was harvested, which is most commonly accomplished with pulmonary al-
lografts.4
Standard cryopreserved allografts are susceptible to valve degeneration, which results 
in an increased risk of reoperation.3 There is increasing experimental and clinical evi-
dence that suggests the limited durability of these valves may be partly caused by the 
elicited host immune response.5-8 In response, decellularization techniques have been 
developed that reduce the graft cellularity, leaving an intact extracellular matrix scaf-
fold.9 These decellularized allografts have been introduced into clinical use for RVOT 
reconstruction, and although early results have been promising, midterm comparisons 
of decellularized allografts (DAs) with standard cryopreserved allografts (SCAs) are 
scarce, often small in size, and seldom focused on the Ross procedure.10-13 Consequently, 
the effect of decellularization on late RVOT allograft function remains unclear, especially 
when applied in the setting of the Ross procedure.
We therefore conducted a propensity-matched comparison of midterm clinical out-
comes and echocardiographic allograft function over time after RVOT reconstruction 
with fresh DAs vs SCAs in the Ross procedure.
MetHoDs
Between May 2005 and July 2014, 144 patients underwent the Ross procedure with the 
use of fresh DAs for RVOT reconstruction at Santa Casa de Curitiba, Pontifícia Universi-
dade Católica do Paraná.14 In addition, 619 patients underwent the Ross procedure with 
the use of SCA for RVOT reconstruction at the University of L€ubeck between February 
1990 and August 2014.15 All allografts were of pulmonary origin, and no aortic allografts 
were used. Demographic, clinical, and echocardiographic data on all patients in the DA 
and the SCA groups were prospectively collected. This study was approved by The Insti-
tutional Review Board of the participating centers, and informed consent was waived.
242
surgical technique and decellularization
The surgical techniques have been previously described.13, 15 In summary, all operations 
were performed by a single surgeon in each center (F.D.A.C. and H.H.S.) through a me-
dian sternotomy with standard cardiopulmonary bypass and mild to moderate systemic 
hypothermia with the use of cold blood or crystalloid cardioplegia for myocardial pro-
tection. Operative details are listed in Table 1. Implantation of the pulmonary allografts 
was performed in a similar fashion for DA and SCA patients (Supplement 1).
All pulmonary allografts in the DA group were decellularized with a proprietary 0.1% 
solution of sodium dodecylsulfate and kept in cold (4°C) phosphate-buffered saline 
solution for up to 90 days before implantation. Further details on the acquisition, pro-
cessing, and decellularization process have been previously described.6, 13
clinical and echocardiographic follow-up
Postoperative clinical and two-dimensional echocardiographic assessment was sched-
uled at discharge and at 6 months, 1 year, and yearly thereafter for all patients. SCA 
patients had an additional examination at 3 months after the operation. Maximum 
velocities across the RVOT allograft were obtained by continuous Doppler measure-
ment, and pressure gradients were calculated by the modified Bernoulli equation. The 
degree of conduit regurgitation was estimated by the maximum length and area of 
the regurgitant jet at the level of the outflow tract 16 and graded as absent, trivial, mild 
(grade 1), moderate (grade 2), or severe (grade 3/4). Follow-up in the unmatched cohort 
was 98.5% complete overall, consisting of 91.8% in the DA group and 98.8% in the SCA 
group.
table 1. Operative details
variablea unmatched Matched
Da (n = 144) sca (n = 619) p value Da (n= 94) sca (n = 94) p value
operative technique <0.001 <0.001
Root replacement 121 (84.0%) 15 (2.4%) 78 (83.0%) 2 (2.1%)
Subcoronary implantation 0 (0.0%) 571 (92.2%) 0 (0.0%) 91 (96.8%)
Inclusion cylinder 23 (16.0%) 33 (5.3%) 16 (17.0%) 1 (1.1%)
allograft diameter, mm 24 (14-30) 26 (22-32) <0.001 24 (18-30) 26 (24-30) <0.001
rvot adjustmentb 70 (48.6%) 232 (37.5%) 0.014 40 (42.6%) 39 (41.5%) 1.000
fenestration 57 (39.6%) 226 (36.5%) 0.492 36 (38.3%) 32 (34.0%) 0.636
Donor age, y 42 (5-59) 49 (0-69) <0.001 42 (18-59) 51 (21-63) <0.001
Male donor 104 (72.2%) 387 (62.5%) 0.641 67 (71.3%) 60 (63.8%) 1.000
a Continuous data are expressed as median (range) and categorical data as count (%). b RVOT myocardial 
resection and/or patch augmentation.
DA = decellularized allograft; RVOT = right ventricular outflow tract; SCA = standard cryopreserved allograft.
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Data collection
All data were prospectively collected. Outcome events were defined according to the 
reporting guidelines.17 Allografts that developed grade 3 or higher regurgitation or a 
peak Doppler gradient of 36 mm Hg or more, or both, were considered dysfunctional 
.18 The composite end point of “any event” included death from any cause, endocarditis, 
thromboembolism, major bleeding, reintervention, development of allograft dysfunc-
tion, and permanent pacemaker implantation.
Propensity score construction and analyses
As there were significant differences between the DA and SCA patients in most baseline 
characteristics (Table 2), we performed both propensity score adjustment and propen-
sity score matching.19, 20 The propensity scores were constructed using a nonparsimo-
nious multivariable logistic regression model with the treatment variable (DA vs SCA) 
as the dependent variable. Because of their statistical and/or clinical significance, all 
baseline characteristics listed in Table 2 were included as covariates in the propensity 
model.19, 21, 22
For propensity score-adjusted analyses, the propensity score and the treatment alloca-
tion variable (DA vs SCA) were both entered into a logistic regression model for 30- day 
mortality and Cox proportional hazards models for late death, allograft reintervention, 
allograft dysfunction, and the occurrence of any event.
In addition, propensity score matching was conducted at a 1:1 ratio with the use of the 
nearest neighbor matching method because there was evidence of inadequate propen-
sity adjustment in the propensity score-adjusted analyses (the propensity score was 
statistically significant in the adjusted Cox regression model for late death and allograft 
dysfunction).22, 23 A propensity score difference of 0.25 was used as a maximum caliper 
width for matching 2 patients.
statistical analysis
Analyses of clinical data
Analyses of clinical data were performed in IBM SPSS Statistics 21.0.0.1 software (IBM 
Corp, Armonk, NY). Continuous data are presented as mean ± SD or median (range), 
and comparison in the unmatched cohort was done using the unpaired t test unless 
the data were not normally distributed (Kolmogorov-Smirnov test); in these instances, 
the Mann-Whitney U test was used for comparison. Categorical data are presented as 
proportions, and comparison in the unmatched cohort was done using the χ2 test or the 
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table 2. Baseline characteristics
variablea unmatched Matched
Da (n = 144) sca (n = 619) p value Da (n= 94) sca (n = 94) p value
implantation period 2005-2014 1990-2014 2005-2014 1995-2014
age at operation, y 30.11
(3.03-60.44)
45.57
(13.80-70.52)
<0.001 33.97
(3.04-60.44)
34.98
(13.81-58.75)
0.607
Body mass index, kg/m2 24.22
(13.19-38.27)
25.18
(16.14-40.48)
0.007 24.5
(14.36-38.27)
24.79
(17.99-40.48)
0.494
Male sex 110 (76.4%) 471 (76.1%) 1.000 74 (78.7%) 75 (79.8%) 1.000
Blood group
O 78 (54.2%) 212 (34.2%) <0.001 48 (51.1%) 45 (47.9%) 0.798
A 46 (31.9%) 258 (41.7%) 0.026 32 (34.0%) 36 (38.3%) 0.607
B 10 (6.9%) 77 (12.4%) 0.056 8 (8.5%) 5 (5.3%) 0.623
AB 10 (6.9%) 37 (6.0%) 0.825 6 (6.4%) 7 (7.4%) 0.958
Missing 0 (0.0%) 35 (5.7%) 0 (0.0%) 1 (1.1%)
etiology
Congenital 96 (66.7%) 366 (59.1%) 0.116 68 (72.3%) 72 (76.6%) 0.618
Rheumatic 26 (18.1%) 6 (1.0%) <0.001 13 (13.8%) 3 (3.2%) 0.322
Degenerative/calcified 9 (6.3%) 28 (4.5%) 0.783 6 (6.4%) 3 (3.2%) 0.743
Prosthetic valve dysfunction 6 (4.2%) 2 (0.3%) 0.309 1 (1.1%) 2 (2.1%) 0.469
Endocarditis 7 (4.9%) 152 (24.6%) <0.001 6 (6.4%) 2 (2.1%) 0.809
Missing 0 (0.0%) 65 (10.5%) 0 (0.0%) 12 (12.8%)
Hemodynamics
Stenosis 48 (33.3%) 104 (16.8%) <0.001 25 (26.6%) 21 (22.3%) 0.618
Regurgitation 49 (34.0%) 159 (25.7%) 0.048 30 (31.9%) 33 (35.1%) 0.755
Combined 47 (32.6%) 355 (57.4%) <0.001 39 (41.5%) 40 (42.6%) 1.000
Missing 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
aortic valve morphology
Tricuspid 39 (27.1%) 140 (22.6%) 0.275 20 (21.3%) 17 (18.1%) 0.884
Bicuspid 91 (63.2%) 450 (72.7%) 0.025 68 (72.3%) 70 (74.5%) 0.677
Unicuspid 14 (9.7%) 15 (2.4%) <0.001 6 (6.4%) 4 (4.3%) 0.754
Missing 0 (0.0%) 12 (1.9%) 0 (0.0%) 3 (3.2%)
angina 2 (1.4%) 158 (25.5%) <0.001 2 (2.1%) 4 (4.3%) 0.625
Missing 0 (0.0%) 1 (0.2%) 0 (0.0%) 0 (0.0%)
nyHa classification <0.001 0.790
I/II 76 (52.8%) 504 (81.4%) 59 (62.8%) 63 (67.0%)
III/IV 45 (31.3%) 114 (18.4%) 22 (23.4%) 31 (33.0%)
Missing 23 (16.0%) 1 (0.2%) 13 (13.8%) 0 (0.0%)
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Fisher exact test where appropriate. Comparison in the matched cohort was done using 
paired-sample t test, McNemar test, or Wilcoxon signed rank test, where appropriate.
Actuarial freedom from events was estimated according to the Kaplan-Meier method, 
and the Tarone-Ware test was used for comparisons. Logistic regression and Cox propor-
tional hazards models were used for propensity-adjusted analyses, as described above. 
All tests were two-sided, and statistical significance was inferred at a p value of less than 
0.05.
Analyses of echocardiographic data
Echocardiographic data were analyzed in R 2.13.0 software (R Foundation for Statistical 
Computing, Vienna, Austria). Mixed-effects models were used to assess changes in echo-
cardiographic measurements over time while accounting for the correlation between 
repeated follow-up measurements in each patient. Linear mixed models were used for 
the continuous outcomes, and mixed-effects continuation ratio models were used for 
the ordinal outcomes. To allow for more flexibility in the specification of the patient-
specific longitudinal trajectories, we used natural cubic splines with three internal knots 
placed at the corresponding percentiles of the follow-up times. Residual plots were used 
to validate the model’s assumption, and transformations of the outcome variables were 
performed when appropriate. Missing echocardiogram measurements were assumed to 
be missing at random.24, 25
table 2. Baseline characteristics (continued)
variablea unmatched Matched
Da (n = 144) sca (n = 619) p value Da (n= 94) sca (n = 94) p value
comorbidities
Concomitant congenital disease 8 (5.6%) 6 (1.0%) 0.001 4 (4.3%) 4 (4.3%) 1.000
Cerebrovascular disease 3 (2.1%) 29 (4.7%) 0.246 1 (1.1%) 1 (1.1%) 1.000
Diabetes mellitus 1 (0.7%) 29 (4.7%) 0.029 1 (1.1%) 1 (1.1%) 1.000
Hypertension 31 (21.5%) 203 (32.8%) 0.009 23 (24.5%) 24 (25.5%) 1.000
Renal disease 0 (0.0%) 35 (5.7%) 0.001 0 (0.0%) 0 (0.0%) NA
Coronary artery disease 3 (2.1%) 36 (5.8%) 0.090 2 (2.1%) 2 (2.1%) 1.000
Peripheral artery disease 1 (0.7%) 3 (0.5%) 0.568 1 (1.1%) 0 (0.0%) NA
Chronic pulmonary disease 2 (1.4%) 12 (1.9%) 1.000 2 (2.1%) 3 (3.2%) 1.000
Previous cardiac operation 29 (20.1%) 31 (5.0%) <0.001 10 (10.6%) 15 (16.0%) 0.405
urgent (<24 h) 1 (0.7%) 4 (0.6%) 1.000 0 (0.0%) 0 (0.0%) NA
a Continuous data are expressed as median (range) and categorical data as count (%).
DA = decellularized allograft; NA = not assessable due to the small number of cases; NYHA = New York 
Heart Association; SCA = standard cryopreserved allograft.
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results
clinical outcome in the unmatched cohort
Baseline characteristics of the unmatched DA (n = 144; mean follow-up, 2.4 ± 1.9 years) and 
SCA (n = 619; mean follow-up, 9.9 ± 4.9 years) patients are listed in Table 2. Outcome events 
in the unmatched cohort are listed in Table 3. Overall, 15-year actuarial freedom from 
allograft reintervention and all Ross-related reinterventions was 94.8% (95% confidence 
interval [CI], 91.4% to 96.9%) and 90.0% (95% CI, 85.9% to 92.9%), respectively. Details of 
outcome in the unmatched DA and SCA groups have been previously published.14, 15
Hazards of allograft dysfunction and reintervention were comparable between DA and 
SCA before and after propensity adjustment (Table 4). After propensity adjustment, the 
hazard of late death was significantly higher in the DA group than in the SCA group. 
However, the propensity score variable was statistically significant in the regression 
model, which suggests inadequate adjustment for baseline differences.
The hazard of any event was significantly higher in the DA group before propensity 
adjustment, but this difference was not significant after propensity adjustment.
Exploration of the propensity score distribution of the two treatment groups revealed 
extreme skewness of the propensity score of the SCA patients (Appendix 2).
clinical outcome in the matched cohort
Baseline characteristics of the matched cohort are listed in Table 2 and those of the 
patients who could not be matched are listed in Supplement 4. The propensity score 
was used to match 94 DA patients (mean follow-up, 2.4±1.9 years) to 94 SCA patients 
(mean followup, 9.4 ± 4.2 years). After propensity matching, there were no significant 
differences in baseline characteristics between the two groups. There was adequate 
covariate balance across the two groups (Appendix 2 and 3). Outcome events in the 
matched cohort are listed in Table 3. In the propensity-matched DA and SCA cohorts, 
respectively, early mortality (1.1% vs 0.0%, p = 1.00) and 5-year actuarial freedom from 
allograft dysfunction (85.6% [95% CI, 53.9% to 96.2%] vs 93.3% [95% CI, 85.7% to 96%.9], 
p = 0.892), freedom from allograft reintervention (98.8% [95% CI, 91.7% to 99.8%] vs 
95.5% [95% CI, 88.5% to 98.3%], p = 0.383), survival (95.3% [95% CI, 87.8% to 98.2%] vs 
97.7% [95% CI, 91.3% to 99.4%], p = 0.323), and event-free survival (83.5% [95% CI, 70.6% 
to 91.1%] vs 84.5% [95% CI, 75.2% to 90.5]%, p = 0.515) were comparable (Fig 1).
In the first 5 years of follow-up of the matched cohort, all cases of allograft dysfunction 
concerned moderate-tosevere stenosis. There was no severe regurgitation in this period.
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table 3. Outcome events
variable unmatched Matched
Da (n = 144) sca (n = 619) Da (n = 94) sca (n = 94)
follow-up
Mean ± SD, years 2.4 ± 1.9 9.9 ± 4.9 2.4 ± 1.9 9.4 ± 4.2
Total, patient-years 339 6,150 225 887
Patients with events, no. 18 169 12 27
early death, no. (%) 2 (1.39) 2 (0.32) 1 (1.06) 0 (-)
late death, no. (%/y) 3 (0.88) 54 (0.88) 3 (1.33) 4 (0.45)
Bleeding, no. (%/y) 1 (0.29) 8 (0.13) 1 (0.44) 0 (-)
thromboembolism, no. (%/y) 2 (0.59) 31 (0.50) 2 (0.89) 4 (0.45)
reintervention, no. (%/y) 3 (0.88) 51 (0.83) 3 (1.33) 11 (1.24)
Autograft only 2 (0.59) 21 (0.34) 2 (0.89) 4 (0.45)
Allograft only 1 (0.29) 21 (0.34) 1 (0.44) 9 (1.01)
Both 0 (-) 9 (0.15) 1 (0.44) 9 (1.01)
allograft dysfunction, no. (%/y) 8 (2.36) 68 (1.11) 4 (1.78) 16 (1.80)
Regurgitation grade ≥3 0 (0.00) 19 (0.31) 0 (0.00) 3 (0.34)
Stenosis, Vmax ≥3.0 m/s 8 (2.36) 56 (0.91) 4 (1.78) 15 (1.69)
endocarditis, no. (%/y) 2 (0.59) 23 (0.37) 2 (0.89) 6 (0.68)
Permanent pacemaker implantation, no. (%/y) 2 (0.59) 5 (0.08) 1 (0.44) 0 (-)
a Data expressed as No. (%/y) is the count (linearized occurrence rate/y). Event counts represent the number 
of events, not the number of patients.
DA = decellularized allograft; No. = number; SCA = standard cryopreserved allograft; RVOT = right ventricu-
lar outflow tract; Vmax = aortic valve area.
table 4. Regression in unmatched cohorta
variable Da compared with sca
unadjusted Propensity adjusted
or/Hrb (95% ci) p value or/Hrb (95% ci) p value
Early death 4.35 (0.61-31.11) 0.144 5.07 (0.35-72.67) 0.232
Late death 2.02 (0.57-7.16) 0.276 4.99 (1.18-21.02)c 0.029
Allograft reintervention 0.70 (0.09-5.51) 0.735 0.60 (0.06-6.22) 0.665
Allograft dysfunction 2.20 (0.998-4.87) 0.051 1.17 (0.44-3.07)c 0.754
Any event 1.70 (1.01-2.86) 0.045 1.58 (0.83-3.00) 0.165
a SCA is the reference group. b Data expressed as OR (95% CI) for early mortality and HR (95% CI) for the 
other outcomes. c The propensity score variable was statistically significant in the regression model, which 
suggests inadequate propensity adjustment.
CI = confidence interval; DA = decellularized allografts; HR = hazard ratio; OR = odds ratio; SCA = standard 
cryopreserved allografts.
248
operated on by 2 different surgeons, interinstitutional
practice variation and differences in background popu-
lation risks, national health care practices, and surgical
technique should also be taken into account [31]. Also,
because the DAs were fresh and the SCAs were cry-
opreserved, the effects of cryopreservation on allograft
function should also be taken into account.
All of the above factors should be taken into consid-
eration in the interpretation of the results of our study,
which to our knowledge is the first to provide such a
comprehensive comparison of DAs vs SCAs in the RVOT
position. Bearing the above in mind, this study found no
substantial evidence of the hypothesized benefit of
decellularization on hemodynamic allograft function at
up to 5 years of follow-up. Longer follow-up of the DAs
may shed light on the effect of decellularization on long-
term allograft function and how these effects translate to
clinical implications such as reintervention and other
valve-related events. Furthermore, future studies should
explore other areas of potential improvement of allograft
function and the effect of decellularization, such as ABO
blood group and human leukocyte antigen matching, use
of antiinflammatory medication, and details of the
decellularization procedure.
Further insight into the mechanism of the effects of
decellularizationmay also provide potential for improving
Fig 1. Kaplan-Meier plots of freedom from allograft dysfunction, freedom from allograft reintervention, survival, and event-free survival. The
dotted lines indicate the 95% confidence interval. (DA ¼ decellularized allografts; SCA ¼ standard cryopreserved allografts.)
Fig 2. Mixed-effects model of mean allograft gradient over time. The
dotted lines indicate the 95% confidence interval. (DA ¼ decellular-
ized allografts; RVOT ¼ right ventricular outflow tract; SCA ¼
standard cryopreserved allografts.)
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figure 2. Mixed-effects model of mean allograft gradient over tim . The dotted lin s indicate the 95% 
confidence interval. (DA = decellular-ized allografts; RVOT = right ventricular outflow tract; SCA = standard 
cryopreserved allografts.)
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lation risks, national health care practices, and surgical
technique should also be taken into account [31]. Also,
because the DAs were fresh and the SCAs were cry-
opreserved, the effects of cryopreservation on allograft
function should also be taken into account.
All of the above factors should be taken into consid-
eration in the interpretation of the results of our study,
which to our knowledge is the first to provide such a
comprehensive comparison of DAs vs SCAs in the RVOT
position. Bearing the above in mind, this study found no
substantial evidence of the hypothesized benefit of
decellularization on hemodynamic allograft function at
up to 5 years of follow-up. Longer follow-up of the DAs
may shed light on the effect of decellularization on long-
term allograft function and how these effects translate to
clinical implications such as reintervention and other
valve-related events. Furthermore, future studies should
explore other areas of potential improvement of allograft
function and the effect of decellularization, such as ABO
blood group and human leukocyte antigen matching, use
of antiinflammatory medication, and details of the
decellularization procedure.
Further insight into the mechanism of the effects of
decellularizationmay also provide potential f r improving
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dotted lines indicate the 95% confidence interval. (DA ¼ decellularized allografts; SCA ¼ standard cryopreserved allografts.)
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ized allografts; RVOT ¼ right ventricular outflow tract; SCA ¼
standard cryopreserved allografts.)
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figure 1. Ka lan-Mei r plots of freedom from allograft dysfunction, fr edom from llograft reintervention, 
survival, and event-free survival. The dotted lines indicate the 95% confidence interval. (DA = decellularized 
allografts; SCA = standard cryopreserved allografts.)
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echocardiographic outcomes in the matched cohort
For the 188 matched patients (94 pairs), 1,066 echocardiograms were available (mean, 5.7 
per patient). During the first 5 years of follow-up, the mean allograft gradient increased 
from 4.5 to 9.6 mm Hg in the DA group and from 7.1 to 9.9 mm Hg in the SCA group (Fig 
2). During this period, there was also a marked increase in allograft regurgitation grades 
over time, although there was no progression to moderate or severe stenosis (Fig 3).
Discussion
Our study shows that fresh DAs and SCAs both perform well up to 5 years postoperative-
ly. After propensity adjustment as well as propensity matching, actuarial freedom from 
allograft dysfunction, freedom from allograft reintervention, survival, and event-free 
survival were comparable between the two groups. Longitudinal echocardiographic 
analyses showed a similarly modest increase in allograft gradient and regurgitation 
grades over time in both groups.
allograft dysfunction
One of the most important limitations of the Ross procedure is that single-valve disease 
is treated with doublevalve replacement because it requires reconstruction of the RVOT 
from which the pulmonary autograft was harvested. This is usually accomplished with 
pulmonary valve allografts. Besides the risk of autograft failure, structural valve deterio-
ration of the RVOT allografts, although less life-threatening, does pose an additional risk 
of reintervention, especially in younger patients.3
its effectiveness. For instance, decellularization may prove
beneficial to allograft function from an immunologic
standpoint but may also be associated with detr mental
effects such as reduction of beneficial inflammation and
impairment of structural integrity resulting from the
decellularization process.
Furthermore, the availability of adequately sized (fresh)
DAs should also be taken into account when considering
their potential for widespread use, although availability
and costs can be expected to improve substantially if a
clear benefit is demonstrated.
Reintervention
The additional risk of reintervention imposed by the
requirement of allograft RVOT reconstruction in the Ross
procedure is substantial. Depending on the operative
technique, patient-related factors, and institutional in-
dications for reintervention, RVOT allograft reinterven-
tions represent approximately 30% to 50% of the total
Ross-related reintervention risk in the first 15 post-
operative years [2, 14, 32, 33]. This is echoed by our
overall results in the unmatched cohort, with a 15-year
actuarial freedom from allograft reintervention of 95%
compared with 90% for all reinterventions.
The 5-year actuarial freedom from allograft reinter-
vention was comparable between the DA and SCA
groups (99% vs 96%, respectively), as a result of the low
incidence of reintervention in both r ups in the first 5
years. This is, however, to be expected because allograft
reinterventions have been previously described to occur
mostly beyond the 5-year or even 10-year mark [14, 27].
Hence, longer follow-up of the decellularized grafts is
required to reveal any differences in reintervention rates.
Long-term follow-up may also elucidate how the effect of
decellularization on allografts translates to reintervention
rates, because there are other important indications for
reintervention besides structural valve deterioration, such
as endocarditis, upon which the effect of decellularization
remains unclear.
Strengths and Limitations
In the absence of a randomized trial, this study used
propensity score matching to produce comparable study
groups, which provides the unique opportunity for a
direct comparison betwee DA and SCA for RVOT
reconstruction in a large cohort of patients undergoing
the Ross procedure. Moreover, the large number of
available echocardiograms and the powerful longitudinal
data analysis techniques allowed us to analyze hemody-
namic allograft function over time in addition to clinical
outcome. Furthermore, all patients were operated on by a
single dedicated surgeon in each of the 2 dedicated cen-
ters, which greatly increases consistency and
comparability.
This study has several limitations. As a consequence of
the novelty of allograft decellularization, the follow-up
duration of the DA group was insufficient to gain
insight into long-term allograft function. There may still
be other factors of influence on outcome that were not
included in the propensity score. As mentio ed, because
the two study groups were recruited from 2 centers in
different countries, international and interinstitutional
practice variation precluded direct statistical echocardio-
graphic comparison and may have affected the results.
Not all DA patients could be matched owing to the
extreme skewness of the propensity score in the SCA
group.
Conclusions
Up to 5 years of follow-up, fresh DAs and SCAs used for
RVOT reconstruction in the Ross procedure are associ-
ated with comparably excellent clinical and hemody-
namic outcome. Longer follow-up is required to shed
light on the long-term performance of the DAs.
Fig 3. Mixed-effects model of allograft regurgitation over time. (DA ¼ decellularized allografts; SCA ¼ standard cryopreserved allografts.)
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figure 3. Mixed-effects model of allograft regurgitation over time. (DA = decellularized allografts; SCA = 
standard cryopreserved allografts.)
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Structural allograft deterioration is a complex multifactorial process that is not yet well 
defined. In general, there are two components of allograft deterioration. Firstly, there is 
a component of early progressive stenosis, characterized by gradients that rise predomi-
nantly within the first 2 to 5 years postoperatively. Secondly, there appears to be a slow, 
linear progression of regurgitation grades, only rarely reaching grade 3 or greater within 
the first postoperative decade.4, 26-28
Immunologic factors appear to play an important role in the mechanism of allograft de-
generation. Research has shown that implantation of valve allografts elicits an immune 
response that has been reported to lead to early, progressive allograft stenosis due to 
inflammatorymediated adventitial fibrosis and neointimal proliferation.5 Furthermore, 
although not consistently, ABO blood group and human leukocyte antigen donor mis-
match have been found to be predictive of structural RVOT allograft failure.8, 29, 30
Decellularization aims to reduce this immune response by removing donor cells from 
the allograft by osmotic or chemical cell lysis while preserving the extracellular matrix, 
thus providing the benefit of acellularity in grafts with biomechanical properties simi-
lar to untreated allografts. Furthermore, the decellularized extracellular matrix is also 
believed to serve as a scaffold for repopulation by autologous cells with the potential 
of providing a valve capable of remodeling and regeneration. Prior histologic analyses 
of allografts explanted from patients in our DA group revealed evidence of partial re-
endothelialization and progressive repopulation of the tunica media with autogenous 
cells.13 Various decellularization techniques have proven to be safe and successful in 
substantially reducing graft cellularity and subsequently reducing the host immune 
response, and early clinical results have been promising.6, 7, 9-13
In present study, the DAs and SCAs both showed excellent performance at 5 years of 
follow-up, with 100% freedom from severe allograft regurgitation in both matched 
groups and freedom from moderate allograft stenosis of 86% and 93% (p = 0.892) in the 
DA and SCA groups, respectively. Longitudinal analysis of serial echocardiographic mea-
surements revealed a similarly modest increase in allograft gradient and regurgitation 
grades over time in both groups. Unfortunately, these echo data represent opportunistic 
clinical echocardiographic reports from 2 different centers that have not been validated 
in a core research laboratory setting, which precludes direct statistical comparison. In 
this light, studies that allow more comprehensive and direct echocardiographic com-
parison, such as high-quality single-center studies and dedicated prospective echocar-
diographic studies, are warranted.
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Moreover, because the two study groups were recruited from 2 centers in different 
countries and were operated on by 2 different surgeons, interinstitutional practice varia-
tion and differences in background population risks, national health care practices, and 
surgical technique should also be taken into account.31 Also, because the DAs were fresh 
and the SCAs were cryopreserved, the effects of cryopreservation on allograft function 
should also be taken into account.
All of the above factors should be taken into consideration in the interpretation of the 
results of our study, which to our knowledge is the first to provide such a comprehen-
sive comparison of DAs vs SCAs in the RVOT position. Bearing the above in mind, this 
study found no substantial evidence of the hypothesized benefit of decellularization on 
hemodynamic allograft function at up to 5 years of follow-up. Longer follow-up of the 
DAs may shed light on the effect of decellularization on long-term allograft function 
and how these effects translate to clinical implications such as reintervention and other 
valve-related events. Furthermore, future studies should explore other areas of potential 
improvement of allograft function and the effect of decellularization, such as ABO blood 
group and human leukocyte antigen matching, use of antiinflammatory medication, 
and details of the decellularization procedure.
Further insight into the mechanism of the effects of decellularization may also provide 
potential for improving its effectiveness. For instance, decellularization may prove ben-
eficial to allograft function from an immunologic standpoint but may also be associated 
with detrimental effects such as reduction of beneficial inflammation and impairment of 
structural integrity resulting from the decellularization process.
Furthermore, the availability of adequately sized (fresh) DAs should also be taken into 
account when considering their potential for widespread use, although availability and 
costs can be expected to improve substantially if a clear benefit is demonstrated.
reintervention
The additional risk of reintervention imposed by the requirement of allograft RVOT 
reconstruction in the Ross procedure is substantial. Depending on the operative tech-
nique, patient-related factors, and institutional indications for reintervention, RVOT 
allograft reinterventions represent approximately 30% to 50% of the total Ross-related 
reintervention risk in the first 15 postoperative years.2, 14, 32, 33 This is echoed by our overall 
results in the unmatched cohort, with a 15-year actuarial freedom from allograft reinter-
vention of 95% compared with 90% for all reinterventions.
252
The 5-year actuarial freedom from allograft reintervention was comparable between the 
DA and SCA groups (99% vs 96%, respectively), as a result of the low incidence of rein-
tervention in both groups in the first 5 years. This is, however, to be expected because 
allograft reinterventions have been previously described to occur mostly beyond the 
5-year or even 10-year mark.14, 27 Hence, longer follow-up of the decellularized grafts is 
required to reveal any differences in reintervention rates. Long-term follow-up may also 
elucidate how the effect of decellularization on allografts translates to reintervention 
rates, because there are other important indications for reintervention besides struc-
tural valve deterioration, such as endocarditis, upon which the effect of decellularization 
remains unclear.
strengths and limitations
In the absence of a randomized trial, this study used propensity score matching to 
produce comparable study groups, which provides the unique opportunity for a direct 
comparison between DA and SCA for RVOT reconstruction in a large cohort of patients 
undergoing the Ross procedure. Moreover, the large number of available echocardio-
grams and the powerful longitudinal data analysis techniques allowed us to analyze 
hemodynamic allograft function over time in addition to clinical outcome. Furthermore, 
all patients were operated on by a single dedicated surgeon in each of the 2 dedicated 
centers, which greatly increases consistency and comparability.
This study has several limitations. As a consequence of the novelty of allograft decel-
lularization, the follow-up duration of the DA group was insufficient to gain insight into 
long-term allograft function. There may still be other factors of influence on outcome 
that were not included in the propensity score. As mentioned, because the two study 
groups were recruited from 2 centers in different countries, international and interin-
stitutional practice variation precluded direct statistical echocardiographic comparison 
and may have affected the results. Not all DA patients could be matched owing to the 
extreme skewness of the propensity score in the SCA group.
conclusions
Up to 5 years of follow-up, fresh DAs and SCAs used for RVOT reconstruction in the 
Ross procedure are associated with comparably excellent clinical and hemodynamic 
outcome. Longer follow-up is required to shed light on the long-term performance of 
the DAs.
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suPPleMentary Material
supplement 1. Technique for implantation of the pulmonary allografts.
In both the DA and SCA groups, the pulmonary allografts were implanted with running 
Prolene 4-0 or 5-0 sutures both proximally and distally, with wide resection of residual 
allograft myocardium, leaving only a 2-3 mm myocardial rim for proximal anastomosis. 
If this did not allow for tension-free anastomosis, the proximal end of the allograft was 
extended with pericardium, which was performed in 70 (48.6%) DA and 232 (37.5%) SCA 
patients to achieve a tension-free anastomosis in all cases. Distal sutures were spaced 
close together to avoid constriction by the suture line. Long allografts (up to the bifurca-
tion) were used whenever possible.
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supplement 2. Kernel density plots of propensity score distribution in each 
treatment group. 
DA=decellularized allografts, SCA=standard cryopreserved allografts.
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supplement 3. Standardized differences in baseline covariate means be-
tween patients receiving fresh decellularized pulmonary allografts versus 
standard cryopreserved pulmonary allografts for right ventricular outflow 
tract reconstruction in the Ross procedure, before and after propensity score 
matching (Love plot). 
BMI=body mass index, AV=aortic valve, NYHA=New York Heart Association.
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supplement 4. Baseline characteristics of the patients that could not be 
matched, as well as the matched and unmatched cohorts.
unmatched (total cohort) Matched?
        yes no
Da sca Da sca Da sca
(n=144) (n=619) (n=94) (n=94) (n=50) (n=525)
age at operation 30.11  (3.03-60.44) 45.57  (13.80-70.52) 33.97  (3.04-60.44) 34.98  (13.81-58.75) 25.23  (3.03-57.07) 46.55  (15.20-70.52)
BMi 24.22  (13.19-38.27) 25.18  (16.14-40.48) 24.50  (14.36-38.27) 24.79  (17.99-40.48) 23.68  (13.19-36.16) 25.53  (16.14-37.86)
Male 110  (76.4%) 471  (76.1%) 74  (78.7%) 75  (79.8%) 36  (72.0%) 396  (75.4%)
Blood group      
0 78  (54.2%) 212  (34.2%) 48  (51.1%) 45  (47.9%) 30  (60.0%) 167  (31.8%)
A 46  (31.9%) 258  (41.7%) 32  (34.0%) 36  (38.3%) 14  (28.0%) 222  (42.3%)
B 10  (6.9%) 77  (12.4%) 8  (8.5%) 5  (5.3%) 2  (4.0%) 72  (13.7%)
AB 10  (6.9%) 37  (6.0%) 6  (6.4%) 7  (7.4%) 4  (8.0%) 30  (5.7%)
Missing 0  (0.0%) 35  (5.7%) 0  (0.0%) 1  (1.1%) 0  (0.0%) 34  (6.5%)
etiology       
Congenital 96  (66.7%) 366  (59.1%) 68  (72.3%) 72  (76.6%) 28  (56.0%) 294  (56.0%)
Rheumatic 26  (18.1%) 6  (1.0%) 13  (13.8%) 3  (3.2%) 13  (26.0%) 3  (0.6%)
Degenerative/Calcified 9  (6.3%) 28  (4.5%) 6  (6.4%) 3  (3.2%) 3  (6.0%) 25  (4.8%)
Prosthetic valve dysfunction 6  (4.2%) 2  (0.3%) 1  (1.1%) 2  (2.1%) 5  (10.0%) 0  (0.0%)
Endocarditis 7  (4.9%) 152  (24.6%) 6  (6.4%) 2  (2.1%) 1  (2.0%) 150  (28.6%)
Missing 0  (0.0%) 65  (10.5%) 0  (0.0%) 12  (12.8%) 0  (0.0%) 53  (10.1%)
Hemodynamics      
Stenosis 48  (33.3%) 104  (16.8%) 25  (26.6%) 21  (22.3%) 23  (46.0%) 83  (15.8%)
Regurgitation 49  (34.0%) 159  (25.7%) 30  (31.9%) 33  (35.1%) 19  (38.0%) 126  (24.0%)
Combined 47  (32.6%) 355  (57.4%) 39  (41.5%) 40  (42.6%) 16  (32.0%) 315  (60.0%)
Missing 0  (0.0%) 1  (0.2%) 0  (0.0%) 0  (0.0%) 0  (0.0%) 1  (0.2%)
av cusps      
Tricuspid 39  (27.1%) 140  (22.6%) 20  (21.3%) 17  (18.1%) 19  (38.0%) 123  (23.4%)
Bicuspid 91  (63.2%) 450  (72.7%) 68  (72.3%) 70  (74.5%) 23  (46.0%) 380  (72.4%)
Unicuspid 14  (9.7%) 15  (2.4%) 6  (6.4%) 4  (4.3%) 8  (16.0%) 11  (2.1%)
Missing 0  (0.0%) 12  (1.9%) 0  (0.0%) 3  (3.2%) 0  (0.0%) 9  (1.7%)
angina 2  (1.4%) 158  (25.5%) 2  (2.1%) 4  (4.3%) 0  (0.0%) 154  (29.3%)
Missing 0  (0.0%) 1  (0.2%) 0  (0.0%) 0  (0.0%) 0  (0.0%) 1  (0.2%)
nyHa       
I/II 76  (52.8%) 504  (81.4%) 59  (62.8%) 63  (67.0%) 17  (34.0%) 441  (84.0%)
III/IV 45  (31.3%) 114  (18.4%) 22  (23.4%) 31  (33.0%) 23  (46.0%) 83  (15.8%)
Missing 23  (16.0%) 1  (0.2%) 13  (13.8%) 0  (0.0%) 0  (0.0%) 1  (0.2%)
comorbidities      
Concomitant Congenital Disease 8  (5.6%) 6  (1.0%) 4  (4.3%) 4  (4.3%) 4  (8.0%) 2  (0.4%)
Cerebrovascular Disease 3  (2.1%) 29  (4.7%) 1  (1.1%) 1  (1.1%) 2  (4.0%) 28  (5.3%)
DM 1  (0.7%) 29  (4.7%) 1  (1.1%) 1  (1.1%) 0  (0.0%) 28  (5.3%)
Hypertension 31  (21.5%) 203  (32.8%) 23  (24.5%) 24  (25.5%) 8  (16.0%) 179  (34.1%)
Renal Disease 0  (0.0%) 35  (5.7%) 0  (0.0%) 0  (0.0%) 0  (0.0%) 35  (6.7%)
Coronary Artery Disease 3  (2.1%) 36  (5.8%) 2  (2.1%) 2  (2.1%) 1  (2.0%) 34  (6.5%)
Peripheral Artery Disease 1  (0.7%) 3  (0.5%) 1  (1.1%) 0  (0.0%) 0  (0.0%) 3  (0.6%)
Chronic Pulmonary Disease 2  (1.4%) 12  (1.9%) 2  (2.1%) 3  (3.2%) 0  (0.0%) 9  (1.7%)
Previous cardiac surgery 29  (20.1%) 31  (5.0%) 10  (10.6%) 15  (16.0%) 19  (38.0%) 16  (3.0%)
urgent (<24h) 1  (0.7%) 4  (0.6%) 0  (0.0%) 0  (0.0%) 1  (2.0%) 4  (0.8%)
Data expressed as “median (range)” or “count (percentage)”. DA=decellularized allografts, SCA=standard 
cryopreserved allografts, BMI=body mass index, AV=aortic valve, NYHA=New York Heart Association.
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aBstract
Background
To assess the current state of patient information and decision-making in congenital 
aortic and pulmonary valve disease, we conducted a survey among patients, parents 
and physicians.
Methods
A questionnaire was sent by ground mail to 157 adults and 32 parents of children who 
previously underwent surgery for congenital aortic or pulmonary valve disease at 0-40 
years of age between January 2005 and February 2014 at the Erasmus University Medi-
cal Center and to all paediatric and adult congenital cardiologists and congenital cardiac 
surgeons in the Netherlands (n=88).
results
73 patients/parents (39% response rate, 62 adult patients, 11 parents of paediatric 
patients) and 35 physicians (40% response rate) responded. Median patient age at the 
time of surgery was 25.7 years. Basic disease-specific knowledge was adequate in 42% 
of patients/parents and numeracy was sufficient in 47%. Patients/parents reported that 
they rely heavily on their physicians for information and often experience difficulty in 
finding reliable information elsewhere. They lack information on psychosocial aspects 
of disease (29% of respondents) and risks and benefits of treatment options (26%). They 
feel less involved in decisionmaking than they would prefer to be (p=0.014). Decisional 
conflict at the time of surgery was experienced by 31% of patients/parents. If they had 
to do it again, 72% of patients/ parents would want the same treatment. Quality of life 
is often impaired due to various valve-related anxieties and lifestyle changes. Physicians 
reported that they are unable to fully inform and sufficiently involve patients, due to 
limited patient/parent knowledge and understanding (56%) and limited time during 
consultations (32%). Patients/parents (98%) and physicians (97%) agree that they should 
have shared roles in decision-making.
conclusions
The substantial shortcomings in our current practice of patient information and decision-
making underline the need for innovative solutions, such as careful implementation of 
patient information tools and shared decision-making in the care path.
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introDuction
Due to major advances in the management of congenital heart disease over the 
past decades, approximately 90% of patients with congenital heart disease currently 
reach adulthood.1-3 This increasingly allows patients to live full, active and longer lives. 
However, congenital heart disease often has consequences that impact many facets 
of life, both clinical and personal.1 4 Furthermore, it often requires important decisions 
to be made about treatment, both in choosing between treatment or a conservative 
approach and choosing between different treatment options such as the choice for a 
mechanical or a bioprosthetic valve replacement. These decisions may have important 
implications for the patients’ further lives with regard to, for instance, longevity, preg-
nancy, career planning and daily life, especially in younger patients with more dynamic 
lifestyles.4 Congenital aortic and pulmonary valve diseases, in particular, usually allow 
for a relatively long and active life, but often with important consequences for lifestyle 
and life planning and requiring multiple crucial decisions about treatment to be made 
along the way.2 3 5
To allow patients to better understand, cope with and adhere to the lifestyle changes im-
posed by their heart defect and to allow treatment to be tailored to their personal values 
and preferences, it is essential to inform patients and their relatives and involve them 
in the decision process.6-19 However, patients may not always be sufficiently informed 
and involved in their own care, which has been previously shown to lead to substantial 
impairments in quality of life, anxiety, depression, poor treatment adherence, poor 
health behaviour, suboptimal treatment decisions and poorer clinical outcome, and also 
poorer healthcare utilisation and higher healthcare costs.6-19
To investigate the current state of patient information and decision-making in congenital 
aortic and pulmonary valve surgery in the Netherlands, we conducted a cross-sectional 
survey among adult patients, parents of paediatric patients and physicians involved in 
the care for these patients.
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Patient survey
This study was approved by the institutional review board (MEC-2015-099) and written 
informed consent was obtained from all participants.
Participants
Between January 2005 and February 2014, 198 consecutive patients aged between 0 and 
40 years underwent valve repair or replacement for congenital aortic and/ or pulmonary 
valve disease at the Erasmus University Medical Center. On 1 March 2015, patients ≥18 
years old and parents of patients <18 years old at the time of the survey who were alive 
and residing in the Netherlands (total n=189, 157 adult patients and 32 parents) were 
approached by ground mail and asked to complete and return a printed questionnaire.
Questionnaire
An example of the patient questionnaire is listed in Supplement 1.
Basic knowledge on postoperative outcome was assessed by asking respondents 
what the largest risk is after mechanical valve replacement (only aortic valve surgery 
patients), biological valve replacement (aortic and pulmonary valve surgery) and valve 
repair (only aortic valve surgery patients) using multiple choice questions for each. Pos-
sible answers were (1) thromboembolism and bleeding, (2) reoperation and (3) I don’t 
know. Knowledge was also assessed by asking respondents which procedure they/their 
child had undergone using a multiple choice question and comparing their answers 
with their medical records. Possible answers in this question were (1) mechanical valve 
replacement, (2) biological valve replacement and (3) valve repair.
Numeracy (ie, the understanding of numerical information, such as quantitative prob-
abilities) was assessed using the validated Numeracy Scale20 and respondents were 
asked to indicate which form of risk visualisation (bar chart, pie chart or icon array) they 
preferred for presentation of risk information.
Experiences and views with regard to patient information and (shared) decision-making 
were assessed using multiple choice questions, 5-point Likert scales, open questions 
and the validated Control Preferences Scale.21
Uncertainty about treatment decision-making was assessed using the Decisional Con-
flict Scale.22
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Postoperative valve-specific quality of life was assessed with a validated valve-specific 
questionnaire.5
Physician survey
Participants
All board registered paediatric cardiologists, adult congenital cardiologists and congeni-
tal cardiac surgeons in the Netherlands (n=88) were approached by email via the Dutch 
Associations for Pediatrics, Cardiology and Thoracic Surgery and asked to complete an 
electronic questionnaire.
Questionnaire
An example of the physician questionnaire is listed in Supplement 2. Physician age, 
specialty and years of experience were recorded. Experiences and views with regard to 
patient information and (shared) decision-making were assessed using multiple choice 
questions, 5-point Likert scales, open questions and the Control Preferences Scale.21
analyses
Analyses of clinical data were performed in Microsoft Office Excel 2011 (Microsoft, 
Redmond, Washington, USA) and in the R statistical software (V.3.3.3, R Development 
Core Team, R Foundation for Statistical Computing, Vienna, Austria). Continuous data 
are presented as mean±SD or median (range) and categorical data (including Likert 
scales) are presented as proportions and/or counts. Paired comparisons of Likert scale 
responses were done using Wilcoxon signed-rank test. All tests were two-tailed and 
statistical significance was inferred at a p<0.05.
results
Patients
A total of 73 patients/parents responded and gave informed consent and were subse-
quently included in the study (39% response rate). Patient and respondent characteris-
tics are shown in table 1.
Knowledge, numeracy and risk visualisation preference
Considering all knowledge questions collectively, 42% of respondents answered all 
questions correctly. Specifically, 51% of respondents answered all questions on postop-
erative risks correctly and 89% of respondents knew which procedure they/their child 
had undergone.
266
Forty-seven per cent of respondents answered all three numeracy questions correctly, 
27% answered two out of three correctly, 16% 1 out of 3, and 10% 0 out of 3. Patients/
parents indicated a strong preference for pie charts (61%) over bar graphs (29%) and 
icon arrays (10%) for visualisation of risk information.
Patient information
Patient/parent experiences and opinions with regard to patient information are pre-
sented in figure 1. Additionally, patients/parents report cardiologists (89%) and cardiac 
surgeons (26%) as their main sources of information, whereas patient information leaf-
lets (8%) and the internet (5%) were less frequently reported as important information 
sources. The advantages and drawbacks of treatment options were discussed with the 
cardiologist in 93% of cases and with the cardiac surgeon in 42% of cases. This con-
sultation took place >1 week prior to surgery in most cases (89%), but sometimes also 
between 1 day and 1 week prior to surgery (3%) or <1 day prior to surgery (8%).
The most important topics patients/parents reported to lack information on (open 
question) were implications for personal life, life planning, prognosis and psychosocial 
aspects (29% of respondents), risks, benefits and drawbacks of treatment (options) 
(26%) and practical information on (early) postoperative care (17%).
table 1. Patient/respondent characteristics
total (n=73) adult patients (n=62) Parents of paediatric 
patients (n=11)
age at survey (years) 36.3 (18.5-56.7) 34.7 (18.5-47.6) 46.2 (32.7-56.7)*
Patient age at surgery (years) 25.7 (0.1-40.0) 28.1 (12.2-40.0) 8.6 (0.1-15.2)†
 time from surgery to survey (years) 6.6 (1.1-10.1) 7.3 (1.1-10.1) 4.6 (1.1-9.3)
surgery
Aortic valve surgery 59% (43) 58% (36) 64% (7)†
Pulmonary valve surgery 41% (30) 42% (26) 36% (4)†
education level
None/elementary 8% (6) 8% (5) 9% (1)
Lower secondary or vocational 5% (4) 5% (3) 9% (1)
Higher secondary 58% (42) 61% (38) 36% (4)
Higher professional 18% (13) 18% (11) 18% (2)
University 11% (8) 8% (5) 27% (3)
Data presented as median (range) or percentage (count). Data on parents of paediatric patients concerns 
the parents, unless indicated otherwise.
*Concerns age of parents, children were 12.9 years (range: 7.7-24.5) of age at the time of survey.
†Concerns children.
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Decision-making
Patient/parent experiences and views with regard to decision-making are presented in 
figure 1. Respondents felt less involved in decision-making than they would prefer to 
be (figure 1, Wilcoxon signed-rank p=0.014). The vast majority of patients/parents (98%) 
agree that they should have shared roles in decision-making (figure 2).
Furthermore, at the time of surgery, 31% of patients/ parents experienced decisional 
conflict (Decisional Conflict Scale score >25) and 13% experienced severe decisional 
conflict (score >37.5). Decisional conflict was highest in the subscales uncertainty about 
the best choice (35%, severe: 30%), clear about personal values for benefits and draw-
backs (30%, severe: 23%) and feeling informed (23%, severe: 16%), followed by feeling 
supported (21%, severe: 16%) and decision effectiveness (16%, severe: 12%).
At the time of survey, 80% of patients/parents were satisfied with their replaced or re-
paired heart valve (10% neutral, 10% not satisfied) and 72% of patients/ parents would 
want the same treatment if they had to do it all over again (18% neutral, 10% different 
treatment).
Valve-specific quality of life
Patients/parents experience impairments to quality of life due to various valve-related 
anxieties and lifestyle changes (figure 3), most frequently related to fear of reinterven-
tion (38% ‘frequently’ or ‘always’), anticoagulation use (34%), fear of thrombosis (31%) or 
bleeding (26%), valve sound (22%), fear of valve failure (22%) or the regular doctor visits 
and blood tests (9%).
5Etnel JRG, et al. Open Heart 2018;5:e000872. doi:10.1136/openhrt-2018-000872
Valvular heart disease
Figure 2 Control Preferences Scale: Who should make the final decisions about treatment? (73 patients/parents and 35 
physicians responded). The sum of the middle three response categories represents the respondents that think that patients/
parents and physicians should have shared roles in decision-making (98%).
Figure 3 Factors that patients/parents (n=73) report as impairments of their quality of life. Always=more 
impairment=unfavourable.
available is often poorly comprehensible, contradictory 
and not tailored to their information needs and their 
specific disease state. Furthermore, current informa-
tion, including information provided by caregivers, 
was reported to focus mainly on medical aspects of 
the disease and patients lack information on practical, 
psychosocial and lifestyle topics. Also, our findings of 
limited numeracy among patients/parents shows that 
the content and the format of patient information 
should be carefully considered.
Limited patient/parent knowledge also has an 
impact on treatment decisions and treatment outcome. 
As treatment decisions have such an important impact 
on patients’ personal lives, treatment outcome and 
goals should always be placed in the perspective of each 
individual patient’s lives and values. Optimal outcome 
for each patient can only be achieved if treatment is in 
alignment with patient preferences.5 19 33–35
As evidenced by our results, physicians are often 
confident that they are capable of reliably determining 
patient values themselves and sometimes even think they 
are capable of making value trade-offs on the patients’ 
behalf. However, prior research in other disease states has 
shown that there is often a substantial mismatch between 
patient values and physicians’ estimation thereof.36–38
Consequently, patients often undergo treatments with 
consequences that they are inadequately informed about 
and that do not match personal values and preferences. 
Our results show that this may be associated with substan-
tial potentially avoidable impairments in quality of life. 
Thus, elucidating patient values and taking these values 
into account in treatment decision-making is crucial. 
Fortunately, the patients themselves are seasoned experts 
on their own values and an integral part of every health-
care setting. Involvement of patients in their own care is 
therefore essential.
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Physicians
A total of 35 physicians responded (40% response rate), 14 paediatric cardiologists, 14 
adult congenital cardiologists and 7 congenital cardiac surgeons. Median physician age 
was 44 years (range 33-64) and median experience in their respective fields was 9 years 
(range 0.3-32).
Patient information
Physician experiences and opinions with regard to patient information are presented in 
figure 4. Additionally, physicians report cardiologists (94%) and cardiac surgeons (19%) 
as the main sources of information for patients/parents and the internet (3%) less so. 
Physicians report that do not always fully inform patients/ parents of all the implications 
of their treatment (figure 5).
Decision-making
Physician experiences and opinions with regard to decision- making are presented 
in figure 4. The vast majority of physicians (97%) agree that they should have shared 
roles in decision-making (figure 2). Additionally, physicians report the most important 
barriers in involving patients/parents in decision-making (open question) to be limited 
patient/parent knowledge and understanding (56% of respondents), limited time dur-
ing consultations (32%) and anxiety and uncertainty among patients/parents (24%).
Open Heart
6 Etnel JRG, et al. Open Heart 2018;5:e000872. doi:10.1136/openhrt-2018-000872
Figure 4 Physician (n=35) experiences and opinions with regard to patient information and decision-making. The graphs are 
centred on the response category ‘Neutral’ (vertical grey line in the centre of the graph).
Figure 5 Physicians (n=35): How often do you inform your patients about the various advantages and drawbacks of 
treatment? INR, international normalised ratio.
However, our findings indicate that there are several 
barriers for patient involvement in clinical practice. Our 
study shows that physicians often experience difficulty in 
involving patients, most often due to a gap in knowledge 
and understanding between physicians and patients. This 
is confirmed by our findings of limited knowledge and 
numeracy among patients and parents. Thus, patients’ 
active participation in their own care first requires ample 
knowledge of m dical and psychosocial aspects of their 
disease. However, this knowledge is currently limited in 
these patients and physicians are currently not always 
capable of sufficiently providing them this knowledge.
Our findings represent a major area for improvement 
in our current practice of congenital cardiac care and 
provides the potential to substantially improve outcome 
in these pati n s.16–18 23–28 Better informed and more 
activated patients have been found to be associated with 
improved quality of life, treatment adherence, health 
behaviour and clinical outcome and also with more 
efficient healthcare utilisation and lower healthcare 
costs.6–19 Furth rmore, improved information and knowl-
edge may provide patients the confidence and reassur-
ance of knowing what to expect and when and how to act, 
thereby reducing anxiety.
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figure 5. Physicians (n=35): How often do you inform your patients about the various advantages and 
drawbacks of treatment? INR, international normalised ratio.
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Discussion
This study shows that in contemporary Dutch practice of congenital aortic and pul-
monary valve surgery, patient/parent knowledge of basic information on their (child’s) 
condition is limited and their numeracy is poor. Patients/parents are not satisfactorily 
informed and rely heavily on their physicians for information. They feel less involved 
in decision-making than they would prefer to be and often experience substantial 
decisional conflict and valve-related anxiety. Physicians in turn are unable to inform 
patients/parents completely in the limited time they have, given the patients’/parents’ 
limited knowledge and understanding. Subsequently, although both physicians and pa-
tients/parents agree that they should have shared roles in decision-making, physicians 
experience challenges in involving patients/ parents in their own care.
In congenital cardiac care, treatment often has a profound impact on lifestyle, life plan-
ning, quality of life and longevity, especially in younger patients with more dynamic life-
styles. Our results show that patients and their parents are often insufficiently informed 
of the consequences of the treatments they undergo. Our findings of limited knowledge 
among patients and parents are in line with prior research in (parents of ) patients with 
congenital heart disease.16-18 23-28 Limited knowledge and limited availability of informa-
tion have been previously described to be associated with anxiety, depression and 
impaired quality of life, which underlines the importance of adequately informing our 
patients and their parents.29 30
But why are patients/parents currently not satisfactorily informed? Our results show 
that they rely heavily on physicians to provide them the information they require and 
often experience difficulty in finding reliable information elsewhere. However, we 
found that the knowledge gap between patients and physicians along with the limited 
time reported to be available during consultations presents a challenge to physicians 
in meeting their patients’ information needs. Subsequently, physicians are not able to 
discuss all relevant information with all patients.
Furthermore, prior studies have shown that, of the information that is discussed during 
the consultation, only a small fraction is retained by patients/ parents, only about 20%-
60% as described in the literature.29 31 32 Our results show that, other than their physicians, 
there are few sources of reliable information available to patients, and the information 
that is available is often poorly comprehensible, contradictory and not tailored to their 
information needs and their specific disease state. Furthermore, current information, 
including information provided by caregivers, was reported to focus mainly on medi-
cal aspects of the disease and patients lack information on practical, psychosocial and 
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lifestyle topics. Also, our findings of limited numeracy among patients/parents shows 
that the content and the format of patient information should be carefully considered.
Limited patient/parent knowledge also has an impact on treatment decisions and 
treatment outcome. As treatment decisions have such an important impact on patients’ 
personal lives, treatment outcome and goals should always be placed in the perspective 
of each individual patient’s lives and values. Optimal outcome for each patient can only 
be achieved if treatment is in alignment with patient preferences.5 19 33-35
As evidenced by our results, physicians are often confident that they are capable of reli-
ably determining patient values themselves and sometimes even think they are capable 
of making value trade-offs on the patients’ behalf. However, prior research in other 
disease states has shown that there is often a substantial mismatch between patient 
values and physicians’ estimation thereof.36-38
Consequently, patients often undergo treatments with consequences that they are 
inadequately informed about and that do not match personal values and preferences. 
Our results show that this may be associated with substantial potentially avoidable im-
pairments in quality of life. Thus, elucidating patient values and taking these values into 
account in treatment decision-making is crucial. Fortunately, the patients themselves 
are seasoned experts on their own values and an integral part of every healthcare set-
ting. Involvement of patients in their own care is therefore essential.
However, our findings indicate that there are several barriers for patient involvement in 
clinical practice. Our study shows that physicians often experience difficulty in involving 
patients, most often due to a gap in knowledge and understanding between physicians 
and patients. This is confirmed by our findings of limited knowledge and numeracy 
among patients and parents. Thus, patients’ active participation in their own care first 
requires ample knowledge of medical and psychosocial aspects of their disease. How-
ever, this knowledge is currently limited in these patients and physicians are currently 
not always capable of sufficiently providing them this knowledge.
Our findings represent a major area for improvement in our current practice of congeni-
tal cardiac care and provides the potential to substantially improve outcome in these 
patients.16-18 23-28 Better informed and more activated patients have been found to be 
associated with improved quality of life, treatment adherence, health behaviour and 
clinical outcome and also with more efficient healthcare utilisation and lower health-
care costs.6-19 Furthermore, improved information and knowledge may provide patients 
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the confidence and reassurance of knowing what to expect and when and how to act, 
thereby reducing anxiety.
This underlines the urgent need for innovative solutions in more effectively informing 
our patients and their parents. A platform easily accessible to users at all times, such as 
an online information portal, presents promising opportunities. This would ideally allow 
for a dynamic environment in which information can be tailored to patients’ information 
needs and their specific disease state. To ensure quality, reliability and acceptance among 
patients/parents and physicians alike, patient information should be evidence-based 
and endorsed, supported and actively used by physicians. Furthermore, the content of 
patient information should not only be focused on medical topics should be tailored 
to the information needs expressed by patients/parents, which are often broader than 
expected, as evidenced by our results. Special attention should be paid to the specific 
needs of different user groups, for instance, patients’ parents, teenage patients, adult 
patients and relatives. The information should also be formatted to be comprehensible 
and attractive to users of a wide variety in education level, health literacy and numeracy. 
In light of our findings of limited numeracy among patients and parents, further re-
search should also focus on how the comprehensibility of patient information can be 
improved and should explore the effectiveness of supporting tools such as illustrations, 
animations, risk visualisations and virtual reality. Furthermore, it remains unclear how 
improved patient knowledge affects anxiety and uncertainty. Further investigation may 
provide insight into how we may best inform patients/parents to also provide them 
the reassurance they often need, thereby reducing anxiety. Last, how improved patient 
information and knowledge relates to patient activation, involvement and concordance 
of treatment decisions with patient values remains to be elucidated.
limitations
As this was a Dutch study in which patients/parents were recruited from a single centre, 
possible international differences in medical practice, culture and language as well as 
interinstitutional practice variation should be taken into consideration, although our 
findings are in line with prior studies in other centres and countries.16-18 23-28 Our disease-
specific knowledge questionnaire was only aimed at capturing the most basic knowl-
edge of disease, and the level of more in-depth disease-specific knowledge among 
these subjects remains to be elucidated. Regarding questions about patient/parent 
personal experiences with decision-making, the time between surgery and survey may 
have given rise to recall bias. Results may differ for disease states other than aortic and 
pulmonary valve surgery, which should be taken into account when interpreting our 
results. The limited sample size did not allow for analysis of the effects of gender, age 
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and prosthesis type. Lastly, as this was a survey, response bias may have had an influ-
ence on our results.
conclusions
Patients, parents and physicians alike experience important shortcomings in patient 
information and decision- making in congenital aortic and pulmonary valve surgery. 
Patient knowledge is severely limited due to the limited availability, reliability and com-
prehensibility of patient information. Furthermore, the provided information often does 
not meet the patients’ information needs. This may be associated with our findings of 
suboptimal patient activation and involvement and substantial decisional conflict and 
valve-related anxiety. This underlines the need for innovative solutions, such as careful 
implementation of patient information tools and shared decision-making in the care 
path.
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suPPleMentary Material
supplement 1. Example of patient questionnaire. 
This example concerns a questionnaire for an adult patient (as opposed to a parent/
caregiver of a pediatric patient) who had undergone aortic valve surgery (as opposed to 
pulmonary valve surgery).
1. Patient information and knowledge
1.1. Did you know that there are different treatment options?
O Yes
O No
1.2. which treatment did you undergo? (if you underwent multiple treatments, this 
question concerns the most recent treatment)
O Valve replacement with a mechanical valve
O Valve replacement with a biological valve
O Valve repair
O Other, namely……………………………………………………………………………
O I don’t know
1.3. which treatment provides the most durable result (i.e. the lowest risk of reop-
eration)?
O Valve replacement with a mechanical valve
O Valve replacement with a biological valve
O Valve repair
O I don’t know
1.4. what is the largest risk after valve repair?
O Reoperation
O Bleeding and thrombosis (blood clots)
O I don’t know
1.5. what is the largest risk after valve replacement with a mechanical valve?
O Reoperation
O Bleeding and thrombosis (blood clots)
O I don’t know
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1.6. what is the largest risk after valve replacement with a biological valve?
O Reoperation
O Bleeding and thrombosis (blood clots)
O I don’t know
1.7. Did your physician inform you about the various treatment options?
O Yes
O No
1.8. Did your physician inform you about the advantages and drawbacks of the 
various treatment options?
O Yes
O No
1.9. Do you feel like you had sufficient knowledge about the advantages and draw-
backs of the various treatment options at the time of surgery?
Strongly disagree  1 2 3 4 5 Strongly agree
1.10. what was your most important source of information about your condition 
and the treatment options?
O The internet
O Patient information leaflets
O The cardiologist
O The heart surgeon
O Friends/relatives
O Other, namely………………………………………………………………………
1.11. and what were other important sources of information about your condition 
and the treatment options?
……………..…………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………...
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1.12. the information about my condition and the treatment options that i ob-
tained from different care providers and/or other sources of information did not 
always correspond.
Strongly disagree  1 2 3 4 5 Strongly agree
Explanation……………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………...
1.13. it was easy to find reliable information.
Strongly disagree  1 2 3 4 5 Strongly agree
What was the source of this information?
………………………………………………………………………………………………
1.14. the available information provided me sufficient certainty about the choice 
for a certain treatment.
Strongly disagree  1 2 3 4 5 Strongly agree
O I did not need to make a decision
1.15. Did you lack any information about your condition and the treatment op-
tions? if so, can you indicate what you would like to have received more informa-
tion about?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………...…
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1.16.Do you have ideas for the improvement of patient information?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………...
2. Decision-making
2.1. was there a choice between different treatment options for you?
O Yes
O No
Explanation……………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………...
2.2. with whom did you have the consultation regarding treatment options? (Mul-
tiple answers possible)
O With the cardiologist
O With the heart surgeon
O Other, namely……………………………………………………………………………
O I did not have such a consultation
2.3. How long prior to surgery was this consultation? (if you had multiple consulta-
tions regarding treatment options, this question concerns the first consultation)
O Less than one day prior to surgery
O More than one day, but less than 1 week prior to surgery
O More than one week prior to surgery
O I did not have such a consultation
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2.4. the final decision for a treatment should be made by:
O The physician
O The physician, after considering the patient’s opinion
O The patient and physician together
O The patient, after considering the physician’s opinion
O The patient
2.5. Did you have enough time to make a well-thought-out decision?
O Yes
O No
O I don’t know
O Not applicable
2.6. Besides your care providers, was anyone else involved in the decision for a 
certain treatment? (multiple answers possible)
O Yes, family
O Yes, a good friend
O Yes, ………………………………………………………………………………………
O No
O Not applicable
2.7. the doctor involved me in the decision for a certain treatment.
Strongly disagree  1 2 3 4 5 Strongly agree
O I don’t know
O Not applicable
2.8. i think it is important to be involved in the decision for a certain treatment.
Strongly disagree  1 2 3 4 5 Strongly agree
O I don’t know
O Not applicable
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2.9. Do you feel like you had a choice in the decision for a certain treatment?
O Yes
O No
O I don’t know
O Not applicable
Explanation……………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………..
2.10. what could have gone better when the decision for a certain treatment was 
being made?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
St
ro
ng
ly
 d
is
ag
re
e
D
is
ag
re
e
N
eu
tr
al
Ag
re
e
St
ro
ng
ly
 a
gr
ee
2.11. this decision was difficult for me to make     
2.12. i was clear about the best choice for me     
2.13. i was not sure what to choose     
2.14. i knew which treatment options were available to me     
2.15. i knew the benefits of each treatment option     
2.16. i knew the risks and side effects of each treatment option     
2.17. i would like to have had more advice and information about the treatment 
options
    
2.18. i was clear about which benefits mattered most to me     
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2.19. i was clear about which risks and side effects mattered most to me     
2.20. it was difficult to decide whether the benefits or the risks and side effects 
were more important to me
    
2.21. i felt pressured by others while making this decision     
2.22. i had enough support from others while making a decision     
2.23. i feel i have made an informed choice     
2.24. My decision shows what is important to me     
2.25. i expect to stick with my decision     
2.26. i am satisfied with my decision     
2.27. i am afraid of bleeding.
Never 1 2 3 4 5 Always
O Not applicable
2.28. i am afraid of thrombosis (blood clots).
Never 1 2 3 4 5 Always
O Not applicable
2.29. i have problems with taking medication.
Never 1 2 3 4 5 Always
O Not applicable
2.30. i am afraid of possibly needing another valve operation in the future.
Never 1 2 3 4 5 Always
O Not applicable
2.31. i am afraid that my valve may fail.
Never 1 2 3 4 5 Always
O Not applicable
2.32. taking anticoagulation for the rest of my life bothers me.
Never 1 2 3 4 5 Always
O Not applicable
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2.33. is there a valve sound that bothers me?
Never 1 2 3 4 5 Always
O Not applicable
2.34. following my valve surgery, the frequency of doctor visits and blood tests 
bothers me.
Never 1 2 3 4 5 Always
O Not applicable
2.35. i am satisfied with my new/repaired aortic valve.
Never 1 2 3 4 5 Always
O Not applicable
2.36. if i had to do it over again, would i make the same decision?
Never 1 2 3 4 5 Always
O Not applicable
a person taking drug a has a 1% chance of having an allergic reaction. if 1,000 
people take drug a, how many would you expect to have an allergic reaction?
……… person(s) out of 1,000.
2.37. a person taking drug B has a 1 in 1,000 chance of having an allergic reaction. 
what percentage of people taking drug B will have an allergic reaction?
……… %
2.38. imagine that a coin was flipped 1,000 times. out of 1,000 flips, how many 
times do you expect the coin to come up heads?
……… times out of 1000.
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2.39. imagine the risk of reoperation after heart valve replacement is 5 percent 
(%). this is represented in the figures below. Please rank the figures based on how 
clear they are to you. 1 = most clear, 4 = least clear. Please fill in figure a, B, c or D 
corresponding to each number. each letter can only be used once.
Most clear 1. Figure ……
2. Figure ……
3. Figure ……
Least clear 4. Figure ……
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Figure A: Figure B:
Figure C: Figure D:
Explanation…………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
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supplement 2. Physician questionnaire.
1. what do you think is the most important source of information about treatment 
options for your patients?
O The internet
O The cardiologist
O The cardiac surgeon
O Patient information leaflets
O Other, namely……………………………………………………………………………...
2. in my opinion, patients are sufficiently informed about treatment options.
Strongly disagree  1 2 3 4 5 Strongly agree
Explanation……………………………………………………………………………………
3. the information about treatment options that is available to patients is reliable.
Strongly disagree  1 2 3 4 5 Strongly agree
Explanation……………………………………………………………………………………
4. in my opinion, better informed patients will … decision-making:
Hinder  1 2 3 4 5 Support
Explanation……………………………………………………………………………………
5. should patients be involved in the choice for a certain treatment?
Never  Sometimes Regularly Often  Always
O I don’t know
Explanation……………………………………………………………………………………
6. if a patient does not wish to be involved in the choice for a certain treatment, 
should the physician still try to involve the patient in the decision?
Never  Sometimes Regularly Often  Always
O I don’t know
Explanation……………………………………………………………………………………
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7. the final decision for a treatment should be made by:
O The physician
O The physician, after considering the patient’s opinion
O The patient and physician together
O The patient, after considering the physician’s opinion
O The patient
Explanation……………………………………………………………………………………
8. in decision-making the advantages and drawbacks of the different treatment 
options are considered. Do you think that physicians are capable of determining 
how important each advantage and drawback is to each patient?
Never  Sometimes Regularly Often  Always
I don’t know
Explanation……………………………………………………………………………………
9. should patients be informed about all drawbacks of a certain treatment option 
(even if the risk is low)?
Never  Sometimes Regularly Often  Always
I don’t know
Explanation……………………………………………………………………………………
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10. How often do you inform your patients about the following factors concerning 
valve replacement with a mechanical valve?
Lifelong anticoagulation
Never  Sometimes Regularly Often  Always
Regular INR checks
Never  Sometimes Regularly Often  Always
Risks of anticoagulation
Never  Sometimes Regularly Often  Always
Thrombogenicity of the valve/thromboembolism
Never  Sometimes Regularly Often  Always
Ticking valve sound
Never  Sometimes Regularly Often  Always
Risk of reintervention lower than with other treatment options, but certainly not zero
Never  Sometimes Regularly Often  Always
Risk of endocarditis
Never  Sometimes Regularly Often  Always
Explanation……………………………………………………………………………………
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11. How often do you inform your patients about the following factors concern-
ing valve replacement with a bioprosthesis, allograft, the Ross procedure or valve 
repair?
Risk of reintervention
Never  Sometimes Regularly Often  Always
Risk of endocarditis
Never  Sometimes Regularly Often  Always
Risk of thromboembolism
Never  Sometimes Regularly Often  Always
Anticoagulation may still be(come) necessary
Never  Sometimes Regularly Often  Always
Percutaneous or transapical valve replacement as a possible option for reintervention
Never  Sometimes Regularly Often  Always
Explanation……………………………………………………………………………………
12. if the decision concerns quality of life versus life expectancy after a certain 
treatment, do you think that physicians are capable of weighing these on the 
patients behalf?
Never  Sometimes Regularly Often  Always
I don’t know
Explanation..
13. in your experience, what are barriers/obstacles in involving patients in deci-
sion-making?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
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14. in your opnion, what are the most important shortcomings in patient informa-
tion on congenital aortic and pulmonary valve disease? and what would you like 
to improve?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
15. which essential components should a newly developed patient information 
portal contain to support you in patient information, decision-making and patient 
communication?
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
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aBstract
Background
Risk visualizations are often employed to support risk communication. However, their 
effectiveness in communication of single absolute risks remains unclear. We investi-
gated the effectiveness of risk visualizations in conveying verbatim knowledge of single 
absolute risks among the general population.
Methods
Randomly sampled members of the general Dutch population completed four basic 
risk conversions from percentages to natural frequencies and vice versa. By random 
investigator-blinded allocation, these conversions were supported by either icon arrays, 
pie charts, bar graphs or no visualization. Verbatim risk knowledge was scored as the 
number of conversions completed correctly.
results
393 subjects were included. Overall, 60% of respondents answered all four questions 
correctly. Risk format (percentages vs. natural frequencies, p=0.677) and risk mag-
nitude (p=0.532) were not associated with verbatim risk knowledge score. Younger 
age (p=0.001) and higher education level (p < 0.001) were independently associated 
with higher scores. The use of risk visualizations was not associated with higher scores 
(OR=1.08; 95% confidence interval: 0.69-1.69; p=0.745). All three forms of risk visualiza-
tion were equally ineffective. These findings held when stratifying by risk format, risk 
magnitude and user preference for a certain form of risk visualization. There were no 
significant interactions with age or education level.
conclusions
Risk visualizations did not improve conveyance of verbatim knowledge of single abso-
lute risks, irrespective of age, education level, risk magnitude, risk format and form of 
risk visualization. Risk visualizations may therefore be less suitable for settings in which 
detailed conveyance of single absolute risks is the main objective, although their ef-
fect on user experience and perception of risk communication and subsequent patient 
activation and participation remains to be elucidated.
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introDuction
With the growing importance of patient empowerment and shared decision-making in 
healthcare, effective patient communication is increasingly important. Better informed 
and more activated patients are associated with improved quality of life, treatment ad-
herence, health behavior and clinical outcome, but also with more efficient healthcare 
utilization and lower healthcare costs.1-13 Therefore, informing patients and their rela-
tives in an adequate and understandable manner is essential in optimizing treatment 
outcome.
One of the most important challenges in informing patients is effective communica-
tion of risk and benefit information about their current disease state and the various 
treatment options. Risk visualizations, such as icon arrays, bar charts and pie charts, are 
often employed to aid in this risk communication. They have been previously found to 
be effective in improving perception, understanding and interpretation of quantitative 
information over textual and numeric formats.14,15
Previous studies have focused largely on risk comparisons, trade-offs and gist knowledge 
(e.g. the understanding of the general risk message). However, many healthcare settings 
require informing patients about single absolute probabilities of risks and prognosis, 
often aside from treatment comparisons and decisions. For example, patients that have 
been diagnosed with a disease in whom treatment is not (yet) indicated or patients that 
have already undergone a certain treatment will face various health risks imposed by 
their disease and/or treatment during the course of their lives, health risks that they will 
need to take into account and that may require lifestyle changes, preventive measures 
or medical management. In this setting, an adequate and accurate understanding of 
the magnitude of the risk (verbatim knowledge), is essential in gaining insight into 
outcome and prognosis, motivating positive health behaviors and improving treatment 
adherence.16 Evidence on the effect of risk visualizations on verbatim knowledge in the 
communication of single absolute risks is scarce.
This study therefore aims to investigate the effectiveness of various risk visualizations 
in improving verbatim knowledge in the communication of single absolute risks in a 
randomized, investigator-blinded general population survey.
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MetHoDs
This study was approved by the institutional review board and written informed consent 
was waived (MEC-2016-424).
Participants
Subjects were recruited at random from 11 public locations across the Netherlands 
(Supplement 1) between June 2016 and August 2016. Surveyors (JMdG, EA, MEJ, AM, 
NAN) were posted in pairs at public locations across these cities and approached every 
person they encountered for participation in the survey. Potential participants were 
verbally approached to participate in the survey, which was introduced as a medical 
research project aimed at improving patient communication with a short background 
about the challenges in risk communication. All subjects 18 years of age or older were 
considered for inclusion. Subjects were excluded if they were color blind and/or were 
not literate in Dutch. There were no quotas for age or gender.
Questionnaire
All participants completed a printed Dutch questionnaire. As there are no validated 
methods for assessing verbatim risk knowledge, we formulated our own questionnaire 
based on the Numeracy Scale.17 The Numeracy Scale tests subjects’ ability to convert 
numerical risks from one format to another (e.g. natural frequencies, percentages, etc.). 
Because adequate verbatim knowledge of the presented risk is a prerequisite for such 
conversions, for the purposes of this study we operationalized verbatim risk knowledge 
as risk conversion tasks such as those in the Numeracy Scale. An adaptation of the Nu-
meracy Scale consisting of four questions on risk conversions from percentages to natu-
ral frequencies (2 questions) and vice versa (2 questions) was used to assess verbatim 
knowledge of the presented numerical risk probabilities (Supplement 2). Furthermore, 
within each of these two pairs of questions, one question concerned a large risk (> 30%) 
and one concerned a small risk (< 5%). As such, each of the four questions represented 
one of the four possible combinations of direction of conversion and risk magnitude. 
The order of the questions was alternated at random between individual copies of the 
questionnaire.
There were four versions of the questionnaire. In each version, the four aforementioned 
questions were supported by either icon arrays, pie charts, bar charts or no visualiza-
tion (Supplement 3). Each of these visualizations were designed to show part-to-whole 
relationship by presenting both affected and unaffected individuals, including the full 
denominator where possible and a legend that indicated which colors represented af-
fected and unaffected individuals.
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All subjects were also asked to indicate whether they preferred pie charts, icon arrays 
or bar charts for risk visualization, before any exposure to the visualization they were 
randomized to.
Gender, age and highest achieved education level were recorded as demographics.
randomization and survey
The various versions of the questionnaires were printed at a 1:1 ratio. Random sequence 
was generated by shuffling by an investigator (JRGE) independent from the surveyors 
(JMdG, EA, MEJ, AM, NAN). Allocation concealment and blinding of surveyors was 
achieved by use of a universal cover page on all versions of the questionnaires. Ques-
tionnaires were handed out in sequence, after which surveyors withheld from further 
assistance with completion of the questionnaire.
analysis
Respondents’ verbatim knowledge of the presented numerical risks was scored ordinally 
from 0-4 corresponding with the number of risk conversion questions they answered 
correctly out of a total of four questions. To investigate the influence of risk magnitude 
and direction of conversion, questions on low vs. high risks (2 questions each) and for 
each direction of conversion (2 questions each) were also scored separately from 0-2, 
also corresponding with the number of these questions answered correctly. Respon-
dents that did not complete all four verbatim knowledge questions were excluded from 
analysis. Analysis of these verbatim risk knowledge scores was conducted using ordinal 
regression and, for paired intra-subject comparisons, the Wilcoxon signed-rank test.
All analyses of the association between visualization preference and effectiveness were 
corrected for the relative difference in effectiveness between the three different forms 
of risk visualization.
Respondent demographics were compared to those of the general Dutch population 
for the year the survey was conducted in (2016) using the Chi-squared test, in which age 
distribution was analyzed categorically in 10-year age groups.
Statistical analyses were conducted in Microsoft Office Excel 2011 (Microsoft Corp., Red-
mond, WA, USA) and IBM SPSS Statistics (version 22.0.0.0, IBM Corp., Armonk, NY, USA).
sample size
Required sample size was calculated based on a previously conducted general popula-
tion survey on numeracy.18 In this previous survey, among subjects that did not receive 
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support of risk visualizations (control group), 40.5% answered all 4 questions correctly, 
16.7% 3 correct, 19.0% 2 correct, 11.9% 1 correct and 11.9% 0 correct. Assuming the 
same score distribution in the control group of present study, we calculated that at 
least 90 subjects per study arm would be required to detect a 10% ordinal difference 
in verbatim risk knowledge scores between groups (meaning that at least 10% of the 
subjects in the intervention group would score on average one point higher or lower 
on verbatim risk knowledge than the subjects in the control group) with 80% power at 
a 0.05 significance level using ordinal regression. Thus, across the four study arms (no 
visualization, pie charts, icon arrays and bar charts) at a 1:1 sampling ratio, this totaled 
a required minimum of 360 subjects. These sample size calculations were conducted 
assuming data-analysis using ordinal regression and based on methodology described 
in the literature for sample size calculations for ordinal data.19
results
Of the 400 subjects who agreed to participate in the survey, a total of 393 subjects 
completed all four verbatim risk knowledge questions and were subsequently included 
in the study (Table 1). The other seven were excluded because they did not complete all 
four verbatim risk knowledge questions.
Gender distribution of this cohort was comparable to the general Dutch population 
(p=0.934), whereas age was lower (p < 0.001) and education level was higher (p < 0.001).
table 1. Respondent demographics.
total no visual Pie chart Bar chart icon array
number of participants 393 100 98 98 97
Median age, years (range) 26 (18-88) 26 (18-74) 27 (18-84) 27 (18-88) 25 (18-81)
Male 194 (49%) 52 (52.0%) 50 (51.0%) 50 (51.0%) 42 (43.3%)
education level
None 4 (1.0%) 1 (1.0%) 0 (0.0%) 1 (1.0%) 2 (2.1%)
Elementary 3 (0.8%) 0 (0.0%) 2 (2.1%) 1 (1.0%) 0 (0.0%)
Lower secondary or vocational 55 (14.1%) 9 (9.0%) 18 (18.8 %) 11 (11.3%) 17 (17.5%)
Higher secondary 171 (43.8%) 47 (47.0%) 37 (38.5 %) 42 (43.3%) 45 (46.4%)
University (bachelor) or higher professional 101 (25.9%) 29 (29.0%) 27 (28.1%) 25 (25.8%) 20 (20.6%)
University (master) or PhD 56 (14.4%) 14 (14.0%) 12 (12.5%) 17 (17.5%) 13 (13.4%)
Missing 3 (0.8%) 0 (0.0%) 2 (2.0%) 1 (1.0%) 0 (0.0%)
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Respondent verbatim risk knowledge score distribution is shown in Fig. 1. Younger age 
and higher education level were independently associated with higher scores, whereas 
gender was not (Table 2). Respondent performance was comparable between conver-
sions from percentages to natural frequencies vs. natural frequencies to percentages 
(Wilcoxon signed-rank p=0.677) and between questions on small risk magnitude vs. 
large risk magnitude (Wilcoxon signed-rank p=0.532).
percentages to natural frequencies vs. natural frequencies to percen-
tages (Wilcoxon signed-rank p=0.677) and between questions on
small risk magnitude vs. large risk magnitude (Wilcoxon signed-rank
p=0.532).
Respondent verbatim risk knowledge score distribution in relation
to the use of risk visualizations and visualization preference are
presented in Fig. 1 and Table 3. The use of risk visualizations was not
associated with higher scores, neither when icon arrays, pie charts and
bar charts were considered separately nor when considered collectively.
The effectiveness of all thr e differ nt forms of risk visualization was
comparable. These findings held when considering small and large risk
magnitude and each conversion direction separately (Appendix D & E)
Table 1
Respondent demographics.
Total No visual Pie chart Bar chart Icon array
Number of participants 393 100 98 98 97
Median age, years (range) 26 (18-88) 26 (18-74) 27 (18-84) 27 (18-88) 25 (18-81)
Male 194 (49%) 52 (52.0%) 50 (51.0%) 50 (51.0%) 42 (43.3%)
Education level
None 4 (1.0%) 1 (1.0%) 0 (0.0%) 1 (1.0%) 2 (2.1%)
Elementary 3 (0.8%) 0 (0.0%) 2 (2.1%) 1 (1.0%) 0 (0.0%)
Lower secondary or vocational 55 (14.1%) 9 (9.0%) 18 (18.8 %) 11 (11.3%) 17 (17.5%)
Higher secondary 171 (43.8%) 47 (47.0 %) 37 (38.5 %) 42 (43.3%) 45 (46.4%)
University (bachelor) or higher professional 101 (25.9%) 29 (29.0%) 27 (28.1%) 25 (25.8%) 20 (20.6%)
University (master) or PhD 56 (14.4%) 14 (14.0%) 12 (12.5%) 17 (17.5%) 13 (13.4%)
Missing 3 (0.8%) 0 (0.0%) 2 (2.0%) 1 (1.0%) 0 (0.0%)
Fig. 1. Respondent verbatim risk knowledge score distribution in relation to the use of risk visualizations and visualization preference. aFour respondents did not
indicate a visualization preference.
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figure 1. Respondent verbatim risk knowledge score distribution in relation to the use of risk visualizations 
and visualization preference. aFour respondents did not indicate a visualization preference.
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Respondent verbatim risk knowledge score distribution in relation to the use of risk 
visualizations and visualization preference are presented in Fig. 1 and Table 3. The use 
of risk visualizations was not associated with higher scores, neither when icon arrays, 
pie charts and bar charts were considered separately nor when considered collectively. 
The effectiveness of all three different forms of risk visualization was comparable. These 
findings held when considering small and large risk magnitude and each conversion 
direction separately (Supplement 4 & 5) and there were no significant interactions be-
tween these effects and age or education level.
Respondents (n = 389; 4 respondents did not report a preference) reported a strong 
preference for pie charts (72%; n=281) over icon arrays (14%; n=54) and bar charts (14%; 
n=54). Of these 389 respondents, 87 (22%) were randomized to the visualization they 
indicated a preference for.
Respondents that were randomized to the visualization that they preferred did not 
achieve higher verbatim risk knowledge scores than those that were not (Fig. 1 & Table 
3). Again, this finding held when considering small and large risk magnitude and each 
conversion direction separately (Supplement 4 & 5) and there were no significant inter-
actions between this effect and age or education level.
To assess the impact of the difference in baseline score distribution between the current 
study and the previous study our sample size calculations were based on, we estimated 
which minimum effect size could have been detected with 80% power at a 0.05 sig-
nificance level with the actual sample size under the observed score distribution. This 
analysis was done using the same methodology described above for our sample size 
calculation.19 At the score distribution observed in the control group (Fig. 1, “No visual-
ization”) we had sufficient sample size (n=393 taking into account the observed actual 
sampling ratio and higher than the projected n=360) to detect an ordinal difference of 
at least 11% (vs. the assumed 10% difference) between groups with 80% power at a 0.05 
significance level.
table 2. Association between demographics and verbatim risk knowledge scores.
univariablea Multivariableb
or (95%ci) p-value or (95%ci) p-value
Younger age (/10 years) 1.17 (1.05-1.30) 0.006 1.20 (1.07-1.34) 0.001
Higher education level 1.82 (1.46-2.27) <0.001 1.85 (1.48-2.30) <0.001
Male vs. female gender 1.25 (0.84-1.85) 0.278 1.31 (0.87-1.98) 0.190
a Model containing only the respective covariate.
b Model containing all three covariates. OR = odds ratio; CI = confidence interval.
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Discussion
This randomized, investigator-blinded survey among a sample of the general Dutch 
population found that risk visualizations do not improve verbatim knowledge of abso-
lute numerical risks, irrespective of risk magnitude and risk format (i.e. natural frequency 
vs. percentage). Furthermore, icon arrays, pie charts and bar charts are equally ineffective 
and user preference for a certain form of risk visualization does not alter its effectiveness. 
Younger age and higher education level are associated with a better understanding of 
numerical risks, but have no interaction with the effectiveness of risk visualizations.
Risk visualizations are increasingly employed to aid in risk communication. They have 
been previously found to be effective in improving perception, understanding and 
interpretation of quantitative information over textual and numeric formats.14,15 How-
ever, in a sufficiently powered, randomized, investigator-blinded setting, we found no 
effect of risk visualizations in improving verbatim knowledge of numerical risks. To our 
knowledge, our study is the first to focus on the conveyance of verbatim knowledge of 
single absolute numerical risks, as opposed to gist knowledge (understanding of the 
general risk message) and/or comparisons/trade-offs of multiple risks as in prior stud-
ies. This may explain in part the differences between our findings and those previously 
described, as many other factors play a role in gist comprehension, risk comparisons and 
trade-offs, for instance anecdotal reasoning, framing effects, denominator neglect, risk 
magnitude and the magnitude of risk differences.20,21 The previously described effects 
of visualizations on gist knowledge may be due to effects on these factors rather than 
effects on the verbatim knowledge that underlies gist knowledge, as risk visualizations 
have been described to reduce the bias of these other factors in understanding the 
gist.20,22 However, besides gist knowledge, verbatim knowledge has been shown to be 
table 3. Association between use of visualization and verbatim risk knowledge scores.
unadjusted adjusteda
or (95%ci) p-value or (95%ci) p-value
Any visualization vs. no visualization 1.08 (0.69-1.69) 0.745 1.16 (0.73-1.85) 0.518
Icon array vs. no visualization 1.06 (0.61-1.84) 0.833 1.17 (0.66-2.07) 0.589
Pie chart vs. no visualization 1.00 (0.57-1.74 0.993 1.15 (0.64-2.05) 0.638
Bar chart vs. no visualization 1.18 (0.67-2.07) 0.561 1.19 (0.67-2.12) 0.562
Icon array vs. pie chart 1.07 (0.61-1.87) 0.821 1.03 (0.58-1.83) 0.917
Bar chart vs. pie chart 1.19 (0.67-2.09) 0.556 1.04 (0.57-1.88) 0.897
Bar chart vs. icon array 1.12 (0.64-1.97) 0.699 1.02 (0.57-1.83) 0.948
Preferred vs. non-preferred/none 1.18 (0.63-2.22) 0.611 1.32 (0.69-2.52) 0.404
a Adjusted for age and education level. OR = odds ratio; CI = confidence interval.
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of substantial importance in risk communication independently of gist knowledge.16,23 
Verbatim knowledge is a precursor to gist knowledge, thus accurate gist knowledge, 
risk comparisons and trade-offs require a fundamental understanding and adequate 
and accurate perception of the probabilistic information they are based on.24 Our find-
ings show that this fundamental understanding is considerably impaired in the general 
population and we found no evidence that it is improved by the use of risk visualiza-
tions. This may be due to the fact that part of the challenge in communicating risk lies 
in inherent difficulties in understanding probabilistic information. Moreover, it has been 
previously described that visual displays may lead users to focus more on the pattern of 
the data or gross-level information and less on the precise values.23,25,26 This may further 
explain why, in our study, risk visualizations appear to be less effective in the commu-
nication of single absolute risks. Thus, risk visualizations may be less suitable for use in 
settings that require a more detailed interpretation of the risk, such as communication 
of absolute risks, than for settings in which gist knowledge or a basic understanding of 
a broad larger-smaller relationship is the objective, as in risk comparisons and trade-offs 
for instance. Further research into how verbatim communication of absolute risks can 
be improved is warranted, as accurate patient understanding of numerical risk data, also 
outside the context of risk comparisons and trade-offs, has been previously found to be 
of essential importance in healthcare by improving patient autonomy and information-
seeking and motivating positive health behaviors.16
Furthermore, graph literacy should also be taken into account. Graph literacy concerns 
the ability to extract data and meaning from visual displays, and has been shown to 
differ strongly between individuals and to be predictive of the potential benefit of risk 
visualizations.27,28 Numeracy should also be taken into account, as it has been previously 
shown to influence the effectiveness of risk visualizations in conveying both verbatim 
and gist knowledge of probabilities. 23 The age of our sample was lower than in the gen-
eral population and the education level was higher, both factors that may be associated 
with higher numeracy levels.29 Future studies with a specific focus on low-numeracy 
individuals in a similar setting as the present study may reveal whether risk visualiza-
tions are more effective among low-numeracy individuals in the verbatim conveyance 
of single absolute risks. However, although we did not formally assess graph literacy and 
numeracy in our study, we found no interactions between the effectiveness of risk visu-
alizations and age and education level. Further exploration of potential demographic 
factors associated with graph literacy and numeracy may allow for a more effective 
selective and individual-tailored application of risk visualizations.
Prior studies have also found differences in effectiveness between different forms of risk 
visualization, such as icon arrays, pie charts and bar charts.23,24,30,31 In these studies, no 
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one form of risk visualization appears to be consistently more effective than the other, 
but rather the effectiveness of each type of visualization appears to depend heavily on 
the type of data being presented (natural frequencies vs. percentages, small vs. large 
risk magnitude) and the goal of the communication (e.g. gist vs. verbatim knowledge, 
comparisons vs. absolute risks).23 However, the studies that describe these differences 
focus largely on risk perception, risk comparisons/relative risks and gist knowledge.
In the setting of single absolute risks, on the other hand, we found no difference in ef-
fectiveness between icon arrays, pie charts and bar charts in conveying verbatim risk 
knowledge, also after taking risk magnitude and textual format (natural frequencies vs. 
percentages) into account. This lack of an effect of risk visualizations in this setting may 
lie in part in the basic concept of graphical representation of risk probabilities rather 
than the specific graphical format.
Although we did not find evidence of the effectiveness of risk visualizations with regard 
to improving verbatim understanding in this setting, their value may lie more in their 
potential to make risk communication more appealing to users and to aid in drawing 
users’ attention to the data, which may improve patient activation and participation. 
Further research on how this may affect risk communication in a broader perspective 
and patient empowerment is therefore warranted.
Future perspective
Further studies on the complex relationship between verbatim knowledge of risk and 
prognosis of the disease and treatment, gist knowledge and ultimately health behavior, 
treatment decisions, treatment adherence and quality of life may help identify in which 
healthcare settings patients could benefit most from risk visualizations. This may inform 
more effective and selective application of risk visualizations.
Also, replication of this study in different countries and languages may yield insight into 
potential cultural, societal and language-related factors that may be of influence on the 
effectiveness of risk visualizations.
Moreover, studies on this topic to date have focused largely on written risk communica-
tion. They also seldom study risk visualizations in real-world healthcare settings, but 
rather often employ methods of presenting hypothetical scenarios to general popula-
tion samples to which the subject matter is not relevant, as in our study. However, the 
role and potential effectiveness of risk visualizations in verbal risk communication and 
in real-world healthcare settings among subjects with a more vested interest in under-
standing the risk information remain to be elucidated.
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Strengths and limitations
To our knowledge, our study is the first randomized general population sample evalua-
tion of the effectiveness of risk visualizations in verbatim communication of single abso-
lute risks. Our adequately powered, randomized and investigator-blinded study design 
allows for accurate and reliable direct inference with a low risk of bias. Furthermore, the 
general population sampling and broad inclusion greatly enhance generalizability.
However, there are some limitations that should be taken into account. There were still 
some demographic differences between our study population and the general Dutch 
population that could not be completely accounted for, however we do not believe 
that this affected our results as we found no interactions between demographics and 
the measured effects. As this was a uni-national study, cultural, societal and language-
related factors could not be taken into account. The baseline score distribution in 
current study was different than the baseline score distribution of the prior study we 
based our sample size calculations on, possibly due in part to a slightly lower age and 
higher education level in the current study. However, our sample size was considerably 
higher than projected (n=393 vs n=360) and our power analysis shows that, therefore, 
the difference in baseline score distribution did not substantially impact the power of 
our study.
conclusions
In the communication of single absolute risks, the use of risk visualizations in addition to 
textual and numeric formats did not improve conveyance of verbatim risk knowledge, 
irrespective of age, education level, risk magnitude and risk format (natural frequency 
vs. percentage). Icon arrays, pie charts and bar charts were equally ineffective. Risk vi-
sualizations may therefore be less suitable for settings in which detailed conveyance of 
single absolute risks is the main objective, although their effect on user experience and 
perception of risk communication and subsequent patient activation and participation 
remains to be elucidated.
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suPPleMentary Material
supplement 1. Surveying locations.
•	 Amsterdam,	North	Holland
•	 Breda,	Brabant
•	 Zwolle,	Overijssel
•	 Utrecht,	Utrecht
•	 Rijswijk,	South	Holland
•	 Den	Haag,	South	Holland
•	 Rotterdam,	South	Holland
•	 Leiden,	South	Holland
•	 Zoetermeer,	South	Holland
•	 Dordrecht,	South	Holland
•	 Barendrecht,	South	Holland
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supplement 2. Verbatim risk knowledge questions.
1. A patient that uses drug A has a 1% chance of having an allergic reaction.
 If 1000 patients take drug A, how many people would you expect to have an allergic 
reaction?
 _______ patient(s) out of 1,000
2. A patient that uses drug B has a 30 in 1,000 chance of having an allergic reaction.
 What percent of patients that take drug B have an allergic reaction?
 _______ %
3. A patient that undergoes operation C has a 32% chance of experiencing pain after 
surgery.
 If 1000 patients undergo operation C, how many people would you expect to experi-
ence pain after surgery?
 _______ patient(s) out of 1,000
4. A patient that undergoes operation D has a 450 in 1,000 chance of experiencing pain 
after surgery.
 What percent of patients that undergo operation D experience pain after surgery?
 _______ %
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supplement 3. Examples of an icon array, pie chart and bar chart.
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supplement 4. Association between use of visualization and verbatim risk 
knowledge scores by risk magnitude.
small risk magnitude (<5%) large risk magnitude (>30%)
unadjusted adjusteda unadjusted adjusteda
or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value
any visualization vs. no visualization 0.91 (0.55-1.48) 0.692 1.00 (0.60-1.67) 0.996 1.23 (0.76-2.01) 0.400 1.38 (0.83-2.29) 0.209
icon array vs. no visualization 0.89 (0.49-1.63) 0.714 1.07 (0.57-2.00) 0.842 1.28 (0.69-2.37) 0.432 1.40 (0.74-2.63) 0.303
Pie chart vs. no visualization 0.92 (0.50-1.68) 0.784 1.11 (0.58-2.13) 0.743 0.98 (0.54-1.78) 0.954 1.13 (0.61-2.09) 0.704
Bar chart vs. no visualization 0.91 (0.50-1.66) 0.752 1.15 (0.61-2.16) 0.666 1.53 (0.81-2.87) 0.188 1.71 (0.88-3.32) 0.113
icon array vs. pie chart 0.98 (0.54-1.77) 0.934 0.94 (0.50-1.76) 0.853 1.30 (0.70-2.43) 0.402 1.26 (0.66-2.39) 0.480
Bar chart vs. pie chart 0.99 (0.54-1.80) 0.962 0.80 (0.42-1.51) 0.493 1.56 (0.82-2.94) 0.172 1.45 (0.74-2.84) 0.274
Bar chart vs. icon array 1.01 (0.56-1.83) 0.975 0.84 (0.45-1.56) 0.583 1.20 (0.62-2.30) 0.592 1.14 (0.58-2.27) 0.702
Preferred vs. non-preferred/none 1.01 (0.51-1.98) 0.983 1.14 (0.56-2.29) 0.719 1.50 (0.74-3.08) 0.263 1.77 (0.84-3.71) 0.130
aAdjusted for age and education level. OR = odds ratio; CI = confidence interval.
supplement 5. Association between use of visualization and verbatim risk 
knowledge scores by direction of conversion.
% → natural frequency natural frequency → %
unadjusted adjusteda unadjusted adjusteda
or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value
any visualization vs. no visualization 1.04 (0.65-1.68) 0.863 1.13 (0.69-1.86) 0.622 1.17 (0.71-1.91) 0.543 1.30 (0.78-2.16) 0.320
icon array vs. no visualization 1.10 (0.61-1.99) 0.754 1.22 (0.66-2.26) 0.523 1.19 (0.65-2.19) 0.578 1.32 (0.70-2.50) 0.394
Pie chart vs. no visualization 0.80 (0.45-1.43) 0.455 0.90 (0.50-1.64) 0.735 1.23 (0.66-2.28) 0.522 1.49 (0.76-2.91) 0.241
Bar chart vs. no visualization 1.32 (0.72-2.43) 0.368 1.31 (0.69-2.46) 0.409 1.09 (0.60-1.99) 0.783 1.16 (0.62-2.19) 0.644
icon array vs. pie chart 1.37 (0.76-2.46) 0.299 1.33 (0.72-2.46) 0.358 0.96 (0.51-1.81) 0.898 0.89 (0.46-1.72) 0.728
Bar chart vs. pie chart 1.64 (0.90-3.00) 0.107 1.42 (0.75-2.70) 0.277 0.88 (0.47-1.65) 0.693 0.76 (0.39-1.48) 0.426
Bar chart vs. icon array 1.20 (0.64-2.24) 0.565 1.04 (0.54-2.00) 0.914 0.91 (0.49-1.69) 0.774 0.86 (0.46-1.63) 0.643
Preferred vs. non-preferred/none 1.21 (0.62-2.36) 0.585 1.31 (0.65-2.63) 0.449 1.72 (0.82-3.57) 0.149 2.03 (0.94-4.36) 0.071
aAdjusted for age and education level. OR = odds ratio; CI = confidence interval.
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supplement 4. Association between use of visualization and verbatim risk 
knowledge scores by risk magnitude.
small risk magnitude (<5%) large risk magnitude (>30%)
unadjusted adjusteda unadjusted adjusteda
or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value
any visualization vs. no visualization 0.91 (0.55-1.48) 0.692 1.00 (0.60-1.67) 0.996 1.23 (0.76-2.01) 0.400 1.38 (0.83-2.29) 0.209
icon array vs. no visualization 0.89 (0.49-1.63) 0.714 1.07 (0.57-2.00) 0.842 1.28 (0.69-2.37) 0.432 1.40 (0.74-2.63) 0.303
Pie chart vs. no visualization 0.92 (0.50-1.68) 0.784 1.11 (0.58-2.13) 0.743 0.98 (0.54-1.78) 0.954 1.13 (0.61-2.09) 0.704
Bar chart vs. no visualization 0.91 (0.50-1.66) 0.752 1.15 (0.61-2.16) 0.666 1.53 (0.81-2.87) 0.188 1.71 (0.88-3.32) 0.113
icon array vs. pie chart 0.98 (0.54-1.77) 0.934 0.94 (0.50-1.76) 0.853 1.30 (0.70-2.43) 0.402 1.26 (0.66-2.39) 0.480
Bar chart vs. pie chart 0.99 (0.54-1.80) 0.962 0.80 (0.42-1.51) 0.493 1.56 (0.82-2.94) 0.172 1.45 (0.74-2.84) 0.274
Bar chart vs. icon array 1.01 (0.56-1.83) 0.975 0.84 (0.45-1.56) 0.583 1.20 (0.62-2.30) 0.592 1.14 (0.58-2.27) 0.702
Preferred vs. non-preferred/none 1.01 (0.51-1.98) 0.983 1.14 (0.56-2.29) 0.719 1.50 (0.74-3.08) 0.263 1.77 (0.84-3.71) 0.130
aAdjusted for age and education level. OR = odds ratio; CI = confidence interval.
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% → natural frequency natural frequency → %
unadjusted adjusteda unadjusted adjusteda
or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value or (95%ci) p-value
any visualization vs. no visualization 1.04 (0.65-1.68) 0.863 1.13 (0.69-1.86) 0.622 1.17 (0.71-1.91) 0.543 1.30 (0.78-2.16) 0.320
icon array vs. no visualization 1.10 (0.61-1.99) 0.754 1.22 (0.66-2.26) 0.523 1.19 (0.65-2.19) 0.578 1.32 (0.70-2.50) 0.394
Pie chart vs. no visualization 0.80 (0.45-1.43) 0.455 0.90 (0.50-1.64) 0.735 1.23 (0.66-2.28) 0.522 1.49 (0.76-2.91) 0.241
Bar chart vs. no visualization 1.32 (0.72-2.43) 0.368 1.31 (0.69-2.46) 0.409 1.09 (0.60-1.99) 0.783 1.16 (0.62-2.19) 0.644
icon array vs. pie chart 1.37 (0.76-2.46) 0.299 1.33 (0.72-2.46) 0.358 0.96 (0.51-1.81) 0.898 0.89 (0.46-1.72) 0.728
Bar chart vs. pie chart 1.64 (0.90-3.00) 0.107 1.42 (0.75-2.70) 0.277 0.88 (0.47-1.65) 0.693 0.76 (0.39-1.48) 0.426
Bar chart vs. icon array 1.20 (0.64-2.24) 0.565 1.04 (0.54-2.00) 0.914 0.91 (0.49-1.69) 0.774 0.86 (0.46-1.63) 0.643
Preferred vs. non-preferred/none 1.21 (0.62-2.36) 0.585 1.31 (0.65-2.63) 0.449 1.72 (0.82-3.57) 0.149 2.03 (0.94-4.36) 0.071
aAdjusted for age and education level. OR = odds ratio; CI = confidence interval.
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Background
In response to an increased need for patient information on congenital heart disease 
in the Netherlands, we initiated a nationwide initiative to develop an online, evidence-
based patient information portal, starting with a pilot project aimed at the subgroup of 
patients with congenital aortic and pulmonary valve disease.
Methods and results
We developed an information portal that aims to (1) improve patient knowledge and 
involvement and to subsequently reduce anxiety and decisional conflict and improve 
mental quality of life and (2) to support physicians in informing and communicating 
with their patients. The information portal was developed according to the systematic 
International Patient Decision Aid Standards development process employing Delphi 
techniques by a multidisciplinary workgroup of pediatric and adult congenital cardiolo-
gists, a congenital cardiothoracic surgeon, a psychologist, an epidemiologist, a patient 
representative, and web and industrial design experts. First, patients and physicians 
were surveyed and interviewed to assess the current state of patient information and 
explore their preferences and needs to determine the focus for the development of 
the information portal. We found that patient knowledge and numeracy are limited, 
reliable information is scarce, physicians inform patients selectively and patient involve-
ment is suboptimal, and there is a need for more reliable, tailored, and multi-faceted 
information. Based on the findings of these surveys and interviews, a patient-tailored 
information portal was designed that presents evidence-based disease- and age-
specific medical and psychosocial information about diagnosis, treatment, prognosis, 
and impact on daily life in a manner that is comprehensible and digestible for patients 
and that meets the needs expressed by both patients and physicians. The effect of the 
website on patient outcome is currently being assessed in a multicenter stepped-wedge 
implementation trial.
conclusions
The present pilot project succeeded in developing an online, evidence-based informa-
tion portal that is supported by both patients and physicians. The information portal 
will be further developed and expanded to include all other major forms of congenital 
heart disease, translations into other languages, and a public information portal to serve 
patients’ relatives and the general public at large.
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introDuction
Congenital heart disease is the most common congenital birth defect with an incidence 
of approximately 1% of all live births.1, 2 Due to major advances in the treatment of con-
genital heart disease over the past decades, approximately 90% of these patients now 
reach adulthood.3 This has, however, made congenital heart disease a chronic illness 
with, for example, an estimated 2.4 million people currently living with a congenital 
heart defect in the United States of America alone and an estimated 65,000 in the Neth-
erlands.
The consequences of congenital heart disease for the individual patient are complex, 
time varying, and heavily dependent on the specific defect(s), individual patient-related 
factors, and treatment options and decisions. These consequences may have a signifi-
cant impact on many facets of the patients’ lives, both clinical and personal. Therefore, 
informing patients and their relatives in a complete, objective, and understandable 
manner is essential in optimizing patient quality of life, lifestyle, health behavior, treat-
ment adherence, and patient involvement in treatment decisions.4-16
In response to an increased need for patient information in congenital heart disease in 
the Netherlands, we therefore initiated a nationwide initiative to improve patient infor-
mation, starting with a pilot project aimed at a subgroup of congenital heart disease 
patients with aortic or pulmonary valve disease, including Tetralogy of Fallot.13-15, 17-21
The objective of this pilot project was to develop an online information portal that aims 
to (1) improve patient knowledge and involvement and to subsequently reduce anxiety, 
depression, and decisional conflict and improve mental quality of life and (2) to support 
physicians in informing and communicating with their patients.
MetHoDs anD results
The present pilot study comprises a complete comprehensive development process for 
a target subgroup restricted to patients with congenital aortic and/or pulmonary valve 
disease and/or Tetralogy of Fallot as a proof of concept. The subsequent full-scale proj-
ect will entail expansion to all other major forms of congenital heart disease, building 
on this proof of concept.
The focus of this pilot project was to develop a nationwide patient-tailored, evidence-
based patient information tool to be incorporated into specialist congenital cardiac 
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care developed by and for patients, caregivers, and physicians, based on both patient/
caregiver and physician preferences.
First, we evaluated the current state of patient information in congenital heart disease 
in the Netherlands to determine key focus points for development. Next, we developed 
the information portal in a multidisciplinary national working group (Table 1) according 
to the systematic International Patient Decision Aid Standards (IPDAS) development 
process, employing Delphi techniques.22, 23 Finally, we designed and are currently con-
ducting a stepped-wedge cluster randomized implementation trial. All three steps are 
described below.
evaluation of tHe current state of Patient inforMation
The first crucial step in the development of the portal was a thorough evaluation of the 
current state of patient information and information needs in congenital heart disease 
in the Netherlands. The results of this phase would define the key focus points for the 
development of the information portal and, thus, represent the primary input for the 
next phase of the project.
We carried out this phase by conducting comprehensive surveys and interviews among 
patients (N = 63), caregivers of pediatric patients (N = 10), and physicians (N = 32). A 
detailed report of these surveys will be published separately, but the main findings 
included the following:
table 1. Working group members.
role center appointed by
clinical
Patient representativea - Dutch Patient Association for Congenital Heart Disease
Pediatric cardiologist LUMC, Leiden Dutch Association for Pediatrics
Adult congenital cardiologist Radboudumc, Nijmegen Dutch Association for Cardiology
Congenital cardiac surgeon AMC, Amsterdam Dutch Association for Cardiothoracic Surgery
Clinical psychologist Erasmus MC, Rotterdam -
Methodological
Epidemiologists Erasmus MC, Rotterdam Dutch Heart Foundation
Web and industrial design firmb - -
aChairman of the Dutch Patient Association for Congenital Heart Disease. bSpecialized in the development 
and implementation of patient information portals and decision aids.
-, not applicable; LUMC, Leiden University Medical Center; Radboudumc, Radboud University Medical Cen-
ter; AMC, Academic Medical Center; Erasmus MC, Erasmus University Medical Center.
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•	 Patient/caregiver knowledge is limited: although patients/ caregivers think they 
are adequately informed, actual diseasespecific knowledge was objectively sufficient 
in only half of the respondents, which is in line with previous findings.13, 14, 17-21
•	 reliable information is scarce: only 62% of patient/caregiver respondents agreed 
that reliable information was readily available to them. Subsequently, patients rely 
heavily on their physicians for information as evidenced by a mere 13% of patients 
citing sources other than their cardiologist or cardiac surgeon as one of their main 
sources of information.
•	 Patient/caregiver numeracy is limited: only 46% of respondents were able to suc-
cessfully complete a 3-question basic numeracy test adapted from the Numeracy 
Scale.24, 25
•	 Patient/caregiver involvement is suboptimal: both physicians and patients/
caregivers agree that patients/caregivers are insufficiently involved. Physicians agree 
that most difficulty they experience in involving patients/caregivers is due to limited 
patient knowledge and comprehension.
•	 Physicians inform patients/caregivers selectively: as selfreported by physicians, 
the information they convey is mostly based on their own judgment of what is 
important and comprehensible to each patient/caregiver. This may not always cor-
respond with what patients/caregivers themselves think is important.
•	 Patient information preferences and needs: in line with previous findings,26 the 
most important preferences and needs with regard to patient information expressed 
by patients/caregivers were as follows:
 o  More (reliable) information on:
  -  Implications for personal life (education, career, pregnancy, insurance, etc.)
  -  Health behavior and lifestyle recommendations
  -  Prognosis
  -  Psychosocial aspects
  -  Pros and cons of various treatment options
  -  Recovery after surgery
 o  Disease-specific information
 o  Age-specific information
 o  Non-contradictory information.
 Whereas physicians expressed a strong need for:
 o  A single, trusted, evidence-based source of reliable patient information to which 
they can refer their patients
 o  Tools to aid communication with patients/caregivers.
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Based on the findings of the surveys and interviews and in response to the needs 
expressed by both patients and physicians therein, a first prototype of an information 
portal was drafted according to the IPDAS development process and employing Delphi 
techniques. This prototype was then internally reviewed and revised by all members of 
the working group in live meetings until a consensus was reached on all topics (Table 1) 
(alpha-testing). The resulting second prototype was then again extensively reviewed by 
independent adult patients (n = 2), caregivers of pediatric patients (n = 2), physicians (n 
= 6; two pediatric cardiologists, two adult congenital cardiologists and two congenital 
cardiac surgeons), and clinical psychologists (n = 2) from outside the working group, 
sampled from clinical practice (beta-testing). All testers were given specific instruc-
tions to focus on all aspects of the information portal, including information content, 
language, illustrations, design, and usability. Additionally, the patients/caregivers were 
also observed as they navigated the portal. The feedback from this beta-testing was the 
input for the final review and revision by the working group.
The product of this development process is a comprehensive patient information tool 
that corresponds with the preferences and needs expressed by patients and physicians 
and addresses the shortcomings identified in the surveys and interviews.
The implementation of the patient information portal in clinical care will take place as 
follows. Patients/caregivers that present to the cardiologist are invited to use the online 
information portal by the cardiologist who hands out a sketchpad during the consulta-
tion (Figure 1). This sketchpad offers a template for the cardiologist to provide a clear 
graphical representation of the patient’s heart defect as well as any other relevant notes 
for the patient/caregiver. On the sketchpad, the cardiologist also indicates which of the 
predefined diagnoses are applicable to the patient. The patients/caregivers can then 
take their sketch sheet home and review the cardiologist’s notes and drawings and visit 
the information portal using the link and personal private account details listed on the 
sketch sheet. When they do so, they enter a private information portal (Figure 2) with the 
following key characteristics.
Disease- and age-specific information
All information on the portal is compiled and presented specifically and separately for 
each congenital heart defect and target group (teenagers, adults, or parents/caregivers) 
with regard to both content and language.
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Upon their first visit to the website, users are prompted to select their target group and 
diagnosis (two simple multiple choice prompts). Based on the combination of these in-
puts, a tailored personal subportal is custom built for each user. Their personal subportal 
contains only the information that is relevant to them. In case of multiple congenital 
heart defects, all relevant information is automatically combined into a single tailored 
subportal for that unique combination of inputs.
Multi-faceted information based on patient/caregiver preferences
As patients/caregivers indicated a discrepancy between their own information needs 
and the information generally provided by physicians and other sources, the informa-
tion provided by the portal is not based solely on what physicians think is important 
but rather represents both the clinical and the patient perspectives. Therefore, the 
information portal contains information on all aspects of disease that were found to be 
important to patients/caregivers and physicians in the surveys and interviews, such as 
diagnosis, treatment, prognosis, psychosocial aspects, and implications for daily life and 
future life planning.
FIgURe 1 | sketchpad.
4
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provided by physicians and other sources, the information 
provided by the portal is not based solely on what physicians 
think is important but rather represents both the clinical and 
the patient perspectives. Therefore, the information portal 
contains information on all aspects of disease that were found 
to be important to patients/caregivers and physicians in the 
surveys and interviews, such as diagnosis, treatment, progno-
sis, psychosocial aspects, and implications for daily life and 
future life planning.
Format hat Is Compreh nsible 
and digestible
To maximize digestibility and comprehensibility, the informa-
tion is fragmented into various f equently asked que tions that 
correspond with the topics that patients/caregivers and physi-
cians indicated to be important in the surveys and interviews. 
Comprehension is further enhanced by the liberal use of custom 
illustrations, designed to the specifications of the multidisciplinary 
working group by a professional medical illustrator. Additionally, 
a professional medical text writer was contracted to optimize the 
linguistics of the textual content for each target group separately 
to maximize comprehensibility, digestibility and attractiveness 
for users of all ages and education levels. Furthermore, to address 
the limited numeracy among the target audience, all numerical 
risks on the information portal are supported by risk visualiza-
tions, such as ic n arrays.
support Patient/Caregiver–Physician 
Communication
Patients/caregivers indicated that they are often unsure 
about which topics should be discussed with the physician. 
Throughout the information portal, we therefore provide 
numerous suggestions for important topics that should be 
discussed, as indicated by both physicians and patients/car-
egivers. Furthermore, there is a comment box on each page 
of the information portal in which patients/caregivers are 
encouraged to note any questions they may have about the 
information on that page. These questions re then save  in 
their personal account. Users can view, edit, and/or print a 
summary of their questions and optionally discuss this with 
their physicians.
Physicians and other involved health-care providers are also 
provided with their own personal accounts for the information 
portal, so that they can use the information portal to aid in 
figure 1. Sketchpad.
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format that is comprehensible and digestible
To maximize digestibility and comprehensibility, the information is fragmented into vari-
ous frequently asked questions that correspond with the topics that patients/caregivers 
and physicians indicated to be important in the surveys and interviews. Comprehension 
is further enhanced by the liberal use of custom illustrations, designed to the specifica-
tions of the multidisciplinary working group by a professional medical illustrator. Ad-
ditionally, a professional medical text writer was contracted to optimize the linguistics 
of the textual content for each target group separately to maximize comprehensibility, 
digestibility and attractiveness for users of all ages and education levels. Furthermore, 
to address the limited numeracy among the target audience, all numerical risks on the 
information portal are supported by risk visualizations, such as icon arrays.
support patient/caregiver-physician communication
Patients/caregivers indicated that they are often unsure about which topics should be 
discussed with the physician. Throughout the information portal, we therefore provide 
numerous suggestions for important topics that should be discussed, as indicated by 
both physicians and patients/caregivers. Furthermore, there is a comment box on each 
FIgURe 2 | screenshot of the pilot online patient information portal.
5
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explaining or illustrating disease-related information to patients/
caregivers in the consulting room. Moreover, the sketchpad, as 
described above, is intended to further facilitate communication 
in the consulting room.
evidence-Based Information
All information on the information portal is based on interna-
tional g idelines a d peer-reviewed published evidence where 
possible. Furthermore, all four centers for congenital cardiac 
surgery in the Netherlands have combined their prospective 
databases of early outcome after all congenital cardiac surgery 
performed in these centers in the past 10  years to allow con-
veyance of reliable, nationwid  data n risks and recovery after 
contemporary cardiac surgery to patients/caregivers.
IMPleMeNtAtIoN tRIAl
As the last phase of this pilot project, we are conducting a 
stepped-wedge cluster randomized (27, 28) implementation trial 
of the information portal in four large congenital cardiac centers 
in the Netherlands, which is ongoing as of writing.
The aim of this last phase of the pilot project is twofold:
• To gain insight into both the practical and cultural intricacies
at each of the eight participating departments (departments of
both adult and pediatric cardiology at each of t  four partici-
pating centers) that need to be taken into account for effective
implementation of the information portal and to subsequently
develop individual implementation plans tailored to each of
these departments and
• To evaluate the ffec  f the implem ntation of the information 
portal on patients and caregivers with regard to:
◦ Disease-specific knowledge
◦ Anxiety and depression
◦ Mental quality of life
◦ Pa ient/car giver invo vement and autonomy
◦ Experiences with and views on patient information
◦ Views on participation in decision-making
◦ Decisional conflict.
figure 2. Screens ot f the pilot o line patient information portal.
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page of the information portal in which patients/caregivers are encouraged to note any 
questions they may have about the information on that page. These questions are then 
saved in their personal account. Users can view, edit, and/or print a summary of their 
questions and optionally discuss this with their physicians.
Physicians and other involved health-care providers are also provided with their own 
personal accounts for the information portal, so that they can use the information portal 
to aid in explaining or illustrating disease-related information to patients/ caregivers 
in the consulting room. Moreover, the sketchpad, as described above, is intended to 
further facilitate communication in the consulting room.
evidence-based information
All information on the information portal is based on international guidelines and peer-
reviewed published evidence where possible. Furthermore, all four centers for congeni-
tal cardiac surgery in the Netherlands have combined their prospective databases of 
early outcome after all congenital cardiac surgery performed in these centers in the past 
10 years to allow conveyance of reliable, nationwide data on risks and recovery after 
contemporary cardiac surgery to patients/caregivers.
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iMPleMentation trial
As the last phase of this pilot project, we are conducting a stepped-wedge cluster 
randomized 27, 28 implementation trial of the information portal in four large congenital 
cardiac centers in the Netherlands, which is ongoing as of writing.
The aim of this last phase of the pilot project is twofold:
•	 To	gain	 insight	 into	both	the	practical	and	cultural	 intricacies	at	each	of	 the	eight	
participating departments (departments of both adult and pediatric cardiology at 
each of the four participating centers) that need to be taken into account for effective 
implementation of the information portal and to subsequently develop individual 
implementation plans tailored to each of these departments and
•	 To	evaluate	the	effect	of	the	implementation	of	the	information	portal	on	patients	
and caregivers with regard to:
 o Disease-specific knowledge
 o Anxiety and depression
 o Mental quality of life
 o Patient/caregiver involvement and autonomy
 o Experiences with and views on patient information
 o Views on participation in decision-making
 o Decisional conflict.
Adult patients and caregivers of pediatric patients with congenital aortic and/or pulmo-
nary valve disease and/or Tetralogy of Fallot that visit the outpatient clinic at one of the 
four participating centers are prospectively included. In total, at least 250 respondents 
will be included, 125 in the control group (no access to the information portal) and 125 
in the intervention group (access to the information portal), all of whom will complete 
an online survey on the above topics 1 month after their visit to the outpatient clinic.
Discussion anD furtHer DeveloPMent
The present pilot project succeeded in developing and implementing a nationwide 
online, evidence-based, disease- and age-specific information portal for (caregivers of ) 
patients with congenital heart disease, based on extensive input from all parties involved 
in congenital cardiac care in the Netherlands and addressing both patient and physi-
cian needs. Our extensive and meticulous nationwide multidisciplinary development 
process ensures broad nationwide acceptance into clinical practice by both patients/
caregivers and health-care providers.
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In various disease states, more informed and activated patients have been previously 
found to be associated not only with improved quality of life, treatment adherence, 
health behavior, and clinical outcome but also with more efficient health-care utilization 
and lower health-care costs.4-16 The implementation trial, the final phase of the current 
pilot project, will shed light on the effect of the implementation of our pilot information 
portal on short-term psychosocial patient outcome. In the further development of the 
information portal, we will also focus specifically on clinical and long-term psychosocial 
effects as well as physician, implementation, and health-care service outcomes.
We are currently planning the further refinement and expansion of this information por-
tal to all major forms of congenital heart disease, in which we aim to cover >90% of all 
cases of congenital heart disease. This full-scale project will build on all the knowledge, 
expertise, methods, framework, and infrastructure gained in the pilot project and will 
also be carried out in a multidisciplinary fashion. Additionally, focus groups with specific 
expertise will be employed when beneficial. This full-scale project will also include trans-
lations into other common languages, first and foremost English. We are also exploring 
innovative and interactive methods for improving patient participation, particularly in 
teenagers and adolescents.
Besides the further development of the current patient-tailored information portal, 
the full-scale project will also include the parallel development of a public information 
portal suited for broader use by patients and caregivers before a definitive diagnosis has 
been made, as well as their relatives and friends and the general public at large.
In the interest of sustainability, all relevant Dutch physician associations and patient 
associations have committed to a long-term partnership in this initiative. A multidis-
ciplinary national working group in which each of these partners is represented will 
remain instated to oversee continuous review, updating, enhancement, and expansion 
of the information portal to ensure that we continue to provide up-to-date, evidence-
based patient information of the highest standard.
Future partnerships and (conceptual) dissemination beyond the field of congenital 
heart disease and internationally may provide unique opportunities for further enhanc-
ing quality, expertise, and sustainability in this initiative.
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aBstract
Background
In response to an increased need for patient information in congenital heart disease, we 
previously developed an online, evidence-based information portal for patients with 
congenital aortic and pulmonary valve disease. To assess its effectiveness, a stepped-
wedge cluster randomized trial was conducted.
Methods
Adult patients and caregivers of pediatric patients with congenital aortic and/or pul-
monary valve disease and/or tetralogy of Fallot who visited the outpatient clinic at any 
of the four participating centers in the Netherlands between 1/3/2016-1/7/2017 were 
prospectively included. The intervention (information portal) was introduced in the 
outpatient clinic according to a stepped-wedge randomized design. One month after 
outpatient clinic visit, each participant completed a questionnaire on disease-specific 
knowledge, anxiety, depression, mental quality of life, involvement and opinion/atti-
tude concerning patient information and involvement.
results
343 participants were included (221 control, 122 intervention). Cardiac diagnosis 
(p=0.873), educational level (p=0.153) and sex (p=0.603) were comparable between the 
two groups. All outcomes were comparable between groups in the intention-to-treat 
analyses. However, only 51.6% of subjects in the intervention group (n=63) reported ac-
tually visiting the portal. Among these subjects (as-treated), disease-specific knowledge 
(p=0.041) and mental health (p=0.039) were significantly better than in control subjects, 
while other baseline and outcome variables were comparable. 
conclusions
Even after being invited by their cardiologists, only half of the participants actually 
visited the information portal. Only in those participants that actually visited the portal, 
knowledge of disease and mental health were significantly better. This underlines the 
importance of effective implementation of online evidence-based patient information 
portals in clinical practice.
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introDuction
Thanks to major advances in the treatment of congenital heart disease over the past 
decades, approximately 90% of patients now reach adulthood.1 However, this has made 
congenital heart disease a chronic illness that represents a growing health burden 
among children and adults. For example, as of 2010 there were an estimated 2.4 million 
people living with congenital heart disease in the United States of America alone among 
a total population of approximately 309 million.2
The consequences of congenital heart disease for the individual patient are complex, 
time-varying and dependent on the specific defect(s), individual patient-related factors 
and treatment options and decisions. These consequences will have a significant impact 
on many aspects of patients’ lives, both physical and psychosocial. Therefore, inform-
ing patients and their relatives in a complete, objective and understandable manner is 
essential and may optimize patient quality of life, lifestyle, health behaviour, treatment 
adherence, involvement and health care utilization.3,4,5,6,7,8,9,10,11,12,13,14
In response to an increased need for patient information in congenital heart disease in 
the Netherlands15, where an estimated 65,000 people live with congenital heart disease, 
we previously developed a patient information portal for congenital heart disease in 
a nationwide initiative, starting with a pilot project aimed at a subgroup of congenital 
heart disease patients with aortic or pulmonary valve disease, including tetralogy of 
Fallot.15,16
To assess the effectiveness of this information portal, we conducted a stepped-wedge 
cluster randomized trial in four congenital heart disease centers in the Netherlands 
among (parents of ) patients with congenital aortic or pulmonary valve disease, includ-
ing tetralogy of Fallot. 
MetHoDs
This study was approved by the institutional review board of the Erasmus University 
Medical Center (MEC-2015-584), registered in the Netherlands Trial Register (NTR6805) 
and written informed consent was obtained from all participants. The study is reported 
in accordance with the CONSORT guidelines.17
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Participants
Participants were recruited from 4 congenital heart disease centers in the Netherlands, 
namely Erasmus University Medical Center (Rotterdam), Leiden University Medical 
Center (Leiden), Academic Medical Center (Amsterdam) and Radboudumc (Nijmegen).
All patients aged between 18 and 40 years and parents/caregivers of patients <18 years 
of age with congenital aortic stenosis/regurgitation, congenital pulmonary stenosis/
regurgitation and/or tetralogy of Fallot who visited the pediatric or adult cardiology out-
patient clinic at one of the participating centers during the study period were considered 
for inclusion. Subjects were only included if their aortic and/or pulmonary valve disease 
was of at least moderate hemodynamic severity (peak Doppler gradient ≥36 mmHg 
and/or ≥moderate regurgitation).18,19 Mentally incompetent subjects and subjects that 
could not read or write Dutch were excluded. Subjects could only participate once, and 
were thus not recruited again at subsequent outpatient clinic visits after prior inclusion 
(no repeated measures). There were no restrictions on the moment during follow-up 
at which subjects could be included (e.g. at diagnosis, routine check-up, preoperative, 
postoperative, etc.).
intervention
The intervention consisted of access to a previously developed evidence-based on-
line patient information portal. The development of this portal has been previously 
described.16 Practical introduction of the information portal in the outpatient clinic 
was tailored to the workflow at each participating department and all participating 
physicians and support staff were trained in its use. After introduction, subjects in the 
intervention group were invited to visit the portal by their treating pediatric or adult 
congenital cardiologist during the outpatient clinic consultation.
Subjects in the control group received standard care, without access to the information 
portal.
trial design
The trial was conducted according to a prospective stepped-wedge cluster randomized 
design from 1 March 2016 to 1 July 2017 (Figure 1).20 All 4 centers started in the control 
phase, in which enrolled subjects did not receive the intervention. Subsequently, each 
of the participating centers transitioned to the intervention phase at a different time 
point, according to a stepped-wedge randomized design.20 All subjects enrolled during 
the intervention phase were invited to visit the information portal by their treating pedi-
atric or adult congenital cardiologist during the outpatient clinic consultation. To ensure 
the accrual of sufficient control subjects, the first center transitioned to the intervention 
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phase after at least 80% of the required total control group sample size had been accrued 
(1 September 2016). The dates for transition from control to intervention at each center 
were 2 months apart (1 September 2016, 1 November 2016, 1 January 2017 and 1 March 
2017) and each of the four participating centers were randomly allocated to one of 
these four starting dates. Randomization was performed by an independent researcher 
by randomly drawing four cards listing the names of each of the four centers, with the 
order of the draw corresponding with the order in time of transition to intervention. 
Allocation concealment was achieved by placing each of the four cards in an opaque 
unmarked sealed envelope by a different independent researcher before random draw. 
Because of the nature of the intervention, it was not possible to blind investigators or 
participants to the allocation.
outcomes
All participants completed a questionnaire 1 month after outpatient clinic visit. Age, 
sex and educational level were recorded as demographics in the questionnaire and 
diagnosis was extracted from the patient’s medical record.
Primary outcome: Disease-specific knowledge
Disease-specific knowledge was assessed using a questionnaire developed specifically 
for the purpose of this study in a multidisciplinary working group consisting of a pediat-
ric cardiologist (RAB), adult congenital cardiologist (APJvD), congenital cardiac surgeon 
(JK), patient (EvG), clinical psychologist (EMWJU) and epidemiologists (JRGE & JJMT). 
This questionnaire (Supplement 2) consisted of 7 multiple choice questions that test 
the subjects’ knowledge of what their own (child’s) personal condition is (2 questions), 
the implications of heart valve disease for lifetime risk of an operation (1 question), 
daily functioning (1 question) and work/career (1 question), the purpose of their regular 
check-ups (1 question) and symptoms that may indicate deterioration of their condition 
(1 question).
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figure 1. Stepped-wedge cluster randomized trial design. The four participating centers were randomly 
allocated as centers 1 through 4 as depicted in this figure and described in the methods section.
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Secondary outcomes
Subjects’ feeling about how well informed they were, experiences with patient informa-
tion, preferences for involvement, anxiety, depression, health-related mental quality of 
life and satisfaction with the information portal (only intervention group) were assessed 
as secondary outcomes (further details in Supplement 1).
sample size
We based our sample size calculations on data from a prior study by Korteland et al 
on a population of adult patients with heart valve disease who were facing heart valve 
replacement surgery.21 Because this study did not assess our primary outcome using 
comparable methods (nor any other study to our knowledge), we based our calculations 
on the secondary outcome measure that was assessed in both studies, namely the Hos-
pital Anxiety and Depression Scale (HADS). Based on the results of Korteland et al, we 
assumed a mean HADS of 10.5±7.9 in the control group and 7.7±6.7 in the intervention 
group. As there was no data available on intracluster correlation, we chose to take its 
possible effect on outcome into account by overpowering our study and thus basing our 
sample size on a power of 0.85 instead of 0.80. At a power of 0.85 and a 0.05 significance 
level, this led us to an estimated required sample size of 244 patients at a 1:1 sampling 
ratio (122 in the control arm and 122 in the intervention arm)
statistical analysis
All outcomes were analyzed according to both the intention-to-treat and the as-treated 
principles.20,22 Analyses were performed in the R statistical software (version 3.3.3, R 
Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). 
Continuous data are presented as mean ± standard deviation or median (range) and 
categorical data (including Likert scales) are presented as proportions and/or counts. 
Comparison of baseline characteristics between groups was done using the Students 
t-test and Chi-square test where appropriate. For comparison of outcome measures 
between groups, linear regression models were used to analyze continuous outcomes 
(including summary scores) and ordinal regression models for ordinal outcomes (single 
Likert scales and Control Preferences Scale). All analyses of outcomes were adjusted for 
center and time effects using mixed models (random effect for center and fixed effect 
for calendar time).20
results
Between 1 March 2016 and 1 July 2017, 962 eligible subjects were asked to participate 
(542 control phase, 420 intervention phase), of which 343 gave written informed con-
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sent and filled out the questionnaire (35.7% inclusion rate), 221 in the control group 
(standard care) and 122 in the intervention group (standard care + access to information 
portal) (Figure 2). Only 63 of the subjects in the intervention group (51.6%) reported 
actually visiting the information portal (as-treated intervention group). Baseline char-
acteristics were comparable between the control group and both the intention-to-treat 
and as-treated intervention groups (Table 1). There were also no significant baseline 
differences between the subjects in the intervention group that visited the information 
portal (as-treated intervention group) and those who did not (Supplement 3). 
Disease-specific knowledge
Disease-specific knowledge among the control and intervention groups are presented 
in Figure 3. All subjects answered at least 2 of the 7 disease-specific knowledge ques-
tions correctly. In the intention-to-treat analysis, there was no significant difference in 
disease-specific knowledge between the control and intervention groups (p=0.891). 
When only considering the 63 subjects that actually visited the information portal as the 
intervention group (as-treated analysis), disease-specific knowledge was significantly 
better in these subjects than in control subjects (p=0.041).
There were significant interactions between the intervention (intention-to-treat) and 
diagnosis (the positive effect of the intervention on disease-specific knowledge was 
greater in pulmonary valve disease/tetralogy of Fallot compared with aortic valve 
disease, p=0.009) and age group (greater positive effect among parents of pediatric pa-
tients compared with adult patients, p=0.009), but not with educational level (p=0.655), 
sex (p=0.189) or center (p=0.472).
figure 2. Flow diagram of inclusion.
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secondary outcomes
Subjects in the intervention group did not feel more informed than control subjects in 
neither the intention-to-treat nor the as-treated analyses (Figure 4). 
There was no association between how well informed subjects felt and their objective 
knowledge (b=0.137, p=0.083, adjusted for intervention [as-treated], time and center).
Contradictions in the information received from various sources were experienced by 
14% of the control group (“Agree” 9%, “Strongly agree” 5%), which was comparable to 
the intervention group in both the intention-to-treat (12%; “Agree” 7%, “Strongly agree” 
5%; p=0.241) and as-treated (15%; “Agree” 7%, “Strongly agree” 8%; p=0.928) analyses.
Anxiety, depression and preferences for involvement in own care and decision-making 
were comparable between control and intervention subjects in both the intention-to-
treat and as-treated analyses (Table 2). 
table 1. Baseline characteristics of the included subjects.
control intervention p-value
  intention-to-treat as-treated intention-to-treat as-treated
n=221 n=122 n=63  
age group       0.395 0.984
Children 48.9% (108) 43.4% (53) 46% (29)  
Adults 51.1% (113) 56.6% (69) 54% (34)  
Male sex* 35.7% (79) 40.2% (49) 31.7% (20) 0.603 0.481
Diagnosis       0.873 0.438
PV disease 67% (148) 65.6% (80) 73% (46)  
 ToF 46.2% (102) 38.5% (47) 47.6% (30)  
AV disease 29.9% (66) 32% (39) 25.4% (16)  
PV+AV disease 3.2% (7) 2.5% (3) 1.6% (1)  
educational level*       0.153 0.613
Elementary 0.5% (1) 1.7% (2) 0% (0)  
Lower vocational 3.7% (8) 7.7% (9) 4.8% (3)  
Lower secondary 3.7% (8) 6% (7) 3.2% (2)  
Intermediate vocational 32% (70) 33.3% (39) 33.9% (21)  
Higher secondary 8.2% (18) 10.3% (12) 6.5% (4)  
Higher vocational 28.8% (63) 28.2% (33) 37.1% (23)  
University 23.3% (51) 12.8% (15) 14.5% (9)  
Data presented as “proportion (count)”. *In the case of pediatric patients, sex and educational level relate 
to the parent that participated in the study. PV=pulmonary valve. ToF=tetralogy of Fallot. AV=aortic valve.
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The total Mental Component Summary score of the SF-36 was also comparable between 
control and intervention subjects in both the intention-to-treat and as-treated analyses 
(Table 2). However, in the Mental Health subscale, intervention subjects reported sig-
nificantly better quality of life than control subjects in the as-treated analysis (p=0.039).
The information portal received high ratings from the 63 subjects that visited it, for both 
contents (median rating on a 1-10 scale: 8, interquartile range 7-8) and design (median 
rating on a 1-10 scale: 8, interquartile range 7-8).
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figure 3. Disease-specific knowledge in the control and intervention groups (according to both the inten-
tion-to-treat and as-treated principles). All subjects answered at least 2 of the 7 disease-specific knowledge 
questions correctly. All significance tests were adjusted for center and time effects using mixed regression 
models (random effect for center and fixed effect for calendar time).
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Discussion
After the introduction of an information portal among patients with congenital aortic 
or pulmonary valve disease, including tetralogy of Fallot, only half of the participants 
invited by their cardiologist to visit the information portal actually visited the portal. 
Among those subjects that actually visited the information portal, disease-specific 
knowledge and mental health were significantly better at one month after outpatient 
clinic visit, while baseline characteristics and all other outcomes were comparable to 
control subjects and to intervention subjects that chose not to visit the portal. These 
findings demonstrate the potential effectiveness of an online evidence-based patient 
information portal in improving knowledge in patients with congenital heart disease, 
but also underline the crucial importance of effective implementation and active use of 
the portal.
Patients, parents and physicians alike have been previously demonstrated to experi-
ence substantial shortcomings in the way that patients and their parents are currently 
informed and involved.15,16 Subsequently, patient/parent knowledge is limited, leading 
to suboptimal patient/parent involvement and substantial decisional conflict and valve-
related anxiety.15,16 In light of these shortcomings, our findings demonstrate the poten-
tial effectiveness of an online evidence-based patient information portal in improving 
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figure 4. How well informed subjects felt in the control and intervention groups (according to both the 
intention-to-treat and as-treated principles). The graphs are centered on the response category “Neutral” 
(vertical grey line in the center of the graph). All significance tests were adjusted for center and time effects 
using mixed regression models (random effect for center and fixed effect for calendar time).
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patient information, as subjects that used the information portal had significantly 
improved disease-specific knowledge and mental health.
However, our results also underline the importance of careful and effective implementa-
tion of such interventions, as only half of the subjects invited to use the information 
portal actually did so and an effect could only be demonstrated in those who did. 
The usage rate of our information portal (52%) is substantially higher than previously 
reported for patient information and decision support interventions (25-35%).23 How-
ever, it remains suboptimal as it still leaves a large proportion of patients inadequately 
informed, as evidenced by their limited disease-specific knowledge. It remains unclear 
why one half of participants in the intervention group chose not to visit the information 
portal and the other half did, as we did not find any differences between these two 
groups in baseline characteristics and outcome measures other than knowledge and 
mental health. The observed lack of an association between how informed patients felt 
and their objective knowledge level may indicate that many patients may be unaware of 
table 2. Autonomy preference, anxiety and depression, mental quality of life and control preferences.
control intervention p-value*
intention-
to-treat as-treated
intention-
to-treat as-treated
n=221 n=122 n=63  
aPi 77.5 ± 8.1 78.0 ± 7.7 78.0 ± 7.9 0.594 0.815
Information seeking 88.7 ± 8.8 89.7 ± 7.7 90.4 ± 7.6 0.850 0.422
Decision-making 62.4 ± 13.7 62.8 ± 14.5 62.0 ± 14.8 0.250 0.970
HaDs 7.4 ± 5.8 7.3 ± 5.9 7.65 ± 6.12 0.954 0.561
Anxiety 4.9 ± 3.4 4.6 ± 3.5 5.05 ± 3.97 0.962 0.225
Depression 2.5 ± 2.9 2.6 ± 2.9 2.57 ± 2.59 0.887 0.740
sf-36 Mcs 75.5 ± 16.0 75.4 ± 16.9 75.8 ± 15.8 0.346 0.482
Vitality 65.3 ± 18.3 67.2 ± 19.3 67.0 ± 17.6 0.066 0.455
Social functioning 84.4 ± 20.4 83.0 ± 20.3 83.5 ± 18.9 0.663 0.657
Role-emotional 78.5 ± 23.0 76.1 ± 24.1 74.5 ± 24.5 0.953 0.444
Mental health 78.1 ± 16.2 78.9 ± 16.4 80.6 ± 15.4 0.160 0.039
cPs (the final treatment decision should be made by:) 0.829 0.738
Physician 0.5% (1) 0.0% (0) 0.0% (0)
Physician, after considering patient opinion 14.3% (31) 12.2% (14) 14.3% (9)
Physician and patient together 82.0% (178) 80.9% (93) 79.4% (50)
Patient, after considering physician opinion 2.8% (6) 5.2% (6) 4.8% (3)
Patient 0.5% (1) 1.7% (2) 1.6% (1)
Data presented as “mean ± standard deviation” or “proportion (count)”. *All significance tests were adjusted 
for center and time effects using mixed regression models (random effect for center and fixed effect for calendar 
time). API=Autonomy Preference Index. HADS=Hospital Anxiety and Depression Scale. SF-36 MCS=Short Form 
36 Health Survey, Mental Component Scale, CPS=Control Preferences Scale
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their knowledge deficits and, thus, do not see the need to seek additional information. 
Interventions aimed at helping such “unconsciously uninformed” patients gain insight 
into their own knowledge level may allow these patients to more reliably estimate how 
well informed they are and subsequently motivate them to seek additional information 
if they are inadequately informed. For instance, a short list of essential knowledge items 
(i.e. “What you should know about your heart defect”) can be provided to patients or 
patients can be asked to take a short knowledge test before outpatient clinic visit, the 
results of which can then be reviewed together with their physician. Timing of informa-
tion provision may be another important factor, as we included participants at all points 
during clinical follow-up (e.g. at diagnosis, at routine check-up, preoperative, postop-
erative, etc.). Providing information to patients at the right time when their information 
need is highest, for instance at diagnosis or surrounding interventions, may improve ac-
tive use of the portal. Other patient barriers such as limited numeracy, anxiety, cultural 
factors and language barriers should also be considered in the conception, design and 
implementation of patient information interventions.15,16,21,24
Physician and healthcare system barriers should also be taken into account. A system-
atic review on the implementation of patient decision support interventions reports 
lack of physician training, disagreement with the contents of the intervention, physician 
views on patient involvement and time pressure as important barriers for physicians to 
motivate active use of the interventions among their patients.23 We addressed many of 
these barriers during the introduction of the information portal with our extensive site 
initiation visits and center-tailored implementation plans, which may explain in part our 
relatively high usage rate compared with those previously described in the literature. 
23 However, implementation may be further improved by more actively involving para-
medical staff such as nurse practitioners, integration into the electronic patient record, 
employing waiting room tools such as computers or tablets and improving ease of use 
of the portal in the consulting room with the physician.
Furthermore, we found that the information portal was less effective among adult pa-
tients than among parents of pediatric patients. Informing, engaging and involving ado-
lescents and young adults with congenital heart disease is a well described challenge 
in current practice, which often leads to suboptimal knowledge, poor health behavior 
and substantial loss to follow-up (up to 50% loss to follow-up during the transition from 
pediatric to adult care).11,25,26 In this light, our findings may advocate a fundamentally 
different approach in informing adolescents and young adults. Although the language 
and contents of our information portal were tailored specifically to the needs of each 
age group (parents of pediatric patients, teenagers and young adults), the overall design 
and format of the portal were generally the same.16 Employing innovative formats such 
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as video/animation, virtual reality, 3D modelling and serious gaming principles may 
prove more effective in engaging and informing adolescents and young adults and sup-
port successful transition from pediatric to adult care.
With regard to secondary effects of improved patient information and knowledge, in this 
study we found significantly improved mental health after use of the information portal, 
however we found no effect on other psychosocial outcomes. Our short follow-up dura-
tion (1 month) should be taken into account in the interpretation of these findings, as a 
longer follow-up or a longer exposure to the intervention may be required for a measur-
able effect on psychosocial outcomes to manifest. In prior studies, better informed and 
more activated patients have been found to be associated with improved quality of life, 
treatment adherence, health behavior and clinical outcome, but also with more efficient 
healthcare utilization and lower healthcare costs.3,4,5,6,7,8,9,10,11,12,13,14,21,27 However, the rela-
tionship between improved patient knowledge of disease and anxiety remains unclear. 
Improving knowledge may not necessarily reduce anxiety, because while patients may 
find reassurance in knowing more about their condition, it may also give them more to 
worry about. Furthermore, besides the effect of improved knowledge, the sole availabil-
ity of reliable information that patients trust, the format and design of the information 
and framing may each also have a direct effect on anxiety. This complex relationship is 
evidenced by inconsistent findings in prior studies regarding the effect of information 
portals and decision aids on anxiety.21,28,29 Further investigation may provide insight into 
how we may best inform patients/parents to improve their knowledge and simultane-
ously reduce anxiety. Lastly, how improved patient information and knowledge relates 
to patient activation, involvement and concordance of treatment decisions with patient 
values remains to be elucidated.
limitations
Although substantially higher than previously reported for comparable interventions, 
the limited usage rate of our information portal may have affected outcome and led 
to a limited sample size of our as-treated analyses. This study represents Dutch clinical 
practice and possible international differences in medical practice, culture and language 
should be taken into consideration. Results may differ for disease states other than aortic 
and pulmonary valve disease, which should be taken into account when interpreting our 
results. Although we found no center effect, the possible influence of any unobserved 
inter-provider differences in patient information should be taken into consideration. 
As this was a stepped-wedge cluster randomized study the inherent limitations of this 
study design, such as possible intracluster correlation, should be taken into account.20
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conclusions
After the introduction of an information portal among patients with congenital aortic 
or pulmonary valve disease, including tetralogy of Fallot, only half of the participants 
invited by their cardiologist to visit the information portal actually visited the portal. 
Among those subjects that actually visited the information portal, disease-specific 
knowledge and mental health were significantly better at one month after outpatient 
clinic visit, while baseline characteristics and all other outcomes were comparable. Thus, 
an online evidence-based patient information portal is potentially effective in improving 
knowledge in patients with congenital heart disease, although active use of the portal is 
crucial. There is an urgent need for efforts aimed at supporting effective implementation 
and use of information portals. 
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suPPleMental Material
supplement 1. Secondary outcomes
feeling informed
How well informed the subject felt about their (child’s) heart defect (1 question), the 
risks thereof (1 question) and treatment options (1 question) was assessed using 5-point 
Likert scales (Supplement 2).
experiences with patient information
Subjects were asked to indicate whether they had experienced contradictions in the 
information they received from various sources using a 5-point Likert scale (Supplement 
2).
Preference for involvement
Preferences for involvement in own care and decision-making were assessed using the 
Autonomy Preference Index30 and the Control Preferences Scale.31,32 A higher score on 
the Autonomy Preference Index indicates a stronger preference for more involvement/
autonomy.
anxiety and depression
Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale 
(HADS).31,32
Health-related mental quality of life
Health-related mental quality of life was assessed using the Mental Component of the 
Dutch version of the Short Form 36 Health Survey (SF-36).33,34 Total Mental Component 
raw scores as well as raw scores for each of its subscales were summed and transformed 
to a 0-100 scale.
satisfaction with the information portal (only intervention group)
Subjects were asked to rate the contents (1 question) and design (1 question) of the 
information portal on a 1-10 scale (Supplement 2).
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information-seeking preferences among medical patients. J Gen Intern Med 1989;4:23-30.
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supplement 2. Questionnaires used in this study that have not been previ-
ously published (translated to English)
Disease-specific knowledge (primary outcome)
1 the heart has two outflow valves, the aortic valve and the pulmonary valve. 
which valve is affected in your case?
 The aortic valve (correct answer depends on the 
patients personal condition, 
as recorded by the (pediatric) 
cardiologist)
 The pulmonary valve
 Both
 I don’t know
2 My heart valve defect concerns a:
 Narrowing (stenosis) (correct answer depends on the 
patients personal condition, 
as recorded by the (pediatric) 
cardiologist)
 Leakage (regurgitation)
 Both
 I don’t know
3 People who have been diagnosed with a heart valve defect: (only one answer 
possible)
 Usually do not need to undergo surgery.
(incorrect)
(correct)
 Usually need to undergo 1 or multiple surgeries 
during their lifetime
4 People with a heart valve defect usually do well in daily functioning.
 True (correct)
(incorrect)
(incorrect)
 False
 I don’t know
5 People with a heart valve defect never need to take this into account when 
considering work/carreer.
 True (incorrect)
(correct)
(incorrect)
 False
 I don’t know
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6 what is the most important purpose of your check-ups?
 A routine check-up, without a specific purpose. (incorrect)
(incorrect)
(correct)
(incorrect)
 Personal reassurance.
 To detect a deterioration in your condition. 
 To continue treatment with the latest techniques.
7 which of the following symptoms may indicate deterioration of your condition, 
in which case you should contact the cardiologist? 
  1. Shortness of breath
  2. Getting exhausted sooner upon exertion
  3. Fainting
 1 and 2 (incorrect)
(incorrect)
(incorrect)
(correct)
(incorrect)
 2 and 3
 1 and 3
 All (1, 2 and 3)
 I don’t know
feeling informed (secondary outcome)
1. Do you feel like you have sufficient knowledge about your heart valve defect? 
Strongly disagree  1 2 3 4 5 Strongly agree
2. Do you feel like you have sufficient knowledge about the risks of your heart 
valve defect?
Strongly disagree  1 2 3 4 5 Strongly agree
3. Do you feel like you have sufficient knowledge about the (possible) treatment 
options for your heart valve defect?
Strongly disagree  1 2 3 4 5 Strongly agree
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experiences with patient information (secondary outcome)
1. the information about my condition and the treatment options that i obtained 
from different care providers and/or other sources of information did not al-
ways correspond.
Strongly disagree  1 2 3 4 5 Strongly agree
satisfaction with the information portal (secondary outcome, only inter-
vention group)
1. How would you rate the website on a scale from 1 to 10 with regard to:
Contents: 1 2 3 4 5 6 7 8 9 10
Design: 1 2 3 4 5 6 7 8 9 10
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supplement 3. Baseline characteristics of the subjects in the intervention 
group who visited the information portal and those who did not. 
intervention group: p-value
Did not visit portal visited portal  
n=59 n=63  
age group     0.679
Children 40.7% (24) 46% (29)  
Adults 59.3% (35) 54% (34)  
Male sex 49.2% (29) 31.7% (20) 0.146
Diagnosis     0.196
PV disease 57.6% (34) 73% (46)  
 ToF 28.8% (17) 47.6% (30)  
AV disease 39% (23) 25.4% (16)  
PV+AV disease 3.4% (2) 1.6% (1)  
educational level     0.083
Elementary 3.6% (2) 0% (0)  
Lower vocational 10.9% (6) 4.8% (3)  
Lower secondary 9.1% (5) 3.2% (2)  
Intermediate vocational 32.7% (18) 33.9% (21)  
Higher secondary 14.5% (8) 6.5% (4)  
Higher vocational 18.2% (10) 37.1% (23)  
University 10.9% (6) 14.5% (9)  
PV=pulmonary valve. ToF=tetralogy of Fallot. AV=aortic valve.
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The aim of this thesis was to make sense of outcome after congenital left ventricular 
outflow tract surgery and improve evidence-based decision-making, patient informa-
tion and patient involvement. In this chapter the results will be discussed in a broader 
perspective and implications for clinical practice and further research will be addressed. 
First, the results with regard to clinical outcome after surgery will be discussed, as well 
as the implications for decision-making. In light of clinical outcome, this chapter will 
then discuss methodology for accurate (patient-tailored) outcome modeling for mean-
ingful and effective application in clinical practice, as well as methodology for reliable 
evaluation of the effect of clinical developments and innovations on outcome. Lastly, 
the conveyance of evidence on outcome to patients will be discussed in the context of 
patient information, patient involvement and informed shared decision-making.
clinical outcoMe
subvalvular aortic stenosis
Thus far, outcome in patients with subvalvular aortic stenosis was not completely clear, 
due in part to the fact that data on outcome in these patients is scattered across an 
exceedingly large number of publications.1-24 Furthermore, there is a large variation in 
outcome between individual patients, and there is little consensus which patient- and 
procedure-related factors play a role in this variation and how these factors may inform 
decision-making, as is also the case in many other disease states.
Chapter 2 was the first study to date aimed at aggregating all published evidence on 
clinical outcome in subvalvular aortic stenosis across numerous international patient 
series, and to investigate determinants of outcome in this setting.
Our results show that, although mortality rates are low after surgery for subvalvular 
aortic stenosis, there remains a substantial rate of reintervention. In light of the large 
variation in outcome between individual patients, we also succeeded in providing novel 
insights into the determinants of outcome. We identified that, among other factors, 
higher left ventricular outflow tract (LVOT) gradient (both pre- and postoperatively) 
and the presence of aortic regurgitation (either pre- or postoperatively) are associated 
with poorer postoperative hemodynamic results and a higher rate of reintervention. The 
distance between the subvalvular obstruction and the base of the aortic valve was also 
associated with outcome, however results were inconsistent across the included studies, 
which warrants further investigation of the prognostic value of this parameter. Unfor-
tunately, it was not possible to quantify the associations between the aforementioned 
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prognostic factors and outcome in our study, due to methodological heterogeneity 
between the included studies.
Although there remains little consensus on the optimal timing of surgery in these pa-
tients, our findings may support decision-making and timing of intervention, as they 
may suggest that earlier intervention before the LVOT gradient progresses excessively 
and before aortic regurgitation develops may improve outcome after surgery, although 
this remains to be investigated in more detail.
In patients with discrete subvalvular aortic stenosis, more aggressive resection in the 
form of myectomy in addition to enucleation of the fibromuscular ridge has also been 
proposed to potentially reduce the recurrence rate and subsequently reoperations.25,26 
However, evidence on the benefit of routine myectomy in these patients is inconsis-
tent.27,28 Myectomy also increases the risk of complete atrioventricular block and its 
influence on aortic valve function remains unclear. Further investigation of the value of 
myectomy in reducing recurrence and subsequent reoperation is therefore warranted.
Thus, there are many patient- and procedure-related factors that influence outcome in 
these patients, as is also the case in most other cardiovascular diseases. Studies aimed 
at reliably quantifying the many associations between patient- and procedure-related 
factors and outcome in cardiovascular disease are therefore urgently needed to inform 
patient-tailored decision-making. In disease states with a relatively low incidence and 
with a relatively low occurrence rate of adverse outcome events, such as congenital left 
ventricular outflow tract disease, large multicenter registries may play an important role 
in these studies by providing the adequate sample size and methodological homoge-
neity necessary for such analyses, which is difficult to achieve in single-center studies. 
Although such registries are unfortunately not yet available for subvalvular aortic steno-
sis, for aortic valve disease the AVIATOR registry and the currently under development 
LEOPARD registry are promising initiatives in this light.29,30
aortic valve disease
In aortic valve disease, when the valve requires replacement, all available aortic valve 
substitutes have their inherent drawbacks. Thus far, evidence on outcome after valve 
replacement has been fragmented across an exceedingly large number of publications 
on single-center series with varying results, and the data therein is often analyzed and 
presented in a manner that cannot be readily implemented in daily clinical practice, 
patient information and (shared) decision-making. In this light, Chapters 3-7 provide a 
unique insight into long-term outcome after aortic valve surgery. Our robust methods of 
systematic review and meta-analysis allow for effective amalgamation of all published 
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data on the subject, providing an exceptionally large sample size to draw inferences 
from and accounting for the heterogeneity encountered between individual publica-
tions. Moreover, as conventional methods for meta-analysis of long-term outcome 
provide results that may not be readily interpretable by clinicians and patients to an in-
dividual patient level (e.g. linearized occurrence rates), our application of novel methods 
of time-to-event meta-analysis and microsimulation provide an unprecedented insight 
into long-term outcome by providing results in a format that are more patient specific 
and readily interpretable by clinicians and patients alike (e.g. Kaplan-Meier estimates, 
lifetime risks of outcome events, life expectancy). This allows for more meaningful and 
direct implementation of this data into daily clinical practice, decision-making and 
patient information.
Outcome after aortic valve replacement
After mechanical aortic valve replacement in non-elderly adults (Chapter 4), there is a 
substantial lifetime risk of thromboembolism and of bleeding ranging from a combined 
risk of 53% for patients aged 20-30 years at surgery to 30% for patients aged 50-60 
years. Also, although we found the long-term durability of mechanical prostheses to be 
excellent, as evidenced by not a single case of structural valve deterioration of modern 
bileaflet prostheses being reported in the reviewed literature, endocarditis and non-
structural dysfunction still give rise to a risk of reintervention that is not to be neglected, 
ranging from a lifetime risk of 15% for patients aged 20-30 years at surgery to 8% for 
patients aged 50-60 years. Lastly, survival after mechanical aortic valve replacement is 
substantially impaired, particularly in younger patients, and little over 50% of the life 
expectancy of the age- and gender-matched general population. In children (Chapter 
3), although lifetime estimates were not available, the linearized occurrence rate of 
reintervention was double the rate in adults (due in part to the additional risk of increas-
ing patient-prosthesis mismatch over time in growing children), thromboembolism and 
bleeding rates were slightly lower and the endocarditis rate was comparable.
After bioprosthetic aortic valve replacement in non-elderly adults (Chapter 6), there is 
an exceptionally high rate of reintervention, with almost all patients aged 20-40 years at 
surgery expected to undergo one or more reinterventions during their lifetime and ap-
proximately 60-75% of patients aged 40-60 years at surgery. The overall reintervention 
rate is higher than after the Ross procedure (Chapter 5), even after taking the additional 
right ventricular outflow tract reinterventions associated with the Ross procedure into 
account, and also higher than after mechanical aortic valve replacement (Chapter 4). 
Rates of thromboembolism and/or bleeding are lower than after mechanical aortic valve 
replacement, with a combined lifetime risk of approximately 15-30% depending on age 
at surgery. However, this risk of thromboembolism and/or bleeding is certainly not zero 
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and higher than in the general population.31 This risk is also higher than observed after 
the Ross procedure and aortic valve repair32,33, even though bioprosthetic valve replace-
ment, the Ross procedure and valve repair similarly aim to avoid the need for lifelong 
anticoagulation. This may be due in part to other indications for anticoagulation arising 
during follow-up after bioprosthetic aortic valve replacement, as two prior studies have 
reported that at approximately 10 years after bioprosthetic aortic valve replacement, 
25% to 30% of patients require oral anticoagulation therapy, mostly due to atrial fibril-
lation.34,35 Life expectancy is also impaired in these patients at approximately 60-75% of 
the life expectancy of the age- and gender-matched general population. In children, the 
use of bioprostheses is exceedingly rare, as there are no series encompassing more than 
20 patients described in contemporary published literature.
Outcome after the Ross procedure (Chapter 5) in both children and non-elderly adults 
is characterized by a substantial reintervention rate, due in part to the additional risk of 
reintervention on the prosthesis in the right ventricular outflow tract when compared 
with other aortic valve substitutes. Consequently, almost all children and adults aged 
<40 years at surgery are expected to require reintervention during their lifetime and 
approximately 45-70% of patients aged 40-60 years at surgery. Nevertheless, the overall 
reintervention rate still appears to be lower than after bioprosthetic aortic valve replace-
ment. Furthermore, lifetime risks of thromboembolism and bleeding are exceedingly 
low in both children and non-elderly adults, ranging from 5-7% depending on age at 
surgery, comparable to the risk in the age- and gender-matched general population.31 
In contrast to the outcome observed after mechanical and bioprosthetic aortic valve 
replacement, survival after the Ross procedure is excellent in both children and non-
elderly adults despite the high reintervention rate, with a life expectancy of 90-95% of 
the life expectancy of the age- and gender-matched general population. Besides the 
lower rates of thromboembolism and bleeding, the favorable hemodynamics of the au-
tograft in comparison with mechanical prostheses and bioprostheses may play a role in 
this observed survival difference, as suboptimal hemodynamics (i.e. patient-prosthesis 
mismatch) have been found to lead to significant excess mortality after both mechani-
cal and bioprosthetic aortic valve replacement, particularly in younger patients.36,37 
However, the possible influence of patient selection and possible differences in patient 
characteristics and concomitant procedures performed at the time of surgery should 
also be taken into account in such comparisons.
Clinical prospects
From a clinical perspective, there are many developments within the field that may 
improve outcome in young adult patients requiring aortic valve replacement.
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In patients undergoing mechanical aortic valve replacement, optimization of antico-
agulation management may reduce complication rates. Studies have shown that, in 
patients treated with currently available anticoagulants, 25% of periodically measured 
International Normalized Ratio (INR) values lie outside of the target range.38 More stable 
anticoagulation management through, for instance, pharmacological advances and 
self-management, may therefore reduce the rate of thromboembolic and bleeding 
complications. This may also translate to an improvement in survival in these patients, 
as there is evidence that, with optimal self-management anticoagulation, mechanical 
aortic valve replacement offers excellent late survival comparable to the general age-
matched population and also comparable to patients undergoing the Ross procedure.39 
Lower dosing of anticoagulation may also prove promising in improving outcome. 
There is increasing evidence that patients with contemporary mechanical valves and 
no comorbidities may be safely managed at a lower INR than currently recommended, 
subsequently reducing bleeding complications without increasing the risk of throm-
boembolic events.38,40,41 Additionally, advances in the design of mechanical valves may 
lead to reduced thrombogenicity and mechanical valves specifically designed with 
this in mind have emerged. One such novel mechanical valve prosthesis has received 
FDA-approval for anticoagulation management at a lower INR than recommended by 
the guidelines.41 However, evidence on the effect thereof on clinical outcome remains 
to be awaited. Design improvements of novel mechanical prostheses should also focus 
on improving their hemodynamics, as patient-prosthesis mismatch currently remains 
a major problem that leads to significant excess mortality after both mechanical and 
bioprosthetic aortic valve replacement, particularly in younger patients.36,37
Lastly, besides clinical outcome, psychosocial outcome in patients with mechanical 
aortic valve prostheses remains suboptimal. After mechanical aortic valve replacement, 
non-elderly adult patients have been found to experience substantial valve-related 
impairments in quality of life due mostly to the valve sound, anticoagulation/INR man-
agement and fear of a reoperation (despite the excellent durability of mechanical 
prostheses).42 These impairments in quality of life were more severe after mechanical 
aortic valve replacement than after the Ross procedure or aortic valve repair.42 Non-
elderly adult patients after mechanical aortic valve replacement also more frequently 
report that their valve prosthesis significantly affects their work, career and income, 
more frequently experience employment disability, and are overall less satisfied with 
their valve prosthesis when compared with patients with bioprostheses, pulmonary 
autografts or allografts.43 Therefore, there is an urgent need for efforts aimed at improv-
ing psychosocial outcome in these patients, for instance through improvements in the 
design of mechanical protheses, postoperative clinical management, patient education 
and counseling, and shared decision-making.
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With regard to bioprostheses further efforts aimed at reducing the exceedingly high rates 
of structural valve deterioration and subsequent reoperation in young adult patients 
are needed. There is still little evidence on the mechanism of increased structural valve 
deterioration in younger patients, although increased immune responsiveness, more 
active calcium metabolism and increased hemodynamic load have all been proposed 
to play a role44-46, which warrants further investigation. Also, structural deterioration of 
aortic valve bioprostheses usually slowly develops and progresses over the course of 
several years, and thus the left ventricle is subjected to slowly deteriorating aortic valve 
function for an extended period of time. It currently remains unclear how this affects 
long-term cardiac function and survival.
In response, improvements in the design of modern bioprostheses have been proposed 
to improve durability, however clinical evidence of the hypothesized benefits provided 
by these modifications is inconclusive.47-49 Lastly, similar to mechanical prostheses as 
discussed above, design improvements may also lead to improved hemodynamics, 
which may reduce patient-prosthesis mismatch and subsequently improve long-term 
survival.36,37
With regard to the Ross procedure there is increasing evidence that there are many fac-
tors that are associated with the large variation in reported clinical outcome.
Patient-related factors such as age, preoperative aortic regurgitation, preoperative 
aortic annulus dilatation, and underlying cause of disease have all been shown to be 
associated with the long-term durability of the procedure50-53, which underlines the 
crucial importance of careful patient selection and patient-tailored decision-making in 
achieving optimal outcome after the Ross procedure. Further development of methods 
that allow for more accurate patient-tailored outcome modeling, for instance based on 
the methodology employed in this thesis, may prove valuable in this light (which will be 
further discussed later in this chapter).
Given the technical complexity of the procedure, variation in surgical technique and 
surgeon and center volume may also play a role in long-term autograft function. Further 
evaluation of modifications to surgical technique (such as subcoronary implantation, the 
inclusion technique, external prosthetic or pericardial support and annuloplasty) and 
perioperative management (such as strict early postoperative systemic blood pressure 
control) that are proposed to improve autograft durability may lead to the development 
of a more standardized and reproducible technique that provides a more durable result.
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With regard to allograft deterioration, decellularization techniques are under ongoing 
development aiming to improve long-term durability by reducing the immune response 
that is thought to play a role in allograft deterioration (Chapter 8). However, accrual of 
larger patient series and longer follow-up are required to shed light on the proposed 
clinical benefit of decellularization.
There is growing interest in transcatheter aortic valve implantation (TAVI) as a primary 
intervention in increasingly younger and lower risk patients. However, to date, they 
have only been studied in elderly patients (even in the low-risk patient trials the mean 
age is >70 years)54,55 and long term follow-up, which is of particular importance in 
younger patients, has yet to be accrued. In addition, its role as a prospective option 
for reintervention of failing surgical bioprostheses has also come into focus, however 
the effectiveness of valve-in-valve TAVI in younger patients, the feasibility of multiple 
sequential valve-in-valve TAVIs, and medium-to-long-term outcome after valve-in-valve 
TAVI remain to be investigated. Therefore, the future potential of TAVI in non-elderly 
patients remains uncertain. If TAVI proves valuable in this patient population, either as a 
primary intervention or in the setting of valve-in-valve TAVI after prior bioprosthetic aor-
tic valve replacement or prior TAVI, the complexity of decision-making in these patients 
will increase considerably. Extensive decision analyses and decision models will then 
be required to shed light on the optimal (sequence of ) procedure(s) for each individual 
patient, also taking patient values and preferences into account.
Considering the limitations of all currently available heart valve prostheses as discussed 
above, tissue engineering of heart valves is a promising development with the aim of 
providing a living autologous heart valve substitute that would ideally last a lifetime 
and reduce or even eliminate the long-term adverse outcomes of current prostheses. 
Although there is ever-growing interest in the development of such valves and much 
progress has been made in research in this field, it is still very experimental in nature, 
there are still many challenges to overcome and a clinically viable product has yet to 
be realized. Further, if and when a clinically viable tissue engineered valve is realized, it 
will also need to prove superior to currently available valve substitutes in the long-term 
with regard to both clinical outcome and cost-effectiveness. Thus, although ongoing de-
velopments are promising, the concept of “one valve for life” is not yet within reach.56,57
Lastly, continuous improvements in aortic valve repair techniques may increasingly pro-
vide options for native valve preservation in young adult patients, avoiding or postpon-
ing the need for valve replacement.58 However, comparison of our findings with current 
literature on outcome after aortic valve repair is difficult, due to a sparsity of available 
outcome data, disparity in indications and a lack of standardization in data reporting.32 
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Collaborative initiatives, such as the AVIATOR international multicenter registry, may 
shed more light on whether the potential benefits of native valve-preservation translate 
to improved outcomes.29,30,32
Optimization of decision-making
With regard to decision-making, direct comparison of the various available valve pros-
theses in children and young adults is hampered by differences in patient characteristics 
and a lack of randomized, matched or adequately adjusted data. However, it is clear 
that each valve substitute provides vastly differing outcome profiles and that no valve 
substitute is consistently superior in all outcome measures.
Therefore, patients and physicians often face a difficult choice when aortic valve replace-
ment is indicated. The difficulty of this decision has been demonstrated in a prior study 
among physicians, in which cardiologists and cardiac surgeons were asked to indicate 
their preference for a mechanical prosthesis or bioprosthesis for a number of patient 
profiles. There was an exceedingly wide variation in preferences between individual 
physicians: for a given patient with a specific patient profile, some physicians indicated 
that they would always choose a mechanical prosthesis while other physicians would 
always choose a bioprosthesis in the very same patient. This large individual variability 
in preferences has also been demonstrated among patients undergoing aortic valve 
surgery in trade-offs between quality of life and quantity of life.59,60 This illustrates the 
complexity and value-sensitivity of decision-making in aortic valve disease.61
Clinical practice guidelines provide some guidance in the selection of a valve substitute, 
based largely on patient age. The 2017 United States and European guidelines for the 
management of valvular heart disease both recommend mechanical prostheses over 
biological alternatives for aortic valve replacement in adults younger than 50 to 60 years 
old. If anticoagulation is contraindicated or if the patient prefers a biological alterna-
tive, both guidelines recommend bioprostheses, and only the United States guidelines 
indicate that the Ross procedure may be considered.62,63
However, what underlies these recommendations is the interpretation of evidence ac-
cording to the collective “outcome hierarchy” (i.e. the relative valuation of each possible 
outcome) of clinicians, investigators and policy makers. It is important to consider that 
individual patients’ outcome hierarchies may differ strongly from those of clinicians, 
investigators and policy makers, and also with an exceedingly wide variation among 
individual patients, driven by personal values and life goals. Therefore, the choice for a 
certain treatment should be driven by individual patient values and preferences, besides 
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clinical and technical considerations. The guidelines therefore also highly recommend a 
shared decision-making process in prosthetic valve selection.62,63
In this light, development and clinical implementation of disease-specific value clarifica-
tion methods that aid both patients and physicians in elucidating individual patient val-
ues may prove promising in promoting individualized value-based decision-making.64 
In a research setting, value clarification studies in this patient population may also 
provide much needed insight into what is really important to patients and thereby aid 
in shifting the focus of future research from investigator-motivated outcomes to more 
patient-centered outcomes.
outcoMe MoDels for clinical Practice anD Patient-
tailoring
There is an ever-growing body of literature on patients with congenital left ventricular 
outflow tract disease. Nevertheless, in current daily clinical practice it often remains 
unclear to both physicians and (parents of ) patients what the expected short- and 
long-term outcome is after surgical treatment. This is due in part to the fact that current 
evidence is fragmented across an exceedingly large number of publications and that 
the data therein is often analyzed and presented in a manner that cannot be readily 
implemented in daily clinical practice, patient information and shared decision-making. 
As a result, currently available evidence remains underutilized in practice.
The advanced meta-analysis and microsimulation methodology employed in Chapters 
4-6 present a means for effective amalgamation of the ever-growing body of evidence 
and for reliable translation thereof to freedom-from-event estimates, lifetime estimates 
of event occurrence and life expectancy, outcome formats that are more readily inter-
pretable and more meaningful to physicians and patients alike than traditional meta-
analytic outcome formats such as linearized occurrence rates.
The microsimulation methodology employed in these studies, also provides an op-
portunity for individual patient-tailored outcome modeling, which would be a further 
development of the outcome models presented in Chapters 4-6. It is well known that 
outcome after cardiac surgery varies considerably among individual patients, depen-
dent in part on patient- and procedure-related factors. For instance, in Chapter 2 we 
succeeded in identifying numerous patient characteristics associated with differences 
in clinical outcome in patients with subvalvular aortic stenosis, however quantitative 
analysis was not possible due to methodological heterogeneity between studies. Future 
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studies aimed at reliably and accurately quantifying such associations (also in valvular 
aortic disease and cardiovascular disease in general), in which large multicenter regis-
tries may play an important role, could provide the data necessary for incorporation of 
these associations into the existing microsimulation model. The microsimulation-based 
outcome estimates as presented in Chapters 4-6 could then be further tailored to 
patient-specific factors (such as underlying cause of disease, hemodynamics, symptoms, 
medical history, concomitant diseases, etc.) to more accurately represent what an indi-
vidual patient can be expected to face after surgery.
Ideally, such patient-tailored outcome models could be incorporated into an open-
access interactive online tool for clinicians, in which users can input patient characteris-
tics and obtain patient-tailored outcome estimates in a clinically meaningful format. For 
patients, the modelled outcomes can be incorporated into online patient information 
portals such the one we developed and validated as described in Chapters 11 and 12. 
This may aid clinicians and patients in selecting the optimal treatment for each indi-
vidual patient. This methodology may also provide similar opportunities in other areas 
of cardiovascular medicine in which long-term outcome modeling and subsequent 
evidence-based and value-sensitive decision-making remain a challenge.
Although microsimulation provides promising opportunities for long-term outcome 
modeling, it is limited by its dependence on a large quantity of high-quality compre-
hensive data as an input for parameterization of the model, with an increasing level 
of detail required as an increasing number of patient- and/or procedure-related fac-
tors are incorporated for patient-tailoring. The availability of such data with sufficient 
sample size is often limited in the setting of cardiac surgery, although large multicenter 
registries may prove valuable in this light as previously discussed. Additionally, due 
to the rapid developments in cardiac surgery over the past decades and the relatively 
favorable survival, the observed follow-up period in contemporary input data is often 
shorter than the modeled time-horizon, which requires assumptions to be made about 
evolution of event occurrence beyond the observed follow-up period. These factors all 
give rise to second-order uncertainty in the microsimulation model (i.e. uncertainty 
in the input parameters). Although such potential inaccuracies can only be effectively 
remedied through accrual of larger sample sizes, longer follow-up and more detailed 
data, they can be incorporated into the modeled outcome estimates through the use of 
probabilistic sensitivity analysis so that these potential inaccuracies in the input data are 
reflected in all generated outcome estimates, as was done in Chapters 5 and 6.
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evaluation of clinical DeveloPMents anD innovations
Randomized controlled trials are often considered the gold standard for the evaluation 
of the efficacy of novel therapies in comparison with standard of care.65
However, randomized controlled trials are not always feasible due to clinical, ethical, 
logistic or financial reasons. Moreover, depending on trial design, the generalizability 
of results to the target population in large is often limited in comparison to other study 
designs, which may hamper inferences on effectiveness (i.e. performance under ‘real-
world’ circumstances) rather than efficacy.
Unfortunately, in the absence of randomized controlled trials, observational studies by 
design introduce bias in comparisons between treatment groups, as a result of con-
founding due to an inherent imbalance of covariates between groups.66
Considering the limitations of all currently available surgical options and the subse-
quent need for innovation, there is an urgent need for methodology that allows for 
reliable evaluation of the effectiveness of these innovations in improving on the current 
standard of care when randomized controlled trials are not feasible.
In this light, Chapter 8 succeeds in reliably evaluating an innovation in the Ross proce-
dure, namely decellularization of the pulmonary allograft, in comparison with standard 
pulmonary allografts in an observational study. This was done employing propensity 
score analysis as conceptualized by Rosenbaum and Rubin, which offers the possibility 
for correction for the imbalance in measured covariates between treatment groups in an 
observational study.67 This provided us the unique opportunity for a direct comparison 
between the novel decellularized allografts and standard cryopreserved allografts in a 
large observational cohort of patients undergoing the Ross procedure.
Our comparison shows that decellularized and standard cryopreserved pulmonary 
allografts, when used for right ventricular outflow tract reconstruction in the Ross 
procedure, both provide comparably excellent clinical and hemodynamic outcome up 
to 5 years postoperatively. Longer follow-up is necessary to shed light on the proposed 
benefits of allograft decellularization.
In the absence of the results of a randomized controlled trial, this propensity score 
analysis represents the most reliable evidence on the effectiveness of this novel therapy 
to date. In other clinical settings in which randomized controlled trials may be ethically 
or practically unfeasible, this methodology provides a unique opportunity to draw in-
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ferences that would otherwise not be possible in observational studies. However, the 
limitations of propensity score analyses should always be carefully considered. Most 
importantly, contrary to randomization, propensity score analyses can only balance 
groups based on observed covariates, while unobserved or unknown covariates (some 
of which may be prognostically important) will remain unbalanced between groups, 
which may introduce bias.68 Also, propensity score matching may reduce generalizabil-
ity of the results of analyses, by producing matched subpopulations that may not be 
representative for the entire unmatched “real-world” target population of interest. This 
is particularly the case if the matched subpopulation is only a small proportion of the 
unmatched patient population.69
Our robust methods of longitudinal data analysis allowed us to accurately analyze 
echocardiographic hemodynamic allograft function over time. In contrast to the clinical 
outcome events that are most frequently analyzed in studies on aortic and pulmonary 
valve substitutes, hemodynamic allograft function is not discrete, but rather subject to 
gradual changes over time (longitudinal outcome). As such, there is a wealth of valuable 
information in serial echocardiographic measurements of hemodynamic allograft func-
tion taken at various points in the follow-up of each patient. Methods for longitudinal 
data analysis, such as the mixed models we used, provide a means to take full advantage 
of the valuable information that lies in the temporal pattern of longitudinal outcomes 
within each patient, rather than analyzing these outcomes as a “snapshot” at a specific 
time in follow-up.70 Although such methodology is highly complex, it is becoming in-
creasingly available to the broader scientific community in the form of user-friendly 
statistical software packages.
In the assessment of these novel decellularized pulmonary allografts in the Ross proce-
dure, because the incidence of clinical outcome events is relatively low in this clinical 
setting and these events tend occur mostly after many years of follow-up rather than 
early in the follow-up, longitudinal analysis of echocardiographic allograft function may 
reveal a benefit of the novel therapy long before a detectable clinical benefit manifests. 
In many other clinical settings, such use of novel methodology for accurate and reliable 
analysis of precursors to clinical events may also provide similar means for drawing 
earlier inferences on treatment innovations.
In the broader perspective of published literature, evaluation of surgical innovations over 
the years often requires the possibility for comparisons between separate study cohorts. 
Although a certain degree of methodological heterogeneity among individual studies 
is unavoidable, we must aim to keep methodological heterogeneity to a minimum to 
increase comparability between reports. Further collaborative implementation of and 
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wide adherence to methodological and reporting guidelines, such as those reported by 
Akins and colleagues with regard to studies on cardiac valve interventions in 200870, are 
instrumental in this light. Establishment of large multicenter registries may further aid 
in improving methodological homogeneity.
It should always be considered that novel treatment options may not provide a “one-
size-fits-all” solution that is universally superior for all patients, especially not in the 
increasingly complex and heterogeneous patient population in the field of cardiac 
surgery. Careful patient selection and consideration of patient values and preferences 
are therefore of utmost importance in the evaluation and clinical application of novel 
therapies as well.
Lastly, with the growing importance of efficiency and sustainability in health care 
expenditures, the cost-effectiveness of novel therapies should always be considered. 
Consequently, (early) health technology assessment will play an increasingly important 
role in how we evaluate ongoing developments in care. The methodology for long-term 
clinical outcome modeling employed in this thesis, as previously discussed in this chap-
ter, provides unique opportunities in this light by providing the possibility for accurate 
patient-tailored long-term outcome modeling, which represents the basis for reliable 
health technology assessment.
Patient inforMation anD involveMent
Considering the important implications of treatment decisions on patients’ lives, it is 
essential to inform patients and their relatives in a complete, objective, and understand-
able manner.
In various disease states, more informed and activated patients have been previously 
found to be associated not only with improved quality of life, treatment adherence, 
health behavior, and clinical outcome but also with more efficient healthcare utilization 
and lower healthcare costs.71-83 However, as evidenced by Chapter 9 of this thesis, there 
are substantial shortcomings in patient information and decision-making in congenital 
aortic valve surgery, as reported by patients, parents and physicians alike. Patient knowl-
edge is severely limited due to the limited availability, reliability and comprehensibility 
of patient information. Furthermore, the provided information often does not meet the 
patients’ information needs. When treatment decisions need to be made, patient activa-
tion and involvement are suboptimal and there is substantial decisional conflict and 
valve-related anxiety.
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Unfortunately, adequately informing patients is no easy task. For instance, if we are to 
communicate outcome after surgery in the form of event risk estimates (such as those 
we estimated in Chapters 3-6) with patients, how well can patients interpret these 
numerical risks? As found in Chapter 9, the understanding of numerical risks is severely 
impaired among congenital aortic valve patients and their parents. Only approximately 
50% of subjects were found to have an adequate understanding of numerical risks. As 
this poses a major challenge in risk communication, risk visualizations (such as icon 
arrays, bar charts and pie charts) have been proposed to improve the understanding 
of numerical risks. However, their effectiveness had not previously been investigated 
in the setting of conveyance of the precise magnitude of absolute risks, such as the 
setting we face in communicating treatment outcome estimates with patients. In Chap-
ter 10 we therefore explored the understanding of the precise magnitude of absolute 
numerical risks in the broader general population and investigated the effectiveness of 
risk visualizations in improving this understanding. We found that in the general popula-
tion, only 60% of subjects have an adequate understanding of the precise magnitude 
of absolute numerical risks (comparable to 50% in our patient population) and that risk 
visualizations do not improve this understanding. This study was, to our knowledge, 
the first to investigate the effectiveness of risk visualizations in supporting the verbatim 
communication of single absolute risks (as is often necessary in cardiac surgery). Our 
findings in this setting are in contrast to those of prior studies that focused on the 
conveyance of gist knowledge (i.e. understanding of the general risk message) and/or 
comparisons/trade-offs of multiple risks, in which a beneficial effect of risk visualiza-
tions was often found.84,85 Our findings challenge the currently prevailing dogma that 
risk visualizations are universally beneficial84,85 and suggest that their effectiveness may 
rather be dependent on the setting in which they are applied, although our study has 
yet to be replicated for external validation.
Thus, there are substantial shortcomings in patient information and involvement and 
important challenges in patient communication.
This underlines the need for innovative solutions, such as the online evidence-based pa-
tient information portal we developed (Chapter 11) and validated in a stepped-wedge 
cluster randomized trial (Chapter 12). In this study, although the information portal was 
received well by physicians and (parents of ) patients alike and received consistently 
high ratings from users, only half of the participants invited by their cardiologist to 
visit the information portal actually visited the portal. Among those subjects that actu-
ally visited the information portal, disease-specific knowledge and mental health were 
significantly better at one month after outpatient clinic visit than in control subjects 
that did not have access to the portal. This demonstrates that an online evidence-based 
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patient information portal is potentially effective in improving knowledge in patients 
with congenital heart disease, although active use of the portal is crucial.
The above shows that, although this thesis provides the basis for much needed improve-
ments in patient information, there are still many challenges in adequately informing 
patients and implementing tools such as the information portal into clinical practice.
For instance, although the usage rate of our information portal (52%) was higher than 
previously reported for other patient information and decision support interventions 
(25-35%)86, it still leaves a large proportion of patients unsatisfactorily informed and it 
remains unclear why so few patients make use of patient information tools. An interest-
ing finding in our study (Chapter 11) was that there was no association between how 
informed patients felt subjectively and their objective knowledge level. This may indi-
cate that many patients may be unaware of their knowledge deficits and, therefore, do 
not see the need to seek additional information. Efforts aimed at helping such “uncon-
sciously uninformed” patients gain insight into their own knowledge level may therefore 
support more active use of patient information interventions and subsequently improve 
patient knowledge.
Additionally, identification of the moments at which the information need is greatest 
among patients may allow for more effective timing of information interventions, which 
may lead to increased usage and knowledge uptake.
Moreover, employing innovative media formats such as video/animation, virtual reality, 
3D modeling and serious gaming principles may prove more effective in engaging and 
informing patients, particularly adolescents and young adults.
Implementation and effectiveness of patient information interventions may be further 
improved by deeper integration into the healthcare system by, for instance, more active 
involvement of paramedical staff such as physician assistants and nurse practitioners, 
integration into electronic patient record systems, employing waiting room tools such 
as computers or tablets, etc.
It also remains to be elucidated what the secondary effects of improved knowledge are 
on patient activation, involvement, concordance of treatment decisions with patient 
values, long-term quality of life, health behaviors.
Besides their effects on patients, patient information interventions probably also have 
an effect on physicians and how they communicate with patients by providing a stimu-
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lus and support in more actively informing and involving their patients. Thus, part of the 
potential effectiveness of patient information interventions may lie in these physician 
effects rather than solely in isolated patient effects. Future studies on physician effects 
of patient information interventions may therefore be valuable in informing design and 
implementation considerations in the interest of improving on their role as physician-
support tools, thereby potentially increasing the net positive effects on patients.
With the growing importance of efficiency and sustainability in health care expendi-
tures, the effect of patient information interventions on health care systems should also 
be considered, as more activated patients have been previously found to be associated 
with significantly lower healthcare costs.87 By potentially improving patient knowledge 
and activation, patient information interventions may therefore not only improve pa-
tient outcome, but also lead to more efficient healthcare utilization and lower healthcare 
costs, although this remains to be investigated.
When it comes to risk communication, we have shown that there is a need for support 
in the verbatim communication of individual absolute risks, as is the case in the com-
munication of estimates of treatment outcome such as those provided by this thesis. 
Our findings suggest that this need may be unmet by currently widely used forms of risk 
visualization. As this was the first study to our knowledge to investigate the effectiveness 
of risk visualizations in the particular setting of verbatim communication of individual 
absolute risks, replication of our study in different countries and languages is warranted 
and may provide insights into potential cultural, societal and language-related factors 
that may be of influence on the effectiveness of these risk visualizations. It should also be 
investigated whether risk visualizations may be more effective in real-world healthcare 
settings among actual patients with a vested interest in understanding the risk informa-
tion as opposed to general population samples presented with a hypothetical scenario. 
The increasing digitalization of patient information over the years also provides the 
opportunity for the use of novel digital media formats, for instance (narrated) anima-
tions, which may further aid in conveying risks to subjects and prove more effective 
than classical static two-dimensional risk visualizations. Finally, the effectiveness of risk 
visualizations in verbal risk communication also remains to be investigated.
conclusions anD ProsPects
This thesis provides novel insights into long-term outcome after congenital left ven-
tricular outflow tract surgery through the use of innovative methods of advanced meta-
analysis, microsimulation, propensity score analyses and longitudinal data analysis. It 
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also demonstrates that there is an urgent need for improvements in patient information 
and involvement and provides the basis for interventions and initiatives that have the 
potential to substantially improve patient knowledge, empowerment, involvement, 
psychosocial outcome and health behavior. Further developments building upon the 
work in this thesis, as proposed above, may offer us a means for more patient-tailored 
outcome modeling, provide a platform for making this information readily available to 
both clinicians and patients in an understandable and meaningful format, and advance 
our knowledge and skills on how we can better inform patients and tailor our treat-
ments to the individual patient, taking personal values and preferences into account. It 
is imperative that we keep trying to make more sense of outcome after surgery to both 
clinicians and patients in the interest of achieving optimal outcome for each individual 
patient.
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chapter 1 is a general introduction to this thesis, in which the background, aims, re-
search questions and outline of this thesis are described.
chapter 2 provides an overview of the natural history of pediatric subvalvular aortic 
stenosis, of outcome after surgery and of factors associated with prognosis. This system-
atic review includes 24 studies, encompassing a total of 809 natural history and 1476 
surgical patients. This chapter shows that approximately half of patients diagnosed with 
subvalvular aortic stenosis require surgery and that after surgery, although mortality 
is low, there is a substantial reintervention rate. This chapter illustrates the prognostic 
value of left ventricular outflow tract gradient, the presence of aortic valve regurgita-
tion and the distance between the subvalvular obstruction and the aortic valve, which 
underlines the importance of these factors in surgical decision-making. There is a need 
for further studies on the optimal timing of surgery based on these factors.
chapter 3 provides an overview of outcome after pediatric aortic valve replacement 
(AVR). In this systematic review and meta-analysis, 34 publications reporting on 42 co-
horts were included: 26 concerning the Ross procedure (2409 patients), 13 concerning 
AVR with a mechanical prosthesis (696 patients), and 3 concerning AVR with an allograft 
(224 patients). There were no studies on bioprostheses that met our inclusion criteria. 
This chapter illustrates that all currently available aortic valve substitutes are associated 
with suboptimal results in children, reflecting the urgent need for reliable and durable 
repair techniques and innovative replacement solutions for this challenging group of 
patients.
chapter 4 provides an overview of outcome after mechanical AVR in non-elderly adults. 
In this systematic review, meta-analysis and microsimulation study, 29 publications 
were included, encompassing a total of 5728 patients. This chapter demonstrates that 
outcome after mechanical AVR in non-elderly adults is characterized by suboptimal 
survival and considerable lifetime risk of anticoagulation-related complications, but also 
reintervention. Non-elderly adult patients who are facing prosthetic valve selection are 
entitled to conveyance of evidence-based estimates of the risks and benefits of both 
mechanical and biological valve options in a shared decision-making process.
chapter 5 provides an overview of outcome after the Ross procedure in both children 
and non-elderly adults. In this systematic review, meta-analysis and microsimulation 
study, 99 publications were included, encompassing a total of 13129 patients. This 
chapter demonstrates that, through excellent survival and avoidance of the burden of 
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anticoagulation, the Ross procedure provides a unique opportunity for patients whose 
preferences do not align with the outcome provided by mechanical valve replacement 
and for growing children who also benefit from autograft diameter increase along with 
somatic growth. On the downside, almost all pediatric and many adult Ross patients will 
require a reintervention in their lifetime.
chapter 6 provides an overview of outcome after bioprosthetic AVR in non-elderly adults. 
In this systematic review, meta-analysis and microsimulation study, 19 publications were 
included, encompassing a total of 2686 patients. This chapter demonstrates that AVR 
with bioprostheses in young adults is associated with high structural valve deterioration 
and reintervention rates, and low, though not absent, hazards of thromboembolism and 
bleeding. Foremostly, most patients will require one or more reinterventions during 
their lifetime and survival is impaired in comparison with the age- and sex-matched 
general population. Prosthesis durability remains the main concern in these patients.
chapter 7 is an expert review that discusses contemporary evidence on clinical and 
psychosocial outcome after AVR and aortic root surgery in non-elderly adults. This 
chapter illustrates that treatment for non-elderly aortic valve and aortic root disease 
patients needs to be tailored to the individual patient, considering both clinical and 
psychosocial outcomes as crucial factors to reach a treatment decision that best reflects 
the individual patient’s values and goals in life.
chapter 8 compares the durability of novel fresh decellularized pulmonary allografts 
with that of standard cryopreserved pulmonary allografts when used for right ven-
tricular outflow tract reconstruction in patients undergoing the Ross procedure. In this 
propensity score-matched analysis of a prospective observational cohort, out of a total 
of 144 fresh decellularized allograft and 619 standard cryopreserved allograft patients, 
94 propensity score-matched pairs were obtained. Analysis of clinical outcome and 
longitudinal echocardiographic analyses show that, up to 5 years of follow-up, fresh 
decellularized and standard cryopreserved allograft used for right ventricular outflow 
tract reconstruction in the Ross procedure are associated with comparably excellent 
clinical and hemodynamic outcome. Longer follow-up will shed light on the long-term 
performance of decellularized allografts.
chapter 9 assesses the current state of patient information and decision-making in con-
genital aortic and pulmonary valve disease in the Netherlands. This survey includes 62 
adult patients, 11 parents of pediatric patients and 35 physicians (pediatric cardiologists, 
adult congenital cardiologists and congenital cardiac surgeons) in the Netherlands. This 
chapter reveals substantial shortcomings in our current practice of patient information 
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and decision-making that underline the need for innovative solutions, such as careful 
implementation of patient information tools and shared decision-making in the care 
path.
chapter 10 investigates the effectiveness of risk visualizations in conveying verbatim 
knowledge of single absolute risks among the general population. In this randomized 
investigator-blinded survey, 393 randomly sampled members of the general Dutch 
population were asked to complete risk conversion tasks and randomized to support of 
these risk conversion tasks by either icon arrays, pie charts, bar graphs or no visualiza-
tion. This chapter, in contrast to prior studies that all focus on the conveyance of gist 
knowledge (i.e. understanding of the general risk message) or comparisons/trade-offs 
of multiple risks, demonstrates that risk visualizations do not improve conveyance of 
verbatim knowledge of single absolute risks, irrespective of age, education level, risk 
magnitude, risk format and form of risk visualization. Risk visualizations may therefore 
be less suitable for settings in which detailed conveyance of single absolute risks is the 
main objective (as is often the case in cardiac surgery), although their effect on user 
experience and perception of risk communication and subsequent patient activation 
and participation remains to be elucidated.
chapter 11 discusses our nationwide Dutch initiative for the development of an online 
evidence-based patient information portal for congenital heart disease in response to an 
increasing need for patient information and the shortcomings identified in chapter 9. It 
describes our systematic methodology for successful multidisciplinary development of 
an online patient-tailored information portal that presents evidence-based disease- and 
age-specific medical and psychosocial information about diagnosis, treatment, prog-
nosis, and impact on daily life in a manner that is comprehensible and digestible for 
patients and that meets the needs expressed by both patients and physicians.
chapter 12 assesses the effectiveness of the patient information portal we developed 
(as described in chapter 11) in improving patient knowledge and psychosocial out-
come. This stepped-wedge cluster randomized trial among 343 (parents of ) patients 
from four participating centers for congenital heart disease in the Netherlands shows 
that only half of the participants invited by their cardiologist to visit the information 
portal actually visited the portal. Among those subjects that actually visited the infor-
mation portal, disease-specific knowledge and mental health were significantly better 
at one month after outpatient clinic visit, while baseline characteristics and all other 
outcomes were comparable. Thus, this chapter demonstrates that an online evidence-
based patient information portal is potentially effective in improving knowledge and 
psychosocial outcome in patients with congenital heart disease, although active use 
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of the portal is crucial. It underlines the urgent need for efforts aimed at supporting 
effective implementation and active use of patient information support tools.
chapter 13 is the general discussion of this thesis. It discusses the results presented in 
this thesis and their implications. It also answers the research questions and proposes 
future research.
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hoofdstuk 1 betreft een algemene introductie van dit proefschrift. In dit hoofdstuk 
wordt de achtergrond van dit proefschrift beschreven en worden de doelen en onder-
zoeksvragen uiteengezet.
Hoofdstuk 2 geeft een overzicht van het natuurlijk beloop van subvalvulaire aortaste-
nose in kinderen, van de resultaten van chirurgie en van factoren die geassocieerd zijn 
met prognose. Deze systematische review van 24 studies omvat in totaal 809 patiënten 
waarvan het natuurlijke beloop is beschreven en 1476 patiënten waarvan de chirur-
gische uitkomsten zijn beschreven. Dit hoofdstuk laat zien dat ongeveer de helft van 
patiënten met subvalvulaire aortastenose een operatie nodig hebben. Na de operatie 
is de mortaliteit laag, hoewel er een substantieel risico is op reoperatie. Dit hoofdstuk 
belicht de prognostische waarde van linker ventrikel uitstroombaan gradiënt, de aan-
wezigheid van aortaklepinsufficiëntie en de afstand tussen de subvalvulaire obstructie 
en de aortaklep en benadrukt daarmee het belang van deze factoren in chirurgische 
besluitvorming. Verder onderzoek is nodig naar de optimale timing van chirurgie op 
basis van deze factoren.
Hoofdstuk 3 geeft een overzicht van de resultaten van aortaklepvervanging (aortic 
valve replacement, AVR) in kinderen. In deze systematische review en meta-analyse zijn 
34 publicaties meegenomen die 42 cohorten omvat: 26 waarvan betrekking hebben 
tot de Ross procedure (2409 patiënten), 13 tot AVR met een mechanische klepprothese 
(696 patiënten), en 3 tot AVR met een menselijke donorklep (224 patiënten). Er waren 
geen publicaties over bioprotheses in kinderen die voldeden aan onze inclusiecriteria. 
Dit hoofdstuk laat zien dat alle huidige mogelijkheden voor aortaklepvervanging in 
kinderen suboptimale resultaten bieden. Er is derhalve een dringende behoefte aan 
betrouwbare en duurzame technieken voor aortaklepreparatie en innovatieve oplos-
singen voor aortaklepvervanging in deze uitdagende groep patiënten.
Hoofdstuk 4 geeft een overzicht van de resultaten van AVR met een mechanische 
klepprothese in jongvolwassenen. Deze systematische review, meta-analyse en micro-
simulatie studie van 29 publicaties omvat in totaal 5728 patiënten. Dit hoofdstuk laat 
zien dat de uitkomst na mechanische AVR bij jongvolwassenen wordt gekenmerkt door 
suboptimale overleving en een aanzienlijk levenslang risico op complicaties gerelateerd 
aan antistolling, maar ook op reoperatie. Jongvolwassen patiënten die een aortaklep-
vervanging moeten ondergaan hebben recht op inzicht in evidence-based schattingen 
van de voor- en nadelen van zowel mechanische klepprotheses als van biologische 
alternatieven in een gezamenlijk besluitvormingsproces.
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Hoofdstuk 5 geeft een overzicht van de resultaten van de Ross procedure bij zowel kin-
deren als jongvolwassenen. Deze systematische review, meta-analyse en microsimulatie 
studie van 99 publicaties omvat in totaal 13129 patiënten. Dit hoofdstuk laat zien dat 
de Ross procedure uitstekende overleving biedt en de complicaties van antistolling ver-
mijdt, waardoor de Ross procedure een unieke mogelijkheid biedt voor patiënten wiens 
voorkeuren niet overeenkomen met de resultaten van mechanische AVR en tevens voor 
groeiende kinderen die ook profiteren van toename van de autograft diameter naar-
mate het kind groeit. De keerzijde van de medaille is wel dat bijna alle kinderen en een 
groot deel van de volwassenen die de Ross procedure ondergaan in de loop van hun 
leven een reoperatie nodig zullen hebben.
Hoofdstuk 6 geeft een overzicht van de resultaten van AVR met een bioprothese in 
jongvolwassenen. Deze systematische review, meta-analyse en microsimulatie studie 
van 19 publicaties omvat in totaal 2686 patiënten. Dit hoofdstuk laat zien dat er na AVR 
met bioprotheses in jongvolwassenen een hoog risico op structurele klepdegeneratie 
en reoperatie is, en hoewel het risico op tromboembolieën en bloedingen laag is, is deze 
niet afwezig. De meeste patiënten die op jongvolwassen leeftijd AVR met een biopro-
these ondergaan zullen in de loop van hun leven een of meerdere reoperaties nodig 
hebben en hun overleving is verminderd in vergelijking met de algemene bevolking. De 
duurzaamheid van bioprotheses blijft bij deze patiënten de grootste zorg.
Hoofdstuk 7 is een expert review waarin het huidige bewijs voor klinische en psychoso-
ciale uitkomsten na AVR en aortawortelchirurgie in jongvolwassenen wordt besproken. 
Dit hoofdstuk illustreert dat de behandeling van aortaklep- en aortawortelpathologie 
in jongvolwassenen moet worden afgestemd op de individuele patiënt, waarbij zowel 
klinische als psychosociale uitkomsten overwogen moeten worden in besluitvorming, 
om zo te komen tot een behandeling die het beste overeenkomt met de waarden en 
doelen van de individuele patiënt.
Hoofdstuk 8 vergelijkt de duurzaamheid van nieuw ontwikkelde verse gedecellulari-
seerde donorkleppen met die van standaard gecryopreserveerde donorkleppen in het 
kader van rechter ventrikel uitstroombaan reconstructie tijdens de Ross procedure. In 
een prospectief observationeel cohort van patiënten die de Ross procedure ondergin-
gen werden in 144 patienten verse gedecellulariseerde donorkleppen gebruikt en in 
619 werden standaard gecryopreserveerde donorkleppen gebruikt. Middels propensity 
score-matching werden uit deze totale cohort 94 patiënten uit elke groep geselecteerd 
die qua patiëntkenmerken vergelijkbaar waren. Analyse van klinische resultaten en lon-
gitudinale echocardiografische analyses toonden aan dat, tot 5 jaar na de operatie, verse 
gedecellulariseerde en standaard gecryopreserveerde donorkleppen vergelijkbare uit-
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stekende klinische en hemodynamische resultaten bieden. Langere follow-up zal nodig 
zijn om een uitspraak te doen over de lange termijn prestaties van gedecellulariseerde 
donorkleppen.
In Hoofdstuk 9 brengen wij de huidige status van patiënten informatievoorziening en 
besluitvorming bij congenitale aorta- en pulmonalisklepaandoeningen in Nederland in 
kaart. Dit onderzoek omvat 62 volwassen patiënten, 11 ouders van pediatrische patiën-
ten en 35 artsen (kindercardiologen, volwassen congenitaal cardiologen en congenitaal 
hartchirurgen) in Nederland. Dit hoofdstuk onthult substantiële tekortkomingen in onze 
huidige praktijk van patiënten informatievoorziening en besluitvorming. Er is derhalve 
een dringende behoefte aan innovatieve oplossingen hiervoor, zoals de ontwikkeling 
van hulpmiddelen voor patiëntinformatie en gezamenlijke besluitvorming en zorgvul-
dige implementatie daarvan in het zorgpad.
Hoofdstuk 10 onderzoekt de effectiviteit van risicovisualisaties in het bevorderen van 
het exacte begrip van absolute risicogetallen onder de algemene bevolking. In deze 
gerandomiseerde enquête werd aan 393 willekeurig geselecteerde leden van de alge-
mene Nederlandse bevolking gevraagd om risicogetallen om te rekenen. De deelnemers 
werden willekeurig ingedeeld in 4 groepen: in één groep werden de rekenopdrachten 
ondersteund door pictogrammen, in een andere groep door cirkeldiagrammen, in een 
derde groep door staafdiagrammen en in de laatste groep werd de rekenopdracht niet 
ondersteund door een risicovisualisatie. In tegenstelling tot eerdere studies die allemaal 
gericht waren op globaal risicobegrip of op vergelijkingen van meerdere risico’s, toont 
dit hoofdstuk aan dat, als het gaat om het exacte begrip van absolute risico getallen, 
het gebruik van risicovisualisaties het begrip niet bevordert, ongeacht leeftijd, oplei-
dingsniveau, de grootte van het risico, het tekstuele format van het risico en het type 
risicovisualisatie. Risicovisualisaties zijn daarom mogelijk minder geschikt voor situaties 
waarin gedetailleerde/exacte communicatie van absolute risico’s het doel is (zoals vaak 
het geval is in de hartchirurgie), hoewel het effect op gebruikerservaring en patiëntbe-
trokkenheid nog onderzocht moet worden.
Hoofdstuk 11 bespreekt ons landelijke Nederlandse initiatief voor de ontwikkeling 
van een online evidence-based patiënteninformatieportaal voor aangeboren hartaf-
wijkingen in respons op een toenemende behoefte aan patiëntinformatie alsook de 
tekortkomingen daarin die zijn geïdentificeerd in Hoofdstuk 9. Het beschrijft onze 
systematische methodologie voor succesvolle multidisciplinaire ontwikkeling van een 
online patiënt-specifiek informatieportaal dat evidence-based ziekte- en leeftijdsspeci-
fieke medische en psychosociale informatie over diagnose, behandeling, prognose en 
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impact op het dagelijks leven presenteert op een manier die begrijpelijk en verteerbaar 
is voor patiënten en die voldoet aan de behoeften van zowel patiënten als artsen.
Hoofdstuk 12 onderzoekt de effectiviteit van het door ons ontwikkelde patiënten 
informatieportaal (zoals beschreven in Hoofdstuk 11) in het verbeteren van kennis 
en psychosociale uitkomsten van patiënten. Uit deze stepped-wedge cluster gerando-
miseerde studie onder 343 (ouders van) patiënten uit vier deelnemende Nederlandse 
centra voor aangeboren hartafwijkingen blijkt dat slechts de helft van de deelnemers 
die door hun cardioloog werden uitgenodigd om het informatieportaal te bezoeken, 
het portaal daadwerkelijk hebben bezocht. Bij de deelnemers die het informatieportaal 
daadwerkelijk bezochten, waren ziekte-specifieke kennis en geestelijke gezondheid sig-
nificant beter één maand na het bezoek aan de polikliniek, terwijl de patiëntkenmerken 
en alle andere uitkomsten vergelijkbaar waren. Dit hoofdstuk laat dus zien dat een online 
evidence-based patiënten informatieportaal potentieel effectief is in het verbeteren van 
kennis en psychosociale uitkomsten bij patiënten met een aangeboren hartaandoening, 
hoewel actief gebruik van het portaal van essentieel belang is. Het onderstreept de 
dringende behoefte aan initiatieven en innovaties gericht op het ondersteunen van 
de effectieve implementatie en het actief gebruik van dergelijke hulpmiddelen voor 
patiënten informatie.
Hoofdstuk 13 is de algemene discussie van dit proefschrift. In dit hoofdstuk worden 
de resultaten van dit proefschrift en de implicaties van deze resultaten bediscussieerd. 
Tevens worden de onderzoeksvragen beantwoord en worden er voorstellen voor verder 
onderzoek gedaan.
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 The Practice of Epidemiologic Analysis 0.7
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2015
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COEUR course Congenital Heart Disease 1.5
Basic course on R 1.4
2016
NIHES Erasmus Winter Program
 Advanced Analysis of Prognosis Studies 0.7
2014-2016
COEUR symposia 2.0
398
compulsory PhD courses  
2015
Research Integrity Course 0.3
CPO-Course on Patient Oriented Research 0.3
conferences  
2015
Heart Valve Society Annual Meeting, Monaco 0.9
2016
Association for European Pediatric and Congenital Cardiology Biennial Psychosocial 
Meeting, Rotterdam
0.6
Heart Valve Society Annual Meeting, New York 0.9
Association for European Pediatric and Congenital Cardiology Annual Meeting, Rome 1.2
Society for Medical Decision Making Annual North American Meeting, Vancouver 1.2
2018
Association for European Pediatric and Congenital Cardiology Biennial Psychosocial 
Meeting, Leicester
0.9
Heart Valve Society Annual Meeting, New York 0.9
Dutch Association for Thoracic Surgery Biannual Meeting, Utrecht 0.6
Society for Medical Decision Making Annual European Meeting, Leiden 0.6
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Society for Medical Decision Making Annual North American Meeting, Vancouver 1.2
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Heart Valve Society Annual Meeting, New York 1.2
Dutch Association for Thoracic Surgery Biannual Meeting, Utrecht 0.6
Society for Medical Decision Making Annual European Meeting, Leiden 0.6
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Supervision of 2nd year medical students in writing a systematic review 0.6
Supervision of 3rd year medical students in writing a systematic review 0.6
Supervision of 3rd year TU Delft students for Medical Delta minor 0.6
Lecture minor congenital heart disease 0.6
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Peer reviewer international scientific journals  
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Annals of Thoracic Surgery 1.0
European Journal for Cardio-Thoracic Surgery 0.5
Patient Education and Counseling 1.0
conference abstract reviewer  
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Society for Medical Decision Making 18th Biennial European Conference 0.5
total ects 48.9
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